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9Executive Summary 
1. Introduction 
On the 18th of June 2003, the Council of the European Union adopted a Recommendation on the 
prevention and reduction on health-related harm associated with drug dependence1, hereafter 
referred to as ’The Council Recommendation’ (CR). It consists of three main parts, namely 1) a 
recommendation that calls for the adoption of harm reduction as a public health objective; 2) a 
recommendation, consisting of 13 sub-recommendations relating to harm reduction services and 
facilities Member States are recommended to implement; and 3) a recommendation consisting of 
nine sub-recommendations including themes regarding quality assurance, needs driven policies, 
monitoring and evaluation.  
With the adoption of the Council Recommendation, the Council of the European Union recognised 
the importance of developing responses and strategies to prevent and reduce drug-related harm. 
The Council Recommendation calls upon the Member States to report on its implementation within 
two years after its adoption and upon request of the European Commission.  
a) Purpose and objectives 
Following an open call for tenders2, the Commission decided to enlist the services of the Trimbos 
Institute to collect and analyse the basic information a Commission report in accordance with the 
EU Action Plan on Drugs 2005-2008 and on the basis of the information submitted by the Member 
States to the Commission and the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). Furthermore, the Trimbos Institute was asked to provide an overview of the latest 
scientific evidence for the effectiveness of HR interventions and formulate advice for the follow-up 
of the Council Recommendation. These activities were planned in close collaboration with and by 
making use of technical support of the EMCDDA. 
b) Methodology, coverage and assessment of scientific literature 
At the request of the European Commission, all EU Member States have provided information on 
the implementation of the Council Recommendation through a reporting tool (RT). Key information 
sources at the EMCDDA have been analysed and used, including National Reports (NR) of the 
Member States to the EMCDDA, and Structured Questionnaires (SQ) to the National Focal Points 
that were specifically designed to monitor the implementation of the Council Recommendation. The 
National Focal Points actively contributed to this study by verifying the information that was put 
together on their respective countries, while – to a limited extent - field organisations were invited 
to provide additional information on harm reduction services and facilities in their country. 
Apart from the assessment of the above mentioned available data sources, a literature review was 
conducted to map the currently available scientific evidence on the main harm reduction 
interventions as adopted in the Council Recommendation. 
In contrast to controlled medical research, interventions in drug demand reduction in general and 
in harm reduction in particular are often carried out in a complex social environment with many 
unknown variables that can not easily be controlled in research situations. This means that the 
evidence-base for harm reduction interventions is slowly increasing step-by-step. And although for 
many interventions the existing evidence is still insufficient, they may still appear to be effective in 
daily practice. This should be tried out and guided by preliminary outcomes in practical situations. 
A positive conclusion of this report is that - so far - no evidently ineffective harm reduction 
interventions have been found in the literature. This report uses the term effective when sufficient 
evidence is found in the literature. When evidence is available but not yet sufficient, the intended 
harm reduction intervention is considered probably effective. An intervention may be effective 
when the evidence is still insufficient.  
Effective interventions are available to prevent and treat the spread of infectious diseases (HIV/  
AIDS, hepatitis B and C. 
Needle and syringe exchange programmes are probably effective (and possibly also cost-effective) 
in reducing risk behaviours and infectious diseases although HIV-testing and counselling may also 
be effective. When these interventions are outreaching (targeting hidden drug users in their daily 
environment) the coverage of these interventions will increase and also the effects on risk 
1 2003/488/EC. 
2 General invitation to tender SANCO/C4/2004/01. (OJ 10/7/2004 - 2004/S 133-112486). 
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behaviours of injecting drug use. Combination of harm reduction measures with informative or
educative strategies may also increase the positive effects on risk behaviours of injecting drug 
users.
Maintenance or substitution treatments with methadone or buprenorphine are effective in reducing 
opiate use and related risk behaviours. Both treatments are also effective in keeping opiate users 
in treatment.  Effectiveness tends to increase with individually adjusted higher doses of these 
substances and when psychosocial interventions are added to these maintenance treatment 
programmes. The most direct and effective intervention to prevent overdose death among drug 
users is naloxone but additional actions are often needed to increase success. Other interventions 
e.g. pre-release counselling are still studied insufficiently. The establishment of (medically 
supervised) drug consumption rooms may be a potentially effective intervention for reducing 
needle sharing and drug-related deaths. Although the available evidence is still inconclusive, no 
negative findings were found. Evidence for effectiveness of medical heroin (co)prescription for 
chronic opiate users shows that this intervention has little adverse effects. It probably improves the 
health situation of drug users who do not respond to maintenance treatment and it possibly also 
reduces public nuisance. It may also increase retention to treatment rates. Several new studies are 
underway that may serve to draw more firm conclusions. 
Maintenance or substitution treatment may also be a feasible treatment option in prisons, provided 
(again) that adequate dosages are distributed during the entire imprisonment period. Both 
methadone and buprenorphine are effective in reducing injecting drug use, needles sharing, and 
transmission of infectious diseases. These maintenance treatments probably also improve the 
health situation of drug using prisoners. There is no evidence yet that pre release counselling and 
after care are preventing relapse or overdose after withdrawal from drug use and release from 
prison, because effect studies on these subjects were not found. Prison-based needle (and syringe) 
exchange programmes are probably stabilising or reducing drug use, are reducing needle sharing 
and consequently the transmission of infectious diseases.  
2. Outcomes of the Council Recommendation 
a) Recommendation 1 - Harm reduction as public health objective 
This study shows that all EU Member States have policies in place that make the prevention of 
drug-related harm a public health objective and six Member States indicated the Council 
Recommendation has been a major instrument in that process. All Member States reported that 
the reduction of drug-related harm is a public health objective and for five Member States the 
Council Recommendation has played a major role in that regard. In all Member States harm 
reduction is part of a National Drug Strategy or Drug Action Plan. 
b) Recommendation 2 – Harm reduction services and facilities in the Member States 
In Table 1.1 a concise but simplified overview is given of the available harm reduction services and 
facilities in the Member States. Note that some of the interventions (e.g. needle exchange/  
substitution treatment) reduce both drug-related infectious diseases and drug-related deaths.  
As the table shows, Member States run a variety of Information, Education and Communication 
programmes. Needle and syringe exchange programmes are available in practically all Member 
States as well as related facilities such as the distribution of paraphernalia3 for drug use and 
condoms. Drug-free treatment4, methadone maintenance5 and methadone detoxification6
programmes are also widely available throughout the EU, while buprenorphine maintenance 
treatment is catching up fast. Member States pay a great deal of attention to the testing, 
screening, treatment and vaccination of drug-related infectious diseases. Overdose response 
measures, e.g., by making naloxone available on ambulances, is available in twenty Member 
3 The term drug paraphernalia refers to equipment used to produce, administer or conceal an illicit drug, e.g. 
bleach, a spoon, ascorbic acid, pipes, etc. 
4 Drug-free treatment involves the application of psychosocial and educational techniques to achieve long-term 
abstinence from drugs. Traditionally, drug-free treatment has been residential and long term, e.g. in 
therapeutic communities. Today, it is often also offered in community-based settings. 
5 In methadone maintenance treatment is a drug user is prescribed methadone as a substitute for heroin, 
usually in a daily dose and under medical supervision. The main aim of methadone maintenance treatment is to 
stabilise opiate users’ medical and social condition, as such allowing for genuine social re-integration. In this 
type of treatment the first concern is improving the drug users’ personal situation and the aim to become 
‘clean’. 
6 With methadone detoxification, a drug user is also prescribed methadone as a substitute for heroin, but in this 
type of treatment, the dosage of methadone is gradually decreased so that the drug user slowly detoxifies and 
can become ‘clean’.
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States. However, in only ten of the Member States emergency staff is being trained to respond to 
drug overdose.  
When harm reduction in prison is concerned, table 1.1 clearly shows that there is still a 
considerable discrepancy between the availability and access to services outside and inside prisons. 
This difference is most apparent regarding the availability of needle and syringe exchange 
programmes in prisons. 
Overall, Member States have adopted harm reduction policies, services and facilities as 
recommended by the Council Recommendation and many harm reduction interventions have been 
implemented. However there are still considerable differences between Member States at the level 
of implementation. 
Table 1.1 – Overview of services and facilities in the Member States 
Intervention (service/  facility) Nr. MS in 
which
intervention 
exists
CR ref. 
Prevention of risk behaviour 
x Information, education & communication (IEC) 
o Helpline 
o Website 
o Pill testing 
o Safer injection training 
x Outreach work (ORW) 
o Training of peers  
o Involvement of peers  
o Networking & cooperation between agencies in ORW 
o Training of staff 
o Drug Consumption Rooms 
25
22
7
13
23
18
19
20
21
4
2.1 
2.1 
2.1 
2.1 
2.2 
2.3 
2.4 
2.4 
2.13 
2.6 
Prevention of Drug-related infectious diseases 
x Needle & syringe exchange outside prison 
 Inside prison 
o Training of staff 
x Paraphernalia distribution outside prison
 Inside prison 
x Condom distribution outside prison 
 Inside prison 
x Testing/  screening 
x Treatment (e.g. Hep. C) 
x Vaccination 
o Vaccination Hep B for drug users 
o Vaccination TB for drug users 
24
3
17
23
11
23
16
22
20
20
13
2.10 
2.8 
2.13 
2.10 
2.8 
2.10 
2.8 
2.9 
2.9 
2.9 
2.9 
Prevention of Drug-related deaths 
x Low threshold/  drop-in centre 
x Substitution treatment 
o Methadone maintenance outside prison 
 Inside prison 
o Methadone detoxification outside prison 
 Inside prison 
o Buprenorphine outside prison 
 Inside prison 
o Naltrexone treatment outside prison 
 Inside prison 
o Heroin prescription outside prison 
 Inside prison 
o Training of staff 
x Drug Free treatment 
x Response to overdose 
o Naloxone in ambulance 
o Naloxone for ‘take home’ 
o Training emergency staff 
23
24
17
23
19
21
10
5
5
4
-
20
25
20
6
10
2.6 
2.6 
2.8 
2.6 
2.8 
2.6 
2.8 
2.6 
2.8 
2.6 
2.8 
2.13 
2.6 
2.11 
2.11 
2.11 
Prevention of diversion of substitution drugs 
x Policy to prevent diversion exists 22 2.7 
Integration of harm reduction in general health care -including mental 
health- and social care 
x Policy aim exists to promote integration 23 2.12 
11
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c) Recommendation 3 – Quality assurance, monitoring and evaluation 
The 3rd recommendation of the Council Recommendation focuses on facilitating the development of 
a sound infrastructure for the development, assessment, monitoring and evaluation of harm 
reduction services and facilities. Not all Member States consider quality assurance, monitoring and 
evaluation as a task for national government. In Member States with a federal or decentralised 
structure, tasks in these areas are divided among different levels of competence. In other Member 
States, e.g. the Netherlands and the UK, quality assurance, monitoring and evaluation are seen as 
a task for independent scientific organisations.  
The examples of studies that are presented in the country reports related to the 3rd Council 
Recommendation suggest that a broad range of Member States make use of scientific research as a 
basis for selecting appropriate interventions. Research is mainly focused on the most common 
harm reduction services and interventions, i.e. outreach work, substitution treatment and needle & 
syringe exchange. Nevertheless, Member States do not yet seem to make use of funding criteria as 
an instrument to promote quality and evaluation. Only the United Kingdom has reported that i.e., a 
needs assessment is a pre-condition for the commissioning of projects. Member States are still 
developing quality control models for harm reduction interventions, including the development of 
evaluation protocols and criteria. Member States like Luxembourg and Denmark have set up 
computerised registration systems in which details on programmes and interventions are collected.  
The Member States have adopted policies to implement the five EMCDDA key-epidemiological 
indicators, but in operational terms, not all Member States comply fully with the EMCDDA 
standards for these key-indicators. The EMCDDA provides Member States with feedback on the 
quality of these and other data collections and reports.  
All EU Member States have developed a National Drug Strategy, Drug Action Plan or other types of 
comprehensive drug policy documents in which harm reduction has been integrated as part of drug 
demand reduction. These policies increasingly point out the need of evaluation of interventions and 
programmes. Yet only a limited number of Member States report examples of evaluation schemes 
that are designed to inform policy. It seems that the evaluation culture is well developed in 
countries in North-Western Europe, i.e. in Member States such as the United Kingdom, the 
Netherlands, Luxembourg and Germany. 
The strengthening of an evaluation culture by providing training to staff and by involving 
stakeholders in evaluation processes is still a point of attention for Member States. Finally, there is 
a lot of collaboration taking place in the field of drug demand reduction and – to a lesser extent – 
harm reduction. In addition to EU funded, multilateral programmes (Twinning, Public Health, Focal 
Point collaborations), Member States also run bi-lateral collaboration programmes.  
3. Conclusions and suggestions for follow up 
x The Council Recommendation of 18 June 2003 has been successful as it has guided and 
supported policy development in the Member States and because it set a ‘benchmark’ for 
existing policies. Member States have – to a great extent – implemented policies, services and 
facilities that correspond with the recommendations in the Council Recommendation. It is still 
early to assess the real impact of the Council Recommendation on the Member States policies, 
services and facilities.  
x The available data at EU level regarding the availability of harm reduction services and facilities 
in the Member States as collected and disseminated by the EMCDDA is comprehensive and of 
high quality and – except perhaps for countries like Australia and Canada – probably 
unmatched outside the European Union. Nevertheless, the quality of data collections on the 
availability and accessibility of harm reduction services and facilities at national level does still 
need improvement. And Member States often do not have a complete overview if, by whom 
and how these services and facilities are used. 
x In general, harm reduction services and facilities as one of the possible approaches to respond 
to problem drug use, are common practice in all Member States, be it to a lesser extent for 
Cyprus and Sweden. Overall, policies of the European Union Member States are in balance with 
the recommendations as reflected in the Council Recommendation. However, the available 
data, which are largely self-reported by the Member States, provide an overview of the 
availability of services and facilities in the Member States, but not a complete picture of the 
accessibility and/ or the coverage of these interventions. Such data – in general – are often not 
available at national level.  
x Member States may consider placing greater emphasis on the further integration of harm 
reduction in a broader public (mental) health and social care and welfare policy, with the aim to 
provide realistic and sustainable exit options (from drug dependence) for drug users in the long 
12
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run. The integration of harm reduction with public health including mental health and social 
care is of great importance, as an integrated system of care may provide dependent drug users 
with the best possibilities to improve their social and health situation and facilitate their 
reintegration in society.  
x Harm reduction seems to be an accepted approach in drug demand reduction policies in all EU 
Member States. Those harm reduction measures that have been implemented most by the 
Member States (IEC, needle & syringe exchange, maintenance treatment, naloxone 
availability) are found  probably effective or effective in scientific literature, especially when 
combined in an integrated harm reduction care system. To date, none of the major harm 
reduction interventions that have been evaluated have been found ineffective or showed 
unwanted or undesirable results. 
x Most harm reduction programmes in the EU Member States are mainly focusing on ‘traditional’ 
drug use patterns, especially opiate dependency. Interventions taking into account new trends 
in drug dependence (e.g. crack cocaine and (Meth-) amphetamine dependence) as well as the 
growing prevalence of the mixed use of licit and illicit drugs are still scarce.  
x The collection of data on problem drug use and drug-related harm at Member States level is 
still not always comparable due to different estimation systems at local level. Furthermore, 
more emphasis could be placed upon the prevalence of drug-related harm in relation to the 
specific at-risk groups in Member States rather than those of the general population. Member 
States with relatively small groups of problem drug users may still have a high prevalence of 
drug-related harms such as infectious diseases among these problem drug users. Although the 
number of problem drug users may be small compared to the general population, the 
prevalence of drug-related harm may be considerable. 
x Scientific evidence on effectiveness is available for many harm reduction interventions. This 
general conclusion is most promising since effect studies are sometimes hard to conduct in this 
type of settings. The circumstances in which harm reduction interventions are implemented, 
hardly accept a division in study groups with different intervention regimes, not in the last 
place because of ethical reasons. It is important that innovations in harm reduction are allowed 
to be based on pragmatism and local or regional constructions of ‘best-practice’. After this try-
out phase, it is sometimes feasible to gather evidence for specific interventions via high-quality 
effect studies.  
x Finally, at EU level and among the Member States there is an increasing awareness of the need 
to make policies more research-based and facts-driven, including harm reduction policies. This 
need is reflected by the 3rd Council Recommendation, but also in the European Drugs Strategy 
2005-2012 and the EU Action Plan on Drugs 2005-2008.  
13
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Résumé exécutif 
1. Introduction 
Le 18 juin 2003, le Conseil de l’Union européenne a adopté une Recommandation sur la prévention 
et la réduction des dommages pour la santé liés à la toxicomanie7, ci-après dénommée ‘La 
Recommandation du Conseil’ (RC). Celle-ci comporte trois parties principales, à savoir, 1) une 
recommandation réclamant l’adoption de la réduction des dommages comme un objectif de santé 
publique ; 2) une recommandation composée de 13 sous-recommandations relatives aux 
installations et services pour la réduction des dommages qu’il est recommandé aux États Membres 
de mettre en œuvre ; et 3) une recommandation constituée de neuf sous-recommandations 
comprenant des thèmes relatifs à l'assurance qualité, des politiques, un suivi et une évaluation 
tournés vers les besoins.  
Par l’adoption de cette Recommandation, le Conseil de l’Union européenne a reconnu l’importance 
de développer des réponses et des stratégies pour prévenir et réduire les dommages liés aux 
drogues. La Recommandation du Conseil invite les États Membres à dresser un rapport de sa mise 
en œuvre dans un délai de deux ans à dater de son adoption et à la demande de la Commission 
européenne.  
a) But et objectifs 
Suite à un appel d’offres ouvert8, la Commission a décidé d’engager les services de l’Institut 
Trimbos pour collecter et analyser les informations de base d’un rapport de la Commission 
conformément au Plan d’action antidrogue de l’UE (2005-2008) et sur la base des informations 
soumises par les États Membres à la Commission et à l’Observatoire européen des drogues et des 
toxicomanies (OEDT).   En outre, l’Institut Trimbos a été invité à fournir un aperçu des dernières 
preuves scientifiques de l’efficacité des interventions de réduction des dommages et à formuler des 
conseils pour le suivi de la Recommandation du Conseil. Ces activités ont été planifiées en étroite 
collaboration avec l'OEDT et en ayant recours à son soutien technique. 
b) Méthodologie, couverture et évaluation de la littérature scientifique 
A la demande de la Commission européenne, tous les États Membres de l’UE ont fourni des 
informations sur la mise en œuvre de la Recommandation du Conseil via un outil de création de 
rapports (RT). Les sources d’informations clés à l’OEDT ont été analysées et utilisées, y compris 
des rapports nationaux (NR) des États Membres à l’OEDT et des questionnaires structurés (SQ) 
adressés aux points focaux nationaux qui ont été spécifiquement conçus pour assurer le suivi de la 
mise en œuvre de la Recommandation du Conseil. Les points focaux nationaux ont activement 
contribué à cette étude en vérifiant les informations rassemblées dans leurs différents pays, alors 
que – dans une moindre mesure – des organisations sur le terrain ont été invitées à fournir des 
informations complémentaires sur les interventions de réduction des dommages dans leur pays. 
Outre l’évaluation des sources de données disponibles mentionnées ci-dessus, une analyse 
documentaire a été menée pour établir un relevé des témoignages scientifiques disponibles 
actuellement relatifs aux principales interventions pour la réduction des dommages telles 
qu’adoptées dans la Recommandation du Conseil. 
A la différence de la recherche médicale contrôlée, les interventions dans le domaine de la 
réduction de la demande de drogues en général et de la réduction des dommages en particulier 
sont souvent menées dans un environnement social complexe présentant de nombreuses variables 
inconnues qui ne peuvent pas être contrôlées facilement dans des situations de recherche. Pour 
cette raison, les données probantes relatives aux interventions de réduction des dommages 
augmentent pas à pas. Et bien que pour de nombreuses interventions, les données existantes 
soient encore insuffisantes, elles peuvent malgré tout s'avérer efficaces dans la pratique de tous les 
jours. Il faut l’essayer et l’adapter en fonction des premiers résultats dans des situations pratiques. 
Une conclusion positive de ce rapport est que – jusqu’à présent – aucunes interventions de 
réduction des dommages manifestement inefficaces n'ont été rencontrées dans la documentation. 
Ce rapport utilise le terme efficace lorsque des preuves suffisantes ont été trouvées dans la 
littérature afférente. Lorsque des preuves sont disponibles mais pas encore en nombre suffisant, 
l'intervention de réduction des dommages visée est considérée comme probablement efficace. Une 
intervention peut être efficace alors que les preuves sont encore insuffisantes.  
7 2003/488/CE. 
8 Appel d’offres général SANCO/C4/2004/01 (JO 10/7/2004 – 2004/5 133-112486).
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Des interventions efficaces existent pour prévenir et traiter la propagation de maladies infectieuses 
(VIH/SIDA, hépatite B et C).   
Des programmes d’échange d’aiguilles et de seringues sont probablement efficaces (et peut-être 
aussi rentables) en termes de réduction des comportements à risque et des maladies infectieuses 
bien que le test VIH et l'assistance psychosociale semblent également efficaces. Lorsque ces 
interventions sont destinées au grand public (visant des utilisateurs de drogues cachés dans leur 
environnement quotidien), leur couverture augmente, de même que les effets sur les 
comportements à risque de l’utilisation de drogues par injection.  Une combinaison de mesures de 
réduction des dommages affichant des stratégies informatives et éducatives peut également 
augmenter les effets positifs sur les comportements à risque des utilisateurs de drogues par 
injection.  
Des traitements d'entretien ou de substitution à la méthadone ou la buprénorphine sont efficaces 
pour réduire l'utilisation d'opiacés et les comportements à risque qui en découlent. Ces deux 
traitements sont également efficaces pour maintenir les utilisateurs d’opiacés en traitement. 
L’efficacité tend à augmenter en présence de doses supérieures de ces substances adaptées au cas 
par cas et lorsque des interventions psychologiques viennent s'ajouter à ces programmes de 
traitement d'entretien. L’intervention la plus directe et la plus efficace pour prévenir les décès par 
overdose parmi les toxicomanes est la naloxone mais des actions complémentaires sont souvent 
nécessaires pour augmenter le taux de réussite. D’autres interventions, comme notamment l’aide
psychosociale avant libération, sont encore insuffisamment étudiées. La mise en place de lieux de 
consommation de drogues (avec supervision médicale) peut s’avérer être une intervention 
potentiellement efficace pour réduire les échanges d’aiguilles et les décès liés à la drogue. Bien que 
les preuves disponibles soient encore peu concluantes, aucune conclusion négative n’a été trouvée. 
Les preuves de l’efficacité des (co)prescriptions médicales d’héroïne pour les utilisateurs chroniques 
d’opiacés montrent que cette intervention présente peu d’effets défavorables. Elle semble 
améliorer l'état de santé des toxicomanes qui ne répondent pas au traitement d'entretien et réduit 
aussi probablement les désagréments publics. Elle peut également favoriser le maintien des taux 
de traitements. Plusieurs nouvelles études susceptibles de permettre l'établissement de conclusions 
plus fermes sont en cours. 
Le traitement d’entretien ou de substitution peut également constituer une option de traitement 
réalisable dans les prisons, pourvu (encore une fois) que des doses adaptées soient distribuées 
pendant toute la durée de l’emprisonnement. La méthadone comme la buprénorphine sont 
efficaces pour réduire l’utilisation de drogues par injection, les échanges d’aiguilles et la 
transmission des maladies infectieuses. Ces traitements d'entretien améliorent aussi probablement 
l'état de santé des prisonniers toxicomanes. L’aide psychosociale avant libération et les soins après 
libération sont peut-être aussi efficaces pour éviter les rechutes ou les overdoses après s’être libéré 
de la drogue et avoir quitté la prison, mais aucune étude sur ces sujets ne semble disponible. Des
programmes d'échange d'aiguilles (et de seringues) au niveau des prisons sont probablement  
efficaces pour réduire le partage des aiguilles et la transmission des maladies infectieuses.  
2. Résultats de la Recommandation du Conseil 
a) Recommandation 1 – Réduction des dommages comme objectif de santé publique 
Cette étude montre que tous les États Membres de l’UE ont mis en place des politiques faisant de 
la prévention des dommages liés à la toxicomanie un objectif de santé publique et six États 
Membres ont indiqué que la Recommandation du Conseil a été un instrument essentiel dans ce 
processus.   Tous les États Membres ont déclaré que la réduction des dommages liés aux drogues 
constitue un objectif de santé publique et pour cinq États Membres, la Recommandation du Conseil 
a joué un rôle capital en ce sens. Dans tous les États Membres, la réduction des dommages fait 
partie d'une Stratégie nationale ou d'un Plan d'action en matière de drogues. 
b) Recommandation 2 – Interventions de réduction des dommages dans les États 
Membres 
Le Tableau 1.1 offre un aperçu concis mais simplifié des installations et services de réduction des 
dommages existants dans les États Membres. Il faut souligner que certaines des interventions 
existantes (par ex. l’échange d’aiguilles/ le traitement de substitution) réduisent à la fois les 
maladies infectieuses et les décès liés aux drogues.  
Comme l’indique le tableau, les États Membres exécutent toute une série de programmes 
d’Information, d’Education et de Communication. Des programmes d’échange d'aiguilles et de 
seringues sont disponibles dans pratiquement tous les États Membres ainsi que les installations 
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correspondantes telles que la distribution de l’attirail9 du toxicomane et de préservatifs. Des 
programmes de traitement sans drogue10, d’entretien à la méthadone11 et de désintoxication à la 
méthadone12 sont également très répandus partout dans l'UE, alors que le traitement d'entretien à 
la buprénorphine se développe rapidement. Les États Membres accordent une attention 
considérable à la gestion de tests, au dépistage, au traitement et à la vaccination des maladies 
infectieuses liées aux drogues. Des mesures de réaction face aux overdoses, par ex., en prévoyant 
de la naloxone dans les ambulances, existent dans vingt États Membres. Cependant, le personnel 
des urgences n’est formé pour réagir à une overdose que dans dix de ces États Membres.  
En ce qui concerne la réduction des dommages dans les prisons, le tableau 1.1 indique clairement 
qu’il existe encore une importante divergence entre la disponibilité et l’accès des services à 
l’intérieur et à l’extérieur des prisons. Cette différence est avant tout constatée en matière de 
disponibilité de programmes d’échange d’aiguilles et de seringues dans les prisons. 
Dans l’ensemble, les États Membres ont adopté des politiques, des services et des installations de 
réduction des dommages comme le préconisait la Recommandation du Conseil et de nombreuses 
interventions de réduction des dommages ont été mises en œuvre. Cependant, on constate encore 
des différences considérables entre les États Membres au niveau de la mise en œuvre. 
Tableau 1.1 – Aperçu des interventions dans les États Membres 
Intervention (service/  installation) Nbre EM 
dans
lesquels 
une
intervention 
existe 
CR réf. 
Prévention des comportements à risque 
x Information, éducation & communication (IEC) 
o Service d’assistance téléphonique 
o Site Web 
o Pill-testing (contrôle des pilules) 
o Formation à des injections plus sûres 
x Travail de proximité (TP) 
o Formation de pairs  
o Implication de pairs  
o Mise en réseau & coopération entre agences de TP 
o Formation de personnel 
o Locaux de consommation de drogues 
25
22
7
13
23
18
19
20
21
4
2,1 
2,1 
2,1 
2,1 
2,2 
2,3 
2,4 
2,4 
2,13 
2,6 
Prévention des maladies infectieuses liées aux drogues 
x Échange d’aiguilles & de seringues en dehors des prisons 
 A l'intérieur des prisons 
o Formation de personnel 
x Distribution de l’attirail du toxicomane en dehors des prisons
 A l’intérieur des prisons 
x Distribution de préservatifs en dehors des prisons 
 A l’intérieur des prisons 
x Tests/ dépistage 
x Traitement (ex. Hép. C) 
x Vaccination 
o Vaccination Hép. B pour les toxicomanes 
o Vaccination TB pour les toxicomanes 
24
3
17
23
11
23
16
22
20
20
13
2,10 
2,8 
2,13 
2,10 
2,8 
2,10 
2,8 
2,9 
2,9 
2,9 
2,9 
Prévention des décès liés aux drogues 
x Seuil bas/  centre d’accueil 
x Traitement de substitution 
23 2,6 
9 Les termes ‘attirail du toxicomane’ désignent tout l’équipement utilisé pour produire, administrer ou dissimuler 
une drogue illicite, ex. éclaircissant, cuillère, acide ascorbique, pipes, etc. 
10 Le traitement sans drogue implique l'application de techniques psychosociales et éducatives pour parvenir à 
une abstinence des drogues sur le long terme. Traditionnellement, le traitement sans drogue était résidentiel et 
s’étendait sur le long terme, par ex. dans des communautés thérapeutiques. Aujourd’hui, il est aussi souvent 
proposé dans des cadres communautaires. 
11 Dans le traitement d’entretien à la méthadone, le toxicomane se voit prescrire de la méthadone comme 
substitut de l’héroïne, habituellement sous la forme d’une dose journalière et sous contrôle médical. Le principal 
objectif du traitement d’entretien à la méthadone est de stabiliser la situation sociale et médicale des 
utilisateurs d’opiacés, permettant ainsi une véritable réintégration sociale. Dans ce type de traitement, la 
principale préoccupation consiste à améliorer la situation personnelle des toxicomanes avec pour objectif de 
devenir ‘clean’ (désintoxiqué). 
12 Dans le cadre d’une désintoxication à la méthadone, un toxicomane se voit également prescrire de la 
méthadone comme substitut de l’héroïne, mais dans ce type de traitement, le dosage de la méthadone est 
progressivement réduit de sorte que le toxicomane se désintoxique peu à peu et devient ‘clean’ (désintoxiqué).
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o Entretien à la méthadone en dehors de la prison 
 A l’intérieur de la prison 
o Désintoxication à la méthadone en dehors de la prison 
 A l’intérieur de la prison 
o Buprénorphine en dehors de la prison 
 A l’intérieur de la prison 
o Traitement à la naltrexone en dehors de la prison 
 A l’intérieur de la prison 
o Prescription d’héroïne en dehors de la prison 
 A l’intérieur de la prison 
o Formation de personnel 
x Traitement sans drogue 
x Réaction à l’overdose 
o Naloxone dans l’ambulance 
o Naloxone pour ‘prise à domicile’ 
o Formation du personnel des urgences 
24
17
23
19
21
10
5
5
4
-
20
25
20
6
10
2,6 
2,8 
2,6 
2,8 
2,6 
2,8 
2,6 
2,8 
2,6 
2,8 
2,13 
2,6 
2,11 
2,11 
2,11 
Prévention de détournement de drogues de substitution  
x Politique de prévention de détournement existante 22 2,7 
Intégration de la réduction des dommages dans les soins de santé 
généraux –y compris la santé mentale- et l'aide sociale 
x Un but politique existe pour promouvoir l’intégration 23 2,12 
c) Recommandation 3 – Assurance qualité, suivi et évaluation 
Le 3ème conseil de la Recommandation du Conseil se concentre sur la facilitation de l’élaboration 
d’une infrastructure solide pour le développement, le contrôle, le suivi et l’évaluation des services 
et installations de réduction des dommages. Tous les États Membres ne considèrent pas l’assurance 
qualité, le suivi et l’évaluation comme une tâche du gouvernement national. Dans certains États 
Membres présentant une structure décentralisée ou fédérale, les tâches dans ces secteurs sont 
réparties entre les différents niveaux de compétence. Dans d’autres États Membres, aux Pays-Bas 
et au RU notamment, l’assurance qualité, le suivi et l’évaluation sont considérés comme une tâche 
relevant d’organisations scientifiques indépendantes.  
Les exemples d’études qui sont présentés dans les rapports nationaux en rapport avec la 3ème
Recommandation du Conseil suggèrent qu’un vaste groupe d’États Membres utilise la recherche 
scientifique comme une des bases de sélection d’interventions appropriées. La recherche est 
essentiellement axée sur les interventions et services de réduction des dommages les plus 
communs, à savoir, le travail de proximité, le traitement de substitution et l’échange d’aiguilles & 
de seringues. Cependant, certains États Membres ne semblent toujours pas prendre en compte des 
critères de financement comme instrument pour promouvoir la qualité et l’évaluation. En effet, seul 
le Royaume Uni a indiqué dans son rapport qu'une évaluation des besoins constitue une condition 
requise pour la mise en œuvre de projets. Les États Membres développent encore des modèles de 
contrôle de la qualité pour les interventions de réduction des dommages, incluant le 
développement de critères et protocoles d’évaluation. Certains États Membres, comme le 
Luxembourg et le Danemark, ont mis au point des systèmes informatisés d'enregistrement dans 
lesquels sont rassemblées des données détaillées concernant les programmes et interventions.  
Les États Membres ont adopté des politiques pour mettre en œuvre les cinq indicateurs 
épidémiologiques clés de l’OEDT, mais dans la pratique, tous les États Membres ne respectent pas 
entièrement les normes de l’OEDT pour ces indicateurs-clés. L’OEDT transmet du feed-back aux 
États Membres concernant la qualité de ceux-ci ainsi que d’autres collectes de données et rapports.  
Tous les États Membres de l’UE ont établi une stratégie nationale en matière de drogue, un plan 
d’action ou d’autres types de documents politiques globaux sur les drogues dans lesquels la 
réduction des dommages a été intégrée comme élément de réduction de la demande de drogues. 
Ces politiques soulignent de plus en plus la nécessité d’une évaluation des interventions et des 
programmes. Mais seul un nombre limité d’États Membres signalent des exemples de systèmes 
d’évaluation conçus pour guider la politique. Il semble que la culture de l’évaluation soit plutôt 
développée au Nord-ouest de l’Europe, c-à-d. dans des États Membres comme le Royaume Uni, les 
Pays-Bas, le Luxembourg et l’Allemagne. 
Le renforcement d’une culture d’évaluation en proposant une formation au personnel et en incluant 
des enjeux dans les processus d’évaluation constitue encore un point de réflexion pour les États 
Membres. Enfin, une collaboration importante se met en place dans le domaine de la réduction de 
la demande de drogues et – dans une moindre mesure – de la réduction des dommages. Outre les 
programmes multilatéraux, financés par l’UE (Jumelage, Santé Publique, Collaborations des points 
focaux), les États Membres mettent également en œuvre des programmes de collaborations 
bilatérales.  
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3. Conclusions et suggestions pour la suite 
x La Recommandation du Conseil du 18 juin 2003 a été un succès en ce sens qu’elle a inspiré et 
soutenu le développement de politiques dans les États Membres et parce qu’elle établit une 
‘référence’ pour les politiques existantes. Les États Membres – dans une large mesure – ont 
mis en œuvre des politiques, des services et des installations qui correspondent aux avis 
donnés dans la Recommandation du Conseil. Il est encore tôt pour apprécier l’impact réel de la 
Recommandation du Conseil sur les politiques, services et installations des États Membres.  
x Les données disponibles au niveau européen concernant l’existence de services et installations 
de réduction des dommages dans les États Membres telles que collectées et communiquées par 
l’OEDT sont globales et de haute qualité et – à l’exception peut-être de certains pays comme 
l’Australie et le Canada – elles sont probablement inégalées en dehors de l’Union européenne. 
Toutefois, la qualité des collectes de données relatives à la disponibilité et à l'accessibilité des 
services et installations de réduction des dommages requiert encore des améliorations au 
niveau national. De plus, les États Membres ne disposent généralement pas d’un aperçu 
complet quant à savoir si, par qui et comment ces installations et services sont utilisés. 
x En règle générale, les services et installations de réduction des dommages utilisés comme une 
des approches éventuelles pour répondre au problème de la toxicomanie, sont une pratique 
commune dans tous les États Membres, même si ce n’est que dans une moindre mesure en ce 
qui concerne Chypre et la Suède. Globalement, les politiques des États Membres de l’Union 
européenne sont alignées sur les recommandations telles que reflétées dans la 
Recommandation du Conseil. Toutefois, les données disponibles, amplement auto-rapportées 
par les États Membres, fournissent une vue d’ensemble de la disponibilité des services et 
installations dans les États Membres, mais pas un aperçu complet de l’accessibilité et/ou la 
couverture de ces interventions. Ces données – en règle générale – ne sont bien souvent pas 
disponibles au niveau national.  
x Certains États Membres envisagent peut-être de mettre davantage l'accent sur une plus grande 
intégration de la réduction des dommages dans une politique plus vaste de santé publique 
(mentale), d’aide sociale et de prévoyance, avec pour objectif de proposer des options de 
résolution (de la dépendance aux drogues) durables et réalistes aux toxicomanes sur le long 
terme. L’intégration de la réduction des dommages au sein de la santé publique, incluant la 
santé mentale et l’aide sociale, est très importante car un système de soins intégré peut offrir 
aux toxicomanes les meilleures possibilités pour améliorer leur situation sociale et de santé et 
favoriser leur réintégration dans la société.  
x La réduction des dommages semble être une approche acceptée dans les politiques de 
réduction de la demande de drogues dans tous les États Membres de l’UE. Les mesures de 
réduction des dommages qui ont été le plus mises en oeuvre par les États Membres (IEC, 
échange d'aiguilles & de seringues, traitement d'entretien, disponibilité de la naloxone) sont 
jugées probablement efficaces ou efficaces dans la littérature scientifique, en particulier 
lorsqu’elles sont combinées à un système de soins intégrant la réduction des dommages. 
Jusqu’à présent, aucune des principales interventions de réduction des dommages qui ont été 
évaluées n’a été estimée inefficace ou n’a révélé des résultats non désirés ou non désirables. 
x La plupart des programmes de réduction des dommages dans les États Membres de l’UE sont 
essentiellement axés sur les modèles ‘traditionnels’ de toxicomanie, et particulièrement la 
dépendance aux opiacés. Les interventions prenant en considération les nouvelles tendances 
en termes de dépendance aux drogues (ex. la dépendance au crack, à la  cocaïne et à la 
(méth-) amphétamine) ainsi que la prévalence croissante de l’utilisation mixte de drogues 
licites et illicites sont encore rares.  
x La collecte de données sur le problème de la toxicomanie et des dommages liés à la drogue au 
niveau des États Membres n’est pas encore comparable dans tous les cas en raison de 
systèmes d’évaluation différents au niveau local. En outre, une plus grande importance pourrait 
être accordée à la prévalence des dommages liés à la drogue en rapport avec les groupes à 
risque spécifiques dans les États Membres plutôt que la population en général. Les États 
Membres présentant des groupes relativement petits de toxicomanes à problème peuvent 
malgré tout avoir une prévalence élevée de dommages liés à la drogue comme notamment des 
maladies infectieuses parmi ces toxicomanes à problème. Bien que le nombre de toxicomanes à 
problème puisse être petit par rapport à la population globale, la prévalence de dommages liés 
à la drogue peut s’avérer considérable. 
x Des preuves scientifiques d’efficacité sont disponibles pour de nombreuses interventions de 
réduction des dommages. Cette conclusion générale est d’autant plus prometteuse que les 
études sur les effets sont quelquefois difficiles à mener dans ce type de situation. Les 
circonstances dans lesquelles les interventions de réduction des dommages sont mises en 
œuvre acceptent difficilement une section de groupes d’étude disposant de différents régimes 
d’intervention, et ce notamment pour des raisons éthiques. Il est important que des 
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innovations soient autorisées dans la réduction des dommages et se fondent sur le 
pragmatisme et les constructions régionales ou locales de 'meilleures pratiques'. Après cette 
phase de tests, il est parfois possible de rassembler des preuves pour des interventions 
spécifiques via des études de haute qualité portant sur les effets.  
x Enfin, au niveau de l’UE et au sein des États Membres, on constate une prise de conscience 
croissante de la nécessité de rendre les politiques davantage basées sur la recherche et 
guidées par des faits réels, incluant des politiques de réduction des dommages. Ce besoin se 
reflète dans la 3ème Recommandation du Conseil, mais aussi dans la Stratégie européenne 
2005-2012 en matière de drogues et le Plan d’Action antidrogue 2005-2008 de l’UE.  
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Kurzfassung
1. Einleitung 
Am 18. Juni 2003 verabschiedete der Rat der Europäischen Union eine Empfehlung zur Prävention 
und Reduzierung gesundheitlicher Schäden im Zusammenhang mit Drogenabhängigkeit13, im 
Weiteren gekennzeichnet als 'Die Empfehlung des Rates' (CR). Sie besteht aus drei Hauptteilen, 
nämlich 1) einer Empfehlung, die Schadensbegrenzung als Zielsetzung des öffentlichen 
Gesundheitswesens verlangt; 2) einer Empfehlung, bestehend aus 13 untergeordneten 
Empfehlungen in bezug auf Dienste und Einrichtungen zur Schadensbegrenzung, die den 
Mitgliedstaaten zur Einführung bzw. Umsetzung empfohlen werden; und 3) einer Empfehlung, 
bestehend aus neun untergeordneten Empfehlungen u.a. zu Themen der Qualitätssicherung, der 
bedarfsorientierten Politik, der Beobachtung und der Evaluierung. 
Mit der Verabschiedung der Empfehlung des Rates würdigte der Rat der Europäischen Union den 
Stellenwert der Entwickelung von Strategien und angemessenen Reaktionen, um drogenbedingte 
Schäden zu verhindern und zu verringern. In der Empfehlung des Rates werden die Mitgliedstaaten 
ersucht, innerhalb von zwei Jahren nach ihrer Verabschiedung und auf Anfrage der Europäischen 
Kommission über ihre Umsetzung zu berichten. 
a) Zweck und Zielsetzung 
Im Zuge einer öffentlichen Ausschreibung14 beschloß die Kommission, die Leistungen des Trimbos 
Institute in Anspruch zu nehmen, um im Rahmen eines Kommissionsberichts in Übereinstimmung 
mit dem EU-Drogenaktionsplan 2005-2008 grundlegende Informationen zu erheben und zu 
analysieren, basierend auf den Informationen, die durch die Mitgliedstaaten bei der Kommission 
und bei der EU-Beobachtungsstelle für Drogen und Drogensucht (EBDD) vorgelegt wurden. 
Ausserdem wurde das Trimbos Institut gebeten, einen Überblick über die neuesten 
wissenschaftlichen Untersuchungsergebnisse für die Wirksamkeit von Maßnahmen zur 
Schadensbegrenzung zur Verfügung zu stellen und Empfehlungen für weitere Maßnahmen im 
Anschluß an die Empfehlung des Rates zu formulieren. Diese Tätigkeiten wurden in enger 
Zusammenarbeit und mit technischer Unterstützung der EU-Beobachtungsstelle (EBDD) geplant.
b) Methodik, Quellenlage und Auswertung der wissenschaftlichen Literatur 
Auf Ersuchen der Europäischen Kommission stellten alle EU-Mitgliedstaaten mithilfe eines 
Berichtsinstruments (RT) Informationen zur Durchführung der Empfehlung des Rates zur 
Verfügung. Es wurden Quellen zu Schlüsselinformationen der EBDD analysiert und genutzt, 
einschließlich der nationalen Berichte (NR) der Mitgliedstaaten an die EBDD und der strukturierten 
Fragebögen (SQ) der Nationalen Knotenpunkte des REITOX-Netzes, welche spezifisch entworfen 
wurden, um die Umsetzung der Empfehlung des Rates zu beobachten. Die nationalen 
Referenzstellen trugen durch die Überprüfung der Informationen über ihre jeweiligen Länder aktiv 
zu dieser Studie bei, während weitere Organisationen in diesem Bereich – in eingeschränktem 
Maße - gebeten wurden, zusätzliche Informationen zu Diensten und Einrichtungen zur 
Schadensbegrenzung in ihrem Land zur Verfügung zu stellen. 
Abgesehen von der Evaluierung der obenerwähnten vorhandenen Datenquellen, wurde eine 
Literaturauswertung erarbeitet, um entsprechend der Empfehlung des Rates die gegenwärtig 
verfügbaren wissenschaftlichen Untersuchungsergebnisse für die Wirksamkeit von Maßnahmen zur 
Schadensbegrenzung darzustellen. 
Im Gegensatz zu kontrollierter medizinischer Forschung werden Maßnahmen zur Reduzierung des 
Drogenkonsums allgemein und Maßnahmen zur Schadensbegrenzung insbesondere häufig in einem 
komplexen sozialen Umfeld mit vielen unbekannten Variablen durchgeführt, die in 
Forschungssituationen nicht ohne weiteres zu steuern sind. Dies bedeutet, dass die Basis der 
Untersuchungsergebnisse für Maßnahmen zur Schadensbegrenzung sich Schritt für Schritt langsam 
erhöht. Und obwohl die vorhandenen Ergebnisse für viele Maßnahmen noch unzulänglich sind, 
können diese Maßnahmen in der täglichen Praxis durchaus effektiv scheinen. Dieses sollte anhand 
von Vorabresultaten in Situationen der Praxis überprüft und angeleitet werden. Ein positives Fazit 
dieses Berichts ist, dass - bis dato - keine offensichtlich unwirksamen Maßnahmen zur 
13 2003/488/EG. 
14 Allgemeine Ausschreibung SANCO/C4/2004/01. (Nr. 2004/S 133-112486 Amtsblatt der Europäischen Union). 
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Schadensbegrenzung in der Literatur gefunden wurden. Dieser Bericht verwendet die Bezeichnung 
‘wirksam’, ‘wirkungsvoll’ oder ‘effektiv’, wenn in der Literatur hinreichende Evidenz dafür gefunden 
wird. Wenn Nachweise vorhanden aber nicht hinreichend sind, wird die jeweils intendierte 
Maßnahme zur Schadensbegrenzung als ‘vermutlich effektiv' betrachtet. Eine Maßnahme kann 
wirksam sein, wenngleich die Nachweislage vorerst unzureichend ist. 
Zur Prävention und Behandlung der Verbreitung von Infektionskrankheiten (HIV/ AIDS, Hepatitis B 
und C) liegen wirksame Maßnahmen vor. Nadel- und Spritzenaustauschprogramme sind vermutlich 
effektiv (und möglicherweise auch kosteneffektiv) indem sie Risikoverhalten und 
Infektionskrankheiten verringern, obgleich HIV-Tests und –Beratung auch wirkungsvoll sein 
können. Wenn diese Maßnahmen übergreifend eingesetzt werden (sodass sie auf verdeckte 
Drogenkonsumenten in ihrem täglichen Umfeld abzielen) erhöht sich die flächendeckende Wirkung 
dieser Maßnahmen ebenso wie die Effekte auf Risikoverhalten im Drogenkonsum durch Injektion. 
Die Kombination von Maßnahmen zur Schadensbegrenzung mit Informations- oder 
Bildungsstrategien kann die positiven Effekte auf Risikoverhalten beim Spritzen durch 
Drogenkonsumenten ebenfalls erhöhen.
Methadon- oder Buprenorphingestützte Erhaltungs- oder Substiturtionstherapien sind effektiv, 
wenn sie den Opiatkonsum und das damit in Verbindung stehende Risikoverhalten verringern. 
Beide Behandlungen sind auch dadurch wirkungsvoll, dass sie Opiatkonsumenten in Behandlung 
halten. Die Wirksamkeit ist tendenziell höher bei individuell eingestellten höheren Dosen dieser 
Substanzen und wenn psychosoziale Maßnahmen zu diesen Erhaltungstherapieprogrammen hinzu 
kommen. Die direkteste und wirksamste Maßnahme zu Prävention von Todesfällen durch Überdosis 
unter Drogenkonsumenten ist Naloxon, allerdings sind oft zusätzliche Aktivitäten erforderlich, um 
den Erfolg zu erhöhen. Andere Maßnahmen z.B. Beratung vor der Haftentlassung sind derzeit noch 
unzulänglich untersucht. Die Einrichtung von (medizinisch betreuten) Drogenkonsumräumen kann 
möglicherweise eine wirkungsvolle Maßnahme für die Verringerung von gemeinsamer 
Nadelbenutzung und drogenbedingten Todesfällen sein. Obgleich die verfügbaren Untersuchungen 
noch ohne abschließende Ergebnissse sind, gibt es auch keine negativen Befunde. Untersuchungen 
zur Wirksamkeit von medizinischer Heroinverschreibung für chronische Opiatkonsumenten zeigen, 
dass diese Maßnahme wenig schädliche Wirkungen hat. Sie verbessert vermutlich die 
gesundheitliche Situation derjenigen Drogenkonsumenten, die nicht auf Erhaltungstherapien 
reagieren und verringert vermutlich auch Vorkommnisse von öffentlichem Ärgernis. Sie erhöht 
möglicherweise auch die Therapieverbleibrate. Es sind einige aktuelle Studien im Gange, die dazu 
dienen können, verwertbarere Schlüsse zu ziehen. 
Für Haftinsassen kann Erhaltungs- oder Substiturtionstherapie ebenfalls eine machbare 
Behandlungsoption sein, vorausgesetzt, dass während der gesamten Inhaftierungszeit 
ausreichende Dosierungen ausgeteilt werden. Sowohl Methadon als auch Buprenorphin verringern 
wirksam injizierenden Drogenkonsum, gemeinsame Nadelbenutzung und die Übertragung 
ansteckender Krankheiten. Erhaltungsbehandlungen verbessern vermutlich auch den 
Gesundheitszustand drogenabhängiger Haftinsassen. Beratung vor der Haftentlassung und 
Nachsorgemaßnahmen verhindern Rückfälle nach der Haftentlassung oder Überdosen nach Entzug, 
jedoch wurden keine Wirksamkeitsstudien zu diesen Themen gefunden. Nadel- und 
Spritzenaustauschprogramme in der Haft wirken vermutlich stabilisierend oder reduzierend auf den 
Drogenkonsum; sie verringern  die gemeinsame Nadelbenutzung und somit die Übertragung 
ansteckender Krankheiten.  
2. Resultate der Empfehlung des Rates 
a) Empfehlung 1 - Schadensbegrenzungsdienste als Ziel im öffentlichen 
Gesundheitswesen 
Diese Studie zeigt, dass alle EU-Mitgliedstaaten politische Richtlinien etabliert haben, in denen die 
Prävention drogenbedingter Schäden im öffentlichen Gesundheitswesen ein Ziel bildet; sechs 
Mitgliedstaaten gaben an, dass die Empfehlung des Rates ein wesentliches Instrument in diesem 
Prozeß war. Alle Mitgliedstaaten berichteten, dass die Reduzierung drogenbedingter Schäden ein 
Ziel im öffentlichen Gesundheitswesen ist; für fünf Mitgliedstaaten hat die Empfehlung des Rates in 
dieser Hinsicht eine wesentliche Rolle gespielt. In allen Mitgliedstaaten ist Schadensbegrenzung Teil 
einer nationalen Drogenstrategie oder des Drogenaktionsplans. 
b) Empfehlung 2 – Schadensbegrenzungsdienste und -einrichtungen in den 
Mitgliedstaaten 
Tabelle 1.1 gibt zusammendfassend einen vereinfachten Überblick über vorhandene 
Schadensbegrenzungsdienste und -einrichtungen in den Mitgliedstaaten. Besonders zu beachten ist 
dabei, dass einige der Maßnahmen (z.B. Nadelaustausch- / Substitutionsbehandlung) 
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drogenbedingte infektiöse Krankheiten und drogenbedingte Todesfälle verringern. Wie in der 
Tabelle dargestellt, laufen in einigen Mitgliedstaaten eine Vielzahl von Informations-, Aufklärungs- 
und Kommunikationsprogrammen. Nadel- und Spritzenaustauschprogramme sind in praktisch allen 
Mitgliedstaaten vorhanden, ebenso wie ähnliche Dienste, etwa die Verteilung von 
Injektionsmaterial15 und Kondomen. Drogenfreie Behandlung16, Erhaltungs17- und
Entgiftungprogramme18 mit Methadon sind in der EU mittlerweile weit verbreitet, wobei die 
Erhaltungstherapie mit Buprenorphin schnell aufholt. Die Mitgliedstaaten richten große 
Aufmerksamkeit auf Tests und Screenings sowie auf Behandlung und Schutzimpfung im 
Zusammenhang mit drogenbedingten infektiösen Krankheiten. Überdosisreaktionsmaßnahmen z.B. 
indem Naloxon in Krankenwagen standardmäßig zur Verfügung steht, existieren in zwanzig 
Mitgliedstaaten. Jedoch in nur zehn der Mitgliedstaaten wird das Notfallpersonal ausgebildet, auf 
Fälle von Drogenüberdosis zu reagieren.  
Was Schadensbegrenzung in Haftanstalten anbetrifft, geht aus Tabelle 1.1 deutlich hervor, dass es 
noch eine beträchtliche Diskrepanz zwischen dem Vorhandensein und der Zugänglichkeit zu 
Diensten außerhalb und innerhalb von Haftanstalten gibt. Hinsichtlich des Zugangs zu Nadel- und 
Spritzenaustauschprogrammen in Gefängnissen ist dieser Unterschied am offensichtlichsten. 
Insgesamt haben die Mitgliedstaaten, der Empfehlung des Rates entsprechend, politische 
Richtlinien, Dienste und Einrichtungen zur Schadensbegrenzung angenommen, und zahlreiche 
Maßnahmen zur Schadensbegrenzung wurden eingeführt. Jedoch gibt es auf der Ebene der 
Durchführung noch beträchtliche Unterschiede zwischen den Mitgliedstaaten.
Tabelle 1.1 – Überblick über Dienste und Einrichtungen in den Mitgliedstaaten 
Maßnahme (Dienst/ Einrichtung) 
Anzahl MS 
in denen 
Maßnahme
existiert 
Empf.
Nr.
Prävention von Risikoverhalten 
x Information, Aufklärung & Kommunikation (IEC) 
o Drogen-Notrufstelle 
o Website 
o Pill-Testing 
o Schulungen für sicheres Injizieren 
x Aufsuchende Sozialarbeit 
o Ausbildung von Gleichaltrigen und Freiwilligen 
o Einbeziehung von Gleichaltrigen und Freiwilligen 
o Arbeit in Netzwerken & Zusammenarbeit zwischen Einrichtungen, die 
Aufsuchende Sozialarbeit leisten 
o Mitarbeiterschulungen 
o Drogenkonsumräume 
25
22
7
13
23
18
19
20
21
4
2.1 
2.1 
2.1 
2.1 
2.2 
2.3 
2.4 
2.4 
2.13 
2.6 
Prävention von drogenbedingten Infektionskrankheiten 
x Nadel- & Spritzenaustauschprogramme außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Mitarbeiterschulungen 
x Verteilung von Injektionsmaterial außerhalb von Haftanstalten
 innerhalb von Haftanstalten 
x Kondomverteilung außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
x Tests/ Screenings 
x Behandlung (z.B. Hep. C) 
x Impfung
24
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17
23
11
23
16
22
20
2.10 
2.8 
2.13 
2.10 
2.8 
2.10 
2.8 
2.9 
2.9 
15 Der Begriff Injektionsmaterial bezieht sich auf die Ausrüstung zur Herstellung, Verabreichung oder dem 
Verstecken einer illegalen Droge, z.B. Bleichmittel, ein Löffel, Ascorbinsäure, Pfeifen etc. 
16 Drogenfreie Behandlung beinhaltet die Anwendung von psychosozialen und edukativen Techniken, um 
Langzeitabstinenz von Drogen zu erreichen. Traditionellerweise wird drogenfreie Behandlung stationär und 
langfristig durchgeführt, z.B. in therapeutischen Wohngemeinschaften. Heute wird sie auch häufig im Umfeld 
von Gemeindeeinrichtungen angeboten. 
17 In Methadonerhaltungstherapien wird dem Drogenkonsumenten Methadon als Ersatzdroge für Heroin 
verschrieben, gewöhnlich in einer täglichen Dosis und unter medizinischer Aufsicht. Das Hauptziel von 
Methadonerhaltungstherapien ist es, die gesundheitliche und soziale Verfassung von Opiatkonsumenten zu  
stabilisieren, um so eine echte soziale Re-integration zu ermöglichen. In dieser Behandlungsform ist die 
Verbesserung der persönlichen Situation des Drogenkonsumenten die erste Sorge, und nicht das Ziel, ‘clean’ zu 
werden. 
18 Bei der Methadonentgiftung wird dem Drogenkonsumenten ebenfalls Methadon als Substitut für Heroin 
verschrieben, allerdings wird in dieser Behandlungsform die Methadondosierung schrittweise verringert, so dass 
der Drogenkonsument langsam entgiftet und ‘clean’ werden kann.
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o Impfung gegen Hep B für Drogenkonsumenten 
o Impfung gegen TB für Drogenkonsumenten 
20
13
2.9 
2.9 
Prävention von drogenbedingten Todesfällen 
x Niederschwellige Dienste 
x Substitutionsbehandlung 
o Methadonerhaltungstherapien außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Methadonentgiftungstherapie außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Buprenorphintherapie außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Naltrexontherapie außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Heroinverschreibung außerhalb von Haftanstalten 
 innerhalb von Haftanstalten 
o Mitarbeiterschulungen 
x Drogenfreie Behandlung 
x Reaktion auf Überdosierung 
o Naloxon in der Ambulanz 
o Naloxonverschreibung 
o Mitarbeiterschulungen für medizinische Notfalldienste 
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2.13 
2.6 
2.11 
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Prävention der Abzweigung von Substitutionsstoffen 
x Vorkehrungen zur Prävention von Abzweigung existieren 22 2.7 
Integration von Schadensbegrenzung in die gesundheitliche - auch im 
Bereich der geistigen Gesundheit - und soziale Versorgung 
x Integrationspolitik mit speziellen Strategien zur Risikominderung existiert 23 2.12 
c) Empfehlung 3 – Qualitätssicherung, Beobachtung und Evaluierung 
Die dritte Empfehlung der Empfehlung des Rates konzentriert sich auf die Unterstützung der 
Entwicklung einer grundlegenden Infrastruktur für die Entwicklung, das Assessment, die 
Beobachtung und die Evaluierung der Schadensbegrenzungsdienste und -einrichtungen. Nicht alle 
Mitgliedstaaten betrachten Qualitätssicherung, Beobachtung und Evaluierung als Aufgabe ihrer 
Nationalregierung. In den Mitgliedstaaten mit einer Bundes- oder dezentralisierten Struktur werden 
Aufgaben in diesen Bereichen unter unterschiedlichen Kompetenzebenen aufgeteilt. In anderen 
Mitgliedstaaten z.B. den Niederlanden und Großbritannien, werden Qualitätssicherung, 
Beobachtung und Evaluierung als Aufgabe für unabhängige wissenschaftliche Organisationen 
gesehen. 
Die Beispiele der Studien, die in den Länderberichten bezüglich der dritten Empfehlung des Rates 
dargestellt werden, legen nahe, dass die Mitgliedstaaten als Grundlage zur Auswahl angemessener 
Maßnahmen weitgehend auf wissenschaftliche Forschung zurückgreifen. Das Augenmerk der 
Forschung richtet sich dabei hauptsächlich auf die üblichen Schadensbegrenzungsdienste und  
-maßnahmen, d.h. Niederschwellige Dienste, Substitutionsbehandlung und Nadel- und 
Spritzentausch. Dennoch scheinen die Mitgliedstaaten noch nicht die 
Finanzierungsförderungskriterien als Instrument zu gebrauchen, um Qualität und Evaluierung zu 
fördern. Lediglich Großbritannien berichtet, dass dort als Vorbedingung für die Beauftragung von 
Projekten eine Bedarfsanalyse erforderlich sei. Einige Mitgliedstaaten entwickeln noch 
Qualitätssteuerungsmodelle für Schadensbegrenzungsmaßnahmen, einschließlich der Entwicklung 
von Evaluierungsprotokollen und -kriterien. Mitgliedstaaten wie Luxemburg und Dänemark haben 
Computererfassungssysteme erstellt, in denen Details zu Programmen und Maßnahmen erhoben 
werden.
Die Mitgliedstaaten haben politische Maßnahmen ergriffen, um die fünf epidemiologischen 
Schlüssel-Indikatoren der EBDD einzuführen, aber auf operationaler Ebene stimmen nicht alle 
Mitgliedstaaten völlig mit den EBDD-Standards für diese Schlüssel-Indikatoren überein. Die EBDD 
versorgt die Mitgliedstaaten mit Feedback zur Qualität dieser und anderer Datenerfassungen und 
Berichte.
Alle EU-Mitgliedstaaten haben eine nationale Drogenstrategie, einen Drogenaktionsplan oder 
andere Dokumente einer umfassenden Drogenpolitik entwickelt, in denen Schadensbegrenzung als 
Teil der Drogennachfragereduzierung integriert wurde. Diese politischen Richtlinien unterstreichen 
in zunehmendem Maße die Notwendigkeit der Evaluierung von Maßnahmen und Programmen. 
Dennoch berichten lediglich eine begrenzte Anzahl von Mitgliedstaaten über Beispiele von 
Evaluierungskonzepten, die so entworfen sind, dass sie die Politik informieren. Es scheint, dass die 
Evaluierungskultur in den nordwestlichen Ländern Europas, d.h. in Mitgliedstaaten wie dem 
Vereinigten Königreich, den Niederlanden, Luxemburg und Deutschland gut entwickelt ist. 
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Die Stärkung einer Evaluierungskultur durch Training der Mitarbeiter und durch die Einbeziehung 
der Beteiligten in Evaluierungsprozesse, bedarf noch der Aufmerksamkeit für die Mitgliedstaaten. 
Letztendlich besteht eine Menge Zusammenarbeit im Bereich der Drogennachfragereduzierung und 
- in geringerem Ausmass – in der Schadensbegrenzung. Zusätzlich zu EU-finanzierten, 
multilateralen Programmen (Twinning, öffentliches Gesundheitswesen, Knotenpunkt-
Kollaborationen), führen die Mitgliedstaaten auch bilaterale Kollaborationsprogramme durch. 
3. Schlußfolgerungen und Vorschläge für weiteres Vorgehen 
x Die Empfehlung des Rates vom 18. Juni 2003 war erfolgreich, insofern sie die 
Politikentwicklung in den Mitgliedstaaten unterstützte und anleitete, und weil sie einen 
‘Bezugswert’ für die vorhandene Politik aufstellte. In großem Umfang führten die 
Mitgliedstaaten Politik, Dienste und Einrichtungen ein, die den Empfehlungen in der 
Empfehlung des Rates entsprechen. Es ist noch zu früh, die Auswirkungen der Empfehlung des 
Rates auf Politik, Dienste und Einrichtungen in den Mitgliedstaaten vollständig einzuschätzen. 
x Die verfügbaren Daten zur Verfügbarkeit von Diensten und Einrichtungen zur 
Schadensbegrenzung in den Mitgliedstaaten, auf EU-Niveau zusammengetragen und verbreitet 
durch die EBDD, sind umfassend und von hoher Qualität und - ausgenommen möglicherweise 
Länder wie Australien und Kanada - vermutlich außerhalb der europäischen Union unerreicht. 
Dennoch bedarf die Qualität der Datenerfassung zur Verfügbarkeit und Zugänglichkeit von 
Diensten und Einrichtungen zur Schadensbegrenzung auf nationalem Niveau noch der 
Verbesserung. Die Mitgliedstaaten haben häufig noch keinen umfassenden Überblick, ob, durch 
wen und wie diese Dienste und Einrichtungen benutzt werden. 
x Generell sind Dienste und Einrichtungen zur Schadensbegrenzung  als eine der möglichen 
Ansätze, auf Problemdrogenkonsum zu reagieren, in allen Mitgliedstaaten allgemein üblich, 
wenn auch in geringerem Ausmass in Zypern und Schweden. Insgesamt korrespondiert die 
Politik der Mitgliedstaaten der Europäischen Union mit den in der Empfehlung des Rates 
reflektierten Empfehlungen. Dennoch liefern die vorhandenen Daten, die weitgehend von den 
Mitgliedstaaten selbst berichtet werden, einen Überblick über die Verwendbarkeit von Diensten 
und Einrichtungen in den Mitgliedstaaten, nicht aber ein vollständiges Bild der Zugänglichkeit 
und/oder der Reichweite dieser Maßnahmen. Allgemein sind diese Daten häufig auf nationaler 
Ebene nicht vorhanden. 
x Die Mitgliedstaaten könnten erwägen, die Organisation einer weiteren Verknüpfung von 
Risikominderung und gesundheitlicher, psychologischer und sozialer Versorgung und 
Gesundheitspolitik mit grösserem Nachdruck zu verfolgen, mit dem Ziel, Drogenkonsumenten 
langfristig realistische und nachhaltige Ausstiegsoptionen zur Verfügung zu stellen. Die 
Integration der Schadensreduzierung im Rahmen des öffentlichen Gesundheitswesens 
einschließlich gesundheitlicher, psychologischer und sozialer Versorgung ist vom großen Wert, 
da ein integriertes System abhängigen Drogenkonsumenten die besten Möglichkeiten gibt, ihre 
soziale und gesundheitliche Situation zu verbessern und ihre Wiedereingliederung in der 
Gesellschaft zu erleichtern. 
x Schadensbegrenzung scheint ein akzeptierter Ansatz im Rahmen der 
Drogennachfragereduzierung in der Politik aller EU-Mitgliedstaaten zu sein. Die Maßnahmen zur 
Schadensbegrenzung, die in den meisten Mitgliedstaaten eingeführt sind (Information, 
Aufklärung & Kommunikation, Nadel- u. Spritzentausch, Erhaltungstherapie, Verwendung von 
Naloxon) werden in der wissenschaftlichen Literatur als vermutlich wirkungsvoll oder 
wirkungsvoll beurteilt, besonders wenn sie innnerhalb eines integrierten Versorgungssystems 
zur Schadensbegrenzung kombiniert werden. Bis jetzt sind bei keiner der ausgewerteten 
Hauptmaßnahmen zur Schadensbegrenzung Ineffektivität oder unerwünschte oder nicht 
wünschenswerte Effekte gefunden worden. 
x Die meisten Schadensbegrenzungsprogramme in den EU-Mitgliedstaaten konzentrieren sich 
hauptsächlich auf `traditionelle' Drogenkonsum-Muster, besonders auf Opiatabhängigkeit. 
Maßnahmen, die neue Tendenzen in der Drogenabhängigkeit (z.B. Crack-Kokain- und 
Amphetamiminabhängigkeit) sowie die wachsende Prävalenz von Mischkonsum legaler und 
illegaler Drogen in Betracht ziehen, sind noch selten. 
x Auf dem Niveau der Mitgliedstaaten ist die Datenerfassung bezüglich der 
Problemdrogenkonsumenten und drogenbedingter Gesundheitsschäden noch nicht immer 
vergleichbar, bedingt durch unterschiedliche Einschätzungsysteme auf lokalem Niveau. 
Ausserdem könnte mehr Gewicht auf die Prävalenz drogenbedingter Schäden in Bezug auf die 
spezifischen Risikogruppen in den Mitgliedstaaten gelegt werden, anstatt sie in Relation zur 
allgemeinen Bevölkerung zu setzten. Mitgliedstaaten mit verhältnismäßig kleinen Gruppen von 
Problemdrogenkonsumenten können dennoch eine hohe Prävalenz von drogenbedingtem 
Schäden aufweisen, wie etwa Infektionskrankheiten bei diesen Problemdrogenkonsumenten. 
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Obgleich die Zahl der Problemdrogenkonsumenten verglichen mit der allgemeinen Bevölkerung 
klein sein kann, kann die Prävalenz drogenbedingter Schäden beträchtlich sein. 
x Wissenschaftliche Evidenz von Wirksamkeit ist für viele Schadensbegrenzungsmaßnahmen 
vorhanden. Diese allgemeine Schlußfolgerung ist höchst vielversprechend, da Effektstudien in 
solchen Settings manchmal schwer durchzuführen sind. Die Umstände, unter denen 
Schadensbegrenzungsmaßnahmen eingeführt werden, nehmen kaum ein Kapitel in 
Untersuchungen mit unterschiedlichen Maßnahmenregulationen ein, nicht zuletzt aufgrund 
ethischer Gründe. Es ist wichtig, dass Innovationen in der Schadensbegrenzung auf 
Pragmatismus und den lokalen oder regionalen Konstruktionen von ‘best-practice’ beruhen 
dürfen. Nach einer Erprobungsphase ist es manchmal möglich, über hochwertige Effektstudien 
Nachweise für spezifische Maßnahmen zu erfassen. 
x Schließlich existiert auf EU-Niveau und bei den Mitgliedstaaten ein zunehmendes Bewußtsein 
der Notwendigkeit, Politik auf Forschung und Fakten zu begründen, einschließlich der 
Schadensbegrenzungspolitik. Diese Notwendigkeit wird durch die dritte Empfehlung des Rates, 
aber auch in der europäischen Drogenstrategie 2005-2012 und im EU-Drogenaktionsplan von 
2005-2008 reflektiert. 
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1. Introduction 
On the 18th of June 2003, the Council of the European Union adopted a Recommendation on the 
prevention and reduction on health-related harm associated with drug dependence19, hereafter 
referred to as ’The Council Recommendation’. With the adoption of the Council Recommendation, 
the Council of the European Union recognised the importance of developing responses and 
strategies to prevent and reduce drug-related harm. Since it is a Recommendation, it does not 
contain binding regulations for the EU Member States.  
The Council Recommendation consists of the following main recommendations: 
1. Member States should, in order to provide for a high level of health protection, set as a public 
health objective the prevention of drug dependence and the reduction of related risks, and 
develops and implements comprehensive strategies accordingly. 
2. Member States should, in order to reduce substantially the incidence of drug-related health 
damage (such as HIV, hepatitis B and C and tuberculosis) and the number of drug-related 
deaths, make available, as an integral part of their overall drug prevention and treatment 
policies, a range of different services and facilities, particularly aiming at risk reduction;  
3. Member States should consider, in order to develop appropriate evaluation to increase the 
effectiveness and efficiency of drug prevention and the reduction of drug-related health risks. 
4. Member States should report to the Commission on the implementation of this 
Recommendation within two years of its adoption and subsequently on request by the 
Commission with a view to contributing to the follow-up of this recommendation at Community 
level and acting as appropriate in the context of the European Union Action Plan on Drugs. 
Recommendations 1 and 3 have an emphasis on drug policy development and implementation, 
while Recommendation 2 represents the key-activities Member States were asked to develop and 
implement. Recommendation 2 and 3 include 13 and 9 sub recommendations. Recommendation 4 
concerns the inventory to which this report contributes and that is planned to be completed by the 
European Commission, such in line with planning of the EU Action Plan on Drugs 2005-2008. In 
annex 5 the full text of the Council Recommendation can be found.  
The Council Recommendation calls upon the Member States to report to the Commission on its 
implementation within two years after its adoption. Following an open call for tenders the 
Commission decided to enlist20 the services of the Trimbos Institute to collect and analyse the basic 
information for a Commission report in accordance with the EU Action Plan on Drugs 2005-2008. 
This analysis included the information submitted by the Member States to the Commission and to 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Furthermore, the 
Trimbos Institute was asked to include an overview of the latest scientific evidence on harm 
reduction and formulate advice for any follow-up of the Council Recommendation. These activities 
were planned in close collaboration with and by making use of technical support of the EMCDDA. 
This report presents the outcome of the preparatory work. In Chapter 2, a brief introduction is 
provided in the epidemiological state-of-affairs regarding drug-related infectious diseases and 
drug-related deaths in the European Union.  
In Chapter 3, the approach and methodology for the development of this report is presented.  
In Chapter 4, a summary of available scientific evidence regarding the effectiveness of harm 
reduction services and facilities in provided.  
Chapter 5 provides an overview of the state-of-play of policies and activities in the field of 
prevention and reduction of health-related harm association to drug dependence in the EU Member 
States, following the structure of the Council Recommendation.  
In Chapter 6 conclusions have been drafted based on the overview presented in this report.  
In Chapter 7 suggestions for future development have been formulated. The details on the 
situation in the Member States as well as more extensive information on evidence and special 
issues can be found in the Annexes to this report.  
In Annex 1, a review of the scientific literature regarding the effectiveness of interventions in the 
field of harm reduction is presented.  
In Annex 2, country-by-country reports on the state-of-play regarding the Council 
Recommendation for each of the 25 EU Member States can be found.  
19 2003/488/EC. 
20 General invitation to tender SANCO/C4/2004/01 (OJ 10/7/2004 – 2004/S 133-112486).
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In Annex 3 attention is paid to four ‘special’ issues that are often debated in the field of harm 
reduction (harm reduction in prisons, drug consumption rooms, pill testing and heroin 
prescription).  
Annex 4 includes a list of field organisations in the Member States that provided information to this 
report.
Annex 5 includes the full text of the Council Recommendation.  
Annex 6 contains a list of abbreviations.  
Finally, Annex 7 includes a glossary for the terminology that is used in this report.  
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2. Epidemiological situation 
The title of the Council Recommendation - prevention and reduction of health-related harm 
associated with drug dependence - suggests that it mainly covers harm reduction efforts that 
prevent drug dependence or reduce the risks associated with it. However, its sub-recommendations 
reflect a wider scope. In this report we have interpreted the content of the Council 
Recommendation in such a way that it reflects key harm reduction services and facilities related to 
problem drug use and acute health risks related to drug use. Given the health oriented focus of the 
Council Recommendation, other issues related to drug use, such as social related harms and cost-
effectiveness of harm reduction, are not covered by this report 
The EMCDDA has defined problem drug use operationally as ‘injecting drug use’ or ‘long duration/ 
regular use of opiates, cocaine and/ or amphetamines’.21. A large part of problem drug users, 
especially when opiates are concerned, is drug dependent22. Problem drug users have a high-risk 
to develop drug-related infectious diseases or suffer from drug overdose with a high risk of 
mortality. However, there are other forms of health-related harm associated with drug use, such as 
the consumption of ecstasy that is polluted with dangerous chemicals that induce acute health 
risks, such as atropine. And the term drug-related harm is also applicable if a first time injecting 
drug user shoots up an overdose of heroin s/ he is not dependent but the health-related harm may 
be considerable.  
2.1 Preventing and reducing drug-related harm  
Harm reduction aims to influence the mediating factors that increase the risk of drug-related health 
and social harm and mental disorders. These factors include risk behaviours, settings and 
circumstances that increase the existing risk of health- and social harms associated to drug use. 
Roughly, drug-related harms can be divided into two types as presented underneath. 
2.1.1 Drug-related Infectious Diseases 
The main drug-related infectious diseases that are associated with problem drug use are HIV/  
AIDS infections, infections with the hepatitis B virus, the hepatitis C virus and tuberculosis (TB). In 
the long-run, these diseases may be life-threatening. HIV/ AIDS suppress the immune system, 
with the result that the drug user becomes susceptible to a wide range of infections and other 
disorders. Hepatitis B and C are serious liver diseases that can result in liver cirrhosis and 
carcinoma. Tuberculosis is a contagious lung-disease, impairing the lung-functions and that – if 
remained undetected - may cause a community outbreak of the disease, even in vaccinated 
populations. Both short- and long term health effects of these drug-related infectious diseases are 
generating costs for society, especially if not treated in time. As they are transmissible to the 
general population (through family, friends, health care professionals, etc.) there is also serious 
concern for public health. Finally, these diseases are sometimes difficult to treat and cure is not 
always possible. Different strains of the hepatitis C virus exist which do not react equally to 
treatment. The progression of AIDS can be stopped, but the disease cannot be cured. So from a 
public health perspective it is important to place emphasis on the prevention of these drug-related 
infectious diseases. 
21 EMCDDA definition of problem drug use: “Injecting drug users” or “long duration/ regular use of opiates, 
cocaine and/ or amphetamines”, EMCDDA [1999]. Methodological guidelines to estimate the prevalence of 
problem drug use at national level. CT.99.RTX.05, Lisbon, Portugal. 
22 Drug dependence is often defined as (DSM-IV): a maladaptive pattern of substance use, leading to clinically 
significant impairment or distress, as manifested by three (or more) of the following, occurring at any time 
within a 12-month period. (1) Tolerance, as defined by either of the following: (a) need for markedly increased 
amounts of the substance to achieve intoxication or desired effect; (b) markedly diminished effect with 
continued use of the same amount of the substance. (2) Withdrawal, as manifested by either of the following: 
(a) the withdrawal characteristic for the substance (refers to Criteria A and B of the criteria sets for withdrawal 
from the specific substances; (b) the same (or closely related) substance is taken to relieve or avoid withdrawal 
symptoms; (3) the substance is often taken in larger amounts or over a longer period than was intended; (4)
there is a persistent desire or unsuccessful effort to cut down or control substance use; (5) a great deal of time 
is spent in activities necessary to obtain the substance (e.g. visiting multiple doctors or driving long distances), 
use of the substance (e.g. chain-smoking), or recovering from its effects; (6) Important social, occupational or 
recreational activities are given up or reduced because of substance use; (7) the substance use is continued 
despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have 
been caused or exacerbated by the substance (e.g. current cocaine use despite recognition of cocaine-induced 
depression, or continued drinking despite recognition that an ulcer was made worse by alcohol consumption). 
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2.1.2 Drug-related Deaths  
Drug use may also cause death. Drug-related death23 is defined in this report as: death caused 
directly by the consumption24 of one or more drug(s) and which generally occurs shortly after the 
consumption of the substance(s). These deaths are known as ‘fatal overdoses’, ‘poisonings’ or 
direct drug-induced deaths. In the EU the exact definition of drug-related death has been debated 
a lot, as Member States tend to have different registration criteria. However, the development and 
implementation of a drug-related death standard by the EMCDDA, which defines the definition for 
direct drug-related death, has improved standardised data-collection at EU level25. Apart from 
direct drug-related deaths, there are also indirect drug-related deaths.  
2.1.3 Special ‘at risk’ groups 
With regard to these two major types of drug-related harm special attention should also be paid to 
specific ‘at risk’ groups. These groups include first-time users (who may e.g. inject drugs 
incorrectly and/ or are unaware of lethal doses) but also drug users in prison. In the literature 
review (annex 1) attention is paid to harm reduction in prisons. Furthermore, also in Chapter 5, a 
special section has been included on harm reduction in prisons. 
2.2 Magnitude of the problem 
In the majority of EU countries, heroin has historically accounted for most problem drug use in the 
EU countries, with the exception of Finland and Sweden (amphetamine) and the Czech Republic 
(methamphetamine)26.
Table 2.1 presents the estimated prevalence of 
problem drug use among the European population. 
It is estimated that on average there are 4-7 
problem drug users per 1000 inhabitants aged 15-
64 years. This results in estimation that there are 
1.2-2.1 million problem drug users in the EU. 
850.000 to 1.3 million of these persons are 
injecting drug users (IDUs). In countries such as 
the Netherlands, Portugal and Spain, the number 
of IDUs among the problem drug user population 
is relatively low, in other EU countries this type of 
use is the norm27.
2.2.1 Prevalence of drug-related infectious diseases 
The seroprevalence of HIV in IDUs varies per country, with the highest national estimates found in 
Italy, Latvia and Portugal (>10% [2002/ 2003])28. There are also big variations within countries, 
even at a local level. The prevalence of antibodies against hepatitis C is in general very high among 
injecting drug users in the EU. Local prevalence rates of over 60% [2002/ 2003] are reported from 
Belgium, Estonia, Greece, Italy, Poland, Portugal and Norway. There are indications that the 
prevalence rate of hepatitis C among tested IDU in the EU seems to decline somewhat29, but the 
conclusion can not be drawn that the problem is decreasing. Prevalence rates may vary a lot from 
location to location (see figure 2a). Hepatitis B prevalence also varies within and between 
countries30. IDU samples with prevalence rates of over 60% [2002/ 2003] were reported from 
Belgium, Estonia and Italy. It must be noted that the collection of data on drug-related infectious 
diseases is a point of attention in Member States. Prevalence data are usually based on many 
different and varying data sources that use different estimation and/ or measurement techniques. 
As a consequence these data are not always easy to compare.  
23 EMCDDA [2006]. Annual Report 2005, p. 69. 
24 Inhaling, injecting, smoking, eating, etc.. 
25 EMCDDA [2002]. The DRD-Standard, version 3.0; EMCDDA standard protocol for the EU Member States to 
collect data and report figures for the Key Indicator Drug-Related Deaths by the Standard Reitox tables; 
EMCDDA project CT.02.P1.05. Lisbon, Portugal.  
26 EMCDDA [2006]. Annual Report 2005, p. 60-61.  
27 EMCDDA [2006]. Annual Report 2005, p. 60-61. 
28 EMCDDA [2006]. Annual Report 2005, p. 65. 
29 EMCDDA [2006]. Preliminary outlook Annual Report 2006. 
30 EMCDDA [2006]. Annual Report 2005, p. 66. 
Table 2.1 – Estimated cases of problem drug 
use per 1000 inhabitants (Source: EMCDDA, 
2006)
Cases per 1000 inhabitants (aged 15-64 years) 
< 4 Germany, the Netherlands, 
Poland
4 to 7 Belgium, Cyprus, Czech 
Republic, Estonia, Greece, 
Finland, France, Hungary, 
Lithuania, Latvia, Malta, Sweden, 
Slovakia, Slovenia 
6 to 10 Denmark, Spain, Ireland, Italy, 
Luxembourg, Austria, Portugal, 
UK
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2.2.2 Number of drug-related deaths 
Member States in the EU have reported that on average 7.000-9.000 deaths related to overdose 
occurred per year in the period of 1990-2002. These data reflect acute drug-related deaths. 
Indirect drug-related deaths are not included in these numbers31.
Figure 2a: HCV prevalence in samples of tested IDUs in the EU  
NB: Data from all countries and all studies available. Small bar indicates the median, large bar the average value (not weighted
for sample size, to avoid very large samples from some geographic regions to dominate). This analysis does not take account of 
changes in data availability over time from different geographic areas or different settings or measurement methods (diagnostic
testing or seroprevalence studies), nor of the fact that some data points are single measurements (mostly prior to 1996) and 
many are part of time series (after 1996). Thus it cannot be concluded that the apparent decline is real. However it shows that
over time the number of samples available strongly increases and that in those samples average and median prevalence 
decreased, either through selection bias or a real decrease or both.  
Source: EMCDDA, Annual Report 2006.  
2.2.3 Special groups: drug users in prison 
Imprisonment often causes a disruption of care for drug dependent users. Studies conducted in the 
EU32 show that about one third of adult male prisoners were drug injectors at the time of entry to 
the prison system. These outcomes seem to be substantiated by National Focal Point (NFP) data 
that show that between 0.2% and 34% of inmates have injected drugs while in prison33. Due to the 
lack of preventative measures, infectious diseases may spread among inmates and outside prison 
(after release). Organisations like UNAIDS34 are concerned about the lack of harm reduction 
measures inside prisons and reiterate that there is an estimated turn-over of 30 million prisoners 
to and from penitentiaries worldwide every year. In the EU it is estimated that 50-100 per 100.000 
inhabitants are imprisoned in a year (app. 250-450.000 prisoners)35. This entails that society 
(families, communities) outside prison is at risk if preventative measures remain unavailable.
2.3 Conclusion
Drug use can cause serious health-related and social harms in drug users and the general 
population as a whole. The numbers of drug-related infectious diseases and drug-related deaths in 
the European Union are substantial. Investing in improved monitoring systems, prevention and 
reduction of these health-related harm makes sense from a public health perspective. The situation 
regarding problem drug use is different from country to country. Harm reduction measures require 
a tailor made approach for local situations, as the patterns of drug use, the harms associated with 
it and therefore the need for interventions differs accordingly.  
31 Indirect drug-related deaths may include: long-term illness due to a drug-related infectious disease, traffic 
accidents (under the influence of substances), deaths due to bad living circumstances of drug dependent users 
(e.g. among the homeless). 
32 Bird and Rotily, 2002; in: EMCDDA, Annual Report 2005, p. 81. 
33 EMCDDA [2006]. Annual Report 2005, p. 81. 
34 UNAIDS [2006]. Report on the Global Aids Epidemic, p. 118-122. 
35 WHO/ Pompidou group [2005]. Status Paper on Prisons, Drugs and Harm Reduction, p. 6. 
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3 Methodology, approach and justification 
3.1 Introduction 
This study provides a baseline overview on existing policies, services and facilities that exist in the 
field of harm reduction within the EU Member States. It also includes a summary of available 
scientific evidence on the effectiveness of harm reduction interventions. The Council 
Recommendation calls for a report on its implementation by the Member States by June 2005. This 
entails that the reporting period on the implementation of the Council Recommendation covers a 
period of 1.5 to 2 years at maximum. This period is short to measure the influence of the Council 
Recommendation on national harm reduction policies. It does provide a baseline overview of harm 
reduction policies, services and facilities in the Member States. 
In order to provide a good overview of the actual state-of-play regarding the field of harm 
reduction, this preparatory work includes an inventory of the existing policies, services and 
facilities in the field harm reduction in all 25 EU Member States.  
3.2 Tasks performed in development of this report 
In preparation to the development of this report, the following activities have been carried out: 
1. An overview has been established regarding the question on how the Council 
Recommendation has been implemented in the EU Member States since 18 June 2003 and 
what policies and services and facilities covered by the Council Recommendations exist 
within the Member States. This overview was created by: 
a. The development of a reporting tool. The European Commission disseminated the 
reporting tool to the Permanent Representatives of the Member States and also 
distributed it to the Council Health Working Group and the Horizontal Working Party on 
Drugs, inviting them to provide details on the implementation of the Council 
Recommendation following the request from the European Commission. 
b. Data referring to the thematic fields in the Council Recommendation was extracted and 
analysed, primarily from data sources available at the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), and from other sources including the WHO, 
Pompidou Group, UNAIDS and field organisations36 in the Member States.  
c. The information on harm reduction services and facilities at the level of the EU Member 
States was subsequently sent back to the Reitox National Focal Points with the request 
to correct possible mistakes or misunderstandings, to add missing information and/ or 
to provide an update on new events. The information that was returned by the Focal 
Points was processed and returned a second time for final approval. 
2. A literature review has been conducted to identify, appraise and summarise scientific 
evidence on harm reduction interventions and approaches, including those aimed at 
preventing drug-related infectious diseases and drug-related deaths.  
3. On the basis of the collected data and the identified scientific evidence, conclusions and 
suggestions have been formulated that aim to contribute to the future development and 
implementation of harm reduction policies, services and facilities within the European 
Union.  
In contrast to the expectations at the beginning of the project, the level of data and information 
that was available on the three recommendations was both of good quality and abundant. In a few 
cases only, information was not available because national respondents indicated that interventions 
or policies did not exist.  
3.3 Data collected for this report 
Throughout the process of producing this report a wide range of data sources have been consulted 
with the aim to obtain a comprehensive picture on the state-of-play in harm reduction in the EU 
Member States as well as on the available evidence from scientific literature. Table 3.1 provides a 
short overview of the most important data sources used.  
36 These organisations include service providers such as Mainline (NL), A-Clinic Foundation (FI), Abraçao (PT), 
Stigma (SI), but also drug user organisations such as Brugerforeningen (DK) (See Annex 3). 
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3.3.1 Reporting tool to the Member States (abbreviated as [RT]) 
The reporting tool was developed by the Trimbos Institute based on a design provided by the 
European Commission. The reporting tool was disseminated by the European Commission to the PR 
of the Member States and also distributed to the Council Health Working Group and the Horizontal 
Working Party on Drugs. By the end of 2005, 24 Member States had replied.  
The reporting tool consistently asked two questions for each of the (sub-) recommendations of the 
Council Recommendation: “Does this policy exist in your country (reflecting the recommendation 
[Ed.])”; and “Was this policy based on the Council Recommendation?” Member States had the 
opportunity to add comments on each (sub-) recommendation. As Annex 2 shows, Member States 
made use of this opportunity and included comments. The last completed questionnaire was 
received in February 2006.  
3.3.2 National Reports to the EMCDDA (abbreviated as: [NR (year)]) 
Annually, the Reitox National Focal Points submit a National Report to the EMCDDA, reflecting on 
the state of affairs regarding drugs in their country. The information in these reports is presented 
in a comparable format, with a great number of predefined topics that also include measures in the 
field of harm reduction. All National Reports that have been submitted to the EMCDDA for the years 
2002-2004 have been screened for information on policies and services and facilities regarding the 
prevention and reduction of health-related harm associated with drug dependence37.
3.3.3 Other EMCDDA data sources 
Overall, it can be said that the EMCDDA data sources regarding drug demand reduction in general 
and harm reduction in particular are very extensive and among the most comprehensive in the 
world. The efforts that have been undertaken in the past 5-10 years to harmonise and improve the 
quality of data collections in the Member States seem to have paid off.  
The EMCDDA annually collects information from the EU Member States through a series of 
Standard Tables which are used for its Annual Report. In addition, the EMCDDA also gathers data 
through Structured Questionnaires that are used to gather in-depth information on specific themes.  
After the adoption of the 2003 Council Recommendation, the EMCDDA has developed special 
reporting tools to collect data and information on Member States’ policies, services and facilities in 
the field of harm reduction. Two structured questionnaires (23 and 29) were designed to collect 
information on the key topics reflected in the Council Recommendation. In 2004 Structured 
Questionnaire 23 on Drug-related Infectious Diseases was sent out to the EU Member States. This 
questionnaire incorporated a number of questions that matched directly with themes in the 2nd
recommendation of the Council Recommendation. In 2005 Structured Questionnaire 29 on Drug-
related Deaths was sent out to the Member States, containing in-depth questions on this theme 
and covering elements of the 2nd and 3rd recommendation of the Council Recommendation. All 
Member States returned the two questionnaires38. The data of these two questionnaires was made 
available for this project. Regarding the 3rd recommendation of the Council Recommendation, in 
the 2002 issue of the National Reports to the EMCDDA special attention was paid to evaluation and 
quality issues, be it not specifically focused on harm reduction.  
Apart from the very rich information collected by analysing the National Reports to the EMCDDA 
and the two structured questionnaires mentioned above, additional information was found in 
Standard Table 10 (part of standard report format) and in the European Legal Database on Drugs 
(ELDD). In 2005, the information available through the Exchange on Drug Demand Reduction 
Action (EDDRA) database was analysed. EDDRA contains hundreds of projects in the field of drug 
demand reduction. Analysis of the available information showed that the database contained a 
limited number of projects in the field of harm reduction, but that the nature and relevance, 
reliability and comprehensiveness of the information was not suitable for the purpose of this 
inventory report. EMCDDA is discussing a re-engineering of the EDDRA projects database.  
In addition to these ‘raw’ data sources, other EMCDDA information sources were consulted, 
including the EMCDDA Annual Reports on the State of Drug Affairs in the EU, the Policy Briefings 
“Drugs in Focus”, the EMCDDA Monographs39 and Insights40 publications. 
37 National Reports were available for the years 2002-2003-2004 from all 25 EU Member States, with the 
exception of the following: Cyprus (only 2004 available), Latvia (2003, 2004), Lithuania (2003, 2004), Malta 
(2004), Poland (2003, 2004) and Slovakia (2004). 
38 Cyprus and Slovakia did not answer (all) the questions in Structured Questionnaire 29.
39 E.g. Monograph nr. 4, “Understanding and responding to drug use: the role of qualitative research”. 
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Table 3.1 – Overview of data sources used  
Council
Recommendation 
Data source EMCDDA  Other 
Recommendation #1 x National Reports to the EMCDDA 
2004
x Structured Questionnaire 23 
(2004) 
x Structured Questionnaire 29 
(2005) 
x European Legal Database on 
Drugs 
x Reporting tool to Member States (2005) 
x Consultation of national drug strategies/  
action plans 
Recommendation #2 x National Reports to the EMCDDA 
2002-2004 
x Structured Questionnaire 23 
(2004) 
x Structured Questionnaire 29 
(2005) 
x Standard Table 10 
x European Legal Database on 
Drugs 
x EDDRA
x Reporting tool to Member States (2005) 
x Feedback from National Focal Points 
(2006) 
x Questionnaire to field organisations 
(2006) 
x Document analysis 
x DG SANCO projects website/  CORDIS 
x CEEHRN/  IHRA database & website 
Recommendation #3 x National Reports to the EMCDDA 
2002-2004 (emphasis on 2002) 
x Structured Questionnaire 29 
(2005) 
x Reporting tool to Member States (2005) 
x Follow-up questions to policy makers 
and/ or consultation of national drug 
strategies/  action plans 
Literature review Primary sources: databases & 
literature searched 
Secondary sources 
Drug-related 
Infectious Diseases; 
Drug-related Deaths; 
Other harm reduction 
interventions (e.g. 
Prisons, Pill Testing) 
x Medline (PubMed) 
x Embase 
x PsycInfo 
x Toxline
x Peer-reviewed journals 
x UNAIDS 
x WHO, incl. Health Evidence Network 
(HEN) 
x Policy briefings (EMCDDA) & 
unpublished (overview) reports  
x Cross references in existing literature 
x Harm reduction guideline documents 
x Suggestions from experts 
3.3.4 Other sources of information 
Between November 2005 and May 2006, information sources, reports and databases other than 
available at the EMCDDA were identified and analysed41. This search did not result in an abundance 
of suitable information for this report. There are project- and research publications available on 
(specific) harm reduction interventions42. But these publications generally did not provide the scope 
and overview that was required vis-à-vis the recommendations in the Council Recommendation.  
The DG SANCO website contains references to projects funded by the ‘Programme of Community 
Action on the Prevention of Drug Dependence43’ (1996-2002) and the ‘Programme on Community 
Action in the field of Public Health' (2003-2008)44. Many of the recent DG SANCO funded projects 
dealing with drug prevention and risk reduction are also registered in the EDDRA database of the 
EMCDDA. These projects did not provide systematically collected information on the state-of-play 
in the Member States. They were not research projects and as such did not provide scientific 
evidence on harm reduction interventions. The Commission’s CORDIS45 website contains references 
to R&D projects funded under the European 4th, 5th and 6th Framework Programmes for Research 
and Technological Development. Although these Framework programmes fund many R&D projects 
in the EU, the thematic field of (illicit) drugs and addiction includes less than a dozen projects, 
40 E.g. Insights nr. 2-3-4 on resp. Outreach Work (2), Drug Substitution Treatment (3) and Injecting Drug Use, 
Risk Behaviour and Qualitative Research (3). 
41 Other sources included the DG SANCO projects’ website, the WHO HEN database, the IHRA literature 
database, reports and publications of UNAIDS, CEEHRN and individual study reports.  
42 E.g. Engelhardt, J. [2006]. ‘Living with the Daily Dose – Comparing National policies and practices to improve 
access and adherence of HIV-infected drug users to Anti-retroviral treatment. Mainline, The Netherlands; 
Stöver, H. , L. Hennebel, J. Casselman [2004]. ‘Substitution Treatment in European prisons: a study of policies 
and practices of substitution treatment in prisons in 18 European Countries’. ENDHASP, UK.  
43 The programme of Community action on the prevention of drug dependence within the framework for action 
in the field of public health, adopted by decision N° 102/97/EC of 16/12/96 of the European Parliament and of 
the Council, OJ L 19, 22.1.1997, p. 25, was extended by DECISION No 521/2001/EC of the European 
Parliament and of the Council of 26 February 2001 (cf. Decision extending certain programmes of Community 
action in the field of public health - Official Journal L 79, 17.03.2001). 
44 Adopted by Decision No. 1786/2002/EC of the European Parliament and of the Council of 23 September 
2002; OJ L 271, 09/12/2002, p. 1-12. 
45 CORDIS – Community Research & Development Information Service (http://cordis.europa.eu).
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mainly concerning fundamental research (genomic studies on i.e. addiction & brain disease and on 
immunology & viral disorders induced by injecting drug use). Two projects were found that directly 
focus on harm reduction related areas46. Where relevant, the outcomes of these studies have been 
included in the literature review. Other information providers like the WHO have developed 
information resources such as the Health Evidence Network (HEN), the contents of which is largely 
based upon scientific literature available through the primary scientific databases (see table 2.1) 
that were searched for the literature review in this report. Where specific country information was 
provided, this information did not add to the in-depth information covered by the National Reports 
of the Reitox National Focal Points or the information itself originated from EMCDDA data sources.
Some interesting studies were found. One of these studies concerns the Casselman, Hennebel & 
Stöver report on substitution treatment in prisons, which provides an overview regarding the prison 
situation in eighteen countries (14 EU Member States (<2004), Poland, Czech Republic, Slovenia 
and Scotland)47.
3.3.5 Field organisations 
In order to obtain additional perspectives to the EMCDDA data sources, a limited query was set out 
among field organisations and national harm reduction networks (see Annex 4 for list of 
organisations). These stakeholders have a leading position in the field of harm reduction in their 
country and were selected by consultation of network partners of Trimbos Institute and Mainline 
(i.e. Rezolat). Following this consultation, a final list of organisations and experts was drafted 
through a ‘snowball’ process. Ultimately, information was received back from sixteen organisations 
in the Member States. Not for all Member States a leading harm reduction organisation could be 
identified. The field organisations did not receive any (country specific) information gathered 
throughout the project, but were sent a standardised query with questions on their assessment of 
the main services and facilities in the field of harm reduction in their country. The information 
gathered through this query has been included in the country reports. It provides additional 
information to the country reports, but is not suitable for comparison at European level. The 
information has a special focus on coverage and accessibility of harm reduction interventions. 
3.4 Remarks on the information gathered for this report 
The main sources of information used in this report concern self-reported data from the EU Member 
States. The reliability and accuracy of this data provided by national correspondents at policy level 
and by Focal Points has not been assessed as the assignment of this report was not to evaluate
harm reduction policy and practice in the EU Member States but to make an inventory what policies 
and services and facilities exist and to what extent these have been inspired by the Council 
Recommendation.  
The self-reported data Member States present in their National Reports and in the questionnaires 
and standard tables to the EMCDDA are collected according to agreed definitions and data 
collection methods. Regarding prevalence data, this mainly concerns estimations. National 
estimates on problem drug use are produced by making use of the agreed definition on problem 
use48. In recent years, the EMCDDA and the Reitox National Focal Points have invested in 
improving and standardising the methodology on national estimates. Estimation methods are based 
on applying multipliers from police data, treatment data, mortality rates or HIV/ AIDS data, 
capture-recapture and a multi-variant indicator regression, which uses various data sources in 
combination with local level prevalence estimates. By 2005, many of these estimates were based 
upon results from more than one estimation method.  
In a limited number of cases a small discrepancy may be found between the answers and 
information provided by the policy makers on the one hand and the National Focal Point on the 
other. In those cases both opinions are included in the country report. Explanations regarding 
these minor differences may be found in possible time lags between the production of a National 
Report and the reporting date of national policymakers. Furthermore, it may be that policies have 
been adopted in strategies and action plans already and therefore ‘exist’, but that in practice 
implementation has not yet been taken at hand. And finally, it may be well so that not every 
respondent had an up-to-date overview of what is going on in the field of harm reduction in their 
46 The two projects found are: COCINEU (project ref. QLG4-CT-2001-02301 - ZIS/ Germany), titled ‘Support 
needs for cocaine and crack users” and ROSE-EU (QLG4-CT-202-01681 - ZIS/ Germany), titled ‘Management of 
high risk opiate addicts in Europe – risk opiate addicts study – Europe”. (Source: CORDIS website).  
47 Stöver, H. , L. Hennebel, J. Casselman [2004]. ‘Substitution Treatment in European prisons: a study of 
policies and practices of substitution treatment in prisons in 18 European Countries’. ENDHASP, UK.  
48 EMCDDA definition on problem drug use: “Injecting drug use or long duration / regular use of opiates, 
cocaine and amphetamines”. 
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country, especially when data collections and reporting structures (for policy) still need 
development. The Reitox National Focal Points offered their assistance to the project twice by 
verifying and confirming data and information they had reported regarding the harm reduction 
services and facilities in their country that took place in the period of 2002 to 200549.
Furthermore, in order to prevent ‘overkill’ in asking details and information from the Member 
States, it was decided that ample use was to be made of existing data sources rather than to send 
extensive questionnaires to the Member States with the risk of duplicating work. In order to 
provide a manageable overview of the state-of-play in the Member States, the detail of information 
focused on the thematic areas introduced by the Council Recommendation itself.  
3.5 Methodology used for the literature review 
An abundance of information, practices and approaches is available in the field of prevention and 
reduction of health-related harm associated with drug dependence. Assessing the value and quality 
of all this information is an enormous task, not only because of time limits but also because the 
considerable variation in the scientific quality of the available studies. Actually there is a lack of 
consensus of what methods are most appropriate in this broad study domain, which also includes 
public health, health promotion, and health education.  
In selecting the literature first emphasis was placed on studies targeting prevention and reduction 
of drug-related infectious diseases, drug-related deaths and on maintenance treatment. We 
additionally report evidence for effectiveness of several interventions (medical heroin prescription, 
pill-testing programmes, pre-release counselling, and drug consumption rooms, and in-prison 
interventions. 
The literature was selected according to the following criteria: 
- Primarily evidence for effectiveness from meta-analyses, systematic reviews and 
randomised controlled trials; 
- Predominantly studies published in the English language (high-quality studies are 
usually published in scientific journals in the English language but many selected 
studies also included publications in other languages); 
- Only interventions that concern selective and/  or indicative prevention/  brief 
treatment for at-risk groups and special settings (universal prevention – meant for the 
general population - was not selected); 
- Research published since 1990. When no or limited (high-quality) evidence was 
available, literature was also included from before 1990 (high-quality evidence on harm 
reduction interventions became available predominantly in the past one-and-a-half 
decade and in many harm reduction interventions only during the past years).  
The search started with a predefined search strategy but was also sensitive to other sources and 
suggestions of the EMCDDA and other experts. Finally, references were checked in selected 
publications on their relevance for this review (when these were not included in already selected 
and evaluated reviews).  
The availability of evidence regarding the effectiveness of harm reduction interventions is in many 
cases rather limited, because most harm reduction interventions are based on trial-and-error in 
practical circumstances, largely excluding controlled research. In many countries harm reduction 
interventions have initially been developed bottom-up and under largely illegal circumstances due 
to policy restrictions. These circumstances also restrict possibilities for controlled effect studies. 
Meta-analyses and systematic review studies were in some cases available (e.g. for maintenance 
treatment) and in other interventions rarely published or not at all (e.g. overdose treatment). In 
these instances, studies with a less optimal design for determining cause-effect relationships were 
used and this was mentioned explicitly. 
It should be borne in mind that interventions that have not yet been studied enough may show 
positive results in practice. When no evidence is available for a specific intervention, this does not 
necessarily mean that the intervention is not effective. It is simply not possible to draw firm 
conclusions yet. In annex 1 further detail is provided on the appraisal of the literature and on the 
assessment of the strength of available evidence. 
Finally there is a multitude of guideline publications and models of good practice. These are often 
very diverse and difficult to summarise in a scientifically sound way. Therefore, in this study, 
49 The Swedish Reitox National Focal Point indicated it did not consider checking the country report as its task. 
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predominantly important parts of general guidelines published by well-known organisations have 
been included (e.g. from the US National Institute on Drug Abuse (NIDA), the World Health 
Organisation, and some other institutions). We refer to appendix 1 of annex 1 (the literature 
review) for a more detailed explanation of this choice.  
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4 Effectiveness of interventions – A summary 
In this chapter a summary is presented on the effectiveness50 of harm reduction interventions. 
These interventions have the following order: prevention and treatment of drug-related infectious 
diseases, prevention of drug-related deaths, other harm reduction interventions and harm 
reduction in prison settings. This summary is based on the literature review that is included in 
Annex 1 to this report. Due to several reasons, it is often difficult and sometimes impossible to 
study the effectiveness of harm reduction interventions in scientific experiments. The consequence 
is that the evidence for effectiveness of most of these interventions remains unclear. This does not 
mean that the interventions are ineffective. We simply do not know yet. In daily practice 
interventions that may be effective should be further tried out. Further research is needed in order 
to enlarge the evidence-base for these interventions. 
4.1 Summary of available evidence 
Studies show that needle and syringe exchange programmes are easily applicable, safe, and they 
are probably effective and possibly also cost-effective in reducing risk behaviours and the 
transmission of infectious diseases. HIV-testing and counselling may also reduce transmission of 
drug-related infectious diseases and it remains undecided yet which of these interventions is most 
effective.
It is uncertain whether merely the delivery of relevant information, education and communication
(IEC) is effective to prevent drug-related infectious diseases among injecting drug users. 
Effectiveness of other harm reduction interventions may be enhanced by IEC. It is therefore 
recommended to combine IEC for instance with distribution of sterile needles and syringes and a 
range of other means to reduce drug-related infectious diseases, e.g. condom distribution, bleach, 
access to HIV-testing and HIV-counselling programmes (distributing information on programme 
locations and opening hours) and on injecting equipment. IEC should further be designed for 
specific drug users instead of for several drug using groups. In general, mass media campaigns are 
a universal prevention method that is expensive but largely ineffective as a harm reduction 
strategy. Techniques for enhancing motivation of drug users are prerequisites and effective, thus 
these should be part of intervention packages.  
Community outreach programmes aim to create access to these hidden populations in their daily 
environment for targeted action against high-risk behaviours. Possible action components are: 
identifying and accessing injecting drug users, identifying and recruiting peer leaders, increasing 
risk awareness among drug users, demonstrating skills to avoid or reduce risks, distributing 
injecting equipment, behavioural counselling, or providing referral to treatment. Drug users 
participating in community outreach are in general less inclined to expose themselves to risk 
behaviours (e.g. needle sharing), reduce drug use. There are indications that community outreach 
programmes improve treatment compliance. Because outreach work is inexpensive, its 
interventions may in most cases also be cost-effective.
Current treatments for HIV/ AIDS, hepatitis B and C and tuberculosis and on the other hand 
preventive vaccination for hepatitis B are all effective in reducing drug-related infectious diseases. 
Because these treatments usually take a long time and may have unpleasant side effects, 
adherence to treatment by drug users should be actively stimulated. Such treatments or therapies 
50 Different levels of evidence are commonly discerned in the review literature. These distinctions in grading 
evidence are largely arbitrary. Important however is to describe explicitly how the evidence has been appraised 
and graded. Here, a rough grading procedure was used, i.e. without systematically specifying quantity and 
quality of the studies. When a systematic review or a meta-analysis of at least three RCTs was available with 
clear cut outcomes or three separately published RCTs with outcomes that were alike and significant, we 
considered the evidence sufficient and the interventions effective. Two RCTs or one RCT plus at least two lesser 
quality studies (e.g. well-done time-series or prospective cohort studies) were considered to give indications for 
effectiveness (interventions are probably effective). In case of doubt, i.e. if only one RCT - or one or two 
studies of lesser quality - with positive findings were found, phrases like ‘may be effective” or “possibly 
effective” are used. This means that there are still doubts about the effectiveness of these interventions. In 
case of absence of studies or studies with other designs than the ones described above, we simply do not know 
enough yet. An intervention is considered ineffective when sufficient evidence is collected on its ineffectiveness. 
However, there are no harm reduction interventions found that have this judgment. An example of an 
ineffective intervention in the treatment literature is acupuncture treatment for cocaine dependence (Rigter et 
al., 2004).  
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should therefore be supported by health professionals, community volunteers or an involved family 
member.
Heroin overdose death is most prominent among direct drug-related deaths, although overdose 
death may also be caused by methadone or other substances. Street injecting, poly drug use, 
differences in drug purity and relapse after treatment or prison, increase the chance of taking an 
overdose.
Reducing drug-related deaths may be one of the targets of substitution or maintenance 
programmes. These programmes are probably reducing mortality among dependent drug users. 
The strongest evidence for effective prevention of overdose death is for the antidote naloxone. 
However, this short-acting opioid ‘antagonist’ does not prevent overdose itself. Instead it can only 
be effective if well-trained emergency staff, peers or relatives are available. To administer this 
medication, the enhancement of education and behaviour skills for ambulance personnel, police 
officers, family members or peers could further increase success rates.  
Maintenance or substitution treatment (methadone and buprenorphine) is probably effective in 
reaching other targets and in daily situations. It improves patient compliance, and reduces opiate 
use and risk behaviour. These programmes are also effective in increasing treatment retention 
(staying in treatment) and they improve or at least stabilise daily life situations for chronic heroin 
users. Effectiveness on these outcomes tends to increase with individually adjusted dosages of 
these substances and also when psychosocial interventions are added to maintenance 
programmes. 
Medical heroin (co)prescription for heroin dependent drug users has little adverse effects. It 
probably reduces public nuisance. It probably also improves the health situation of drug users who 
do not respond to maintenance treatment and retention to treatment rates may be higher. In 
countries with comprehensive treatment systems (including easily accessible maintenance 
treatment) heroin prescription may be a valuable additive option for these groups. However, heroin 
prescription is not considered as a treatment of first choice and there is consensus that it should 
not be implemented instead of, or on the expense of methadone maintenance treatment. Six new 
effect studies on heroin prescription are underway.
Due to a lack of high-quality studies, there remain considerable doubts about the effects of both 
pill testing programmes and drug consumption rooms. Some studies indicate that pill testing may 
decrease the use of potentially dangerous drugs. Pill testing programmes have several 
disadvantages. Firstly, pill testing methods are not standardised. Secondly, simple tests like colour 
tests give limited information about the content of synthetic drugs. This necessitates full laboratory 
analysis. Thirdly, pill testing is only one factor influencing drug use in recreational settings and 
probably not the most important one. Pill testing is not expected to diminish drug use. On the other 
hand, pill testing probably does not stimulate non-users to start with drug use, either. An 
advantage of well organised pill testing facilities is that these allow for the monitoring of trends in 
the composition of synthetic drugs. Finally, these interventions are prerequisites for early warning 
systems.
Drug consumption rooms may reduce needle sharing among injecting drug users, and may reduce 
drug-related death. However, we need more studies to draw more firm conclusions. 
Prison-based maintenance treatment appears to be feasible and if adequate doses are distributed 
during imprisonment, it reduces injecting drug use, needle sharing, and transmissions of drug-
related infectious diseases.  
The utility of pre-release counselling may be equal to information, education and communication 
(IEC). It is recommended that pre-release counselling is part of other interventions e.g. after care 
provisions in order to prevent relapse or even overdose death after release.  
Needle (and syringe) exchange programmes in prison are probably effective in reducing needle 
sharing among injecting drug users, and the transmission of drug-related infectious diseases. HIV
testing and counselling, may also reduce needle sharing and concomitant infections. Both 
experience and scientific evidence show that prison needle exchange programmes have a positive 
effect on safety in prison, both for staff and prisoners.  
There is no evidence of any major, unintended consequences of condom distribution for safety and 
security in prisons. Measures to combat aggressive sexual behaviours in prison remain important.  
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Counselling (information, education) should be part of the introduction of prison-based harm 
reduction interventions. The literature suggests that effectiveness of information and education 
possibly increases when these interventions are part of intervention packages. Evidence is 
currently lacking for disinfection and decontamination schemes, and strategies to reduce tattooing.
4.2 Some general suggestions from guideline publications 
The success of prevention and treatment of infectious diseases among drug users assumes that 
these drug users are reached and motivated to participate in the interventions. Guideline 
publications stress the importance of tackling the consequences of a fairly strong association 
between drug use, mental illness and bad physical conditions. Since social stigmatisation of drug 
users remains prominent, both in society in general and in medical care, granting access to medical 
and psychiatric treatment for drug users remains an important challenge for public health policy. 
From a common sense perspective, success rates of harm reduction programmes for drug users 
increase with high accessibility, free-of-charge services, and low threshold provision of services. It 
has been recommended that these programmes should be part of the general health care system, 
offering optimal care possibilities per location. Programmes should also be as intensive as is 
acceptable for individual patients (not driving them away). Possible interactions of different 
treatment drugs (e.g. maintenance treatment drugs, antidepressants or antiretroviral drugs) have 
to be carefully monitored so that individual dosages can be adjusted appropriately.  
A reduction of overdose death is facilitated by skill training of medical staff or ambulance 
personnel, peers or relatives who may be present in case of an overdose. Further important 
messages for prevention of overdose death are: avoid poly-drug use, inform drug users about 
differences in purity of drugs and when they are released from penitentiary institutions. Finally it 
has been recommended that naloxone should be easily accessible for family and peers because the 
majority of overdose occurs in the home of a victim or that of another user. 
The effectiveness of drug consumption rooms is largely dependent on their coverage among the 
drug using population, i.e. they should be located in those places where drug users are 
concentrated. Coverage can be enlarged by support from the local authorities, including the police, 
easy accessibility (low threshold), and some control measures (e.g. identity cards) in order to 
avoid undesirable behaviour.  
Starting maintenance treatment with low doses is recommended for prevention of methadone 
deaths. Each patient should be assessed at least several times annually by an experienced 
clinician. Effective control procedures and supervised administration of maintenance medication can 
prevent the risk of diversion or illicit use of maintenance substances. Random urine testing may be 
indicated for evaluating programme effectiveness. Screening for mental illness (co-morbidity) is 
recommended. Given the scale of problems, it is also recommended to make maintenance 
treatment part of community-based health systems, in order to enable continuity and quality of 
maintenance programmes and to enable counselling and testing for drug-related infectious 
diseases.  
When prison-based maintenance programmes are well implemented, they have additional effects 
for the health situation of participating prisoners, for the prison system and ultimately also for 
society. Alternative programmes or treatment options as a substitute for prison for drug users are 
probably more cost-effective than imprisonment itself. These programmes may cover a range of 
interventions aiming to avoid, replace, delay or complement prison sentences for drug users. Drug-
free units in prisons should also be offered for prisoners who are not using drugs or who do not 
want to. Finally, prison-based harm reduction activities should best be adapted to meet the needs 
of both staff and prisoners in order to be successful.
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5 Inventory of policies, services and facilities in the 
Member States 
5.1 Main responsible department for Implementation of Council 
Recommendation
In sixteen EU Member States, the implementation of the Council Recommendation is mainly the 
responsibility of the Ministry of Health. In one Member State51 the Ministry of Social Affairs is the 
main responsible body. In five Member States the task of implementation is mainly the task of a 
special drug coordination structure52. In three Member States the task of implementation is the 
equal responsibility of two or more departments53 or divided between national government and 
regional structures and organisations54.
5.2 Recommendation #1 - Risk reduction and public health policy 
5.2.1 Member States should, in order to provide for a high level of health protection, set 
as a public health objective the prevention of drug dependence and the reduction 
of related risks, and develop and implement comprehensive strategies 
accordingly.
All EU Member States have adopted (public health) policy objectives that have the aim to prevent 
and reduce health-related harm associated with drug dependence. Belgium indicated that the 
Council Recommendation has had an impact on the development of a risk reduction policy in the 
Walloon Region. Five55 of the ten ‘New’ EU Member States have indicated that the Council 
Recommendation had a direct influence on their policies.  
All Member States indicate they have stipulated the public health objectives regarding drug abuse 
in their National Drug Action Plans or National Drug Strategies. Finland clearly links the aims of its 
Drug Strategy to its national Health Agenda (which in turn is linked to the Health 21 agenda of the 
WHO). All Member States subscribe to the premises of the Council Recommendation. National Drug 
Strategies generally reflect the balanced approach that was adopted in the EU Drug Strategy 2000-
2004 and the EU Drug Strategy 2005-2012. As such these strategies reflect the spectrum of drug 
demand reduction and drug supply reduction interventions and actions.  
With their adherence to the principles and recommendations made in the Council Recommendation, 
the Member States of the European Union clearly seem to support the balanced and 
multidisciplinary approach as laid down in the EU Drug Strategies 2000-2004 and – in particular – 
2005-2012. At international level the level of support for harm reduction measures is not as 
widespread. Within the United Nations Commission on Narcotic Drugs (CND), the term harm 
reduction is not used and fierce debates have taken place on i.e. the effectiveness of needle and 
syringe exchange programmes. In recent years, a number of resolutions have been adopted that 
support the prevention and reduction of (the spread of) HIV/ AIDS and other blood borne infections 
among drug users56. In 2004, an important resolution regarding maintenance treatment was 
adopted57 by the UN Economic and Social Council which invited the World Health Organisation 
(WHO) “...(..) to develop and publish minimum requirements and international guidelines on 
psychosocially assisted pharmacological treatment of persons dependent on opioids, taking into 
account regional initiatives in this field, in order to assist the Member States concerned.”.
The implementation of the Council Recommendation is mostly a task for the Ministry of Health in 
the Member States, except for those cases where a special coordination structure has been set 
51 Estonia. 
52 Cyprus, Czech Republic, France, Hungary & Malta. 
53 Ireland. 
54 Belgium & Italy. 
55 Cyprus, Estonia, Lithuania, Slovakia and Slovenia. 
56 E.g. 48th Session of the United Nations Commission on Narcotic Drugs [2004]. Expanding the capacity of 
communities to provide information, treatment, health care, and social services to people living with HIV/ AIDS 
and other blood-borne diseases in the context of drug abuse and strengthening monitoring, evaluation and 
reporting systems. Resolution 48/12, Vienna, 2005. 
57 47th plenary meeting of the United Nations Economic and Social Council [2004]. Guidelines for psychosocially 
assisted pharmacological treatment of persons dependent on opioids. E/RES/2004/40, New York.  
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up58. In Member States that have a decentralised structure59, the implementation of the Council 
Recommendation (and of harm reduction policies and services and facilities) is a shared 
responsibility. For many of the Member States, the development of Harm Reduction policies and 
interventions has taken off by the end of the 1990-ies, and in the period since 2000.  
The question to which extent the policies in the Member States converge, is reflected in the 
overview of services and facilities regarding the prevention and reduction of health-related harm 
associated to drug dependence as covered by the 2nd recommendation of the Council 
Recommendation. Nevertheless, there is a reasonable consensus among the Member States when 
the implementation of a ‘basic’ set of harm reduction services and facilities is concerned: 
information, education and counselling; needle and syringe exchange, outreach work; maintenance 
treatment (methadone/ buprenorphine).  
5.3 Recommendation #2 – services and facilities in the Member States 
This Recommendation calls upon the Member States to reduce substantially the incidence of drug-
related health damage (such as HIV, hepatitis B and C and tuberculosis) and the number of drug-
related deaths, by making available, as an integral part of their overall drug prevention and 
treatment policies, a range of different services and facilities, particularly aiming at risk reduction. 
5.3.1 Recommendation 2.1: provide information and counselling to drug users to 
promote risk reduction and to facilitate their access to appropriate services 
This sub-recommendation calls for harm reduction-based information, education and 
communication (IEC) services and facilities with regard to drug users. Emphasis is placed on the 
reduction of drug-related harm to the drug user and may include interventions such as information 
(leaflets, websites, help lines), education or training (such as risk education/  response training:
practical training on responses to occurring overdose, or safer injecting training: techniques to 
inject drugs more safely, e.g. by always shooting in the direction of the heart or by using clean 
equipment) or communication (individual risk counselling, e.g. one-on-one meetings giving 
practical advice on safer ways of drug taking, and support, among which referral to treatment). Pill 
testing (the testing of –mainly- ecstasy tablets) can also be viewed as an example of information, 
education and communication. 
A policy on this recommendation exists in all Member States. Five Member States indicate that this 
policy is the result of the adoption of the Council Recommendation (these are all ‘new’ Member 
States: Cyprus, Estonia, Lithuania, Slovakia and Slovenia).  
The provision of information and counselling to promote harm reduction is widely available60 in the 
European Union. In all Member States telephone help lines and educational leaflets are available to 
drug users61, and 22 Member States also run websites62, while 21 Member States provide training 
courses promoting harm reduction (see Figure 5.1). Five Member States provide drug testing 
services (either on site, i.e. at dance events, by using colour tests, or at laboratories) to drug 
users, mainly pill-testing.  
58 E.g. in Cyprus, Czech Republic, Hungary, Slovenia. 
59 Austria, Belgium, Germany, Italy, UK. 
60 Data have been analysed by differentiating between ‘nationwide available’, and ‘in specific geographical areas 
only’. The aim was to obtain a picture of the coverage of the respective harm reduction services and facilities. 
As such these terms can be compared with the EMCDDA terms: predominant and common. 
61 In Krakow, Poland, a magazine for drug users is issued through an NGO. The journal focuses on harm 
reduction issues. 
62 In a number of Member States internet-counselling is also available. 
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Figure 5.1 - IEC measures targeting drug users in Member States 
(R2.1)
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The major response strategies to prevent infectious diseases among drug users include 
information, education and communication (IEC) in general (22 Member States), and IEC via 
counselling and advice by drugs and health professionals (23 Member States). Training on safer 
injecting is a common or predominant response strategy on drug-related infectious diseases in 
thirteen Member States. In order to reduce drug-related deaths among drug users, in sixteen 
Member States dissemination of information materials and risk education/  response training are 
either common or predominant measures, as is (individual) risk counselling, which is available in 
fifteen Member States (see Figure 5.2). 
Figure 5.2 - Predominant or common response strategy to prevent DRID 
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5.3.2 Recommendation 2.2: inform communities and families and enable them to be 
involved in the prevention and reduction of health risks associated with drug 
dependence 
This sub-recommendation promotes the availability of information materials on the prevention of 
health risks such as drug overdose and wound infection. It is specifically designed for families and 
communities. Furthermore, this sub-recommendation promotes the involvement of families and 
N
um
be
r M
S 
w
ith
 re
s p
on
s e
 
s t
r a
te
gy
N
um
be
r M
S 
w
ith
 s
er
vi
ce
 
r 
fa
c i
lit
y
47
11350-HRI Rapport binnenwerk.ind47   47 13-03-2007   14:18:56
48
communities in harm reduction interventions, such as needle and syringe exchange, or calls for 
training courses for these groups to educate them, e.g., on overdose prevention. 
A policy on this recommendation exists in all 25 Member States, and in six Member States this 
policy was adopted as a direct result of the Council Recommendation.  
Nineteen Member States report that communities and families of drug users are involved in harm 
reduction63 and in fourteen Member States, specific IEC for communities and families on harm 
reduction is available. 
5.3.3 Recommendation 2.3: include outreach work methodologies within the national 
health and social drug policies, and support appropriate outreach work training 
and the development of working standards and methods; outreach work is 
defined as a community-oriented activity undertaken in order to contact 
individuals or groups from particular target populations, who are not effectively 
contacted or reached by existing services or through traditional health education 
channels
One of the main interventions in harm reduction is the concept of outreach work. Outreach workers 
reach out to those subpopulations that are not easily found through regular drug services. 
Outreach work is targeted especially at subgroups (sex workers, homeless injecting drug users) 
that do not visit regular services and that have a relatively high risk of contracting or transmitting 
drug-related infectious diseases. One of the aims of outreach work is to get into contact with these 
groups, gain their trust, give clear and fact-based information on the risks associated with drug use 
(especially regarding injecting drug use), but also other information is provided on e.g. 
transmission and prevention of infectious diseases. Another aim of outreach work concerns the 
referral of drug users to treatment. Two predominant types of outreach work are available: street-
based (or community-based) outreach work, which aims to get in touch with (dependent) drug 
users in their natural environment, e.g. in the streets, at home, in low threshold agencies and 
other locations where drug users gather. The second type concerns outreach work at dance events, 
especially targeting young ‘amphetamine-type stimulants’ drug users at raves and clubs, with a 
strong emphasis on users of synthetic drugs such as ecstasy. 
This policy exists in 24 Member States. In Italy, this policy does not exist at a national level. Five 
Member States have adopted this policy as a result of the Council Recommendation.  
In nine Member States, both street-based outreach work64 and outreach work at dance parties/ 
raves and in clubs are available throughout the country. Fourteen Member States report to have 
street-based outreach work available in specific geographical areas; eleven Member States report 
to have outreach work at dance parties/ raves, and in clubs, at specific areas. In Cyprus, outreach 
work does not exist at all; in Malta no street-based outreach work exists. In Latvia, outreach work 
at dance parties / raves and in clubs is not available at all.  
Outreach work is regarded a predominant or common response strategy to prevent drug-related 
infectious diseases in twenty Member States. Outreach work is a major implementation setting for 
measures targeting the prevention of infectious diseases in nineteen Member States. 
Measures targeting the reduction of drug-related deaths (such as the dissemination of information 
materials and the deliverance of risk education/ response training), are provided by sixteen 
Member States. 
5.3.4 Recommendation 2.4: encourage, when appropriate, the involvement of, and 
promote training for, peers and volunteers in outreach work, including measures 
to reduce drug-related deaths, first aid and early involvement of the emergency 
services
63 In the United Kingdom, families are involved in overdose training to help reduce drug-related deaths. 
64 Outreach projects and low threshold agencies exist throughout Italy, although they are more predominantly 
available in urban and northern Regions than in the southern Regions. The ‘unità di strada’ is a well established 
drug service. Over time, the facilities provided through outreach have extended and may now include advice 
and counselling, referral to a range of different services, including drug treatment, provision of information 
leaflets and guidelines to avoid or deal with drug-related emergencies, provision and/or exchange of sterile 
injection equipment, guidance on safer sex and the provision of condoms. More recently, in some areas there 
has been the introduction of mobile methadone treatment services aimed at reaching clients who are not 
presently able to use the fixed site service.  
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This recommendation is related to the involvement of peers and volunteers in the practice of 
outreach work. The use of peers - often current or former drug users - has some advantages over 
the use of merely harm reduction professionals. The main advantage is that peers know the codes 
used among drug users, e.g. the daily life rituals. Peers also have personal experience with the 
effects of specific drugs and therefore can place themselves in the position of drug users much 
better than professionals might. Therefore peers can be quintessential in transferring knowledge 
and skills to the target group, such on the basis of trust and equality. But peers also know where to 
find the hidden drug users, the at–risk groups, and will be accepted in their midst more easy as 
they are part of the same subpopulation. 
A policy regarding this recommendation exists in nineteen Member States and four Member States 
based this policy upon the Council Recommendation. In Lithuania and Portugal, the implementation 
of this policy is pending for approval by the national government. In Denmark, Italy, Hungary and 
Slovakia such a policy does not exist, or is not considered a priority or task for the government. 
In eighteen Member States training for peers and volunteers is provided65, and outreach work 
agencies involve peers and volunteers in outreach work in nineteen Member States66.
5.3.5 Recommendation 2.5: promote networking and cooperation between agencies 
involved in outreach work, to permit continuity of services and better users' 
accessibility 
This policy exists in eighteen Member States. Three new EU Member States based this policy upon 
the Council Recommendation. In Denmark, Greece, Italy, and Slovakia this policy does not exist 
(e.g. as it is no priority for government), and in Lithuania, Latvia and Portugal the implementation 
of this policy is pending for approval. 
Networking and cooperation between outreach work agencies is prevalent in twenty Member 
States. In Luxembourg this policy is not put in practice as – given the geographical dimensions of 
the country – only one organisation is involved in outreach work. 
5.3.6 Recommendation 2.6: provide, in accordance with the individual needs of the 
drug abuser, drug-free treatment as well as appropriate substitution treatment 
supported by adequate psychosocial care and rehabilitation taking into account 
the fact that a wide variety of different treatment options should be provided for 
the drug-abuser 
One of the harm reduction interventions most widely implemented throughout the European Union, 
concerns the provision of maintenance treatment. This type of treatment involves the use of 
substitution drugs such as buprenorphine and methadone to assist opioid (mainly heroin) users to 
stabilise their drug use and to move from injecting and other possible hazardous methods of taking 
drugs to (usually) oral drug consumption. The substitution drug is provided under supervised 
conditions as part of an intervention that may also involve counselling, primary health care, HIV 
treatment and other services67. In general, there are two types of substitution treatment: 
maintenance treatment and detoxification treatment.  
Maintenance or substitution treatment involves the prescription of a substitution drug to a 
dependent drug user for a longer period of time (in general, years). Its primary aim is to stabilise 
one’s living and health conditions. Maintenance treatment resulting in abstinence is possible, but 
less common in practice. Positive side effects include a reduction in the risk of acquiring drug-
related infectious diseases and prevention of drug overdose (see literature review in Annex 1). 
Detoxification treatment involves the care that is provided to a dependent drug user who is 
reducing or terminating the use of a dependence-producing substance, with the aim of withdrawing 
from the substance safely and effectively68. The detoxification treatment is provided until 
abstinence has been reached. In general maintenance treatment is available to opioid dependent 
drug users. The most important substitution drugs that replace opioids are methadone and 
buprenorphine (brand name: Subutex).  
65 In Belgium, (ex-) drug users are trained to diffuse HIV prevention and overdose prevention messages. 
66 Almost all needle and syringe exchange points in Estonia recruit hard-to-reach risk groups in the framework 
of outreach work; they also provide syringes, needles and/or other injection paraphernalia, condoms, leaflets 
with risk reduction materials in the framework of outreach work. 
67 WHO [2003]. Training Guide for HIV prevention outreach to injecting drug users. Department of HIV/ AIDS. 
68 WHO [2003].
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A third substitution drug is Naltrexone. Naltrexone is an opioid antagonist: it blocks the effects of 
opioids so that the user does not feel the specific effects of the opioid anymore. As such it can be 
used as a substitution for heroin. During the withdrawal period it may help dependent drug users 
to refrain the simultaneous use of opioids. Naltrexone is not as frequently used as methadone and 
buprenorphine, partly because acceptance is poor. Another, not yet widely implemented, 
intervention is the prescription of heroin to heroin dependent users (see Annex 3.2). 
Maintenance or substitution treatment and detoxification treatment is supported by psychosocial 
care (such as individual counselling) in all 24 Member States where this treatment is available, 
thus excluding Cyprus. This psychosocial care is obligatory in 9 Member States, and is available 
upon request by the client in 10 Member States; 5 Member States report that this treatment-
related psychosocial care is sometimes obligatory, sometimes upon request by the client 
(depending on the prescribing institution or general practitioner). 
Another important element of harm reduction involves the provision of low threshold agencies, 
services that aim to provide basic needs for (homeless) drug users, where the threshold to enter is 
low (few preconditions, e.g., it is not necessary to express the wish to stop using drugs). By doing 
so, low threshold agencies can get in touch with a large number of drug users. Drop-in centres and 
day or night shelters are important low threshold services. Drug consumption rooms are harm 
reduction facilities that are offered to drug users in only a few EU countries. In general these 
facilities have a higher threshold (see Annex 3.1). 
A policy on this sub-recommendation exists in all 25 Member States, and in Cyprus, Estonia, 
Slovakia, and Slovenia this policy exists as a result of the Council Recommendation. 
Methadone maintenance treatment is available nationwide in fourteen Member States, and 
available in specific geographical areas in ten Member States69. In Cyprus, substitution treatment is 
not provided. Methadone detoxification treatment is nationwide available in sixteen Member States 
and in specific geographical areas in seven Member States (there is no information about the 
availability of methadone detoxification treatment in Sweden). Treatment with buprenorphine is 
available in 21 Member States, and treatment with Naltrexone in eighteen Member States. In all 
Member States drug-free outpatient and drug-free inpatient treatment and rehabilitation centres 
are available, and in all Member States except for Latvia and Slovakia drop-in centres/ shelters 
exist. 
Four Member States – Germany, Spain70, the Netherlands71 and the United Kingdom72- operate 
heroin prescription programmes. In Luxembourg controlled prescription of heroin may start in 
200873. Within the European Union, drug consumption rooms exist in Germany74, Spain, 
Luxembourg and the Netherlands. In all other Member States this intervention is not available.  
In nineteen Member States, opioid substitution treatment is considered to be a predominant or 
common response strategy to reduce drug-related deaths (see Figure 5.3). 
69 Sweden was the first Member State to provide methadone maintenance treatment and started this treatment 
in 1966. Currently, there is a very strict high threshold methadone maintenance programme for in total 800 
persons. 
70 Two trials are running. 
71 This includes only medical co-prescription of heroin together with methadone. The government decided that 
places at treatment units for medical prescription of heroin to chronic treatment resistant opiate addicts can be 
extended up to 1000 places. 
72 300-500 persons receive heroin in England and Wales. 
73 In Luxembourg, the introduction of heroin prescription is an aim in the National Drugs Action Plan 2005-
2009, but it was decided to wait with introduction until the evaluation of the development and impact of the 
drug consumption room in 2008 (Source: NFP 2006).  
74 In 2003, there were 24 drug consumption rooms in Germany, in urban areas. 
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Figure 5.3 - Availability of harm reduction services and facilities (R 2.6)
24 23
21
18
25 25
23
4 4
0
5
10
15
20
25
30
Me
th
ad
on
e m
ain
ten
an
ce
Me
th
ad
on
e d
et
ox
ific
at
ion
Bu
pr
en
or
ph
ine
tre
atm
en
t
Na
ltr
ex
on
e t
re
atm
en
t
Dr
ug
-fr
ee
in
&
ou
tp
ati
en
t t
re
at
me
nt
Re
ha
bi
lit
ati
on
ce
nt
re
s
Dr
op
-in
ce
nt
re
s/
sh
elt
er
s
He
ro
in
pr
es
cr
ip
tio
n
Dr
ug
co
ns
um
pt
ion
ro
om
s
Harm reduction service or facility
N
um
be
r M
S 
w
ith
 s
er
v i
c e
 o
r f
a c
ili
ty
5.3.7 Recommendation 2.7: establish measures to prevent diversion of substitution 
substances while ensuring appropriate access to treatment 
Some critics of harm reduction measures are concerned that the prescription of substitution drugs 
to dependent drug users will result in diversion (leakage) of these substitutions to the illicit drug 
market, thus adding to the drug problem. This concern is based upon the perception that many 
dependent drug users will choose their original drug over the substitution drug and will sell the 
replacement for the ‘real thing’. This recommendation calls for action to prevent or reduce such 
diversion. 
A policy regarding this recommendation exists in 23 Member States. Estonia and Slovenia 
implemented this policy as a result of the Council Recommendation. Hungary does not have such a 
policy and there is no information about this policy in Slovakia. 
Measures to prevent diversion of substitution substances include – among other - supervised 
consumption, daily pick-up of the substitute drug, urine checking as to check whether the 
substitution drug has actually been consumed (in that case, traces should be visible in the urine 
sample) or centralised registration to avoid shopping (collecting the substitution drug at multiple 
outlets). These measures are available in 22 Member States. In Cyprus, Italy75 and Malta, 
measures to prevent diversion of substitution substances are not effectuated. 
5.3.8 Recommendation 2.8: consider making available to drug abusers in prison access 
to services similar to those provided to drug abusers not in prison, in a way that 
does not compromise the continuous and overall efforts of keeping drugs out of 
prison
Prisons are a setting with a large potential for increased health-risk related situations for drug 
users (e.g. re-use of dirty needles among a large population of inmates). The ‘principle of 
equivalence’ mentioned in this recommendation has already been adopted by the UN General 
Assembly76 in 1990 and by its organisations and agencies including UNAIDS/ WHO77 and UNODC78.
75 Diversion of substitution substances is a minor problem in Italy. 
76 “Prisoners shall have access to the health services available in the country without discrimination on the 
grounds of their legal situation.” UN General Assembly, res. 45/111, annex, 45 U.N. GAOR Supp. (No. 49A) at 
200, U.N. Doc. A/45/49 (1990).  
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It promotes the provision of equal health care services and measures, including harm reduction, 
inside and outside prison (see also Annex 3.4). 
A policy on this sub-recommendation exists in twenty Member States. Five of these Member States 
have based this policy upon the Council Recommendation. In the Czech Republic, this policy does 
not exist, as it is not a priority for the government. In Greece, Lithuania, Luxembourg and Latvia 
this policy is pending for approval.  
Figure 5.4 - Harm reduction services available in prison (R2.8)
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Methadone maintenance treatment is available in prison in seventeen Member States. Nineteen 
Member States also provide methadone detoxification treatment in prison. Ten Member States 
provide treatment with buprenorphine, in five Member States antagonist treatment with Naltrexone 
is available in prison. Heroin prescription programmes in prison are not available in any of the EU 
Member States or anywhere in the word. In prisons of eleven Member States drug paraphernalia 
(e.g. bleach) are available, in sixteen Member States, prisons provide condoms and only three 
Member States –Germany79, Spain80 and Luxembourg81 - allow needle and syringe exchange from 
within prison walls. In Austria such an intervention is currently under preparation and Portugal may 
start this type of intervention in 2008. 
Measures targeting drug-related infectious diseases are available in prisons in 23 Member States: 
in prisons in Cyprus and Malta only counselling is provided, and in Latvian prisons no measures are 
available. There is no information concerning drug-related infectious diseases measures in prisons 
in Lithuania. In fifteen Member States, prisons are a main implementation setting for drug-related 
infectious diseases measures, and in ten Member States, prisons are an implementation setting for 
measures targeted at the reduction of drug-related deaths (see Figure 5.4). 
77 “All prisoners have the right to receive health care, including preventive measures, equivalent to that 
available in the community without discrimination, in particular with respect to their legal status or nationality”.
WHO/ UNAIDS [1993]. WHO Guidelines on HIV infection and AIDS in Prison. United Nations Joint Programme 
on HIV/ AIDS, UNAIDS/99.47/E (English original, September 1999), p. 4. 
78 UNODC [2006]. HIV/ Aids Prevention, Care, Treatment and Support in Prison Settings – A framework for an 
effective national response. Vienna, Austria.  
79 There were 7 pilots but only one prison (in Berlin) continued to operate needle and syringe exchange. 
80 Needle and syringe exchange is available in 38 prisons in Spain. 
81 Needle and syringe exchange is available in prisons in Luxembourg since the end of 2005.
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5.3.9 Recommendation 2.9: promote adequate hepatitis B vaccination coverage and 
prophylactic measures against HIV, hepatitis B and C, tuberculosis and sexually 
transmitted diseases, as well as screening for all the aforementioned diseases 
among injection drug users and their immediate social networks, and take the 
appropriate medical actions 
This recommendation promotes the prevention and treatment of infectious diseases among drug 
users. Injecting drug use is a risky way of administrating drugs, especially if not done hygienically 
and without clean injecting equipment. Because of a risky life-style, some drug users also have an 
increased risk of acquiring sexually transmitted diseases (STD’s). The recommendation calls for 
preventative measures, both by vaccination (only available for hepatitis B and tuberculosis) or 
other prophylactic measures, and by proactive detection of drug-related infectious diseases 
through testing/ screening programmes.  
A policy on this recommendation exists in all Member States, except for Latvia. Five Member States 
indicate that this policy was implemented as a result of the Council Recommendation. 
Testing/ screening on infectious diseases are available nationwide to drug users in nineteen 
Member States82 and in specific geographical areas in three Member States. Prevention and 
education measures are nationwide available in fifteen Member States and at specific areas in five 
Member States. Treatment of infectious diseases is available nationwide in fifteen Member States83,
and at specific areas in five Member States84.
Vaccination campaigns against hepatitis B focusing specifically on drug users are available 
nationwide in fifteen Member States85, and at specific areas in five Member states. In Member 
States where universal vaccination programmes (incl. hepatitis B vaccination) are provided to the 
general population, programmes targeting drug users in particular may not be necessary, as drug 
users may have been vaccinated already. Vaccination programmes against tuberculosis targeting 
specifically at drug users are nationwide available in ten Member States, and in specific areas in 
three Member States, but data are incomplete. However, many Member States run generic 
vaccination programmes for the whole population. In Cyprus measures to prevent drug-related 
infectious diseases (including treatment and vaccination programmes) are not available at all. 
Voluntary counselling and testing (VCT) is either a predominant or a common response strategy to 
prevent infectious diseases among drug users in seventeen Member States. Routine screening of 
high risk groups and easy access programmes to treatment of infectious diseases for drug users 
are predominant or common response strategies in eleven Member States (see Figure 5.5). 
5.3.10 Recommendation 2.10: provide where appropriate, access to distribution of 
condoms and injection materials, and also to programmes and points for their 
exchange
Needle and syringe exchange programmes are programmes that aim to reduce the transmission of 
drug-related infectious diseases by the repeated use and sharing of needles or syringes in order to 
reduce the transmission of blood-borne viruses.  
This policy exists in 23 Member States, and four Member States implemented this policy as a result 
of the Council Recommendation. A policy on this sub-recommendation does not exist in Cyprus and 
Italy.
82 In Luxembourg, an action-research programme was initiated in 2005 by the National Focal Point providing 
on-site testing (hepatitis A, B, C, HIV) and vaccination (hepatitis A and B) through specialised national NGOs. 
83 In some Member States, such as Latvia, treatment of infectious diseases is available to all people, and 
specific programmes for the treatment of infectious diseases among drug users are not in place. 
84 Some Member States exclude drug users from treatment of infectious diseases: in Slovakia drug users are 
excluded from treatment of hepatitis C; in Poland, active drug users are excluded from anti-retroviral treatment 
against AIDS. 
85 E.g., in Denmark, an executive order from the Danish Government on “Hepatitis vaccination, free of charge 
for injecting drug users and their relatives” was implemented April 2005. 
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Figure 5.5 - Measures & response strategies to prevent DRID (R2.9)
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Besides Cyprus (where no needle and syringe exchange is available), all Member States provide 
needle and syringe exchange for injecting drug users. In fifteen Member States, needle and syringe 
exchange is available nationwide, and nine more Member States providing this intervention in 
specific geographic areas only86. In Estonia and Sweden, drug paraphernalia87 are not provided to 
drug users88. For Cyprus, no information is available. All other Member States provide drug 
paraphernalia to drug users89. Condom distribution is available throughout the European Union with 
the exception of Latvia and Malta. 
In 21 Member States needle and syringe exchange is considered a predominant or common 
response strategy to prevent infectious diseases. Needle and syringe exchange programmes are 
the main implementation setting for measures targeting at the reduction of drug-related deaths in 
eighteen Member States. 
5.3.11 Recommendation 2.11: ensure that emergency services are trained and equipped 
to deal with overdoses 
In case of a drug overdose, immediate professional help is needed. Emergency services are often 
the first professionals available on the spot. Therefore it is necessary that emergency staff is 
trained in dealing with drug overdose. Furthermore, it is important that necessary equipment and 
medication is available, including naloxone. Naloxone is a narcotic antagonist which reverses the 
respiratory, sedative and hypotensive effects of heroin overdose90. In harm reduction, naloxone 
may be generally available for emergency services or on a ‘take home’ basis for drug users. 
A policy regarding this recommendation exists in all Member States, and in seven Member States 
this policy was based upon the Council Recommendation.  
86 In Sweden, 2 needle and syringe exchange programmes exist, in conflict with repressive policy. There are 
two needle-exchange programmes in the southern county of Skåne – Lund since 1986 and Malmö since 1987 – 
at the clinics for infectious diseases.
87 The term drug paraphernalia refers to equipment used to produce, administer or conceal an illicit drug, e.g. 
bleach, a spoon, ascorbic acid, pipes, etc. 
88 Bleach is not distributed in Ireland, as it is supposed not to prevent the spread of drug-related infectious 
diseases, e.g. hepatitis C. 
89 Distribution of paraphernalia (spoons, acid, water, also disinfection materials) is a standard part of needle 
and syringe exchange programmes in the Czech Republic. Syringes are available in pharmacies without 
prescription, but not free of charge. It is estimated that about a million syringes are sold annually in the Czech 
Republic in pharmacies to injecting drug users.
90 UNDCP [2000]. 
Nu
m
be
r 
M
S
 w
ith
 m
ea
s
re
 
r 
re
sp
on
se
 s
tr
at
eg
y
54
11350-HRI Rapport binnenwerk.ind54   54 13-03-2007   14:19:01
55
Despite this policy, in only ten Member States training for staff of emergency units is available91. In 
two Member States emergency services are considered a setting for the dissemination of 
information materials that aim at the reduction of drug-related deaths. In three Member States 
emergency services are a setting for the deliverance of risk education/ response training. In twenty 
Member States, ambulances carry naloxone. No information is available on this topic in 4 Member 
States. In Cyprus, ambulances do not carry naloxone. In six Member States, naloxone is available 
to drug users on a ‘take home’ basis. 
5.3.12 Recommendation 2.12: promote appropriate integration between health, 
including mental health, and social care, and specialised approaches in risk 
reduction
This recommendation focuses on the integration of harm reduction services and facilities within 
general health care. If harm reduction is integrated with mental health care (e.g. to deal with co-
morbidity) and social care (e.g. reintegration: housing, jobs, income provision), the social and 
health situation of dependent drug users may be stabilised and possibly improved.  
A policy regarding this recommendation exists in 23 Member States and is pending for approval in 
Lithuania and Portugal.  
Risk reduction is part of an integrated health strategy for drug users in nineteen Member States92,
and in four Member States no information is available. In all Member States risk reduction is part of 
the National drug policy. 
5.3.13 Recommendation 2.13: support training leading to a recognised qualification for 
professionals responsible for the prevention and reduction of health-related risks 
associated with drug dependence 
This recommendation focuses on skills building for staff in harm reduction, with the aim to develop 
a standardisation of working methods. Ideally skills building programmes should result in a 
recognised qualification 
This policy exists in 22 Member States, of which three Member States based this policy upon the 
Council Recommendation. This policy does not exist in Cyprus, the Czech Republic and Italy.  
Training for personnel in needle and syringe exchange is available in 1seven Member States, 
training for professionals in maintenance treatment is provided in twenty Member States93. In 21 
Member States, training for outreach workers is available. In nineteen Member States training for 
professionals in low threshold agencies is available. Finally nineteen Member States provide 
training for professionals in treatment facilities as well as training for prison staff. 
91 In Spain, e.g. “Counselling for emergency services related to young people and drug use” is given by the 
Department of Health of Catalonia. 
92 In France, risk reduction is part of a larger approach. A concrete example lies in the RMS program (“Réseau 
Micro-Structures”, or Microstructures network), originally based in Alsace: attention and care to any kind of 
addicted patients are provided by physicians in presence of social-workers and psychologists. 
93 In many Member States, the prescription of substitution substances to drug users is only allowed after 
training of physicians or other staff.
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5.4 Recommendation #3 - information and evaluation 
The 3rd recommendation of the Council Recommendation consists of nine sub-recommendations. 
Where the Member States show good compliance and coverage with the different elements of the 
2nd recommendation of the Council Recommendation, compliance with the 3rd recommendation of 
the Council Recommendation shows a greater deal of diversity.  
Figure 5.6 - 3rd CR - Recommendations adopted in policy by MS
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Although overall Member States support the need for these recommendations in drug strategies 
and health policy plans, the overview underneath shows that not every Member State has adopted 
specific policies (see Figure 5.6) to actively stimulate quality assurance, monitoring and evaluation.  
Not all Member States value quality assurance, monitoring and evaluation as a task for national 
government. In Member States with a federal or decentralised structure94, tasks in these areas are 
divided among different levels of competence. In other Member States, e.g. the Netherlands and 
the UK, quality assurance, monitoring and evaluation is often seen as a task for independent 
(scientific) organisations. The United Kingdom reports to have made compliance with quality 
assurance models (including needs assessment at the early stages of a programme, R3.2) a 
condition for funding. Figure 5.7 provides some details on the level of implementation of the sub-
recommendations.  
5.4.1 Recommendation 3.1: using scientific evidence of effectiveness as a main basis to 
select the appropriate intervention 
This recommendation was adopted in nineteen of the 25 EU Member States95. Five Member States 
indicate that this was the result of the Council Recommendation96. Several Member States run 
research and evaluation projects regarding interventions in harm reduction97.
In recent years many national or regional studies have been carried out into maintenance 
treatment and detoxification treatment. For example, in Italy, a longitudinal study was conducted 
into the evaluation of effectiveness of methadone treatment [NR 2002]. In Ireland, small scale 
studies have been conducted into the effectiveness of methadone maintenance treatment [NR 
2004]. In Finland similar research was conducted on medical assisted treatment with 
buprenorphine in two cities [NR 2003]. In Luxembourg, the first scientific evaluation of methadone 
94 E.g. Belgium, Italy, Germany. 
95 Belgium, Hungary, Latvia, Lithuania, Malta and the UK indicate they have not implemented it. In Belgium this 
is not the case for the whole country. In Latvia and Lithuania, the policy is pending for approval while in the UK 
the National government does not see it as its responsibility. 
96 Cyprus, Germany, Estonia, Slovakia, Slovenia.
97 E.g. evaluations of substitution treatment (methadone, buprenorphine, and heroin) have been reported in 
Germany (Saarland), Finland, Luxembourg, the Netherlands; Evaluations of low threshold agencies are reported 
in Finland and France. 
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programmes took place in 1995. In 2002 a report on a comprehensive study on the national 
substitution programme was published. In the Netherlands, research and evaluation is used to 
adapt interventions. Examples are the Randomised Controlled Trial into heroin prescription and 
rapid detoxification studies (e.g. Naltrexone detoxification under general anaesthesia) [NR 2004].  
Figure 5.7 - Implementation 3rd Council Recommendation
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In Slovenia a needle exchange programme was evaluated (Stigma) [NR 2002], as well as in 
Portugal [NR 2003]. Other Member States like Slovakia make use of existing (international) 
evidence to select interventions with [NR 2004].  
5.4.2 Recommendation 3.2: supporting the inclusion of needs assessments at the initial 
stage of any programme 
The recommendation was implemented by nineteen Member States98, while four99 Member States 
indicate it was based on the Council Recommendation.
Despite the fact that many Member States indicate that supporting needs assessment at the initial 
stage of any programme is important, Member States usually do not promote such a policy with 
specific policy instruments (e.g. adopt such in funding guidelines).  
A limited number of Member States has incorporated needs assessment in their drug policies. 
Luxembourg has included an exploratory study into prevention in nightlife settings in its drug 
action plan 2005-2009 [NR 2004]. In the Czech Republic, a needs assessment was carried out 
(Rapid Assessment & Response methodology) for the evaluation of drug policy in the Central 
Bohemian region [NR 2004], while several Phare Twinning projects were run (incl. on maintenance 
treatment) that included needs assessment. [NR 2003] In Ireland, a baseline assessment was 
conducted (incl. hepatitis B vaccination coverage) at the early stages of a pilot project to improve 
the care for injecting drug users. [NR 2004]. 
5.4.3 Recommendation 3.3: developing and implementing adequate evaluation 
protocols for all drug prevention and risk reduction programmes 
This recommendation has been implemented in twelve Member States100, while four101 of these 
indicate they based there policy on the Council Recommendation.
98 The Czech Republic does not see this recommendation as a priority. In Italy the policy exists but is not a task 
for national government. Hungary and the Netherlands do not consider this recommendation as a task for 
national government, while a policy on this topic is pending for approval in Malta and Slovakia. Latvia does not 
indicate a specific reason for not implementing the recommendation. 
99 Belgium, Cyprus, Estonia and Slovenia. 
100 Italy has implemented the recommendation, but indicates this is not a task for national government. 
Hungary has not implemented it for the same reason. In the Czech Republic, Lithuania, Latvia, Malta and 
Slovakia a policy on this recommendation is pending for approval. The Netherlands indicate that guidelines and 
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In Cyprus, in mid-2003 the Anti-drug council’s scientific committee developed specific guidelines 
for drug treatment centres to ensure minimum quality standards. In Denmark the programmes are 
based on evaluation protocols. In Estonia, a policy on this recommendation was adopted, but still 
has to be implemented. In Greece, a policy was adopted to include evaluation in every programme. 
In Finland, evaluation is mandatory for all programmes funded by Ministries. In Luxembourg, 
evaluation of drug prevention and risk reduction programmes is common practice and evaluation 
protocols are available in the RELIS database. In Poland, an expert committee has conducted a 
review of the evaluation process of programmes in treatment, rehabilitation and harm reduction. In 
Slovenia, a policy on this recommendation has been adopted as an aim in the government 
Resolution on the National Programme in the field of Drugs (ReNPPD), but still needs to be 
implemented.  
5.4.4 Recommendation 3.4: establishing and implementing evaluation quality criteria, 
taking into account the Recommendations of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) 
The recommendation has been implemented by fourteen Member States102, four103 of which 
indicated the Council Recommendation was the basis for this policy. In those countries where a 
policy has been developed, the establishment of quality criteria is often still in the early stages of 
development. The EMCDDA has developed several manuals104 and Monographs105 on quality and 
evaluation, but Member States do not specifically refer to the use of these. 
In Germany, no unified formal criteria for evaluation of harm reduction programmes exist due to 
the federal structure of the health system. Quality guidelines are not mandatory, but incorporated 
by professional organisations and funding institutions. In Denmark, in 2003 a project has been 
started (DANRIS) that aims to collect documentation and information on drug treatment 
programmes. It includes aspects of quality control. The Spanish Action Plan on Drugs calls for the 
evaluation of drug demand reduction programmes and in several autonomous regions quality 
assessment systems have been set up. In Estonia and Poland, a policy on this recommendation 
was adopted, but not implemented satisfactory so far. In Finland, the Drug Policy Action 
Programme 2004-2007 calls for the development of a quality framework for drug service providers. 
The Finnish Centre for Health Promotion has developed a guidebook on quality criteria for health 
promotion programmes.  
In Italy, programmes have been funded that assess the quality of services offered to drug addicts. 
In Sweden, the new Drug Action Plan incorporates clear objectives to develop quality criteria for 
drug treatment services. Finally, in Slovenia, there are general quality criteria for programmes 
funded by government, but specific evaluation quality criteria for drug demand reduction still have 
to be developed. 
protocols are available but not compulsory or supported by policies. Sweden has not implemented a policy on 
this recommendation as methodologies and protocols are under development. In Austria, resources to develop 
such instruments are no longer available, while the UK reports that performance monitoring is common, but 
that no established evaluation protocols exist. In the Czech Republic a policy is pending for approval. However, 
minimum standards for quality as well as evaluation tools are being developed. One of these tools concerns the 
Minimum Evaluation Set, developed to evaluate treatment effectiveness. For France, no additional information 
is available.  
101 Cyprus, Germany, Estonia and Slovenia. 
102 A policy on this recommendation is pending for approval or adoption in Belgium, the Czech Republic, 
Lithuania, Latvia, Malta and Slovakia. The Flemish Community in Belgium is preparing a system of evaluation. 
In the Czech Republic, quality assurance is a pillar for drug demand reduction. Professional standards have 
been developed and are being applied. In Hungary, the development of quality criteria for harm reduction is not 
considered a task for national government. However, an ‘EDDRA-style’ database has been developed which will 
incorporate examples of good practice (SZIP). In the Netherlands, several quality assessment protocols and 
guidelines have been developed by scientific organisations. In Austria, there is no official policy available, but 
applications for programme funding at national and Laender level have to comply with quality standards. In the 
UK a policy on this recommendation does not exist, but the National Treatment Agency has developed four Key 
Performance Indicators for local Drug Action Teams. 
103 Cyprus, Germany, Estonia and Slovenia. 
104 EMCDDA [1998]. Guidelines for the evaluation of drug prevention: a manual for programme-planners and 
evaluators. Lisbon, Portugal. ISBN: 92-9168-052-4; EMCDDA [2001]. Guidelines for the evaluation of outreach 
work: a manual for outreach practitioners. Lisbon, Portugal. ISBN: 92-9156-024-3. 
105 EMCDDA [2000]. Understanding and responding to drug use: the role of qualitative research. Scientific 
Monograph no.4. Lisbon, Portugal. ISBN: 92-9168-088-5.
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5.4.5 Recommendation 3.5: organising standardised data-collection and information 
dissemination according to the EMCDDA recommendations through the REITOX 
national focal points 
This sub-recommendation has been implemented by 23 Member States106 and seven Member 
States indicate the Council Recommendation was instrumental for that result107. The Member 
States report compliance with the aim to implement the five key-epidemiological indicators of the 
EMCDDA108 [RT] and their participation in the EDDRA database. Adoption of the key-indicators is 
part of the ‘hard’ Acquis Communautaire and an important condition participation in the Reitox 
Network. However, in operational terms quite a few Member States do not comply fully yet with all 
the EMCDDA standards and methodologies109.
Comparative overviews regarding the quality of data (and compliance towards information 
requests) provided by Member States to the EMCDDA, are not available. Annually the EMCDDA 
provides individual Member States with feedback information of the quality of their input (e.g. of 
National Reports and regarding specific questionnaires and data tables) and possible deficiencies in 
information. Member States usually publish their National Reports on national websites. However, 
there is no clear picture to what extent Member States use data collections including those 
gathered for the EMCDDA for national purposes.  
5.4.6 Recommendation 3.6: making effective use of evaluation results for the refining 
and development of drug prevention policies 
This sub-recommendation has been implemented in nineteen Member States110, while three111
Member States indicate this was the result of the Council Recommendation.  
In Belgium, a policy on this recommendation exists in the French, Flemish and German 
Communities, while evaluation of quality to inform policy making was an objective in the Flemish 
Drug Plan 2002-2005. Evaluation is a task of the Cypriote Anti-Drugs Council. In the Czech 
Republic, the national drug policy has been evaluated. New initiatives to make use of evaluation for 
policy development are introduced in various areas of drug policy. In Germany, many different 
projects on evaluation and monitoring of drug demand reduction interventions have been 
implemented, including a study on drug consumption rooms (ZEUS). The Bundeslaender are quite 
active in this area as well and have developed a joint position paper on the future focus of 
outpatient drug and addiction aid systems. In Denmark, an Act regulating guaranteed social 
treatment for drug abuse has been adopted that is monitored for evaluation purposes. The results 
of the evaluation will be used to evaluate the Act.  
In Spain, a mid-term evaluation of the National Drug Strategy 2000-2008 has been conducted, 
while in Catalonia, clinical trials on heroin prescription are being conducted. In Estonia, a policy on 
this recommendation exists, but still needs further development and content. In Finland a health 
counselling scheme for drug users has been implemented as part of the HIV/ AIDS strategy. It has 
been evaluated in 2004. In France, the three-year action plan on drugs 1999-2001 called for the 
evaluation of five priority programmes/  services, among which harm reduction and social 
mediation services in Paris. 
106 In Belgium, the TDI is pending for approval by National government, although other data collections exist. In 
Latvia the policy is pending for approval. 
107 Cyprus, Germany, Lithuania, Slovakia and Slovenia. 
108 The five key epidemiological indicators are: prevalence and patterns of drug use among the general 
population (population surveys); prevalence and patterns of problem drug use (statistical prevalence/incidence 
estimates and surveys among drug users); drug-related infectious diseases (prevalence and incidence rates of 
HIV, hepatitis B and C in injecting drug users); drug-related deaths and mortality of drug users (general 
population mortality special registers statistics, and mortality cohort studies among drug users); demand for 
drug treatment (statistics from drug treatment centres on clients starting treatment). 
109 EMCDDA [2006]. Progress review of the EU Drugs Action Plan (2005-2008) - EMCDDA thematic paper for 
objective 39. Lisbon, Portugal. 
110 In Lithuania and Malta a policy on this recommendation is pending for approval. In Austria, a specific policy 
does not exist, although use of evidence for policy is increasingly common practice at all levels of government. 
In Latvia, evaluation of drug policy actions is an objective of the Drug Control and Drug Abuse Prevention 
Programme. In Hungary, there is no formal policy that prescribes the use of evaluation results of drug demand 
reduction services for the (re-) development of drug policies. However, the government did call for an external 
evaluation of the National Drug Policy in 2004-2005. In Italy, there is no specific policy on this 
recommendation, as it is not considered a task for the national government. In Slovakia, this recommendation 
is not a priority. 
111 Cyprus, Estonia and Slovenia. 
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In Ireland, one action of the National Drugs Strategy called for the evaluation of outreach work. 
Based upon the evaluation, quantitative and qualitative indicators for this type of harm reduction 
were established. In Luxembourg, a study as conducted – in line with the EMCDDA work plan – to 
assess the direct economic costs of drug policies and interventions. The RELIS database provides 
ample information to inform drug policy in Luxembourg. In the Netherlands, a five-year 
programme ‘Getting Results’ was started in 1999. The programme facilitated the evaluation of 
many drug demand reduction programmes and interventions and resulted in new tools, protocols, 
model designs and also policy adjustments. In Poland, an evaluation of drug therapy programmes 
for women in prisons resulted in new objectives for the National Programme for Drug Prevention. 
In the UK, the monitoring of performance rather than evaluation of the drug demand reduction 
sector is broadly implemented. This is a continuous process of quality control.   
5.4.7 Recommendation 3.7: setting up evaluation training programmes for different 
levels and audiences 
This recommendation has been implemented in fourteen Member States112, while three113 of these 
indicate this policy was based on the Council Recommendation.
In Austria, quality assurance and evaluation is part of the curricula for drug specific further 
education. The Reitox National Focal Point is involved in this type of training in Austria, Cyprus and 
the Netherlands. In the Czech Republic, in the framework of a Phare Twinning project, quality 
standards for services in addiction treatment were developed and adopted in a training programme 
for professionals. In Luxembourg, evaluation training programmes are provided by the drug 
prevention institute CePT and a pedagogical research department. In the Netherlands, the National 
Consultancy on Prevention (LSP) provides a variety of training programmes for professionals in 
addiction care. In Poland, evaluation training programmes are available for NGO’s at local and 
regional level; while in Slovenia an expert body is being created that will produce professional 
standards and guidelines in this field.   
5.4.8 Recommendation 3.8: integrating innovative methods that enable all actors and 
stakeholders to be involved in evaluation, in order to increase acceptance of 
evaluation
This recommendation has been implemented in fourteen Member States114, while three115 of these 
indicate this policy was based on the Council Recommendation.
Often participation of stakeholders is mentioned as an important factor in the implementation of a 
national drug strategy. But seldom participation in evaluation is mentioned.  
In Spain, the involvement of stakeholders in evaluation is a priority in the National Action Plan on 
Drugs. In Estonia, there used to be programmes to encourage participation. In Greece, stakeholder 
involvement is a policy aim, but not a general requirement. The Polish drug coordination promotes 
the involvement of service providers and users in evaluation of drug demand reduction. The EU 
funded project “Rezolat” has as one of its aims the development and application of innovative and 
inclusive evaluation methodologies. 
Limited information is available on innovative methods aimed at involving drug users/ family, 
professionals and/ or the broader community. Methods mentioned include competitions (Germany) 
and awards (Preffi-award, Netherlands). A European network has been set up (Rezolat) which has 
innovation and participation as one of its aims.  
112 In Belgium, a policy on this recommendation is pending for approval in Flanders. In Denmark no policy in 
this area exists, but at times evaluation training seminars for local and regional drug professionals are 
organised. In Hungary and in Italy, this recommendation is not considered a task for national government. In 
Lithuania, Latvia, Malta and Portugal a policy on this recommendation is pending for approval. In Slovakia and 
the UK, this policy is not considered a priority for national government. 
113 Cyprus, Estonia and Slovenia. 
114 A policy on this recommendation is pending for approval in the Czech Republic, Lithuania and Malta, while it 
is not a priority for national government in Slovakia and the UK. In Belgium, a policy in this regard is pending 
for approval in a part of the Communities. In Italy a policy to this extent does not exist. In the Netherlands, a 
system of client-councils for patients in addiction and mental health care has been created, in which clients of 
service providers can provide feedback on quality and organisation of services. These councils are mandatory 
by Law. In Hungary, this recommendation is not considered a task for national government. 
115 Cyprus, Estonia and Slovenia. 
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5.4.9 Recommendation 3.9: encouraging, in collaboration with the Commission, the 
exchange of programme results, skills and experience within the European Union 
and with third countries, especially the applicant countries 
This recommendation concerns the question whether the Member States have a policy to 
encourage exchange and collaboration with other Member States. All 21 Member States indicate 
they have such a policy, while seven of them indicate this sub-recommendation was based on the 
Council Recommendation116. The recommendation is formulated quite broadly and does not specify 
harm reduction collaboration as such.  
There is a lot of collaboration between EU Member States (and vis-à-vis third countries outside the 
EU) in the field of drug demand reduction. Official collaboration takes place in the Horizontal 
Working Party on Drugs, the Pompidou Group (Council of Europe), the EMCDDA and Europol and 
international structures such as UNODC. 
Both ‘old’ and ‘new’ EU Member States, have been or are still collaborating within Phare Twinning 
projects in the field of drug demand reduction117. Member States also participate in the Exchange 
on Drug Demand Reduction Action (EDDRA) of the EMCDDA, a database with information on 
projects in the demand reduction field118. The ‘European Survey Project of Alcohol and Drugs’ 
(ESPAD)119 is an important monitoring project in which many EU Member States participate. 
However, ESPAD does not collect any data on harm reduction. 
Through the Programme on Community Action on the Prevention of Drug Dependence (1996-
2002)120, bi- and multilateral projects were funded, some focusing at harm reduction services and 
facilities, involving a variety of Member States121. The Public Health Programme 2003-2008122
provides further possibilities for cooperation, but due to the fact that bigger networks with many 
partners are funded and the average project duration is extended , the number of projects in the 
field of drugs and HIV\AIDS has been reduced 123.
EU Member States allocate specific funds to collaboration in the drug field. Several countries such 
as Italy fund European and international organisations working in the field of drugs. The 
Netherlands have been running the MATRA projects124 programme since 1995, which has also 
funded several projects in the field of prevention and harm reduction in Central- and Eastern 
European countries.  
Several multi- and bilateral networks exist in which countries and/ or organisations from Member 
States participate, such as the ‘Living with the Daily Dose’ project, the Rezolat network, BINAD (D-
NL), Mondorf (D-B-F-Lu) and – for example – the European Network of Drug and Infections 
Prevention in Prison (ENDIPP). Finally, EU Member States run projects aimed at other regions 
116 Cyprus, Germany, Estonia, Luxembourg, Latvia, Slovakia and Slovenia. 
117 There are several examples of such collaboration: Hungary and the Netherlands/ UK; Slovenia and Austria/ 
Spain, etc. In 2001 the EMCDDA – CEEC Co-operation Project was implemented by the EMCDDA, aiming at the 
integration of the Accession Countries into the activities of the EMCDDA and establishment of structural links 
with the REITOX network. References to Twinning collaborations can be found in Phare annual and country 
reports: www.ec.europa.eu/enlargement/key_documents/ phare_legislation_and_publications_en.htm
118 Specifically mentioned by UK, Portugal, Lithuania and Germany. 
119 European Survey Project on Alcohol and Drugs, an international prevalence survey among secondary school 
students aged 15-16, which is conducted every 4 years. The ESPAD project incorporates over 35 European 
countries. It is run by the Swedish Council for Information on Alcohol and other Drugs (CAN). 
120 The programme of Community action on the prevention of drug dependence within the framework for action 
in the field of public health, adopted by decision N° 102/97/EC of 16/12/96 of the European Parliament and of 
the Council, OJ L 19, 22.1.1997, p. 25, was extended by DECISION No 521/2001/EC of the European 
Parliament and of the Council of 26 February 2001 (cf. Decision extending certain programmes of Community 
action in the field of public health - Official Journal L 79, 17.03.2001). 
121 Relevant projects include: European Peer Support Programme (harm reduction among drug peers, 
coordinated by Trimbos Institute), SEARCH (prevention for refugees and asylum seekers, coordinated by 
Landesverband Lippe-Westphalia), ENDIPP (European Network on Drugs and Infections Prevention in Prisons, 
coordinated by Cranstoun), EUROMETHwork (exchange on methadone treatment, coordinated by Q4Q), 
EmTREND (Early Information Function for Emerging Drugs, coordinated by OFDT), etc. 
122 Programme of community action in the field of public health (2003-2008), adopted by Decision No 
1786/2002/EC of the European Parliament and of the Council of 23 September 2002; OJ L 271 , 09/10/2002 
p. 1–12.
123 Examples of drug-related projects that were awarded funding in recent years are: European Network on 
Drugs and Infections Prevention in Prison (ENDIPP), Democracy, Cities and Drugs, Correlation Network; 
124 Maatschappelijk Transformatie Programma voor Centraal- en Oost-Europa; a national funding programme of 
the Netherlands Ministry of Foreign Affairs, supporting the societal transformation in countries in Central- and 
Eastern Europe, with the aim to strengthen democracy, civil society and the rule of law.  
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outside the EU, such as the Candidate Countries, the MAGREB region and South American countries 
like Peru and Chile. 
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6 Conclusions 
The objective of this report is to provide an overview of existing policies and practices in the EU 
Member States regarding the implementation of the Council Recommendation on the prevention 
and reduction of health-related harm associated with drug dependence and an overview on the 
effectiveness of scientifically evaluated harm reduction interventions.  
Like most public health interventions, harm reduction services and facilities are best implemented 
as part of an integrated system of prevention and care, in conjunction with other areas of drug 
demand reduction. The general assumption is that drug prevention, harm reduction and drug 
treatment reinforce each other.  
6.1 Inventory of policies and practices in the EU Member States 
6.1.1 Recommendation 1 – harm reduction and public health policy 
Investment in preventing and reducing drug-related health harms makes good sense from a public 
health perspective. The short- and long term health effects of drug-related infectious diseases are 
generating costs for society as they are transmissible to the general population, especially if not 
discovered and treated in time. Drug-related deaths through drug overdose can be avoided to a 
great extent. 
This inventory shows that harm reduction is accepted as a part of drug demand reduction and 
public health policy in practically all EU Member States. All Member States have policies in place 
that reflect the majority of recommendations from the Council Recommendation. The Council 
Recommendation has provided guidance and a basis for policy development.  
Despite the above, there is often a time lag between policy formulation and adoption of harm 
reduction measures (i.e. in National Drug Strategies and Drug Action Plans) and their actual 
implementation in practice. The implementation of harm reduction policies takes time and requires 
regular adjustments because patterns in problem drug use and drug dependency change over time.  
6.1.2 Recommendation 2 – harm reduction measures in the Member States 
In general, harm reduction services and facilities as one of the possible approaches to respond to 
problem drug use, are common practice in all Member States, be it to a lesser extent for Cyprus 
and Sweden. Overall, policies of the European Union Member States are in balance with the 
recommendations as reflected in the Council Recommendation. However, the available data, which 
are largely self-reported by the Member States, provide an overview of the availability of services 
and facilities in the Member States, but not a complete picture of the accessibility125 and/ or the 
coverage126 of these interventions. Such data –in general– are often not available at national level.  
[R2.1] Information, Education and Communication (IEC) is a harm reduction instrument 
that is common in the countries of the European Union. Telephone help lines, harm 
reduction-based websites, educational leaflets and training for drug users focused on the 
reduction of drug-related harm (safer use, overdose prevention) are available in all or 
almost all Member States. Pill-testing as an IEC measure is not widely available: currently 
in five Member States such a service is provided. 
[R2.2] Communities and families of drug users seem widely involved in risk reduction in 
the Member States, and specific information is available to these groups in a majority of 
these countries. However, more in-depth analysis might be useful regarding the nature of 
this involvement and/ or the content of the available information. Further information is 
needed regarding the question how these stakeholders are involved in harm reduction, and 
what specific materials or courses are available. 
125 Accessibility implies that harm reduction services are open to all drug users that are in specific need of these 
services. For example, drop-in centres may exist throughout a country, but may be accessible to clients of 
(certain) drug services only (and not to those who are not in touch with these). In that case their accessibility is 
limited. Another example: treatment of hepatitis C or Aids may be available nationwide. But it may be that drug 
users are refused treatment. In that case accessibility to treatment is insufficient. Coverage in itself is not an 
indicator for the level of access drug users have to any given intervention. 
126 Coverage refers to the distribution of interventions and services among drug user communities in a country 
or region. For example, interventions may be available in places where large groups of drug users are situated, 
in one place only or available throughout a country. Adequate coverage means that interventions and services 
are in place where they are needed. 
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[R2.3] Outreach work, either street-based or at dance parties/ raves, is quite widespread 
in the European Union, albeit that in most of the countries this service is not available 
nationwide but only in specific geographical areas. 
[R2.4] Peers and volunteers seem to be involved in outreach work in the majority of 
Member States, and this holds true for the availability of training for peer and volunteers 
too.
[R2.5] Networking and cooperation between outreach work agencies exist in the vast 
majority of Member States, but in some Member States the amount of agencies that exists 
is too small to really speak of networking and cooperation. In a number of Member States 
networks of harm reduction-based organisations have been established over the past 
years, aiming at continuation and improving of services, and to improve users’ accessibility, 
for instance in the Czech Republic. In other countries, such as Spain (with autonomous 
regions), cooperation and the exchange of information between agencies in outreach work 
is not established, at least not formally. 
[R2.6] (Substitution) Treatment with methadone and buprenorphine, supported by 
psycho-social care is available in almost all Member States. This may indicate that the use 
of this harm reduction intervention is widely accepted among the Member States. Medical 
prescription of heroin to opiate dependent drug users, however, is available in only four 
Member States, and is mainly a Western European phenomenon (except for Spain, heroin 
maintenance is available in the United Kingdom, Germany and the Netherlands). The same 
holds true for drug consumption rooms. Similar to heroin prescription, this type of harm 
reduction intervention is controversial in the majority of Member States, and is only 
available in Germany, the Netherlands, Luxembourg, and Spain. 
[R2.7] Measures to prevent diversion of substituted substances are taken in 22 Member 
States. Diversion of prescribed substances, especially methadone and buprenorphine, is 
being reported by a number of Member States and measures are taken to prevent the 
leakage of substituted drugs to the black market; measures include strict registration, 
supervised consumption, urine check, and daily pick-up of the substance by drug users in 
maintenance programmes. In Italy, as reported by the National Focal Point, diversion of 
prescribed drugs is a minor problem that does not call for specific action. Overall, the 
number of drug users who sell their drugs for opiates, is not estimated to be high.  
[R2.8] Harm reduction interventions in prisons in the European Union are still not in 
accordance with the equivalence principle adopted by the UN General Assembly, UNAIDS, 
WHO and EU and which calls for equivalence in health services and care for drug using 
inmates (among which harm reduction) inside prison compared to services available in the 
community outside prison. Substitution treatment is available in prisons in the majority of 
the Member States, although the coverage in each country varies considerably. Sterile drug 
paraphernalia like filters, alcohol swabs and spoons, as a means to prevent the 
transmission of drug-related infectious diseases, are not provided in the majority of prisons 
in the Member States. Needle and syringe exchange is available in prisons in a limited 
number of prisons in Germany, Spain and Luxembourg only. 
[R2.9] A policy supporting the prevention of infectious diseases exists in 24 Member 
 States.  
Testing/ screening on infectious diseases are available to drug users in 22 Member States. 
Prevention and education measures, and treatment of infectious diseases targeting 
specifically at drug users are available in 20 Member States. Vaccinations programmes 
exist in all EU Member States but are not always targeting drug users: 13 Member States 
reported that they have vaccination programmes against tuberculosis that are targeted 
specifically at drug users.
[R2.10] Needle and syringe exchange is available to drug users in 24 out of 25 Member 
States. In fifteen Member States this service is provided nationwide. Almost all MS also 
provide (other) drug paraphernalia and condoms to drug users. Generally speaking, this 
harm reduction intervention is well provided. Needle and syringe exchange is a 
predominant or common response strategy to prevent infectious diseases among drug 
users, and low threshold agencies, including needle and syringe programmes are a 
predominant or common setting for measures targeting at the reduction of drug-related 
deaths, in the majority of Member States. 
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[R2.11] Despite the fact that all Member States have a policy that ensures that emergency 
medical services are trained and equipped to deal with overdoses, only ten Member States 
report to offer such training to emergency services. Naloxone, an opiate antagonist that 
counters the effects of opiates and therefore effective in case of an opioid overdose, is 
reported to be available to ambulances in twenty Member States. Information materials 
aiming at the reduction of drug-related deaths and risk reduction/ response training are 
provided to emergency services in just a few Member States. 
[R2.12] In total 23 Member States report that a policy is in place that promotes the 
integration of harm reduction with health, including mental health, and social care. The 
operationalisation of this policy still needs development as there are no indications that any 
Member State has succeeded in providing a fully integrated system of care for drug users.  
Even though the Member States indicate that harm reduction is considered an integrated 
part of (mental) health care and social care, this integration has not always been realised in 
practice. Member States continue to struggle with drug users who have both a dependency 
problem and a mental health problem (co morbidity or double diagnosis) and the 
reintegration of former drug users to a regular working life and housing is often still 
problematic.  
[R2.13] A policy supporting training leading to a recognised qualification for harm 
reduction professionals, exists in 22 Member States. Training in major harm reduction 
interventions such as needle and syringe exchange, outreach work, substitution treatment, 
low threshold agencies in general and for prison staff exists in the majority of Member 
States.
6.1.3 Recommendation 3 – harm reduction and monitoring & evaluation 
In regards to the 3rd Recommendation of the Council Recommendation, the impression is that 
Member States – in general – subscribe to the need for greater emphasis and use of scientific 
evidence for harm reduction practice. There seems to be a difference in approach between Member 
States regarding the question whether policy should prescribe the use and development of 
evidence for policy and practice, or whether this is a task for independent (scientific) structures in 
the drug field.  
[R3.1] Member States seek for scientific evidence to support the selection of interventions,
but this practice is not implemented in every EU Member State. Research that is mentioned 
in the data reported by the Member States includes research programmes into the 
effectiveness of e.g. substitution programmes, outreach work and needle exchange.  
[R3.2] The 2nd sub recommendation advocates the use of needs assessment in the 
selection of programmes. The inventory shows that this is still an area that needs further 
development. Member States do subscribe to the need of needs assessment, but have 
often not implemented it. Yet, needs assessment (e.g. Rapid Assessment and Response) is 
one of the important tools to assess what the coverage and accessibility of harm reduction 
interventions is and how it should be improved.  
[R3.3] The 3rd sub recommendation that calls for the development of evaluation protocols 
for the evaluation of interventions is among the least implemented sub recommendations. 
This recommendation is rather abstract from a perspective of policy formulation. A number 
of Member States considered this recommendation as a task for scientific institutions 
dealing with quality evaluation. Nevertheless, Member States such as the Czech Republic 
and Denmark have developed evaluation protocols and guidelines.  
[R3.4] Of all Member States, a little more than half have adopted a policy that aims to 
support the development of evaluation quality criteria. In the countries that have 
developed quality criteria, these are often part of a broader quality assurance programme 
for drug demand reduction, including prevention and treatment. It is unclear to what extent 
Member States have implemented quality guidelines in practice. Although the EMCDDA has 
developed several publications on quality and evaluation, Member States do not refer to 
these in their reports. 
[R3.5] This 5th sub recommendation calls upon Member States to collect and disseminate 
data in accordance with EMCDDA guidelines. Overall, the Member States have adopted the 
policy aim to implement the EMCDDA five key epidemiological indicators, but in operational 
terms, not all Member States comply fully with all standards and methodologies of these 
key-indicators. Furthermore, for the production of National Reports and other information 
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carriers, standard tables and structured questionnaires are completed by National Focal 
Points that exist in each Member State. The compliance with the Structured Questionnaires 
23 and 29 was satisfactory. However, overall there is no overview available to what extent 
Member States fully comply with EMCDDA guidelines. Member States do receive individual 
feedback from the EMCDDA on the quality and completeness of their input every year.  
[R3.6] Further research for scientific evidence on harm reduction measures and 
interventions is still needed. As the collection of hard evidence on effectiveness through 
RCT’s is not always possible for public health interventions other forms of evidence are 
needed. The response from the Member States regarding the use of scientific evidence on 
harm reduction to inform policy shows that this is not common practice. Member States 
increasingly report the evaluation of national drug strategies and national action plans, but 
only a limited number of Member States seem to systematically run evaluation schemes 
that aim to identify effective interventions. For a number of countries (e.g. France) the field 
of evaluation for policy is still relatively new. Many evaluation schemes are not specifically 
targeted at harm reduction interventions, but target a broader drug demand reduction 
field.  
[R3.7] Over half of the Member States indicate that they have policies in place that 
promote the development of evaluation training programmes. Reitox National Focal Points 
are mentioned frequently as (co-) organiser of such training programmes, but the overall 
picture is that evaluation training programmes are not yet part of the regular curricula for 
professionals in addiction care.  
[R3.8] More than half of the Member States have adopted a policy that aims to promote 
the involvement of stakeholders in the evaluation of (harm reduction) interventions.
However, very few Member States give concrete examples of structural participation and 
involvement. Limited information is available on the use of innovative methods aimed at 
involving drug users & family/ friends, professionals and/ or the broader community. 
Methods mentioned include competitions and awards .A European network has been set up 
(Rezolat) which has innovation and participation as one of its aims.  
[R3.9] This sub recommendation has seen quite some follow up. There is and has been a 
lot of collaboration between Member States in recent years in the field of drug demand 
reduction and – in a smaller number of instances – in the field of harm reduction, mainly 
through the DG SANCO Programme 'Community Action on the Prevention of Drug 
Dependence 1996-2002'. Furthermore, regarding the collaboration between the old and 
new EU Member States, the Phare Twinning programme has been instrumental. The 
EMCDDA has served National Focal Points with concrete support and advice. Finally, 
bilateral and multi-lateral programmes between Member States have been developed as 
well.
6.2 Effectiveness of harm reduction interventions 
Scientific evidence on effectiveness is available for many harm reduction interventions. This 
general conclusion is most promising since effect studies are sometimes hard to conduct in settings 
where these interventions take place. The circumstances in which harm reduction interventions are 
implemented, hardly accept a division in study groups for comparing effects of different 
intervention regimes. Obstructions may be practical or ethical. It is important that innovations in 
harm reduction are allowed to be based in the first place on pragmatism and local or regional 
constructions of ‘best-practice’. After this try-out phase, it may in some cases be feasible to gather 
evidence for specific interventions via high-quality effect studies.  
Regarding the prevention of infectious diseases, community outreach programmes are found to be 
effective in reducing several risk behaviours (e.g. injecting drug use). Interventions that include 
information, education and communication are possibly effective, when combined with other harm 
reduction interventions. Needle and syringe exchange programmes are probably reducing risk 
behaviours (needle sharing) and infectious diseases. They may possibly also reduce hepatitis C 
transmission. 
All existing preventive strategies and treatments of infectious diseases (i.e. HIV/ AIDS, hepatitis B 
and C) are effective. Due to the long treatment periods and its frequently occurring adverse 
effects, patient compliance should be stimulated during treatment.  
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In many different circumstances or settings, methadone and probably also buprenorphine 
maintenance treatment increases treatment retention and patient compliance, HIV risk behaviours,  
and opiate use, especially when individually adjusted doses are prescribed. 
In avoiding drug-related deaths, naloxone (if properly administered) is an effective crisis-
intervention tool. Methadone and probably also buprenorphine maintenance treatment are probably 
reducing the risk of drug-related deaths. Individually adapted high-doses probably reduce opiate 
use, and improve treatment retention. Interventions that include information, education and 
communication may possibly further reduce drug-related deaths when combined with maintenance 
treatment.
Other harm reduction interventions show fairly positive results as well, but we need more high-
quality studies to further confirm or rephrase conclusions. Medical (co)prescription of heroin show 
promising results. It is probably a safe and manageable intervention for chronic and treatment-
resistant opiate users and it probably also improves the health situation of drug users who do not 
respond to maintenance treatment. Pill testing programmes possibly reduce the use of potentially 
dangerous drugs (early warning). The fear that pill-testing programmes might encourage non-
users to start using drugs in recreational settings may be false. Drug consumption rooms may 
reduce needle sharing and probably also overdose death.  
Maintenance treatment in prisons is effective in reducing drug use, needle sharing and 
transmissions of drug-related infectious diseases. It possibly improves the health situation of both 
participating prisoners and prison personnel.  
Needle exchange in prisons is probably effective in reducing syringe or needle sharing, the 
reduction of transmission of infectious diseases.  
Information and education services and facilities in prison as well as improved living conditions for 
prisoners may be effective, but further research is needed. Overdose death after release from 
prison often results from reduced drug tolerance following a period of abstinence during 
imprisonment. 
Pre-release counselling may reduce overdose deaths after release from prison, but this has not 
been shown in effect studies. 
6.3 Final remarks 
Harm reduction seems to be an accepted approach in drug demand reduction policies in all EU 
Member States. Those harm reduction measures that have been implemented most by the Member 
States (IEC, needle & syringe exchange, substitution or maintenance treatment, naloxone 
availability) are found promising or effective in scientific literature, especially when combined in an 
integrated health care system. To date, none of the major harm reduction interventions that have 
been evaluated have been found ineffective or showed unwanted or undesirable results. 
The Council Recommendation of 18 June 2003 has been successful as it has guided and supported 
policy development in the Member States and because it set a ‘benchmark’ for existing policies. 
Most harm reduction programmes in the EU Member States are mainly focusing on ‘traditional’ 
drug use patterns, especially opiate dependency. Interventions taking into account new trends in 
drug dependence (e.g. crack cocaine and (Meth-) amphetamine dependence) as well as the 
growing prevalence of the mixed use of licit and illicit drugs are still scarce.  
The available data at EU level regarding the availability of harm reduction services and facilities in 
the Member States as collected and disseminated by the EMCDDA is comprehensive and of high 
quality. Nevertheless, the quality of data collections on the availability and accessibility of harm 
reduction services and facilities at national level does still need improvement because Member 
States do not always have a reliable overview of these services, nor do they always know by whom 
and how these services and facilities are used. 
Finally, at EU level and among the Member States there is an increasing awareness of the need to 
make policies more research-based and facts-driven, including harm reduction policies. This need is 
reflected by the 3rd Council Recommendation, but also in the European Drugs Strategy 2005-2012 
and the EU Action Plan on Drugs 2005-2008.  
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7 Suggestions for further steps on the field of harm 
reduction at EU level 
As reflected in this report, many of the harm reduction services and facilities mentioned in the 
Council Recommendation are available in the European Union Member States. The Council 
Recommendation of 18 June 2003 can be seen as an accelerator regarding harm reduction policies, 
services and facilities. The Council Recommendation seems to have confirmed the existing views 
and approaches within the EU. At the same time, there are clear differences between Member 
States regarding the choice for and implementation of specific services and facilities. In order to 
further develop the scope and quality of harm reduction services in the European Union, as well as 
to increase the possibilities for further comparison, a number of suggestions for further steps and 
improvements can be made. These suggestions are presented in the paragraphs underneath. 
7.1 Suggestions for further development of harm reduction policies 
x Member States may consider placing greater emphasis on the further integration of harm 
reduction in a broader public (mental) health and social care and welfare policy, with the aim to 
provide realistic and sustainable exit options (from drug dependence) for drug users in the long 
run. The integration of harm reduction with public health including mental health and social 
care is of great importance, as an integrated system of care may provide dependent drug users 
with the best possibilities to improve their social and health situation and facilitate their 
reintegration in society.  
x All EU Member States are confronted with the phenomenon of dual diagnosis among drug 
users, both regarding poly-drug use as well as psychiatric co morbidity. Co morbidity requires 
specific attention, especially when the integration of addiction care, (mental) health care and 
social care is concerned.  
x It is also important that harm reduction is part of an integrated system of addiction care and 
that different types of problem drug use(rs) are addressed by a diversity of responses. This 
requires diversity in treatment options that reflect the different stages in the drug addiction 
cycle and client’s needs (prevention, detection and screening, ambulant-care/ outreach, short-
term care, long-term care, aftercare and rehabilitation).  
x When further developing low threshold approaches to reach problem drug users and/ or to 
increase the success rates of early detection interventions (especially regarding new types of 
drug-related risks), Member States may consider to involve to a greater extent the primary 
health care system, including general physicians, nurses and family care systems.  
x It is essential that harm reduction services and facilities are provided structurally and on a 
continuous basis. Member States sometimes discontinue even successful programmes, because 
of political or financial reasons or because new approaches and treatments emerge. 
Discontinuing successful services may prove to be counterproductive and costly when problems 
re-emerge and/ or no suitable alternatives (with proven effectiveness) are available. In some 
cases, it may even be unethical if the consequence is that a relatively successful treatment is 
abolished without having an alternative in place. Professional ethics that apply in general 
health care should apply in harm reduction as well.  
7.2 Suggestions for further development of harm reduction services and 
facilities
x The effectiveness of maintenance treatment is clearly supported by evidence. Therefore it 
makes sense to match the accessibility to and coverage of this type of treatment to the 
demand among drug users.  
x It is advisable that maintenance treatment programmes take into account the need of drug 
users and their response to this type of treatment. Although methadone and buprenorphine are 
equivalent substances in maintenance treatment, drug users may experience different, 
sometimes more positive effects from one alternative over the other. It is advisable that both 
methadone and buprenorphine are available (i.e. covered by health insurance) to meet drug 
users needs. 
x The principle of equivalence regarding health care – including harm reduction – in prisons 
requires serious attention and ongoing investment. More than a decade of debate on minimum 
requirements, strategies and approaches towards harm reduction in prison has not resulted in 
a satisfactory availability, accessibility and coverage of effective measures in prisons.  
x The continuity of care and rehabilitation for drug users that are released from prison requires 
serious attention, as they are important to prevent drug-related death and relapse.  
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x Given the high prevalence rates among (former) injecting drug users, pro-active testing & 
screening for drug-related infectious diseases among high-risk groups is essential, so that 
vaccination and/ or low threshold treatment can be made available for all problem drug users. 
x It is important that policy makers realise that the visible effects of vaccination and treatment 
policies on the reduction of drug-related infectious diseases may show serious delays, as 
viruses may have been transmitted in the past but still cause illnesses and costs (e.g. chronic 
hepatitis, HIV, cirrhosis, carcinoma).  
x It is important that targeted prevention efforts are developed for special at-risk populations, 
including pregnant women and children, children of parents with psychological and addiction 
problems (incl. alcohol) co occurring disorders such as ADHD and drug addiction. Through early 
detection and interventions, problem drug use may be prevented or treated at an early stage.  
x In harm reduction, treatment retention by drug users is sometimes difficult to maintain in the 
long run, i.e. due to their unstable social situation, arrest, relapse, etc. It is therefore important 
that Member States continue to improve their addiction care system by increasing the 
accessibility of services and by applying flexible, pragmatic approaches that may provide tailor-
made solutions for specific needs. 
7.3 Suggestions for further development of quality, monitoring and 
evaluation in harm reduction 
x The use of scientific evidence to select interventions and to inform policy making, needs further 
encouragement. Needs assessments and the application of quality assurance models are 
needed to further improve the coverage, accessibility and effectiveness of harm reduction 
interventions.  
x Harm reduction interventions might best be evidence-based where possible. But science alone 
should not be the only advisor for policymakers and intervention decision makers. The 
effectiveness of some public health interventions implemented in a real-life situation cannot 
easily be evaluated through strict evaluation methods, such as RCT’s. Therefore it is advisable 
that appropriate instruments are developed to measure and establish the effectiveness of these 
interventions.  
x The absence of evidence supporting the effectiveness of interventions (in contrast to the 
evidence that indicates interventions are not effective) should also not stop Member States 
from implementing harm reduction measures if they seem to make sense from a pragmatic 
point of view.  
x Harm reduction interventions, including drug prevention and risk reduction measures, are 
culturally sensitive and need to be adjusted to local situations.  
x There is a need to improve the quality of data on availability and accessibility of harm reduction 
interventions in the Member States. In order to do so, it is important to improve the 
documentation of the range of services provided at specialised low threshold harm reduction 
agencies in EU Member States. For this purpose a standardised tool may be developed for 
describing the work of agencies (inventory). 
x There is also a need to determine better if harm reduction services are actually used, if they 
are used by those they are targeting and if those who need services have access to them. In 
order to do so, it is necessary to increase research on accessibility of services by documenting 
utilisation patterns on socio-demographic profiles of clients through a standardised client 
survey. This could be done by using harmonised approach/ tool across all Member States to 
generate added European value. 
x Like many other health-care interventions, some harm reduction services can be costly, 
especially when provided for a longer period of time. It is therefore useful to evaluate the cost-
effectiveness of harm reduction interventions, including social and economic costs to society127.
x And finally, the development of a bottom-up approach by involving key stakeholders in harm 
reduction may improve quality.  
7.4 The need for further research 
x Further research into (scientific) evidence on harm reduction measures and interventions is 
needed. In some cases – where hard evidence on effectiveness through RCTs is not possible - a 
further debate and development of innovative research methodologies is required, with the aim 
to bridge the gap between strictly controlled, often medical research (RCT’s) and research in 
the field of social sciences, including those in the field of public health interventions. For the 
time being, however, it should be considered to give innovative and pragmatic approaches the 
127 Example: Van den Brink [2003]: the Dutch heroin prescription trial also included a cost-benefit analysis of 
the intervention versus the original maintenance treatment scheme. A net benefit of US$ 13.000 per client on 
an annual basis was gained as well as a serious reduction of drug-related petty crimes and misdemeanors (up 
to 70% reduction).
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benefit of the doubt, especially if there are indications that they are successful and do not do 
any harm in daily practice. Not doing anything in these cases would result in unnecessary harm 
to drug user’s health, which might not only cause risk for public health but would also be 
questionable from an ethical perspective.  
x At the same time, it is advisable that the EU further invests in research and development of 
harm reduction measures. The European Union Drug Strategy 2005-2012 incorporates a 
balanced approach towards the drug problem which is relatively unique in the world. Research, 
including in the field of harm reduction that can provide a sound scientific basis for the principle 
of that balanced approach is much needed. EU research and development programmes (Public 
Health Programme, Framework Programmes) may support the development of such a scientific 
basis. Furthermore, Member States may consider conducting joint research or developing 
common interventions for specific challenges regarding drug-related harms they may 
encounter.
x Further research is also needed regarding the effectiveness of Information, Education and 
Communication interventions to prevent drug-related infectious diseases and drug overdose. 
And even if the evidence for needle and syringe exchange is showing good indications for 
effectiveness, more research is required for the implementation of this type of intervention in 
prison settings.  
x Maintenance treatment shows good results in improving drug dependent users’ health and 
social conditions, however further research is needed to examine its effectiveness in  
combination with psychosocial interventions. Regarding the effectiveness of services and 
facilities such as drug consumption rooms but also pill-testing programmes, further research is 
needed, also regarding the interaction of these interventions with other interventions. As stated 
earlier: by providing an integrated and comprehensive harm reduction response to infectious 
diseases and drug-related death, the benefits of a combination of interventions may be larger 
than the effectiveness of isolated interventions.  
x Regarding new types of problematic drug use and the drug-related harms associated with it, it 
is advisable to conduct further research into the effectiveness of selective and indicative 
prevention aimed at specific groups of drug users. This includes prevention and harm reduction 
in a-typical drug user communities.  
x Research into integrated interventions and treatments for drug users with a co morbid 
condition requires higher priority so that dependent drug users can receive the support they 
need.
x Furthermore, research into effective treatments for cocaine and amphetamine dependency is 
needed as a basis for cocaine maintenance treatment (for heavy cocaine users) and cocaine 
detoxification treatment. Also contingency management or reward-based interventions (giving 
rewards to drug users in treatment, e.g. small allowances for not using cocaine) needs more 
research.
7.5 Final suggestions 
x It is important that Member States continue to develop new harm reduction measures - parallel 
to those that already exist– that address new patterns and emerging trends in drug use and 
drug dependence. Most harm reduction policies, services and facilities that have been identified 
in this inventory study concern ‘traditional’ interventions in response to traditional forms of 
drug use. Drug use patterns change (e.g. shifts from injecting heroin use to smoking heroin), 
as well as at-risk groups and the types of drugs used.  
x Recently the EC’s Horizontal Working Party on Drugs128 emphasized the developments in 
Cocaine use among young adults. In several EU Member States recent cocaine use among this 
group (age 15-34) is rising129. Cocaine is often used in combination with other licit and illicit 
drugs in predominantly recreational, nightlife settings. Against this background, additional 
harm reduction measures may be developed. Such measures may include: 
x Improvements in data collection, both qualitative as quantitative in order to monitor 
emerging trends and patters. 
x Innovative methods to reach out to specific ‘at risk’ groups, e.g. in club settings. 
x Research into effective methods of (maintenance) treatment for cocaine and (meth-) 
amphetamine dependence130.
x Development of preventative interventions for ‘at risk’ groups. 
x The collection of data on problem drug use and drug-related harm at Member States level is 
still not always comparable due to different estimation systems at local level. Furthermore, 
128 HWPD, Cocaine – Identifying specific demand-reduction measures – Conclusions paper for the meeting of 10 
January 2006, CORDROGUE 11083/06, 29 June 2006. 
129 E.g. UK, Spain, the Netherlands, France, Italy, etc. Source: EMCDDA [2006]. Annual Report 2005. p. 56. 
130 New developments in research on the treatment of cocaine addiction include a.o. the development of a 
vaccine against cocaine dependence and treatment with Modafinil (mainly US based research). 
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more emphasis could be placed upon the prevalence of drug-related harm in relation to the 
specific at-risk groups in Member States rather than those of the general population. Member 
States with relatively small groups of problem drug users may have a high prevalence of drug-
related harms such as infectious diseases among these problem drug users. Although the 
number of problem drug users may be small compared to the general population, the 
prevalence of drug-related harm may be considerable. 
Finally, it might be interesting to examine whether – by the end of the EU Action Plan 2005-2008 – 
the implementation of policies, services and facilities regarding harm reduction as presented in this 
report, has progressed. Therefore it might be worthwhile to repeat the exercise that formed the 
basis of this baseline report and analyse what further progress has been made.  
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Introduction
This literature review primarily summarises scientific evidence for effectiveness of harm reduction 
interventions for drug users. Harm reduction largely overlaps with treatment, prevention and 
reintegration. The main focus of this review has been predefined on interventions targeting 
infectious diseases, drug-related deaths among drug users and maintenance treatment. We 
additionally report evidence for effectiveness on medical heroin prescription, pill-testing 
programmes, pre-release counselling, drug consumption rooms and in-prison interventions. The 
result of this selection procedure is that some prevention and treatment interventions have been 
kept out of this review, e.g. drug-free treatment or harm reduction interventions for cocaine and 
amphetamine dependence.  
This review also presents some results from general guideline publications that may be important 
for decision making on a national and European level. While scientific publications tell us what is 
known, guidelines are telling us what to do. A review of guideline publications is not considered 
feasible in a scientifically valid manner, because these publications vary too much in level of 
abstraction and methods. Appendix 1 of this review gives a more elaborate explanation on this 
subject. Instead this literature review presents some general remarks and recommendations from 
guidelines published by (inter)national funding organisations, e.g. the National Institute on Drug 
Abuse (NIDA), the World Health Organisation (WHO) and some other organisations.  
The references that have been used in this review are presented in appendix 2.
1 Methods 
Medline, PsycInfo, Embase and Toxline were screened with database-specific strings of key terms 
to identify and select relevant studies. The key terms used focussed on several indicators for 
effectiveness, (users of) illicit drugs and harm reduction. The literature search went from 1990 until 
mid 2005. We further checked the indices of several journals and websites in this domain for more 
recent publications. Reference lists in selected publications were screened on relevant additional 
publications and some experts were contacted. Predominantly English publications were selected. 
In many of the review studies however, publications in other languages were included. More recent 
publications were added based on tips from experts and screening websites of scientific databases 
and websites, for instance from the Cochrane Library, the World Health Organisation or 
governmental organisations. 
One of the key issues of this literature review is the question when a harm reduction intervention is 
considered to be evidently effective. An answer to this question assumes a two step procedure: 1) 
determine the evidence for effectiveness in the scientific literature, and 2) appraise or grade this 
evidence on a scale of being (in)sufficient for deciding an intervention or programme as 
(in)effective.    
A. Effectiveness 
There is an ongoing debate about the best methodology to be used in determining effectiveness of 
interventions in public health. Traditionally, medical science uses strict rules for experimental 
research and the gold standard is a so called randomised controlled trial (RCT). However, in public 
health issues, a design as applied in an RCT is often difficult or even impossible. In a strict scientific 
sense, alternative designs are not optimal to proof effectiveness. Thus, the methodological debate 
on the study design suitable to produce evidence of effectiveness in public health currently remains 
unsolved. 
In this report, we have chosen to follow the conservative methodological rules of experiment as 
applied in medical and psychological research, such in line with well-known scientific networks as 
the Cochrane Collaboration and the Campbell Collaboration. We have expanded the methodological 
scope somewhat by including studies that deviate from the RCT design (e.g. time-series or 
prospective cohort studies, preferably combined with a multivariate analysis, including factors that 
may also influence the outcomes). Finally, the results of some systematic reviews that used an 
adapted methodology for grading evidence, were also included in this review. This was done 
because the methodology used, adds value to the well-known methods for grading scientific 
evidence that are used in this literature review. Although this alternative methodology still needs to 
be evaluated, it offers a progressive step in determining the effectiveness of interventions in public 
health domains where randomised clinical trials are in many cases considered impossible, 
unfeasible or not desirable due to practical or ethical problems.  
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B. Evidence
Different levels of evidence are commonly discerned in grading evidence for literature reviews. 
Distinctions in cut-off-points between what is considered ‘sufficient’ and ‘insufficient’ evidence are 
largely arbitrary. Important however is to describe explicitly how the evidence has been appraised 
and graded. A rough grading procedure was used, i.e. without systematically specifying quantity 
and quality of the studies. When a systematic review or a meta-analysis of at least three RCT’s was 
available with equally directed significant outcomes or three separately published RCT’s with 
outcomes that were alike and significant, the evidence is considered ‘sufficient’, thus the 
intervention is considered effective. An amount of two RCT’s or one RCT combined with at least two 
studies of lesser quality (i.e. well-done time-series or prospective cohort studies) was considered to 
give valuable indications for effectiveness. In these cases the intervention is probably effective. In 
case of doubt, i.e. only one RCT (with or without one study of lesser quality) or merely one or two 
studies that are all of lesser quality but with positive findings, the evidence is in fact still 
insufficient. In this case we use phrases like ‘may be effective’ or ‘possibly effective’ because we 
don’t know enough about this subject yet. For some interventions no studies were found or studies 
showed no consistent positive findings. In this last case there is no evidence or the evidence is 
unknown yet.  
For many interventions conclusive proof for the effectiveness is not available yet. This does not 
necessarily mean that these interventions are ineffective. It merely means that we still do not 
know enough about the effects of these interventions. These interventions may appear to be 
effective if enough high-quality studies would be available. This implies that many of these 
interventions are worthwhile trying out in real life situations. Daily experience and results of 
studies of lesser quality may suggest that these interventions do have positive outcomes on drug 
users and their environment. However, although this kind of ‘evidence’ is often used in constructing 
guidelines, it is not the primary subject of this review.   
Note that in most studies that have been evaluated, effectiveness means effectiveness under 
controlled conditions (efficacy). Effectiveness in everyday practice will be explicitly labelled as such.  
2 Prevention and treatment of infectious diseases among drug users 
Drug-related infectious diseases can cause serious health problems among drug users that may 
lead to chronic complications and eventually death. Injecting drug use increases the risk of 
hepatitis C considerably. Together with unsafe sexual behaviours, injecting drug use increases risks 
of HIV and hepatitis B infections. Drug-related infectious diseases exert a high financial and social 
burden on society. Below we report scientific results on the effectiveness of several prevention 
interventions of drug-related infectious diseases and treatments of viral infections. 
2.1 Prevention of infectious diseases 
In theory, prevention of injecting drug use could be one of the most effective strategies to reduce 
drug-related infectious diseases (DRID). However, these diseases are not solely related to injecting 
drug use but also to unsafe sexual contacts and unsafe life style in general.  
2.1.1 Information, education and communication (IEC) 
Many types of information, education and communication (IEC) are being used in prevention of 
injecting drug use. IEC-messages may be spread via leaflets, booklets, audio-visual media or 
advocacy. IEC may be part of any other intervention, e.g. mass media campaigns, outreach and 
other harm reduction interventions, treatment, HIV-testing and counselling, or harm reduction 
counselling.  
Few high-quality studies can currently be found in the international literature on IEC, and the 
evidence of effectiveness of IEC is weak. IEC may at best be short-term effective in raising 
awareness and in more specific variants in changing knowledge and understanding, not in changing 
behaviour. These interventions are widely used as part of more extensive prevention or treatment 
packages. In general it is assumed that these interventions are more effective when combined with 
other prevention strategies (Miller & Rollnick, 1991; Walitzer et al., 1999). The literature also 
stresses the importance of applying IEC after adapting messages and strategies to the needs of 
specific target groups (Aggleton et al., 2005).  
Many studies concentrate on mass media messages, fear-arousal and motivational enhancement 
techniques. Mass media campaigns in preventive messages appeared to be largely ineffective 
(Derzon & Lipsey, 2002; Westat, 2003). Other studies show that when mass media messages are 
not paternalistic but invite people to make choices based on ones own insights and opinions they 
tend to be more effective (Burgoon et al., 2002).  
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Individual motivational enhancement may be a promising intervention (Dunn et al., 2001). 
Actually, to be motivated is a prerequisite for both the success of treatment and harm reduction 
(Joe et al., 1998; Dakof et al., 2003).  
2.1.2 Community-outreach programmes 
Community-based outreach programmes are considered another component of preventing drug-
related infectious diseases among risk groups i.e. those exposing sexual risk behaviour or injecting 
drug use. These outreach programmes aim to create access to hidden populations in their daily 
environment for targeted action against high-risk behaviours. Outreach activities are matched to 
the individual needs of members of the target group. Activities include increasing risk awareness, 
demonstrating skills to avoid or reduce risks, behavioural counselling, distributing injecting 
equipment (see 2.1.3), or providing referral to regular treatment.  
Other components of prevention of infectious diseases are needle and syringe exchange 
programmes and a range of means to reduce harm indirectly. Examples are promotion of condom 
use, bleach, access to HIV-testing and counselling programmes, e.g. distributing information on 
programme locations and times and/ or on injecting equipment.  
Contents of community-based outreach programmes may vary widely and have changed in time. 
Examples of programme components are: identifying and establishing contacts with injecting drug 
users, identifying and recruiting peer leaders, increasing risk awareness, demonstrating skills to 
avoid or reduce risks, distributing injecting equipment, behavioural counselling, or providing 
referral to treatment.  
These programmes serve to access (partly) hidden populations of drug users in their natural 
surroundings and enable them to reduce drug-related risk-behaviours. Desired outcomes were 
increase in programme coverage, programme participation, and a reduction of both risk behaviour 
and infection rates.  
The results of more than 40 published studies, including multi-country, multi-site studies and 
meta-analyses (sufficient evidence), reveal that community outreach programmes are effective on 
several outcomes. Injecting drug users (IDUs) reached by these programmes and who are offered 
access to harm reduction services, report reducing their risk behaviour and lowering their exposure 
to HIV (Needle et al., 2004; 2005). IDUs referred by outreach workers to available, accessible and 
acceptable services (e.g. voluntary testing, counselling, and drug dependence treatment) 
increasingly use these services and reduce their injecting drug use. In general, drug users who 
participated in a community-based outreach intervention were also slightly more likely to reduce 
their sexual risk behaviour, compared to those who followed another (unspecified) intervention 
strategy. In studies focussing on sex behaviours, there were indications that treatment compliance 
increased and drug use reduced considerably when the intervention-group was compared to a 
group that had no intervention at all (Semaan et al., 2002; Des Jarlais & Semaan, 2005). Most 
findings in the above-mentioned studies were consistently reported in different places, under 
different circumstances and at different times during HIV epidemics (WHO, 2004a). Besides being 
effective on several outcomes, outreach programmes are relatively inexpensive interventions for 
preventing HIV and other drug-related infections among IDUs. Empirical studies of outreach 
programmes that also include preventing HIV infections (sero-incidence) are rare and of lesser 
quality, but the outcomes suggest that outreach work may substantially reduce HIV infections 
among injecting drug users.  
The available literature strongly suggests that community-based outreach work for drug users 
should be made accessible and disseminated. Training, supervision and compensation of outreach 
workers (often ex-users) are essential for sustaining (the quality of) outreach work. Prevention of 
relapse of supporting staff (partly ex-users) is also important. Advice, information, support is 
crucial, together with careful selection and debriefing of the outreach workers.  
2.1.3 Needle and syringe exchange programmes   
Sharing injecting equipment is a main risk factor for the transmission of drug-related infectious 
diseases. In general, the incidence of these diseases among injecting drug users is highest 
compared with non-injecting drug users (Anderson & May, 1991). Needle and syringe exchange 
programmes are meant to reduce the spread of infectious diseases among injecting drug users. 
The introduction of needle and syringe exchange programmes has grown considerably from 1985 
on to 2001 in 24 European countries including Bulgaria and Norway (EMCDDA, 2005).  
The WHO published the first comprehensive international review on evidence for sterile needle and 
syringe exchange programmes (NSPs), showing that these programmes probably reduce HIV 
transmission (i.e. incidence, prevalence, risk behaviour) that these are probably safe and – based 
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on one of the added criteria for grading evidence – these programmes are probably also cost-
effective (Wodak & Cooney, 2004). A second review showed specifically the cost-effectiveness and 
even cost-saving effects of needle exchange programmes in HIV prevention. In preventing 
hepatitis C, cost-effectiveness of needle and syringe exchange programmes is less clear (De Wit & 
Bos, 2004).
The systematic review of Gibson et al. found that NSPs reduce risk behaviours that are strongly 
related to HIV infection. Two-thirds of the reviewed studies (28) had positive outcomes of needles 
or syringe exchange (reductions in HIV infection rates), and one-third had null/ mixed (fourteen) or 
negative (2) results (Gibson, 2001).  
In several studies unanticipated benefits were also found, e.g. increased enrolment in drug 
treatment or higher treatment retention rates (WHO, 2004a; 2004b). These findings are consistent 
with earlier reviews (e.g. Satcher 2000; Institute of Medicine, 2001; Gibson et al., 2001).  
Wodak and Cooney’s review compared changes over time in HIV sero-prevalence rates (traces of 
HIV-infection in the blood) among IDUs worldwide for cities with and without needle exchange 
programmes. There was a remarkable difference in average sero- prevalence rate per year 
between cities without NSPs and those with NSPs. The average annual change in sero-prevalence 
was significantly lower (11%) in cities with NSPs (Hurley et al., 1997).  
Recently Amundsen noted however, that the design of this and some other studies that were 
analysed in these reviews lack adequate control groups or analysis of confounders. Thus, actually it 
cannot be decided yet which factors are more important for reducing HIV-transmission, NSPs or - 
for instance - HIV testing and counselling (Amundsen, 2006).
Results of long-term monitoring activities should also be interpreted with caution (cf. Emmanuelli & 
Desenclos, 2005). French monitoring results show associations between NSPs and several 
outcomes, i.e.: growing (and later declining) numbers of syringes distributed or sold over a period 
of 7-8 years; lower HIV prevalence rates among injecting drug users; a decline of deaths due to 
overdoses; and a decline of injecting drug users that have been arrested by the police. The 
hepatitis C rate remained high. These results suggest the NSPs may have positive effects on HIV 
prevalence rates, deaths due to overdoses, and on numbers of arrested drug users by the police. 
This monitoring study shows that access has improved and that the coverage of NSPs in France is 
large. Although these are important prerequisites for success, large coverage rates and improved 
access are not sufficient conditions for reductions in drug-related harm. Monitoring studies can at 
best give circumstantial evidence for possible causal relationships.  
2.1.4 Treatment of drug dependence for preventing infectious diseases 
Maintenance treatment involves the prescription of a substitution drug to a dependent drug user 
for a longer period of time (in general, years). Its primary aim is to stabilize one’s living and health 
conditions. Maintenance treatments are also assumed to be useful for prevention of infectious 
diseases, e.g. by reducing or stopping injecting drug use. The risk of getting these diseases is on 
its turn assumed to be reduced. Methadone maintenance treatment is already introduced in most 
European Member States and buprenorphine maintenance treatment predominantly in France and 
the Czech Republic.  
Methadone maintenance treatment is most studied (see also 4.1) and a narrative review shows 
that maintenance treatment may prevent needle sharing and HIV infection (Sorensen & Copeland, 
2000).  
Another narrative review of meta-analyses and systematic reviews (WHO/  UNODC/  UNAIDS, 
2004; Farrell et al., 2005) covered methadone, buprenorphine, naltrexone and their effect on 
preventing HIV/AIDS. Methadone maintenance treatment (MMT) is not only associated with a 
significant reduction of (injecting) opiate use, but also with a reduction of sharing of injection 
equipment. It does not seem to lead to more protected sex behaviour. These findings are 
consistent with those of a Cochrane Review (Gowing et al., 2004; Gowing e.a., 2006).  
2.1.5 Vaccination for hepatitis B
Series of vaccination are effective in preventing hepatitis B infections. Hepatitis B infection may 
ultimately end in serious liver disease (cirrhosis or cancer). Effective vaccination is several decades 
old and has proven to be effective in protecting against clinical hepatitis B infection and chronic 
carriage of this disease for those who responded to complete hepatitis B primary vaccination series 
(three vaccinations). Follow-up studies showed that from ten to fifteen years after completed 
vaccination, no infections occurred and development of a chronic infection was very rare. These 
(already) favourable results were valid for infants, children and adults (cf. Jilg & Van Damme, 
2004). Larger follow-up periods should be investigated before a firm conclusion can be drawn 
regarding the duration of this favourable effect.  
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2.2 Treatment of viral infections 
Most studies on treatments of viral infections are not specifically directed to drug users, but the 
results are also considered valid for this subgroup of patients. In case of doubt this is mentioned 
explicitly.  
2.2.1 Treatment of HIV/ AIDS 
Highly Active Antiretroviral therapy (commonly abbreviated as HAART and nowadays more briefly 
labelled as antiretroviral therapy) became available in 1996 as an effective treatment for HIV 
infections in general. HAART suppresses the viral HIV load in the human body and this was more 
than welcome during the epidemic that started two decades ago.  
Combination Antiretroviral Therapy (CAT) may be administered to HIV-infected individuals as a 
maintenance treatment after successful initial antiretroviral mono-therapy. CAT has been shown to 
decrease viral replication, to improve immunologic function and to delay the progression rate of the 
infection. But CAT also has some draw-backs. There are concerns about possible cumulative 
toxicity of CAT. Furthermore, positive outcomes of (combination) antiretroviral therapy require 
much discipline of patients to adhere to the prescribed regimens in order to stay effective. This 
adherence is burdened by a range of severe adverse effects of these therapies. The results of a 
systematic review show that pharmacy-led educational counselling and telephone support is 
helping those people living with HIV/  AIDS to keep to their therapy regimens (Haddad et al., 
2000). Whether this strategy also helps for infected drug users is still questionable.  
A second review of four trials showed that reducing the number of treatment drugs in CAT also 
reduces its effectiveness (Rutherford et al., 2003). Thus the need to find less complicated 
treatment regimens with fewer potential drug interactions and less adherence difficulties remains. 
Research should address “(…) longer and more potent initial therapy, alternating drugs, or 
beginning initial therapy much earlier in the course of infection.” (ibid.). People with HIV often seek 
alternative or ‘complementary’ treatment for their disease. However, evidence for effectiveness of 
herbal medicines for HIV-infection is still insufficient. Many small studies have been published but 
the bulk of these have – on average - low methodological quality (Liu et al., 2005). Finally, 
people’s beliefs about antiretroviral therapy and viral load may be of influence on sexual behaviour 
(Crepaz et al., 2004).  
2.2.2 Treatment of hepatitis B and C 
Treating hepatitis B and C with antiviral therapy evolved quickly during the past decade. Injecting 
drug use appears to be an important way of transmission of hepatitis C although sexual behaviour 
is probably more important.  
One of the aims of antiviral therapies is to interrupt the progression of acute hepatitis B and C. 
Once chronic, hepatitis B and C may have devastating effects on health. Due to the overall health 
morbidity of this disease and its long-term consequences, wider availability of a range of 
interventions (e.g. needle and syringe exchange programmes, maintenance therapies, behavioural 
interventions, bleach distribution, supervised injection rooms) is very likely to lead to significant 
health and economic savings (WHO/ HEN, 2005). 
Although interferon monotherapy was in former years the best-known intervention for this disease, 
current evidence points at polyethylene-glycol interferon, i.e. pegylated interferon or abbreviated 
“peg interferon”, administered as a once-a-week injection during a year, as the most effective 
treatment option now available. When peg interferon is combined with ribavirin it results in a far 
more effective treatment option compared with interferon monotherapy (Chander et al., 2002; 
Stein et al., 2002). Depending on the viral strain, six to twelve months of this “new” combination 
treatment can achieve a stabilisation of viral responses in 46% to 82% of the treated persons. On 
the other hand adverse side effects are prominent among some three quarters of those who are 
treated. Medical support is often needed in order to alleviate these side effects. Starting somewhat 
later with therapy (8-12 weeks after the onset of the disease) does not endanger the success of 
this treatment (WHO/ HEN, 2005).  
A systematic review also assessed beneficial effects of interferon (Alpha-2b) and ribavirin 
combination therapy when compared with interferon mono-therapy for chronic hepatitis C. 
Combination therapy was significantly more beneficial. Moreover, this favourable result was also 
valid for naïve, non-responding and relapsed patients (Brok et al., 2005b). Professionals should be 
alert to the fact that adding ribavirin to interferon therapy significantly increases several adverse 
events, e.g. anaemia (22% of the patients), dermatological problems, gastrointestinal problems, 
cough, fatigue, and some other physical inconveniences.  
It should be born in mind that the risk of developing severe liver disease for people with co-
infections of HIV and HCV (not uncommon among injecting drug users) is significantly higher. 
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Timely diagnosis is essential and adjusted treatment regimes should be considered (Graham et al., 
2001; Strathdee & Patterson, 2006). Treatment of hepatitis B and C is in principle equally effective 
for drug users, but it is more demanding for this subpopulation because it requires long-term 
disciplined behaviour to successfully end this therapy. Finally, interactions between interferon 
treatment and addiction treatment drugs should be anticipated and monitored.  
2.3 Treatment of tuberculosis 
Effective tuberculosis treatment has been available since the 1940s. Strategies that improve 
adherence to treatment with anti-tuberculosis drugs for patients with clinically active tuberculosis 
are important, because 20 to 50% of these patients do not finish the two-year treatment. Not 
complying with treatment can result in prolonged infectiousness, relapse in tuberculosis, or even 
death. For drug users these percentages may even be higher.  
Two high quality American studies on completion rates of drug users in tuberculosis treatment 
were traced. The results showed that when such therapies are directly monitored by a health 
worker, a community volunteer or a family member, no differences could be observed compared 
with routine self therapy without monitoring (Volmink & Garner, 2003).  
2.4 Remarks from general guidelines 
Drug dependent people with infectious diseases are often stigmatised and the risk of neglecting 
people who are drug dependent among medical treatment professionals is considerably higher than 
for those who are not drug dependent. Programmes that integrate maintenance treatment with 
HIV/  AIDS treatment should therefore be encouraged (WHO/  UNODC/  UNAIDS, 2004). 
Preferences of professionals are even stronger prejudiced for infected dual diagnosis patients who 
also have psychiatric disorders. Thus, people with mental illness and drug dependence are often 
“double stigmatised”. Mental illness and drug dependence however are related, and co-occurring 
psychiatric and substance use disorders tend to reduce treatment effects considerably (RachBeisel 
et al., 1999; Compton et al., 2003). Conclusive evidence for integrated treatment options for dual 
diagnosis patients is still absent (cf. Nunes et al., 2004). Either the focus of treating infected 
patients is on mental illness or on drug dependence, but rarely on both (Drake & Brunette, 1998; 
Shaner et al., 1993).  
A clinical practice guideline publication recommends monitoring of symptoms of depression of 
injecting drug users during the early weeks of interferon treatment. Anti-depressant treatment 
should start early and continuing this treatment throughout the interferon treatment period is often 
necessary (De Bie et al., 2005).  
In general, granting easy access and taking care of additional supporting activities for improving 
adherence to medical treatment (or vaccination) of infectious diseases is crucial for drug users. 
Access should be granted, based on common medical eligibility criteria for antiretroviral treatment, 
and not on vague non-medical ones that leave much room for individual interpretations by the 
professionals who are in charge of deciding upon access to treatment or not. Examples of non-
medical criteria are unstable living conditions or uncontrolled drug use (Engelhardt, 2005; New 
York State Department of Health, 2005).  
Drug dependence may reduce adherence to therapy. Medical complications and co-morbid 
infections may further hamper treatment and decrease responses. Because many opiate addicts 
are also heavy alcohol users, exclusion of alcoholism in RCT’s may bias (improve) outcomes 
(Lehman et al., 1990). Yet, exclusion of drug users from access to tailored treatment of infectious 
diseases is undesirable both from a health and a human rights perspective. Access and 
participation may be an entry point to other prevention and treatment options and increase the 
coverage of care among a risk group that may also infect non drug users.   
Interactions between methadone or buprenorphine and antiretroviral drugs or anti-tuberculosis 
drugs should be anticipated by properly adjusting doses of substitution drugs on individual level. 
Adverse interaction effects may create distrust in medical providers and result in unwillingness to 
take medication. In general, people with tuberculosis and HIV should end their tuberculosis therapy 
first, unless the risk of progression or death from HIV is high. Careful assessment and education of 
both treatment professionals and participants will maximise treatment adherence for the vulnerable 
subgroup of drug users (WHO, 2002; WHO/  UNODC/  UNAIDS, 2006).  
Some principles for successful medical care programmes for active injecting drug users are: 
x High accessibility, and situated in facilities that are part of the general health care system, 
free-of-charge and low threshold. 
x Optimal comprehensiveness of care per location. 
x As intensive as is acceptable for individual patients (not driving them away). 
x Close linkage between harm reduction services and facilities and treatment programmes. 
(WHO/  UNODC/  UNAIDS, 2006).  
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2.5 Conclusions
Information, education or communication may at best be short-term effective in raising awareness 
and in more specific variants in changing knowledge and understanding, not in changing behaviour. 
These interventions are possibly most effective when they are part of more extensive prevention or 
treatment packages.  
From a public health perspective, it is recommended that community-based outreach work for 
hidden populations of drug users should be made accessible and disseminated, since it is an 
effective strategy. Adequate training facilities, supervision and compensation of outreach workers 
are essential ingredients for sustaining the quality of outreach work.  
Needle and syringe exchange programmes are both probably effective and cost-effective in 
preventing needle and syringe sharing and the spread of drug-related infectious diseases. Still, 
prevention by testing on HIV, vaccination against hepatitis B and C or tuberculosis and counselling 
are also important activities for of drug users. Effective treatments are also available for HIV/  
AIDS, and hepatitis B and C. Treatment is needed for months to years, or even life-long, and needs 
to be properly monitored on adherence, especially among drug users.  
Prejudice and other psychological barriers within medical care services due to prevailing stigmata 
against drug users, are hampering effective treatment. The same barriers can be found for dual 
diagnosis patients (drug users who also have mental illnesses).  
From a humanitarian and public health perspective these barriers should be alleviated. Current 
brain research points at drug dependence as a mental illness. It has been recommended to apply 
medical and mental health criteria for disease or illness in treatment of drug dependence rather 
than the largely prevailing subjective perceptions among medical professionals (e.g. proclaiming 
that drug dependence is a matter of choice).  
3 Prevention of drug-related deaths 
“Death by drug overdose, mostly involving opiates, is a major cause of deaths among young 
people in Europe, where over 8000 such deaths are recorded each year, and is currently the 
leading cause of death among drug injectors.” (EMCDDA, 2004). Heroin overdose constitute the 
primary problem when thinking about drug-related death. In many cases death is caused by the 
use of more than one substance, e.g. heroin, alcohol, benzodiazepines (EMCDDA, 2005). However, 
overdose death may also be caused by methadone, cocaine and other substances (Caplehorn et 
al., 1999). A cohort study shows that the risk of methadone overdose death seems to be highest 
during the first two treatment weeks (Buster et al., 2002). Street injecting, poly drug use and 
relapse after treatment or prison, increase the risk of overdose (cf. Advisory Council on the Misuse 
of Drugs, 2000; Zador & Sunjic, 2000; Corkery et al., 2004). The focus in this paragraph is on 
prevention of death from opiate overdose, due to the paucity of studies on the effects of activities 
that aim to reduce the risk of an overdose of other drugs. The definition of the EMCDDA is 
restricted to those deaths that are caused directly by (and in general shortly after) drug use 
(EMCDDA, 2004). It should be noted however, that many factors in the life of drug dependents 
may ultimately result in death, e.g. risky behaviours resulting in accidents or infectious diseases 
that afterwards may result in death.  
Drug-related death may be prevented by participating in needle or syringe exchange programmes 
(see 2.1.3). Examples of other preventive interventions that target a reduction of the number of 
deaths and that were not mentioned in the paragraph on infectious diseases are: prevention of 
death caused by an overdose with the antidote naloxone (the most direct way to prevent opiate 
related deaths); and four interventions with broader targets than exclusively reducing deaths by 
overdose, for instance: maintenance treatment; pill or drug testing programmes (for users of 
synthetic drugs but also users of cannabis and cocaine); pre-release counselling (avoiding the risk 
of drug overdose due to getting out of the habit after leaving prison or treatment); and drug 
consumption rooms (mainly but not exclusively for injecting drug users). The three last ones are 
reported in paragraph 4 of this annex. Furthermore, some important conditions for effectiveness of 
harm reduction interventions are also valid for preventing drug-related deaths, e.g. information 
and education, increasing access to interventions and behaviour protocols for police officers when 
in contact with drug users (Warner-Smith et al., 2001).  
Most of these interventions cannot be studied on their effectiveness in high quality experiments 
due to practical or ethical problems. The consequence is that the effects of many probably effective 
interventions remain somewhat unclear from a scientific viewpoint. As has been stated before, this 
does not mean that these interventions do not have desirable effects. Daily experience and results 
of studies of lesser quality may suggest that these interventions do have positive outcomes on 
drug users and their environment. However, this review is focussing on the available scientific 
evidence.  
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3.1 Preventing opiate overdose death with naloxone 
Factors associated with overdose are poly drug use, route of administration (injecting drugs), 
differences in drug purity, and reduced drug tolerance levels due to enforced abstinence or reduced 
drug use during treatment or in prison settings (Darke & Hall, 2003). Naloxone is known as a 
specific and effective but short acting and expensive antidote to opiate overdose, without showing 
adverse effects (Dettmer et al., 2001). Provision of naloxone reverses the effects of acute narcosis, 
including respiratory depression, sedation, and hypotension (Darke & Hall, 2003).  
It should be noted however, that the evidence for avoiding overdose death in real life situations by 
using naloxone is not straightforward. In real life circumstances administration of naloxone may be 
hampered by psychological restrictions (misconceptions and negative views of its impact and use). 
Peers or others who are present are rarely behaving adequately to overdose (ibid.). And even when 
naloxone is used timely, this potentially rescuing substance alone may be insufficient to keep the 
victim alive. Especially rescue breathing, may also be needed. Furthermore, an additional dose of 
naloxone may be necessary depending on the severity of the overdose taken, and sometimes 
complications will necessitate in-hospital care (Schulz-Schaeffer & Puschel, 1995).  
There is little evidence on the safety and efficacy of peer administration of naloxone in the 
prevention of opiate overdose, nor is there sufficient evidence for take-home naloxone (NACD, 
2003) but this does not mean that these activities are ineffective. They probably become more 
effective when accompanied by training of peers in knowledge about overdose symptoms and 
administration skills (Worthington et al., in press). And also for take-home naloxone, mortality 
from overdose may remain unaffected when other persons are not acting properly, or when those 
who are willing and able to act are absent. Thus peers and others should be trained to act properly 
in that situation (Baca & Grant, 2005). Pre-hospital, intranasal administered naloxone may also be 
a safe and effective first line treatment option, both for reducing overdose death and for preventing 
needle stick injury during the injecting process by semi-professionals or others (Ashton & Hassan, 
2006).  
Thus, naloxone is an effective drug for prevention of opiate overdose deaths, but additional 
measures should be taken in order to increase its success.  
3.2 Maintenance treatment for opiate dependence and drug-related death 
Several studies show a relationship between maintenance treatment of opiate users and a 
reduction of drug-related death. Most studies address methadone programmes. Though there are 
hardly any randomised controlled trials on this subject, some studies show that maintenance 
treatment is still a promising alternative in reducing drug-related deaths.  
A meta-analysis of one RCT and five cohort studies (Caplehorn et al., 1996) shows that the risk of 
dying from opiate use probably reduces when opiate dependent persons participate in methadone 
programmes (on average to a quarter compared with not attending a methadone programme). 
High doses of methadone (i.e. more than 80 mg per day) improve treatment retention, patient 
compliance and reduce other opiate use (Faggiano et al., 2003). Individually adapted high doses 
may also reduce the risk of overdose. Although only one controlled prospective study reports this 
outcome, the results are highly plausible. Identical conclusions are probably valid for higher doses 
of buprenorphine maintenance treatment (Ling & Smith, 2002). Low threshold maintenance 
treatment will most probably further reduce overdose deaths because it is more attractive for drug 
users who are not participating in traditional maintenance programmes (Reinås et al., 2002).  
Finally, a high-quality Spanish cohort study among more than 5000 opiate dependent people 
strongly supports a causal relationship between not attending low threshold methadone 
programmes and overdose death rate (Brugal et al., 2005). The evidence is supported by the 
number of drug-related deaths analysed, the analysis procedures and the size of the outcomes. All 
heroin dependents seeking treatment in Barcelona between 1992 and 1997 were (on average) 
assessed every nine months until the end of 1999. The death rate among this population was some 
twenty percent (N=1005). Thirty-five percent of those who died in this period, did so from 
overdose, 38% from AIDS and 27% caused by other factors. Approximately half of this population 
participated in methadone programmes. Methadone most probably contributed to a reduction in 
mortality rates or HIV infections. The total death rate reduced from 5.9 per 100 person years in 
1992 to 1.6 in 1999. The most important factor associated with mortality was “not participating in 
a methadone programme”.  
3.3 Preventing overdose death with information, education and communication 
Research on effectiveness of information, education and communication (IEC) for injecting drug 
users was already evaluated in paragraph 2.1.1. The conclusion was that the evidence for 
effectiveness of IEC still appears to be weak (Aggleton et al., 2005). Possibly IEC works better 
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when it is combined with other interventions or when it is part of a broader intervention package, 
specified for different target groups. When this is done, it motivates clients and retains them in 
treatment (Noonan & Moyers, 1997; Dunn et al., 2001; Burke et al., 2002).  
Techniques to enhance motivation to change risk behaviours are not sufficient for success, but may 
be necessary still (Dakof et al., 2003). Equal to IEC, motivational enhancement techniques may 
possibly best be used as part of multiple treatment packages. In fact this is already done to a 
considerable extent. IEC may also be more effective when combined with distribution of sterile 
needles, syringes or condoms (Miller & Rollnick, 1991; Walitzer et al., 1999).  
Firm conclusions about effects of IEC on preventing overdose are not possible but it should be 
repeated that effectiveness of other preventive intervention packages may be increased by also 
supplying IEC in these programmes.  
3.4 Remarks from general guidelines 
Guideline remarks on methadone programmes can be found in paragraph 4.6. Medical guidelines 
exist for diagnosis and treatment of acute heroin overdose (cf. Sporer, 1999). More general 
guidelines should address the fact that often medical staff is not trained to treat drug users, nor 
are peers or relatives who may be present when an overdose occurs (cf. Advisory Council for the 
Misuse of Drugs, 2000; Darke & Hall, 2003). Key messages for prevention of overdose death for 
drug users and professionals are: avoid poly drug use, inform drug users when they are released 
from penitentiary institutions, organise training sessions for medical staff and ambulance 
personnel, inform peers and families of drug users about the phenomena and about proper actions 
in case of overdose (e.g. methods of administering naloxone, call an ambulance, take good notice 
of the need for a second naloxone dose) and organise skill training sessions for peers and family 
members of opiate users. Finally it has been defended that naloxone should be made easily 
available for family and peers, because the majority of overdose occur in the home of a victim or 
that of another user (Zador, Sunjic et al., 1996).  
3.5 Conclusions 
Maintenance treatment probably reduces overdose mortality among opiate dependent people. 
Other studies indicate that reductions of drug use and retention to treatment are larger with 
appropriate higher doses of methadone. This is often assumed to reduce overdose mortality. The 
most direct and effective intervention to prevent overdose death among drug users is naloxone, 
provided that it is administered properly. However, in daily circumstances additional measures 
should be taken in order to decrease the danger of needle stick injury for the treating person and 
increase recovery rates among the treated ones. In addition, depending on the addict’s motivation 
and the access to it, information and educational interventions (IEC) possibly improve the 
effectiveness of other interventions.  
4 Other harm reduction interventions 
Outcomes of prevention and treatment of infectious diseases and drug-related deaths were the 
subjects of chapters 2 and 3 of this annex. In this chapter several interventions are reported that 
may also be effective for preventing infectious diseases or drug-related deaths but not specifically. 
In paragraph 4.1 other outcomes are reported for substitution or maintenance treatment because 
this is also considered a harm reduction intervention. In the paragraphs thereafter the subjects of 
medical heroin prescription, pill testing, pre-release counselling and drug consumption rooms are 
covered.
4.1 Maintenance treatment 
Besides lower risks of overdose and drug-related death, often mentioned targets of maintenance 
treatment are reduction of illegal drug use and drug-related crime, improvement of the social and 
health situation of the addicted individual, and higher contact rates of dependents with regular 
addiction care (cf. Dolan et al., 2005).  
Methadone is the most frequently studied treatment option for drug addiction and maintenance 
treatment (Krambeer et al., 2001). Cochrane Reviews and other studies show that maintenance 
treatment with methadone or buprenorphine is effective, not only under controlled conditions, 
but also in daily practice. Both treatments improve treatment retention, patient compliance, and 
reduce opiate use (Mattick et al., 2003a; 2003b; Barnett et al., 2001; Ling & Wesson, 2003; West 
et al., 2000) and individually controlled higher doses (more than 80 mg per day) increase 
effectiveness on these outcomes (Faggiano et al., 2003). Research shows that maintenance 
treatment is also effective in reducing risky behaviours related to HIV transmission, but it possibly 
does not reduce risky sexual behaviour (Gowing et al., 2004; 2006). Abstinence is not a feasible 
objective for most participants in maintenance programmes (Driessen et al., 1999; Hiltunen et al., 
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2002) and available studies did not show reductions in drug-related criminality either (Mattick et 
al., 2003a).  
Finally, a systematic review of five Cochrane Reviews shows that retention rates (staying in 
treatment) are higher for methadone maintenance compared to 1) methadone detoxification, 2) 
buprenorphine maintenance, 3) maintenance treatment with levomethadyl acetate hydrochloride 
(LAAM) or 4) heroin plus methadone (Amato et al., 2005a). Methadone and probably also 
buprenorphine show considerable reductions in opiate use. Buprenorphine is well tolerated by 
addicts with little side effects. It is considered a qualified alternative maintenance treatment for 
methadone, when – for whatever reason – addicts are preferring buprenorphine or do not tolerate 
methadone very well (Davids & Gastpar, 2004).  
When psychosocial interventions are added to maintenance treatment, these possibly tend to 
increase its effectiveness, although supporting scientific evidence remains weak for several of these 
interventions when taken separately. It is defendable from daily experience that supportive care by 
medical nurses during maintenance treatment is more beneficial for participants than merely the 
act of distribution of the substitution drug (Loth et al., 2003; Hunt et al., 2005). For buprenorphine 
this combination with psychosocial interventions is less well studied than methadone (Amato et al., 
2004) but it is likewise possible that psychosocial interventions will increase the effectiveness of 
buprenorphine among opiate users. It has also been shown that contingency management (e.g. 
rewarding abstinence or reductions in drug use) and counselling, when added to maintenance 
treatment, probably further reduce illegal drug use for three months. Longer-term effects are 
unknown yet. Contingency management did not always result in increasing rates of treatment 
retention or counselling participation (Griffith et al., 2000; Preston et al., 2000; 2002). This 
conclusion also holds true for reducing cocaine and alcohol use among methadone clients (Peirce et 
al., 2006).  
Levomethadyl acetate hydrochloride (LAAM) has been a promising maintenance treatment as 
it is more effective in reducing illegal drug use than methadone or buprenorphine (Longshore et al., 
2005). However its adverse effects may be serious (Clark et al., 2002). When dosages of LAAM are 
adjusted, dependent on professional judgment of individual clients’ physical conditions, these side 
effects may be reduced. LAAM can be equally effective as methadone with regard to treatment 
retention. Despite its clinical effectiveness LAAM has not been accepted in the European Union 
because of its potentially serious side effects.    
Studies on maintenance treatment or relapse prevention with Naltrexone (in some studies 
combined with drug free treatment) do not show enough consistency on its capacity to reduce 
relapses in opiate use (Minozzi et al., 2006).  
4.2 Medical heroin (co)prescription 
Medical heroin (co)prescription is exclusively meant for a subgroup of chronic, treatment resistant 
or treatment refractory patients that did not fare well with other treatment options during their 
drug taking career. Frequently mentioned aims of medical heroin (co)prescription for this group are 
improving the physical and psychosocial health situation of opiate dependent persons, a reduction 
in drug-related criminality, an increase in several beneficial effects on society i.e. a reduction of 
public nuisance and lower costs of addiction in general. Several European countries are 
experimenting with medical prescription of heroin to difficult-to-treat chronic opiate dependents.  
The only (systematic) review study on this subject, included four trials. Six trials are currently 
running. One English randomised trial from 1980, two related Dutch trials from 2002 and one 
German non-randomised experiment from 1998 (Ferri et al., 2005; 2006). The duration of the 
German trial was six months, that of the other three RCTs twelve months. Overall, the three 
experiments differed in many aspects, including the outcomes, thus we report some main results.  
Retention to treatment did not differ in two trials, while in the other two trials these outcomes 
contradict each other. In one retention to treatment was more favourable for methadone, in the 
other this appeared to be so for people who were prescribed heroin. The results of two studies 
reporting relapses to illegal heroin were also mixed. In one trial illegal heroin use was less in the 
heroine prescription group, in the other higher. There was no difference in social functioning after 
heroin prescription in two trials. In the other two, this outcome was part of a multi-domain 
outcome measure also including integration at work and family relationships. Here people who 
were in the heroin prescription group improved on this outcome compared to those on methadone.  
A separate cost utility analysis of the Dutch experiment showed that the societal costs were on 
average US$ 13.000 less per patient per year, corrections for judicial costs included (Dijkgraaf et 
al., 2005). All trials showed that medical heroin prescription is probably safe (few critical adverse 
events), and manageable (less public nuisance) compared to not prescribing heroin. It was also 
shown that continued prescription practices probably avoid a quick deterioration of the health 
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situation of participating addicts. These programmes possibly reduce public nuisance. Finally, 
stopping these experiments may result in quick relapses of former participants (Perneger et al., 
1998; Uchtenhagen et al, 1999; Rehm et al., 2001; Van den Brink et al., 2002). The results of 
these trials are both mixed and promising. Results of the six trials currently running, will have to 
be included in due course in order to draw more firm conclusions.  
4.3 Pill testing programmes 
Purity testing of samples of pills (powders or liquids) that ‘go around’ in recreational settings serves 
to warn against the risk of unexpected substances that may be part of substances that are for sale.  
In some instances, testing practices are not limited to pills (i.e. synthetic drugs) but also cover 
other substances. Individuals who deliver these pills for testing remain anonymous to the 
authorities. The tests can be done on-the-spot (simple tests) or office-based (in a laboratory), and 
it can be combined with preventive information delivery. The results of these tests inform potential 
users about purity and health risks of substances bought. Drug testing programmes may also be 
accompanied by distributing leaflets with information. They can also be used for informing the 
authorities or drug agencies. They give insight in changing patterns of use and are a prerequisite 
for early warning systems. 
From the common sense perspective of the individual drug user, pill testing programmes are useful 
in minimising the additional risk of synthetic drugs. The direct coverage of these programmes may 
often be small, but rumours about dangerous pills or mixed drugs seem to be quite effective in 
terms of potential users being more conscious of potential dangers of certain pills, but not 
necessarily in reductions of drug use in user groups (Van de Wijngaart et al., 1999; Benschop et 
al., 2002; Korf et al., 2003).  
It has been amply shown that information alone at best changes behaviour in a very limited way. 
Still, these testing programmes may reduce the use of potentially dangerous drugs in recreational 
settings or at home. However, delays or reductions of drug use caused by the results of pill testing 
programmes are hardly measurable via experiments. Making use of these facilities presumes 
anonymity and easy accessibility. There are no studies showing that on-site pill testing is more 
effective than office-based pill testing but it is reasonable to assume that office-based testing – 
when people can deliver their pills for testing voluntarily and without danger for legal authorities – 
increases the coverage of drugs tested in specific periods. A draw-back of relative simple test 
methods used in on-site testing is that measurements may not be adequate. Finally, there is some 
evidence that the often cited fear that pill testing encourages non-drug users to start using drugs is 
untrue (Benschop et al., 2002). 
4.4 Pre-release counselling 
Pre-release counselling is often aimed at reducing the high risk of overdose after leaving prison 
(when drug users are not used anymore to the doses that were consumed before prison). In this 
case overdose is mainly due to a lowered tolerance for drugs during the period after detoxification 
or enforced abstinence in prison. From a common sense perspective, information about this risk 
and what to do against it before inmates are released from prison is certainly helpful. Pre-release 
counselling may also focus on possibilities for treatment or after care after imprisonment. Realising 
this type of counselling is largely dependent on local habits and culture. High-quality effect studies 
on this type of intervention are not known. There are no other studies found that may give more 
insight in the evidence of effectiveness of pre-release counselling. 
4.5 Drug consumption rooms 
Drug consumption rooms (DCRs) have several targets that are still insufficiently evaluated. The 
following targets are mentioned. For the surrounding neighbourhood DCRs are supposed to reduce 
public nuisance, e.g. publicly using illegal drugs, leaving needles around or drug dealing. Important 
are also the health benefits for drug users (prevention of infectious diseases and drug-related 
death) because they can take their drugs in a safe, non-harassing, supervised  environment, with 
clean needles and syringes and medical support on request. DCRs generally have a staff room (also 
for consultation and screening), a consumption room and a living room (resting, drinks and food, 
watching TV). They may be independent or part of an existing low threshold facility.  
It should be born in mind that DCRs are difficult to evaluate via RCTs. A recent comprehensive 
study on drug consumption rooms partly reviews studies that focus on relationships between 
reductions of drug overdose and the availability of drug consumption rooms (Hedrich, 2004). Two 
well-designed government-commissioned evaluation reports (no RCTs) are interesting in this 
respect.  
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During an 18-months evaluation of a consumption room in Sydney, 3810 drug users were 
registered with an average of fifteen visits. The authors conclude that the numbers of deaths by 
heroin overdose were not changed after the introduction of these rooms (MSIC Evaluation 
Committee, 2003). Reductions of overdose ambulance attendances and deaths already occurred in 
the months preceding the opening of the drug consumption room. These were probably caused by 
a substantial reduction of heroin supply during the same period. It was not possible to determine 
which development was more important as a causal factor for the reduction of overdoses or death 
rates, the reduced heroin supply or the introduction of this drug consumption room.  
Poschadel and colleagues (2003) analysed monthly police data on drug-related death on national 
level and in four German cities over a period of maximum eleven years (1990-2001). In this study, 
drug-related death is defined broader than the EMCDDA definition. Here this concept also includes 
indirect mortality (partly) due to drug use. The analysis focussed on long-lasting and stable effects 
of drug consumption rooms. Equal to the data of the study in Sydney (see above), reductions of 
drug-related deaths were already present in the period before the establishment of the drug 
consumption rooms. Nevertheless, a substantial association could be determined between the 
presence of drug consumption rooms and a reduction of the number of drug-related death. 
Additionally, this relationship was maintained after corrections for other potential explanatory 
factors.
A third (prospective cohort) study, indirectly supports the claim that these rooms reduce infectious 
diseases (Kerr et al., 2005). This study was done in Vancouver and may suggest that drug 
consumption rooms reduce needle sharing among injecting drug users.  
In short, the outcomes of three studies evaluating drug consumption rooms show that these rooms 
may reduce needle sharing, infectious diseases and drug related death among opiate users but we 
need more studies to draw more firm conclusions.  
4.6 Remarks from general guidelines 
For maintenance treatment, psychosocial interventions should ideally be delivered as a standard 
additional type of care, equal to the original methadone programme from Dole & Nyswander in 
1967 (Hunt et al., 2005). The practice of maintenance treatment has in some places changed to 
pure methadone distribution (cf. Loth et al.,  2003; Schlusemann, 2006). Therefore it has been 
recommended that legal arrangements should be made in order to enforce improvements of 
methadone treatment, e.g. by prescribing sufficiently high doses and adding psychosocial 
interventions – when needed - for this target group (Schlusemann, 2006). Low doses of 
methadone are recommended at the beginning of maintenance treatment in order to prevent 
methadone deaths.
In general, when selecting maintenance treatments the following factors are relevant: patient 
preference, response to treatment, individual variation in absorption, metabolism and clearance 
rates, and adverse effects (Lintzeris et al., 2006). Frequency of patient assessment depends on the 
stability of his/ her situation, but preferably each patient should be assessed at least several times 
per year by an experienced clinician. Effective control procedures and supervised administration of 
medication can prevent the risk of diversion or illicit use of substitution substances.  
It should be born in mind that effectiveness of maintenance treatment is also dependent on co-
occurring mental illnesses (dual diagnosis patients); therefore screening for mental illness (co 
morbidity) is recommended. All this may best be based on an assessment of the individual patient, 
i.e. those who need and want it. Random urine testing may be indicated for evaluating programme 
effectiveness. Given the scale of problems, maintenance treatment should best be part of 
community-based health systems in order to enable continuity and quality of maintenance 
programmes and offering counselling and testing for infectious diseases (New South Wales Health 
Department, 1999; WHO/ UNODC/ UNAIDS, 2004).  
Based on the results of the Dutch trials on heroin prescription it was recommended that heroin 
should be registered as a medical product and that quality assurance procedures should be 
implemented for heroin prescription. Heroin prescription should further be strictly supervised and 
executed in specialised treatment units offering state of the art medical and psychosocial treatment 
(Van den Brink et al., 2002). Finally, several trials showed a rapid increase in relapse rates among 
former participants of heroin prescription. Therefore, setting time limits to heroin prescription is not 
recommended. Participants in heroin prescription should be enabled to continue this treatment 
(Uchtenhagen et al, 1999; Van den Brink et al., 2002).  
Heroin prescription seems a valuable additive option for some countries with comprehensive 
treatment systems including easily accessible maintenance treatment. However, heroin prescription 
is not considered as a treatment of first choice and there is consensus that it should not be 
implemented instead of, or on the expense of methadone maintenance treatment.  
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Drug consumption rooms (DCRs) are of growing interest in several European countries. These 
rooms are in most countries meant for injecting drug users. Thus when street injecting is common 
practice DCRs may be most useful. First, these rooms should be supported by the authorities and 
should be non-threatening for drug users themselves, e.g. authorities should keep the police away 
(De Jong & Weber, 1999). The success of DCRs may be dependent on the perceived usefulness of 
these rooms for drug users themselves. A second factor is that although DCRs should be easily 
accessible (low threshold), some control (e.g. identity cards) may be necessary in order to avoid 
violation of the DCR-rules (e.g. no nuisance and offences in- and outside the consumption room). 
On the other hand, the coverage of these rooms should be large in order to be effective in reducing 
the numbers of overdose death (Reinås et al., 2002). It has been mentioned as a guideline, that 
personnel of DCRs should be a mix of medical professionals, social workers, a judicial advisor or a 
probation officer and a guard (Linssen et al., 2002).  
Data on the effectiveness of drug testing or pill testing and pre-release counselling are largely 
anecdotal and based on common sense reasoning. Still, drug or pill testing in combination with 
early warning systems have been proven useful in some circumstances, e.g. in tracing undesired 
mixtures of synthetic drugs, in explaining sudden drug-related deaths caused by cocaine combined 
with atropine or in warnings of increased THC concentrations in cannabis. And it is highly unlikely 
that (former) drug users, without pre-release counselling, are sufficiently aware of the risk of 
overdose when starting drug use again after release.  
4.7 Conclusions 
An abundance of evidence indicates that methadone and buprenorphine are effective in daily 
practice circumstances for reducing opiate use and improving treatment retention or patient 
compliance. These effects tend to increase with controlled higher doses of these substances and 
when psychosocial interventions are added to these maintenance treatment programmes. 
Considering the indications for effectiveness of buprenorphine as a substitution drug, it remains 
unclear why methadone is the main maintenance treatment in most EU Member States and 
buprenorphine only in two. Voucher-based or price-based interventions are possibly most 
successful in producing short-term reductions in drug use but are rarely used yet in European 
countries.
The evidence for effectiveness of medical heroin (co)prescription for opiate dependents is still 
insufficient as a number of studies are still running. This does not mean that it is ineffective. There 
are indications that it improves health outcomes for seriously drug dependent people that are not 
willing to enter into maintenance treatment or that do not respond to this treatment (see also 
special section 5.2). Other interventions e.g. pill testing programmes, and pre-release counselling 
are in fact variations of information and education (IEC), and are studied insufficiently yet. Pill 
testing programmes probably increase consciousness of the risks of (synthetic) drug use but have 
limited effect on reducing drug use.  
Drug consumption rooms may be an effective intervention for reducing needle sharing and 
indirectly in reducing drug-related deaths. Although the available evidence is still inconclusive, 
study findings did not contradict these desirable results.  
5. Prison settings 
Life in prison is changing in Europe and the presence of illicit drugs strongly influences this change. 
Specifically injecting drug use increases health risks that may easily be transported in and out of 
prison. HIV/  AIDS, hepatitis B and C are a threatening perspective for public health and 
specifically prisons should cope with these threats inside their institutional settings. “Prisons are 
extremely high-risk environments for HIV transmission because of overcrowding, poor nutrition, 
limited access to health care, continued illicit drug use and unsafe injecting practices, unprotected 
sex and tattooing.”  (WHO, 2005b). 
5.1 Prison settings: maintenance treatment 
Maintenance treatment (methadone) is feasible and effective in prison settings, and – if adequate 
doses are distributed and it is provided for the total duration of imprisonment – it reduces injecting 
drug use, needle sharing and infections (Dolan & Wodak, 1996; Stöver et al., 2003; Jürgens, 
2006). When prison-based maintenance programmes are well implemented, they finally may have 
additional effects for the health situation of participating prisoners, for the prison system and 
consequently also for society. Continuity of treatment is possibly required when people move 
between prison and the community, in order to prevent quick relapses after release and maintain 
desirable effects of maintenance treatment. Thus, after care is essential.  
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5.2 Prison settings: prevention of infectious diseases 
Data from the EMCDDA show that drug users are over-represented in prison settings. Considering 
the high turnover rate in prisons, hundred thousands of drug users may annually go through the 
European prison system (Hedrich et al., 2006).  
Prison-based needle (and syringe) exchange programmes (NSPs) are probably effective in 
reducing needle and syringe sharing and resulting HIV or hepatitis infection (Dolan et al., 2003; 
Lines et al., 2006). Several studies offer insight in the effects of needle exchange programmes in 
prisons in Germany, Spain, Switzerland, Moldavia, Belarus and Kyrgyzstan. The reported 
evaluation studies (predominantly studies with exclusively measurement points before and after 
treatment and without control or comparison groups) show consistently positive results. Drug use 
remained stable or decreased. Congruent with the above mentioned reviews, syringe sharing was 
reported less than before, and HIV or hepatitis B or C transmission rates reduced. Besides, none of 
the reports could find serious negative events, e.g. initiation or increase in (injecting) drug use or 
undesired disposal of used syringes. (Dolan et al., 2003; Stöver & Nelles, 2003; Lines et al., 2006).  
The effectiveness of prison-based educational interventions (IEC) on HIV transmission rates 
is largely unknown (Jürgens, 2006). IEC should be a component of prison-based HIV-prevention, 
as these interventions are possibly useful in combination with other interventions (see 2.1.1).  
Routinely offering HIV counselling and testing on entry to prison, especially when it is part of a 
comprehensive care and treatment programme for HIV, possibly also increases the acceptance rate 
among prisoners and staff.  
Provision of condoms is probably feasible in a wide range of prison settings. There is still no 
evidence for effectiveness, but neither are there indications for of any major, unintended 
consequences of condom distribution for safety and security in prisons. Structural interventions 
such as better lighting, offering showers and sleeping arrangements, are also needed. IEC activities 
should anticipate the introduction of such a programme and measures to combat aggressive sexual 
behaviours in prison are even more important.  
Disinfection and decontamination schemes are in principle useful practices although these are 
not supported by evidence in the community outside prison yet. In prison settings the effectiveness 
may expected to be even less, because drug use is more hidden and hurried than outside prison.  
No evidence is found for effective strategies to reduce tattooing practices in prison. Tattooing 
implies increasing the risk of HCV transmission and to a lesser extent HIV transmission. A large 
Canadian study is underway that may shed more light on this subject. 
5.3 Prison settings: prevention of drug-related death 
No specific studies on this subject were found. Pre-release counselling may reduce overdose death 
but this has not been shown by research (see 4.4). Drug consumption rooms may have the same 
advantageous effect, but these rooms are still very rare in prisons (see A3.1.8).  
5.4 Remarks from general guidelines 
Imprisonment of drug users is an expensive intervention and recidivism is - in general - high. 
These conclusions may even be more valid for inmates with mental health problems or those who 
use drugs (both are overlapping phenomena). In several guideline publications governments are 
recommended to adhere to basic principles guiding action for prisoners in general and especially for 
drug using inmates or those in need of psychiatric care.  
Public health in general is served by preventing infectious diseases and health care in prisons. This 
appears also to increase workplace health and safety for prison staff. Prison legislation and policies 
should mirror respect for human rights and international law and avoid vulnerability, stigma, 
discrimination and violence. Prison health care should fit with international health care and health 
prevention standards. Interventions should as far as possible be evidence-based. It has been 
recommended that prisons should organise and realise adherence to these principles.  
It has further been recommended to affirm and strengthen the principle of providing treatment, 
education and rehabilitation as an alternative to conviction and punishment for drug-related 
offences. Alternatives to prison for drug users are most probably more cost-effective. These 
alternatives may cover a range of sanctions or drug treatment interventions aiming to avoid, 
replace, delay or complement prison sentences for drug users (Lines & Stöver, 2005).  
The prison environment is an opportunity for introducing harm reduction measures among drug 
using prisoners and consequently also in improving the public health situation over a longer period.  
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Prisoners who participated in maintenance programmes prior to imprisonment should be enabled to 
continue this treatment. The available evidence suggests that prison-based treatment may be 
ineffective in the longer run when no additional care is provided on and after their release.  
Drug-free units in prisons are attractive to many prisoners, including those who are not using 
drugs. Although there is no evidence that these units are successful for drug using prisoners the 
opportunity should be stimulated to escape from drug use in drug-free units.  
HIV counselling and testing on entry to prison should be offered routinely and on voluntary basis. 
Lessons learned from experience with and evidence for prison needle exchange programmes are 
that such programmes do not endanger staff or prisoners safety; on the contrary, these 
programmes make prisons a safer place to live, both for inmates and prison personnel. Methods of 
needle distribution should be adapted in order to meet the needs of staff and prisoners (Jürgens, 
2006).  
Prisons systems are recommended to: 
x accept the importance of information about the harmful consequences of inappropriate 
drug use 
x acknowledge the limitations of depending on an official enforcement of total abstinence 
x receive new drug-dependent prisoners from a public health perspective and with respect 
for their needs, supporting and providing solutions for immediate problems arising in this 
target group 
x provide what is required for prison staff in order to ensure that all prisoners are informed 
about risk behaviours and their consequences and the necessary actions to reduce these 
x provide clinical management to drug dependent prisoners equal to what is done outside 
prison 
x give sufficient information and guidance  at the pre-release stage in order to prevent 
overdose and other risks outside the closed prison environment 
x provide after care with links to community services (WHO, 2005b) 
5.5 Conclusions 
Both preventing and treating drug-related harm in prison settings offer an opportunity for 
contributing to improvements of the public health situation in general.  
Prison-based maintenance treatment appears to be feasible and if adequate doses are distributed 
during imprisonment, it reduces injecting drug use, needle sharing, and infections. It should be 
noted that pre release counselling and after care is possibly necessary to prevent relapse or even 
overdose death after release. Needle and syringe exchange programmes in prison are probably 
effective in reducing needle sharing and infections. Lessons learned from experience with and 
evidence for prison needle exchange programmes are that such programmes do not endanger staff 
or prisoners safety. Instead, these may possibly make prisons a safer place to live. 
There is no evidence of any major, unintended consequences of condom distribution for safety and 
security in prisons. Important safety measures are sufficient lighting, offering showers and sleeping 
arrangements, and interventions against aggressive sexual behaviours. Although counselling 
(information, education) should be part of the introduction of such activities, the literature does not 
present much evidence for effectiveness of these activities. Evidence is also lacking for disinfection 
and decontamination schemes, and strategies to reduce tattooing. Still, these strategies should be 
stimulated because they have not been proven ineffective.  
When prison-based maintenance programmes are well implemented, they possibly improve the 
health situation of participating prisoners, and prison personnel. Alternatives to prison for drug 
users are possibly more cost-effective than imprisonment itself, and may cover a range of 
treatment interventions aiming to avoid, replace, delay or complement prison sentences for drug 
users. Drug-free units in prisons should also be offered for prisoners, especially those who are not 
using drugs. In general however, prison-based harm reduction activities should be adapted in order 
to meet the needs of staff and prisoners.  
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Appendix 1 - Systematically reviewing guideline publications 
A brief exploration of possibilities 
Introduction
Guidelines are papers that tell you what to do instead of what is known (Greenhalgh, 2001), but 
since the nineties these publications are also increasingly based on what is known from scientific 
studies (Burgers & Van Everdingen, 2004). Many types of guideline-like publications are available 
nowadays. These publications vary considerably in level of abstraction and labelling (guidelines, 
status papers, evidence for action papers, protocols, and models of good practice, etcetera). 
Originally, methods for constructing guidelines vary from informal consensus methods (‘old boys’ 
network’) to more formal ones (e.g. consensus conferences, Delphi methods and ‘evidence-based’ 
guideline programmes).  
Construction of evidence-based guidelines is increasingly structured and co-ordinated in advance. 
This does not mean that guidelines about equal practices for the same target groups are look-
alikes. It does not mean either that congruent recommendations from guidelines are necessarily 
more valid than others. The chance of biased information is much larger than in systematic reviews 
of scientific studies. Nevertheless, guidelines are generally more useful for daily practice than 
scientific research results. This may especially be true for many interventions in the field of harm 
reduction, where scientific evidence is not abundant for many interventions. In these cases, the 
role of daily experience (of professionals and clients) is necessarily more prominent. Still, guideline 
construction remains a strongly biased process. Thus, summarising the recommendations from 
various guidelines is even more difficult up to date. However, guidelines for guideline synthesis are 
underway.
Stages of guideline construction 
Guideline construction is a long and arduous process, resulting in an increased risk of eminence-
based, instead of evidence-based information. Furthermore, in most cases scientific evidence needs 
to be partly adjusted to national, regional or even local practice. In order to minimise bias, 
guideline construction has to be structured.  
Proposed stages of guideline construction are: preparation by a working group representing the 
different relevant disciplines; needs assessment; division of work to be done by the workgroup 
members depending on their expertise; development of a draft guideline text by the members of 
the working group; an national guideline meeting for discussion and comments; evaluation and 
integrating the comments; authorisation of the text; dissemination; implementation; evaluation 
and revision. Guidelines need to be updated regularly (cf. Mickan & Askew, 2006). 
Guidelines are expensive, thus increasingly organised by big (supra) governmental organisations. 
The challenge remains to: 1) summarise the scientific evidence in a consistent manner; 2) 
structure guideline publications; 3) organise long-term guideline programmes (in order to ensure 
continuity and updating activities), and to leave the ultimate decision making about best practices 
to each country or region separately (Burgers et al., 2003a; 2003b; Van Everdingen et al., 2004; 
Vlayen et al., 2005).  
Structuring judgment? 
Despite these structuring activities, evidence-based guidelines still show much variation. Expert 
knowledge may differ considerably between entities with specific interests, i.e. between individual 
professionals, professional groups, organisations, countries or other contextual boundaries. Social 
influence mechanisms within multidisciplinary groups may distort judgements (Pagliari et al., 
2001). Furthermore, there are considerable differences between judicial systems, health care 
systems, perceptions of drug dependence, and concomitant perceptions of addictive behaviours. 
Despite their apparent importance for daily practice, the information in national guidelines may not 
be valid in other countries and should be tested in national contexts, in order to fit specific 
situations and to stimulate or enhance implementation. Existent guideline publications should be 
judged and adapted by consensus mechanisms in every country separately (Van Everdingen et al., 
2004). And even then, the problem remains of considerable differences in judgment of the same 
amount of evidence by different professional participants in consensus groups that are constructing 
guidelines. Measures should be taken to increase probabilities of neutrality within these groups. 
Examples given in the literature are: a strong but neutral chairman and a balanced group in order 
to prevent one professional group from biasing the outcome (Burgers & Van Everdingen, 2004; 
Raine et al., 2004).  
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Constructing pathways for synthesis of guideline recommendations 
Some suggestions and recommendations that deal with synthesis methods of guideline information 
(Burgers, personal communication) are submitted for publication. These recommendations cover 
the following stages of selection and synthesis.  
First, existent and well developed search procedures and data sources should preferably be used 
instead of ad hoc developed procedures and sources (e.g. those on PubMed or the database of 
evidence-based guidelines in the US, www.guideline.gov). Selection of guidelines is further 
facilitated by using the PIPOH principle in specifying guideline subjects: Patients, Population or 
Problem; Intervention (screening, diagnosis or treatment); Professional target group; Outcome 
(e.g. survival, quality of life...) and Health care setting. For critical appraisal of guidelines the 
AGREE instrument is recommended. At least two professionals should do this part. This instrument 
evaluates methods and reporting, but it does not judge the clinical content of recommendations in 
guidelines (AGREE, 2001, Cluzeau et al., 2003). Appraisal of clinical content of guidelines should be 
done by review experts and clinical experts, who check: the method of systematically reviewing the 
literature; the fit between results, conclusions and recommendations; and other considerations that 
may have influenced this all. During the reporting phase tables should be used to give an overview 
of important characteristics.  
At best a summary may be possible of some guidelines that may be perceived as good enough, 
while ‘good enough’ rather needs judgement from multidisciplinary groups who are vulnerable of 
bias. Judgments can be at odds with the published literature. If they are, reasons should be made 
explicit (Raine et al., 2004).  
Implementation of guidelines 
Evidence-based guidelines develop from a consensus-mix of available scientific evidence, expert 
knowledge, and client perspectives. Scientific evidence should be updated first, because systematic 
review knowledge may already be obsolete. The phase of implementation of guideline 
recommendations generally also lags behind. Practitioners may be selective or it appears to be 
difficult applying general guidelines to specific situations (Garfield & Garfield, 2000). In the 
Netherlands and elsewhere it has been shown that a) when guidelines are strictly and specifically 
formulated, b) when publications are too extensive, and c) when workers of professionals are not 
involved in guideline formulation, they tend to be less used by practitioners in the field 
(Greenhalgh, 2001; Van Everdingen et al. 2004; Schippers et al., 2005). Many barriers may delay 
or even abandon adoption of guidelines in practice. Examples are: disagreement among experts 
about the quality of evidence, psychological defence mechanisms of professionals in the field, 
practical constraints, failure of clients to accept procedures, and lack of client feedback. Whether 
guidelines will be used or not is largely dependent on applying principles of change management 
that often deliver uncertain outcomes when it deals with non-enforced activities (Grimshaw & 
Russell, 1999; Greenhalgh, 2001). Incentives to stimulate implementation can be sought in quality 
care programmes or ‘break through’-strategies. In fact guidelines are guide-lines and not rules that 
should be followed completely. All these potential disturbing factors make implementation of 
guidelines a hazardous but still useful endeavour for guiding and changing professional practice.  
Presenting recommendations from guidelines for non-clinical decision making? 
Considering the former paragraphs, it is not feasible to present a valid synthesis of guideline 
recommendations for decision making. Therefore we do not intend to give generally valid 
instructions for daily practice. Instead, we merely present – when available - more general 
recommendations, mainly but not exclusively drawn from some exemplary guideline publications in 
the field of harm reduction that are plausible and straightforward. Because general guidelines are 
mostly published by (inter)national organisations, specifically these may be considered as useful 
for decision making on a national or international level. Therefore we also summarise in this report 
some conclusions from general guidelines that may be useful on European level.  
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Annex 2 – State of play in the EU Member States – Country 
reports  
In the following pages the state of play on the prevention and reduction of health-related harm 
associated with drug dependence is presented for each of the 25 Member States of the European 
Union. The overviews per country are categorised in accordance with the structure of the Council 
Recommendation of 18 June 2003 on the prevention and reduction of health-related harm 
associated with drug dependence.  
For reasons of comparability and transparency, the reports are written in a similar framework, 
making a clear distinction in feedback obtained from policy-level, the Reitox National Focal Point 
and their correspondents and other sources of information. The availability of harm reduction 
services and facilities in the Member States has been presented in overview tables in tables A1 to 
A14 in the next pages. 
In order to keep the information manageable, the selection of information that has been included in 
this report was guided by the contents of the Council Recommendation. In other words, the Council 
Recommendation limited the scope and width of the information gathering process.  
The main data sources used for this overview are:  
 EC reporting tool [RT] 
 EMCDDA National Reports to the EMCDDA [NR 200X]: (www.emcdda.europa.eu/ 
index.cfm?fuseaction=public.Content&nNodeID=435&sLanguageISO=EN)
 EMCDDA Standard Table 10 [ST10]: www.emcdda.europa.eu/ ?nNodeID=5777
 EMCDDA Structured questionnaire 23 [SQ23]: www.emcdda.europa.eu/ ?nNodeID=5777
 EMCDDA Structured questionnaire 29 [SQ29]: www.emcdda.europa.eu/ ?nNodeID=1333
 EMCDDA European Legal Database on Drugs [ELDD]: www.eldd.emcdda.europa.eu/ 
Other data sources:  
 CEEHRN website: www.ceehrn.org/
 CORDIS projects database (EU Framework programme): www.cordis.europa.eu
 ESPAD website: http://www.espad.org/
 Community Action Programme on the Prevention of Drug Dependence projects database: 
www.ec.europa.eu/health/ph_projects/drug_project_en.htm
 PHARE Twinning annual reports: 
www.ec.europa.eu/enlargement/key_documents/phare_legislation_and_publications_en.htm
 IHRA: http://www.ihra.net/KeyPublications
 WHO Health Evidence Network: www.euro.who.int/HEN
 UNAIDS: www.unaids.org
 UNODC: www.unodc.org/unodc/en/drug_demand_reduction.html
NOTE:
The country reports in this annex have been arranged according to the EU protocol order.
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Annex A2.1 State of play on harm reduction in Belgium 
2.1.1 Summary 
Public health policy In Belgium, harm reduction has been adopted as public health objective in 
most of its independent communities, but policies differ between the Regional communities. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and a broad range of educational leaflets. 
Trainings for drug users and pill-testing are available in specific geographical areas only. Specific 
IEC is available for communities and families of drug users, which are involved in the prevention 
and reduction of health risks associated with drug dependence in specific geographical areas. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs are nationwide available. Outreach work as a health education approach is a common 
response strategy to prevent drug-related infectious diseases among drug users. Outreach work is 
the predominant setting for the dissemination of information materials on the prevention of drug-
related deaths, and a common setting for the deliverance of risk education/ response training. In 
specific geographical areas, peers and volunteers are trained and included in outreach work 
practice. Networking and cooperation between outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes and methadone detoxification programmes, treatment with buprenorphine and with 
naltrexone are available nationwide. Drug-free outpatient and drug-free inpatient treatment, 
rehabilitation centres, and drop-in centres/ shelters are also nationwide available. Drug 
consumption rooms and heroin prescription programmes do not exist in Belgium. Opioid 
substitution treatment is a common response strategy aiming at the reduction of drug-related 
deaths. Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Methadone maintenance and methadone detoxification programmes, 
treatment with buprenorphine and with naltrexone, and condoms are available nationwide. Drug 
paraphernalia are available in specific geographical areas. There are no needle and syringe 
exchange programmes in prisons in Belgium. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/  screening, education, prevention, counselling, and treatment for drug-related 
infectious diseases are available nationwide. To prevent drug-related infectious diseases among 
drug users, the predominant response strategies are IEC in general, IEC via counselling and advice 
by drugs and health professionals, outreach health education approach, condom promotion among 
drug users, and needle and syringe exchange programmes. Needle and syringe exchange, drug 
paraphernalia and the distribution of condoms are available nationwide in Belgium.
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available..
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in needle and syringe exchange programmes and to prison 
staff. Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation Belgium is well underway with the introduction of 
qualitative instruments to monitor and evaluate harm reduction interventions and policies. 
Research is increasingly used to adjust and improve interventions and the harm reduction 
programmes increasingly have to include evaluation in their activities as a condition for funding.  
2.1.2 Legal environment and existing policies 
Due to the Federal structure of the government in Belgium, the tasks in the field of drug demand 
reduction and – as a result – also regarding the implementation of the Council Recommendation. 
As a result, the Federal Government141 has competence in matters others than prevention and 
harm reduction (e.g. regarding hospitals, social security, justice). It did adopt a Federal Drug Policy 
141 Minister of Public Health and Minister of Justice. 
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Note in 2001, which called for harm reduction measures, including the prevention of drug-related 
deaths. [SQ 29]
The Flemish Community142 has a large competence in prevention and harm reduction. The French 
Community143 and the Walloon Region have also have arge competences in prevention and harm 
reduction. The same counts for the German Community144. [RT]. Harm reduction is a public health 
objective in Belgium, but it was not based upon the Council Recommendation with the exception of 
risk reduction measures in the Walloon region. [RT]  
In Belgium, developments took place in each of the Regional Communities. In the Flemish 
community, the prevention of drug dependence and the reduction of drug-related risks have been 
clearly formulated as an important public health objective. This has been stated in the policy 
declaration of the Flemish government, and more specifically in the policy note of the Flemish 
minister of Public Health. Before the end of 2007 the government aims to set clear the policy 
objectives concerning health damage that is related to the use of illicit drugs. [RT]  
In the French Community Commission (Brussels), services providing aid in drug-related matters 
can be officially approved and financed. Prevention and harm reduction can be one of their main 
tasks and goals. In the Walloon Region the policy objectives on the reduction of health-related 
harm associated with drug use are based upon the Council Recommendation. [RT] 
2.1.3 Recommendation 2: Harm reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Telephone help lines, websites, and a broad range of educational leaflets are available nationwide 
in Belgium. Training for drug users is available in specific geographical areas only, and so is pill-
testing145. [NR 2004; NFP 2006] 
To prevent drug-related infectious diseases among drug users, providing information, 
education and communication (IEC) in general is a predominant response strategy; IEC via 
counselling and advice by drugs and health professionals is a common response strategy. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy: materials are predominantly disseminated at low threshold 
agencies, including needle and syringe exchange programmes, outreach workers and information 
materials, are commonly disseminated through mass media/ internet, in nightlife or at 
entertainment venues, rave events/ festivals. [SQ 29] 
2.1 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation.146 [RT] 
In specific geographical areas only, communities and families of drug users are involved in the 
prevention and reduction of health risks associated with drug dependence and specific information, 
education and communication is available for communities and families of drug users. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation147. [RT] 
142 Minister of Public Health. 
143 Minister of Public Health and the Walloon Region. 
144 Minister of Public Health. 
145 Modus Vivendi, www.modusvivendi-be.org. 
146 The Flemish Community has a network of drug prevention workers. Their goal is to raise awareness in the 
local communities and to promote participation from all kinds of settings in local drug policy. 
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In Belgium, street-based outreach work and outreach work at dance parties, raves and in clubs148
are nationwide available. [NR 2003/ 2004; NFP 2006] 
To prevent drug-related infectious diseases among drug users, outreach work as a health 
education approach is a common response strategy. The availability of outreach work and targeted 
high risk group interventions as implementation settings for drug-related infectious diseases 
prevention measures varies greatly in Belgium (in geographical coverage). [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are predominant settings for the dissemination of information materials, aimed at the reduction of 
drug-related deaths, and outreach work is a common setting for the deliverance of risk 
education/  response training. [SQ29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation149. [RT] 
Training for outreach workers and for peers and volunteers are organised. In specific geographical 
areas only, peers and volunteers are included in outreach work150. [ NR 2003; NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work151 agencies exist nationwide. [NR 2003] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but is not based upon the Council Recommendation. [RT] 
Methadone maintenance programmes, methadone detoxification programmes, treatment with 
buprenorphine and with naltrexone, drug-free inpatient and drug-free outpatient treatment 
facilities, rehabilitation centres, and drop-in centres/ shelters are available nationwide. Substitution 
treatment is supported by psychosocial care, and is sometimes obligatory sometimes upon request 
by the client (depending on the institution or general practitioner). [NR 2003, NR 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a common 
response strategy. [SQ 29] 
Drug consumption rooms and heroin prescription programmes do not exist in Belgium152.
147 The Flemish Community has given financial impulses to better integrate the problem of substance use in the 
daily work of community outreach workers. 
148 French community: information, fresh water, needles, and bad trip management; Flemish community:  
Partywise (global prevention concept for nightlife).  
149 French Community: this is part of official policy, but due to financial reasons it is limited to distribution of 
brochures for drug users. 
150 (ex) Drug users are trained to disseminate HIV prevention and OD prevention messages (French 
Community: by using the snowball method). 
151 Between harm reduction agencies. 
152 An experimental clinical trial project on controlled distribution of heroin is envisaged to start in Liege.  
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2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation.153 [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide154. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Treatment with buprenorphine and with naltrexone is available in prisons nationwide. Methadone 
maintenance, methadone detoxification programmes and condoms are available nationwide in 
prisons, and drug paraphernalia are available in specific geographical areas only. There are no 
needle and syringe exchange programmes in prisons in Belgium. [NR 2003/ 2004; NFP 2006] 
Depending on the region, prisons are a common to rare implementation setting for infectious
disease prevention measures targeted at drug users. [SQ23] Prisons are a common 
implementation setting for disseminating information materials on prevention of drug-related 
deaths. [SQ29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation155. [RT] 
Testing/ screening, education, prevention, counselling and treatment of drug-related infectious 
diseases are available nationwide. In specific geographical areas only, vaccination against hepatitis 
B and/ or tuberculosis, targeting at drug users, is available. [NR 2003/ 2004] 
To prevent drug-related infectious diseases among drug users response strategies most 
commonly used are IEC in general, IEC via counselling and advice by drugs and health 
professionals, outreach health education approach, condom promotion among drug users, and 
needle and syringe exchange programmes. Low threshold counselling services are a common to 
predominant setting for measures aimed at the prevention of drug-related infectious diseases 
among drug users. The use of outreach work and targeted high-risk group interventions as a 
setting for drug-related infectious diseases prevention measures varies across the country. [SQ23]
2.10  Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes, drug paraphernalia and the distribution of condoms are 
available nationwide. [NR 2003/ 2004] Needle and syringe exchange programmes are a 
predominant response strategy to prevent drug-related infectious diseases among drug users 
in Belgium. [SQ 23] Low threshold agencies, including needle and syringe exchange programmes, 
also are a predominant setting to provide information materials on the reduction of drug-related 
deaths among drug users. [SQ 29] 
Belgium has 39 non-pharmacy based and 49 pharmacy-based needle and syringe exchange points. 
Needle and syringe exchange takes place through fixed sites, through outreach workers/ peers, 
and via pharmacies. [ST 10]  
There are no legal restrictions to the possession of unused sterile needles in Belgium, and also no 
prescription is required to obtain or exchange156 needles and syringes. [ELDD] 
153 A Royal Decree 19/03/2004  ensures coordination of substitution and ensures appropriate access to 
treatment for opiate users. 
154  Royal Decree 19/03/2004 on substitution treatment. 
155 Commission Communautaire Française (COCOF), Flemish and French Communities promote screening for 
infectious diseases, safer sex counselling and the use of condoms, but there are no plans to promote hepatitis B 
vaccination. 
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2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation157. [RT] 
Belgian ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated by regulations. naloxone is only available on medical prescription and only in 
hospitals. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in harm reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Harm reduction is part of an integrated health strategy for drug users158. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation159. [RT] 
Training is offered nationwide to professionals in needle and syringe exchange programmes and for 
prison staff. Training for professionals in substitution programmes, in low threshold agencies and 
treatment facilities is available in specific geographical areas only. [NR 2003/ 2004] 
2.1.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
NOTE: As the competences for public health are spread over several governments in Belgium, an 
answer whether a policy exists is only positive if it is representative for 90% for Belgium. 
Furthermore, in the Flemish Community, by 2007 all actions should be evidence-based and focus 
on clear public health objectives.  
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists in Flanders and in the German Community, but is not based on the Council 
Recommendation. The Flemish Community has adopted a standard procedure for the development 
of new strategies. The policy does not exist in the Walloon region, French Community and COCOF 
(Brussels) as research on scientific evidence is not developed sufficiently. [RT] 
in Brussels, a research project was run about the pertinence of a harm reduction intervention in 
recreational settings160 in 2002. [NR2002] At federal level, the activities take place in research and 
development of evidence-based new concepts, information, training, networking and coordination. 
Provincial networks, involved in the coordination, implementation of concepts and data collection 
have no longer a covenant with the Flemish government, but will be coordinated by the provinces. 
[NR 2003, NR 2004, NR 2005]  
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists in the Walloon region, the Flemish, German and French communities, but it is not 
based on the Council Recommendation. The Flemish Community has adopted a standard procedure 
for the development of new strategies. The policy does not exist in the COCOF. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
156 The Royal Decree of 5 June 2000 outlines the law on needle exchange for drug users.  This decree stipulates 
that only general practitioners, pharmacies, specialised personnel of drug services, and street corner workers 
are allowed to exchange needles. The delivery of sterile injection equipment must be accompanied by written 
information on the good use of the equipment, of accessibility to HIV and hepatitis screening services, to 
existing services for treatment. 
157 Every hospital in a city has appropriate equipment (such as naloxone) and personnel trained to deal with 
overdose.
158 Mentioned in the Federal Drug Policy Note 2001. 
159 Plans and curricula for drug-related training of five selected occupational groups have been completed.
160 Modus Vivendi research project. 
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This policy is pending for approval in the Flemish Community. It has ordered a scientific report 
concerning the feasibility of different kinds of criteria for evaluation. This report will be used for the 
development of a system of evaluation. The policy exists in the German and French Community. In 
the other regions of Belgium the policy does not exist. [RT] 
Community and Regional stakeholders have power to implement certain drug-related prevention 
and treatment programmes. Concerning their policy, the French-speaking Community e.g. says to 
evaluate results, the context and the means used.  In the Flemish Community, the government has 
changed its policy from projects to covenants. In these covenants clear objectives and indicators 
are formulated and every organisation reports annually on the basis of these indicators. Within the 
development of concepts and methods, systematic evaluation of process and implementation is 
carried out. Some specific drug-related prevention and harm reduction projects or programmes are 
evaluated at regular basis. In practice the policy initiatives are evaluated in function of indicators 
specifically created for them. Objectives are to be chosen according to the drug situation, for 
optimal results to be attained. [NR 2003]  
All health promotion projects funded by the French Community must have an evaluation built in the 
project. In addition, the French Community is funding two departments in universities (Promes in 
ULB and Ceres in ULG) to provide technical support and to advise the promoters of the projects. 
However, most evaluations are process evaluation and internal evaluations. [NR 2004] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy is pending for approval in the Flemish Community. It has ordered a scientific report 
concerning the feasibility of different kinds of criteria for evaluation. This report will be used for the 
development of a system of evaluation. In the other regions and communities in Belgium the policy 
does not exist. [RT] 
An organisation in the Flemish Community161 (De Sleutel) uses the ‘European Foundation of Quality 
Management’ model (EFQM). The model has two main principles: self-evaluation and self-control. 
The model focuses on aspects that can be optimised. It takes into account organisational and 
results indicators. [NR 2003] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
The implementation of standardised data collections according to the EMCDDA recommendations is 
pending for approval in Belgium. Regarding the Treatment Demand Indicator (TDI) a national 
political decision has to be taken regarding the implementation of the registration data at national 
level. Some communities already have their own system of data collection, but these are not 
necessarily in line with the TDI/ EMCDDA protocols. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists in the French, Flemish and German Communities but was not based upon the 
Council Recommendation. Policy does not exist in the COCOF and Walloon region. [RT]  
Until 2002, Belgium has lacked any significant, concrete data on the drug policy it is pursuing. No 
comprehensive overview exists of all the actors directly and indirectly involved, or of differences 
between funding sources. [NR 2002]. At Federal level a policy plan was developed in which four 
domains were defined to implement a Flemish drug policy 2002-2005. The plan contains different 
actions in each domain, with indicators for evaluation. The main areas of work are: research and 
development of evidence-based new concepts, information, training, networking and coordination. 
[NR 2003] 
161 De Sleutel. 
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3.7 Setting up evaluation training programmes for different levels and audiences 
This policy is pending for approval in the Flemish Community, but is not based on the Council 
Recommendation. The policy does not exist in the other regions and communities. [RT] 
A ‘research platform substance abuse’ was created by the Flemish VAD162, which aims at bringing 
research and practice in the Flemish alcohol and drug field closer together. [NR 2005] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists in the French Community and Walloon region, but is not based upon the Council 
Recommendation. The policy is pending for approval in the Flemish Community, but is not based 
on the Council Recommendation. The policy does not exist in the COCOF and German Community. 
[RT]
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists in the Flemish and German Community, but is not based upon the Council 
Recommendation. The policy does not exist in the other communities and regions. [RT] 
Since April 2004, Trempoline163 has introduced the Europ-ASI questionnaire164 for each client of the 
institution. This tool aims to measure the severity of addiction of new clients, to follow the 
evolution of the clients and to assess the outcome of the treatment. This instrument also offers the 
possibility to compare results with other Therapeutic Communities in Belgium and in the EU. [NR 
2005] 
2.1.5 Information from third data sources
Issues raised by Free Clinic, related to Flanders 
Information, education, communication. Information, education and communication is 
inadequate in coverage and accessibility. Drug testing, mainly pill-testing, does not exist in 
Flanders. 
Outreach work. Outreach work is considered to be adequate in coverage and accessibility.  
(Medically assisted) treatment and specific interventions. Coverage and accessibility of 
medically assisted treatment for opiate users is adequate throughout the country. Medically 
assisted treatment for amphetamine-type stimulants (ATS) or cocaine users are inadequate, as 
there is no general policy. Access to treatment depends on the treating physician and is not 
structurally regulated. There are no heroin, ATS or cocaine prescription programmes. The coverage 
and accessibility of needle and syringe exchange programmes is adequate throughout the nation. 
For drug paraphernalia coverage and accessibility is inadequate because of lack of funding. Low 
threshold agencies are not widely available in Flanders, which means that coverage and 
accessibility is inadequate. The services are only available in big cities. Drug consumption rooms 
are not available in Flanders. Specific harm reduction interventions targeted at cocaine or ATS 
users are not available, although needle and syringe exchange programmes try to focus also on 
crack cocaine users, cocaine injectors and ATS users.  
Prison interventions. Information, education and communication is not available in prison. 
Outreach work is not available. Medically assisted treatment for opiate users in prison may be 
limited in access, if drug users were not enrolled in a methadone maintenance programme before 
incarceration. Medically assisted treatment for ATS or cocaine users is not available in prison. In 
prison neither needle and syringe exchange programmes nor the distribution of drug paraphernalia 
exist. In Flemish prisons services to prevent drug-related infectious diseases are considered to be 
inadequate in coverage and accessibility. In prison, hepatitis B or tuberculosis vaccination 
programmes are not available.  
162 Flemish association for alcohol and other drug problems.  
163 Trempoline is a Therapeutic Community. 
164 ASI = Addiction Severity Index. 
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Infectious diseases (HIV, hepatitis B and c, tuberculosis and sexually transmitted 
diseases). Measures to prevent drug-related infectious diseases are adequately taken in Flanders 
and easily accessible for drug users as long as they are not incarcerated. Hepatitis B vaccination 
programmes are considered inadequate in coverage, as there is not enough funding to conduct 
them thoroughly.
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Annex A2.2 State of play on harm reduction in the Czech Republic 
2.2.1 Summary 
Public health policy. Harm reduction has been a public health objective within the Czech Republic 
for a considerable period of time already. The principle has  also been adopted in the Czech 
National Drug Strategy 2005-2009.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through various websites, telephone help lines, training for drug users, educational 
materials and through pill-testing. For the reduction of drug-related deaths, the dissemination of 
information materials and risk counselling are the predominant strategies. Communities and 
families of drug users are involved in the prevention and reduction of health risks associated with 
drug dependence at specific areas. 
Outreach work. Street-based outreach work is nationwide available. Outreach work as a health 
education approach is a common response strategy to prevent drug-related infectious diseases 
among drug users. For the reduction of drug-related deaths, outreach work is the predominant 
setting for the dissemination of information materials, as well as for the deliverance of risk 
education/  response training. Furthermore, peers and volunteers are included nationwide in 
outreach work practice. Finally, networking and cooperation between outreach work agencies exist 
nationwide. 
(Medically assisted) treatment and specific interventions. Methadone detoxification 
programmes and treatment with naltrexone, drug-free outpatient and inpatient treatment and 
drop-in centres are widely available. Methadone maintenance treatment, treatment with 
buprenorphine and rehabilitation programmes (after-care centres) are available in specific 
geographical areas only. Drug consumption rooms and heroin prescription programmes do not exist 
in the Czech Republic. Opioid substitution treatment is a common response strategy aiming at the 
reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs are available 
nationwide. 
Prison interventions. Testing for drug-related infectious diseases and other drug-related 
infectious diseases measures including treatment are available nationwide in prisons. Methadone 
detoxification programmes and counselling are available in specific geographical areas only. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/  screening, education, prevention, counselling, treatment and vaccination 
programmes (hepatitis B and tuberculosis) targeting drug users are available nationwide. To 
prevent drug-related infectious diseases among drug users, the predominant response strategies 
are IEC in general, IEC via counselling and advice by drugs and health professionals, safer injection 
training for drug users, condom promotion among drug users, and needle and syringe exchange. 
Needle and syringe exchange, drug paraphernalia and the distribution of condoms are available 
nationwide in the Czech Republic.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g., to 
deal with overdoses. The distribution, possession or administration of naloxone is not regulated. 
Naloxone on a ‘take home’ basis is not available. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in outreach work, needle and syringe exchange programmes 
and low threshold programmes. Training for professionals in substitution treatment, prison staff 
and treatment facilities is only available in specific geographical areas. Risk reduction is part of an 
integrated health strategy for drug users.
Quality, monitoring and evaluation. The Czech Republic has invested in the development of 
quality assessment tools and protocols for the evaluation of harm reduction interventions. In 2003, 
a Minimum Evaluation Set was drawn up with the purpose to evaluate treatment effectiveness. 
Although the Czech Republic does not have a policy so far on the establishment of quality criteria in 
demand reduction, it is pending for approval and in practice, initiatives exist that allow for 
independent evaluation of interventions.  
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Evaluation to inform policy development exists in the sense that the National Drugs Strategy 2001-
2004 has been evaluated, giving feedback on accomplishments. 
2.2.2 Recommendation 1: Risk reduction and public health policy 
In the Czech Republic, the main responsible body for the implementation of the Council 
Recommendation is the Office of the Government of the Czech Republic165. [RT] 
Harm reduction is an objective in public health in the Czech Republic and is part of the National 
Drug Strategy 2005-2009 and its Action Plan for the years 2005-2006166 [SQ29] . A policy on the 
prevention and reduction of health-related harm associated with drug dependence already existed 
in the Czech Republic before the adoption of the Council Recommendation. The Council 
Recommendation did have impact on the introduction of some additional measures. 
2.2.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but is not based upon the Council Recommendation. [RT] 
In the Czech Republic, the dissemination of information through various websites, telephone help 
lines167, trainings for drug users, through pill-testing and through a broad range of educational 
materials168 are available nationwide. [NR 2002; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) via counselling and advice by drugs and health professionals and IEC in 
general are predominant response strategies, whereas IEC via peer involvement/  peer approach is 
a common response strategy. Safer injection training is offered in all or most cities169. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
and risk counselling are the predominant response strategies: materials are predominantly 
disseminated through specialised drug treatment services, low threshold agencies, including needle 
and syringe programmes, outreach work and they are commonly disseminated through rave events 
and festivals. A common but not predominant response strategy to reduce drug–related deaths is 
risk education/  response training. These trainings are delivered predominantly at specialised drug 
treatment services, low threshold agencies, including needle and syringe programmes and through 
outreach workers, peers and are common in prisons and rave events. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation170. [RT] 
At specific areas only, communities and families of drug users are involved in the prevention and 
reduction of health risks associated with drug dependence171. [NR 2003] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
165 Department: Secretariat of the Council of the Government for Drug Policy Coordination. 
166 http://vlada.cz/apac/www.htm.
167 Approximately 130 telephone help lines exist; (ref. Sadilek, Mravcik, 2005, in press). 
168 The National Focal Point bimonthly publishes fact sheets, and published many other drug-related 
publications. 
169 Standard service of all 93 low threshold facilities that are available nationwide. 
170 Prevention measures are primarily implemented at the local and regional levels and coordinated by the 
Addiction Prevention Units of the individual provinces. Work with parents is given more and more importance.
171 Preventive programmes with active parental involvement.
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In the Czech Republic, street-based outreach work is available nationwide, and outreach work at 
dance parties, rave events is provided in specific geographical areas only. [NR 2002/ 2003] 
To prevent drug-related infectious diseases among drug users, outreach work as a health 
education approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a predominant implementation setting for infectious diseases prevention 
measures targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths, and outreach work is also a predominant setting for the deliverance of 
risk education/  response training, which is delivered in all or most cities in the Czech Republic. [SQ 
29]
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training in outreach work is provided nationwide for peer and volunteers172. Peers and volunteers 
are included in outreach work nationwide. [NR 2003; NFP 2006]173
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies exist nationwide174. [NR 2002] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation.  
Methadone detoxification programmes, drug-free outpatient and inpatient treatment, drop-in 
centres and treatment with naltrexone175 are widely available. Methadone maintenance treatment, 
treatment with buprenorphine and rehabilitation programmes (after-care centres) are available in 
specific geographical areas only. Substitution treatment is supported by psychosocial care and is 
sometimes obligatory, sometimes upon request by the client (depending on the prescribing 
institution or general practitioner. [NR 2002/ 2003; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a common 
response strategy. Drug consumption rooms and heroin prescription programmes do not exist in 
the Czech Republic. [SQ 29] 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide176. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy does not exist, as it is not a priority for national government177. [RT] 
172 Training courses and seminars are organised annually by different NGO’s, associations, training institutions. 
173 Secondary needle exchange. 
174  Harm reduction organisations; Czech street work association. 
175 Widely available in medical care facilities, detoxification units and emergency units.
176 Change in law for prescription of buprenorphine; registration of all patients receiving prescribed drugs. 
177 Treatment and detoxification is available in prison. Substitution treatment is in preparation. Needle and 
syringe exchange programmes do not exist. 
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Testing for drug-related infectious diseases and other infectious diseases measures including 
treatment are available nationwide in prisons178. Methadone detoxification programmes179 and 
counselling are available in specific geographical areas only. Methadone maintenance 
programmes180, treatment with buprenorphine or naltrexone, needle and syringe exchange 
programmes, drug paraphernalia, and condom distribution181 are not available in Czech prisons. 
[NR 2002/ 2003; NFP 2006] 
Prisons are an uncommon implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ23] 
Information materials aimed at the prevention and reduction of drug – related deaths are 
rarely disseminated in Czech prisons, and the deliverance of risk education/  response trainings for 
drug users is common practice in Czech prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
With regard to infectious diseases among drug users, testing/ screening182, education, prevention, 
counselling and treatment are available nationwide, as is vaccination (hepatitis B and tuberculosis) 
targeting at drug users. [NR 2002/ 2003] 
Predominant response strategies to prevent infectious diseases among drug users are IEC in 
general, IEC via counselling by drugs and health professionals, safer injection training for drug 
users, condom promotion among drug users, and needle and syringe exchange. IEC via peer 
involvement/  peer approach, outreach health education approach, routine screening of high risk 
groups and easy access’ programmes for drug users to treatment of infectious diseases, e.g., at 
low threshold agencies, are common responses in the Czech Republic. Predominant implementation 
settings for infectious diseases prevention measures targeting drug users include specialised drug 
treatment services, low threshold counselling services, outreach work and high risk group 
interventions. Primary care/  general practitioners are a common setting for infectious diseases 
prevention measures. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes, drug paraphernalia and the distribution of condoms are 
available nationwide in the Czech Republic183. [NR 2002/ 2003]. Needle and syringe exchange 
programmes are a predominant response strategy to prevent drug-related infectious diseases
among drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, are also a 
predominant setting for providing information materials on the reduction of drug-related deaths
among drug users and for the deliverance of risk education/  response trainings. [SQ 29] 
There are 89 non-pharmacy based needle and syringe exchange programmes184 in the Czech 
Republic. Fixed sites and distribution through outreach/ peers are existing types of needle 
exchange, but there are no vans/ buses, no vending machines, no pharmacy-based and no prison-
based needle and syringe exchange programmes in the Czech Republic. [ST 10] 
178 Special infectious diseases department exists within prison hospital. 
179 Two prisons. 
180 A pilot methadone maintenance programme has started in April 2006 in two prisons with a capacity of 80 
slots.  
181 Condoms are being sold in prisons.
182  A rapid screening hepatitis C antibody test from finger prick was used widely. As of January 2006 this test is 
not available anymore, and thus availability of IDU tests for HCV decreased dramatically. 
183 Distribution of paraphernalia (spoons, acid, water, also disinfection) is a standard part of needle and syringe 
exchange programmes in CR. Syringes are freely available in pharmacies. It is estimated, that about 1 million 
of syringes are sold in pharmacies to injecting drug users annually. 
184 Data from Standard Table 10 (EMCDDA): 89 fixed needle and syringe exchange programmes of which 75-80 
also provide the exchange of needles and syringes through street-based outreach work, including peer-
distribution. 
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There are no specific laws on needle and syringe exchange or on the possession of sterile needles 
in the Czech Republic; it is considered legal. Also no prescription is required to obtain or exchange 
needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT]
Training programmes for professionals of emergency departments are available nationwide185. [NFP 
2006]   
Emergency departments are an uncommon setting for dissemination of information materials that 
aim at the reduction of drug-related deaths or for risk education/  response training. [SQ 29] 
Czech ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is not regulated. Naloxone on a ‘take home’ basis is not available. [SQ 29; NFP 2006] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT]
Risk reduction is part of an integrated health strategy for drug users186. [NR 2003] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT]
Training for professionals in substitution treatment, prison staff and treatment facilities is available 
in specific geographical areas only. Training programmes for professionals working in needle and 
syringe exchange programmes and low threshold programmes and for outreach workers are 
available nationwide187. [NR 2002/2003; NFP 2006] 
2.2.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
In 2002, upon request of the Secretariat of the National Drug Commission, external experts drew 
up a draft of individual tools for evaluation of efficiency of field exchange programmes, low 
threshold outreach centres and therapeutic communities. Several surveys carried out pilot 
verification of evaluation tools for each of the mentioned types of programmes. The final draft of 
tools for program efficiency evaluation was reported to the Government Council for Drug Policy 
Coordination. [NR 2002] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, as it is not a priority for national government. [RT] 
Despite the fact that there is no governmental policy in including needs assessment in 
programmes, there are quite some examples in the Czech Republic that needs assessments are 
conducted at operational level. For example, a needs assessment was conducted among clients of 
185 Organised regularly by the Institute for Post-Graduate Studies in Medicine, Prague.
186 The 1st Medical Faculty at Charles University in Prague has accredited a new bachelors study programme on 
addiction. The programme aims to provide students with the necessary theoretical knowledge and practical 
skills required for work in the field of prevention, treatment, aftercare, probation and mediation work, prison 
and post-prison care, etc. It especially focuses on addictive substances and types of addictive behaviour. 
Therefore, graduates will be able to work in a wide spectrum of services designed for (not only) drug users. 
187 A summer school of harm reduction is held yearly by one of the biggest providers of services for drug users 
(SANANIM). This seminar is for professionals from addiction services. Needle exchange is one of the topics on 
the agenda. The NFP organises national seminars on drug-related infectious diseases for service providers. NSP 
is a topic on the agenda.
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low threshold facilities in the Central Bohemian region by using Rapid Assessment and Response 
methodology, such within the framework of the project of evaluation of the drug policy in that 
region [NR 2004]. Needs assessments were furthermore conducted in the framework of Phare 
Twinning Projects in 2002 and 2003 [NR 2002/  2003]. 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist yet, but is pending for approval. [RT] 
With the objective of finding a systematic solution for assuring quality and efficiency of services in 
the specific fields of the drug policy (primary prevention, treatment, social services), in 2002 the 
appropriate ministries started to work on drawing up of minimum standards of quality and on the 
preparation of tools for evaluation of efficiency of programmes. [NR 2002] 
In 2003, a Minimum Evaluation Set (MES) was drawn up for the purpose of evaluation of treatment 
effectiveness. It consisted of three main parts: a self-evaluation questionnaire, a uniform system of 
reporting of treatment care, and a questionnaire for monitoring of basic economic indicators. [NR 
2004]. 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist yet, but is pending for approval. [RT] 
Evaluation of quality of services is one of the pillars of a complex evaluation of services. Other 
pillars involve effectiveness evaluation and economic evaluation (cost effectiveness). Observance of 
Standards of Professional Competency with an evaluation scheme and series of sample manuals, 
which are part of the system of certification of competency of services for drug users, contributes 
to the evaluation of quality and availability of provided services.  
According to this system, certification is an assessment and formal acknowledgement that a service 
complies with the specified criteria of quality and complexity (standards); external evaluators will 
carry out this assessment according to the criteria specified in standards and in compliance with 
the Certification Guide and Local Investigation Methodology. [NR 2004] 
Standards for low threshold facilities and evaluation tools for the evaluation of the efficiency of 
services in the field of harm reduction are part of the standards of professional competency and the 
defining of indicators of evaluation of quality and effectiveness of these facilities. 
Guaranteeing the quality of treatment, with the objective of achieving maximum efficiency, has 
been playing an increasingly important role in the treatment of drug users. Quality assessment can 
be divided into user assessment and professional assessment. The existence of criteria and 
introduction of mechanisms that assess the level of service delivery according to these criteria is a 
prerequisite for professional quality assessment (Kalina, 2001). Standards of Service Quality and 
the consequent process of certification of quality are tools for the improvement of quality and 
efficiency of treatment; in addition, they can be used for the monitoring and optimization of 
treatment costs. [NR 2003] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
The Czech Republic complies with the EMCDDA data collections but this was not the result of the 
Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The Secretariat of the Council of the Government for Drug Policy Coordination drew up a Balance 
Report on the Fulfilment of Targets from the 2001 – 2004 National Drugs Policy Strategy and from 
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the Government Resolution188 regarding the outputs of the 2000 Phare Twinning Project 
“Strengthening National Drug Policy”. The Secretariat used questionnaires to collect the data for 
this Balance Report from individual sectors and regions. [NR 2004] 
The report showed that the number of unaccomplished tasks increased from 15 in 2002 to 25 in 
2003. These unaccomplished tasks especially involved the plans of activities of individual sectors in 
the field of drug policy, personnel reinforcement and workforce education, introduction of 
evaluation tools, and the development of the quality of and availability of services. [NR 2004] 
The 2001 – 2004 National Drug Policy Strategy has not yet been systematically evaluated 
according to the determined indicators of success and defined evaluation tools. It is one of the 
roles of the National Drug Commission to evaluate drugs policy measures and activities and 
conduct control activities. The National Drug Commission has been asked to prepare an annual 
Evaluation Report on the Fulfilment of Targets Following from the 2001 – 2004 National Drug Policy 
Strategy. [NR 2003].  
Quality evaluation studies are not available. The current practice is limited to implementation of 
several types of internal evaluation of programmes according to various criteria.189 The Ministry of 
Education, Youth and Physical Education published a publication dedicated to evaluation of 
preventive programmes.190 The document was drawn up in a relatively quality manner and it 
contains explanation of basic terms and starting points of evaluation. [NR 2002]. 
The General Directorate of the Prison Service evaluated the efficiency of drug activities and quality 
of treatment programmes of the prisons; in March 2001, on the basis of this analysis it adopted the 
document ”2001 – 2004 Set of Drug Measures during Custody and Execution of Punishment”. [NR 
2002]. 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists,  but was not based upon the Council Recommendation. [RT] 
The Phare Twinning project ‘Strengthening National Drug Policy’ included an “Accreditations” 
working group. During the project, the working group analyzed the development of standards of 
quality of services in addiction treatment and the process of quality assessment by the Ministry of 
Health and Ministry of Labour and Social Affairs (see below). The main objective was to assess 
whether it is possible to consolidate the accreditation processes of both ministries.  
After the reviewed version of the standards had been published, a first course for future members 
of accreditation teams (auditors) was conducted. The training focused especially on three main 
fields of education: general issues (quality assurance systems, accreditation, verification process, 
psychology of audit, and execution and evaluation of audit); quality assurance (interpretation and 
analysis of accreditation standards according to individual service modalities, measurement of 
system performance, quality, and effectiveness); organisation (accreditation process, 
organizational guarantee of audit, documentation required for an audit, and consequent 
evaluation). [NR 2003]  
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
The policy does not exist yet, but is pending for approval. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] 
188 Government resolution No. 549/03. 
189 In most cases, implementation of internal evaluation is usually restricted to a short verbal assessment by 
the organizer or implementer. Sometimes a short assessment by programme participants is added. However, 
implementation of these evaluations is not uniform and it is not possible to amend them.  
190 Evaluation and Diagnostics of Preventive Programmes (MŠMT ýR, 2001).
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The Czech Republic participates in the ESPAD project191 [NR2004]. ESPAD does not include 
information on drug dependence or on harm reduction. As indicated in this chapter, the Czech 
Republic has been the beneficiary of several Twinning projects in the field of drug demand 
reduction. 
2.2.5 Information from third data sources  
Issues raised by ANO/ Sananim 
Information, education and communication (IEC). IEC is adequate in coverage and  
accessibility throughout the country. Drug testing (mainly pill-testing) is available, but inadequate 
in coverage and accessibility, as funding is limited and the health sector does not regard it as a 
priority. Measures to involve families and friends of drug users in harm reduction interventions is 
adequate in coverage and accessibility.  
Outreach work. Outreach work is adequate in coverage and accessibility.  
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users, which mostly consists of methadone detoxification treatment, is adequate in 
coverage, but accessibility varies from adequate to inadequate. A heroin prescription program is 
not available.  
Medically assisted treatment for ATS users is inadequate in coverage and varies from adequate to 
inadequate for accessibility. There is 1 centre prescribing methylphenidate (Ritalin), but this 
happens occasionally. Elsewhere medically assisted treatment for ATS users is not available. 
Medically assisted treatment for cocaine users is not available, but needs thereof are limited as 
cocaine is rarely used. Specific harm reduction interventions targeted at cocaine users are not 
available. Harm reduction interventions for ATS users are adequate in coverage and accessibility. 
There are no drug consumption rooms in the Czech Republic. Coverage and accessibility of needle 
and syringe exchange programmes is adequate throughout the country and drug paraphernalia are 
adequately available. Low threshold agencies are adequately available and accessible.   
Prison interventions. IEC in prison is inadequate in coverage and accessibility. Most IEC is 
provided by NGOs working in selected prisons. Generally standards in prisons are not adapted to 
the need for IEC, because prisons are still considered drug free areas. There is no outreach work 
available in Czech prisons. 
Availability of and access to substitution treatment is inadequate, as methadone detoxification 
treatment is available only in 2 prisons as a pilot, allowing 35 prisoners to participate. Methadone 
detoxification is the only form of medically assisted treatment for opiate users in prison. Medically 
assisted treatment for ATS users in prison ranges from inadequate to not available and is purely 
abstinence-oriented. Pharmacotherapy is only provided in cases of serious withdrawal symptoms. 
Neither medically assisted treatment for cocaine users nor specific harm reduction interventions 
targeted at cocaine and ATS users are available in Czech prisons. There are no needle and syringe 
exchange programmes available in Czech prisons and drug paraphernalia are not available. 
Measures implemented to prevent infectious diseases are inadequate, because basic harm 
reduction activities such as the provision of information is missing. Testing is performed, but it 
lacks integration into a broader range of measures. Hepatitis B or tuberculosis vaccination 
programmes targeted at drug users are not available in Czech prisons. The involvement of family 
and friends of drug users in harm reduction interventions is inadequate to lacking. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are adequate in coverage.  
Hepatitis B vaccination programmes targeting drug users are inadequate in coverage and 
accessibility and not made a priority of the health care system. Tuberculosis vaccination 
programmes targeted at drug users are not available.  
191 European Survey Project on Alcohol and Drugs, an international prevalence survey among secondary school 
students aged 15-16, which is conducted every four years. The ESPAD project incorporates over 35 European 
countries. It is run by the Swedish Council for Information on Alcohol and other Drugs. 
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Annex A2.3 State of play on harm reduction in Denmark 
2.3.1 Summary 
Public health policy. In Denmark, harm reduction has been an objective in public health policy 
for some time already and specified this in its National Drug Action Plan “The Fight Against Drugs” 
in 2003. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through websites, telephone help lines, and educational leaflets. With regard to the 
prevention of infectious diseases among drug users, IEC in general, and IEC via counselling and 
advice by drugs and health professionals are common response strategies. For the reduction of 
drug-related deaths, the dissemination of information materials is a predominant response 
strategy. Although this policy exists, it is unclear whether communities and families of drug users 
are involved in the prevention and reduction of health risks associated with drug dependence. 
Outreach work. Outreach work at dance parties/  rave events is nationwide available. Outreach 
work as a health education approach is a common response strategy to prevent infectious diseases 
among drug users. For the reduction of drug-related deaths, outreach work is the predominant 
setting for the dissemination of information materials, as well as for the deliverance of risk 
education/  response training. Furthermore, peers and volunteers are included nationwide in 
outreach work practice. Finally, networking and cooperation between outreach work agencies also 
exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
detoxification programmes, treatment with naltrexone, drug-free outpatient and inpatient 
treatment, rehabilitation centres and drop-in centres/  shelters are available nationwide. Treatment 
with buprenorphine is only offered in specific geographical areas. Drug consumption rooms and 
heroin prescription programmes do not exist in Denmark. Opioid substitution treatment is a 
predominant response strategy aiming at the reduction of drug-related deaths. Measures to 
prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Methadone maintenance and detoxification programmes, buprenorphine 
treatment and treatment with naltrexone are available nationwide in Danish prisons. Also testing/ 
screening, prevention, education, counselling and treatment of infectious diseases, as well as 
vaccination against hepatitis B, are nationwide available. There is no needle and syringe exchange 
in prison, though drug paraphernalia and condoms are available. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/  screening, and treatment of infectious diseases are available nationwide, just 
as vaccination against hepatitis B. To prevent infectious diseases among drug users, the 
predominant response strategies are condom distribution and needle and syringe exchange. Needle 
and syringe exchange is available nationwide; drug paraphernalia and the distribution of condoms 
are only available in specific geographical regions in Denmark.  
Drug-related deaths. Professionals of emergency departments are not specifically trained, e.g., 
to deal with overdoses. The distribution, possession or administration of naloxone is regulated by 
laws. Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to prison staff; and to professionals in substitution programmes in specific 
geographical areas only. Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. The Danish government actively uses scientific evidence of 
effectiveness as a main basis to select interventions. An effectiveness study on methadone 
treatment is underway. Evaluation of programmes is used to adjust policies, i.e. regarding the 
Social Services Act, which aims to provide the necessary social services to drug users.  
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2.3.2 Recommendation 1: Risk reduction and public health policy 
The responsible structure for the implementation of the Council Recommendation is the Danish 
Ministry of the Interior and Health192. [RT] 
Harm reduction is an objective in public health, but was not based upon the Council 
Recommendation. The Danish policy is presented in the action plan: "The Fight Against Drugs" 
(Action Plan Against Drugs, Danish Government, October 2003). The Action Plan has a broad scope 
and is partly inspired by the international dialogue, including that within the European Community. 
However, the Council Recommendation was not the primary inspiration of the Action Plan. [RT]
2.3.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Denmark, the dissemination of information through various websites, telephone help lines, and 
through a broad range of educational leaflets are available nationwide. [NR 2003] 
Information, education, communication (IEC) in general, and IEC via counselling and advice by 
drugs and health professionals are common response strategies to prevent infectious diseases
among drug users. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is a predominant response strategy. Information materials are disseminated at specialised drug 
treatment services, and are also commonly spread via low threshold agencies, needle and syringe 
exchange programmes, and schools/  educational systems. Training (safer injecting/  risk 
education/  response) for drug users is not provided at a national and formal level.193,194 [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Denmark, outreach work at dance parties/ rave events is available nationwide. Street-based 
outreach work is available in specific geographical areas only195 as well as some other types of 
outreach work196,197. [NR 2003; NFP 2006] 
Outreach work as a health education approach is a common response strategy to prevent 
infectious diseases among drug users. Outreach work and targeted high-risk group interventions 
are a common implementation setting for infectious diseases prevention measures targeting drug 
users. [SQ 23] 
192 Division of International Affairs and Narcotic Drugs – Unit Narcotic Drugs. 
193 In some areas trainings for drug users are offered. In Copenhagen there are a number of nurses available 
for outreach work to drug users' homes and in the down-town area. This counselling includes among other 
things information on general injecting hygiene.  
194 On an individual basis, workers of treatment centres give counselling. 
195 Several projects for street-based outreach work; street work among youth. 
196 Special “teams” for handling dual–diagnosis and somatic co-occurring disorders are established, but not 
nationwide. 
197 In October 2005, a Political Agreement was made to fund, by pooled reserves, outreach work initiatives 
(among other initiatives) in the years to come. 
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Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are a common setting for the dissemination of information materials, aimed at the reduction of 
drug-related deaths, and outreach work is a predominant setting for the deliverance of risk 
education/  response training, which is delivered in all or most cities198. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy is not a task for national government. [RT] 
Peers and volunteers are included in outreach work nationwide199. No training for peers and 
volunteers exist200. [NR 2003/ 2004; NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy is not a task for the national government. [RT] 
Networking and cooperation between outreach work agencies exist nationwide201. [NR 2003/ 2004] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance programmes202, methadone detoxification programmes, treatment with 
naltrexone, drug-free outpatient and inpatient treatment203, rehabilitation centres and drop-in 
centres204/ shelters are available nationwide. Treatment with buprenorphine is limited to specific 
geographical areas. Substitution treatment is supported by (obligatory) psychosocial care. [NR 
2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy in Denmark. [SQ 29] Drug consumption rooms and heroin prescription 
programmes do not exist in Denmark. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists , but was not based upon the Council Recommendation. 205[RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. 206[NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance and methadone detoxification programmes, buprenorphine treatment and 
treatment with naltrexone are available nationwide in Danish prisons. There are no needle and 
syringe exchange programmes in prison, but drug paraphernalia207 and condoms are available. 
Testing, prevention, education, counselling and treatment of infectious diseases is available 
nationwide in prisons, as is testing and vaccination against hepatitis B. [NR 2003; NFP 2006] 
198 Availability is linked to drug treatment services, mainly in the big cities. 
199 Specific peer teams for young drug users. 
200 Individual training is given regarding the different and specific interventions. 
201 The government supports the building of a network; association of drop-in centres. 
202 Including a methadone injections programme.
203 About 40 inpatient institutions, of which 31 are drug-free. 
204 Over 70 drop-in centres.
205 Control measures regarding prescription aim to prevent diversion. 
206 Indirectly by optimizing the treatment system for drug users (ongoing quality assurance of the treatment). 
207 Cleaning liquid is provided. 
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Prisons are a rare, uncommon implementation setting both for infectious disease prevention
measures targeting drug users and for measures targeting the reduction of drug – related 
deaths. [SQ 23, SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions; 
This policy exists, but was not based upon the Council Recommendation208. [RT] 
Testing/ screening and treatment of infectious diseases and vaccination against hepatitis B are 
available nationwide. [NR 2004] 
To prevent infectious diseases209 among drug users, the predominant response strategies are 
condom distribution and needle and syringe exchange programmes. IEC in general, IEC via 
counselling and advice by drugs and health professionals, outreach health education approach, 
routine screening of high-risk groups, hepatitis vaccination programme for drug users, and easy 
access’ programmes for drug users to treatment of infectious diseases are common response 
strategies. [SQ 23] 
Specialised drug treatment services, low threshold counselling, and outreach work and targeted 
high risk group interventions, are common implementation settings for infectious diseases 
prevention measures targeting drug users. [SQ 23] 
2.10  Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes are available nationwide210. In specific geographical 
areas, including Copenhagen, drug paraphernalia211 and the distribution of condoms are available. 
[NR 2004; NFP 2006]  
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Denmark. [SQ 23]. Low threshold agencies, including 
needle and syringe exchange programmes, are also a common setting for the dissemination of 
information materials on the reduction of drug-related deaths among drug users, and for risk 
education/  response trainings for drug users. [SQ 29] 
Denmark has 135 non-pharmacy based and 108 pharmacy based needle and syringe exchange 
programmes, and 7 vending machines. Needle exchange takes place at fixed sites, and through 
outreach work and peers, but there are no vans/ buses, and no prison-based needle and syringe 
exchange programmes. [ST 10] There are no legal restrictions to the possession of sterile needles 
in Denmark, and also no prescription is required to obtain or exchange needles and syringes. 
[ELDD]
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training seminars for professionals of emergency departments are not available. [NFP 2006]  
Emergency departments are not a setting for the dissemination of information materials that aim at 
the reduction of drug-related deaths. In Denmark, the distribution, possession or administration of 
naloxone is regulated by laws. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
208 An executive order from the Danish Government on “Hepatitis vaccination, free of charge for injecting drug 
users and their relatives” was implemented in April 2005. 
209 In October 2005, a Political Agreement was made to fund, by pooled reserves, harm reduction initiatives the 
coming years, to reduce infectious diseases among drug users. 
210 As a supplement for interventions in the Municipality of Copenhagen, members of the drug user association 
Brugerforeningen, remove used needles and syringes from the streets. 
211 Cleaning tissues, cotton wool, sterile water etc, together with needle and syringe distribution. 
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2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Risk reduction is part of an integrated health strategy for drug users212. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but is not based upon the Council Recommendation. [RT] 
Trainings are offered nationwide to prison staff. Training for professionals in substitution 
programmes213 is available in specific geographical areas only. Training programmes for 
professionals in other areas of risk reduction, except for substitution treatment, do not exist214. [NR 
2003/ 2004; NFP 2006] 
2.3.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. Governmental initiated 
programmes and projects are based on the available scientific evidence (if available). Informational 
material, that recommends the implementation of validated methods are produced national and 
distributed regional and locally. [RT] 
Additionally, the Danish Government prioritises the initiation and completion of a quality 
assessment of methadone treatment as the basis for future quality assurance and development in 
line with the interventions planned within this area of the health care sector in general. [NR 2004] 
As regards prevention, the counties regularly conduct evaluations of local programmes. These 
evaluation reports typically describe experience gained and are included in the continuing work. 
The methodological quality of these studies covers a wide field. Actual scientific evaluations are 
rare, given that on a local level, there is a shortage of resources and competencies. [NR 2003] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. Governmental initiated 
programmes and projects are based on needs assessment. Informational material, that 
recommends needs assessment are produced national and distributed regional and locally. [RT] 
The Government’s cross-ministerial action plan, “The Fight Against Drugs”, proposes, among other 
things, that based on the evaluation of a pilot project of health care intervention targeted at the 
most severely addicted drug abusers, the Government will consider the need for and possibility of 
providing such services as permanent schemes in particularly affected city areas.  
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. Governmental initiated 
programmes and projects are based on adequate evaluation protocols. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
212 The overall “concept” of interventions towards drug users in Denmark is to integrate treatment approach 
combining health and social care.
213 Not for providers of buprenorphine. 
214 Bartenders and employees in night-life-settings are sometimes trained in risk reduction.
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No formally drafted strategy or guidelines have been prepared on quality assurance. However, 
Within the in-patient treatment sector, the Ministry of Social Affairs, the Association of County 
Councils in Denmark, and the Centre for Alcohol and Drug Research have launched a 
documentation and monitoring system within the drug use area (DANRIS). This is a pilot project 
with the overall purpose being to achieve registered and documented treatment programmes as 
well as to monitor the quality and effects of the various kinds of drug treatments. The system is 
being developed over a three-year-period in the counties of Copenhagen and Aarhus. From the 
government’s action programme for the most marginalized groups, it appears that the DANRIS 
system as a new initiative will be extended to include the entire country within the next few years. 
[NR 2003]  
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
On 1 January 2003, the Act amending the Social Services Act (Guaranteed social treatment for 
drug abuse) came into force. According to the Act, county authorities must provide social 
treatment for drug abusers no later than 14 days after referral to the county. Also, the drug abuser 
has the right to choose between public and private approved treatment services similar to those 
offered by the county.
The Act subjects the implementation of the scheme to monitoring for evaluation purposes. In the 
evaluation it will be determined whether the effects of the proposed scheme are consistent with the 
intentions of the law. Based on this evaluation, a report will be prepared and after a hearing in the 
other authorities and organisations, the report will be submitted to the Social Committee of the 
Danish Parliament after the Law has been in effect for three years. [NR 2004] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist. Evaluation trainings seminars for regional and local drug professionals 
are occasionally part of national programmes. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy does not exist. Results, skills and exprerince are shared through international co-
operation in general. [RT] 
Denmark participates in the ESPAD project [NR 2004]. This does not concern harm reduction. 
International Cooperation is a priority aim of the cross-Ministerial Action Plan “The Fight Against 
Drugs”, which was adopted in 2003. [NR 2003]  
2.3.5 Information from third data sources  
Issues raised by the Danish Drug User Union Brugerforeningen 
Information, education and communication (IEC). IEC is inadequate in coverage and 
accessibility, as opening hours are insufficient. Drug testing is not available in Denmark. Measures 
to involve families and friends of drug users in harm reduction interventions are incorporated in 
some programmes, but these are mostly privately owned or running on a voluntary basis. 
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Outreach work. Coverage and accessibility of outreach work is not adequate. It is mostly 
performed by volunteer workers and there seems to be a constant need for more activity. 
(Medically assisted) treatment and specific interventions. Coverage of medically assisted 
treatment for opiate users is adequate, but regional differences in accessibility exist.  
There is no heroin prescription program in Denmark. Medically assisted treatment for ATS or 
cocaine users is inadequate in coverage and accessibility. ATS and cocaine prescription 
programmes  as well as specific harm reduction interventions for cocaine or ATS users do not exist 
in Denmark. There are no drug consumption rooms.  
Needle and syringe exchange programmes and the distribution of drug paraphernalia are 
inadequate in coverage and accessibility, as there is a big discrepancy between urban centres and 
the periphery. In rural areas it is nearly impossible to get clean equipment, whereas access in the 
capital is adequate.  
The coverage of low threshold agencies is inadequate throughout the country, whereas it can be 
considered sufficient in the urban centres. 
Prison interventions. IEC in prison is inadequate in coverage as well as in accessibility. Outreach 
work in prison exists, but is inadequate in coverage and accessibility, as it is performed by 
volunteers rather than being an integral part of the prison system.   
Medically assisted treatment in prison is adequate in coverage and accessibility. The law assures 
everyone medically assisted treatment within two weeks, but there is no mentioning of which 
treatment is guaranteed.  
The coverage and accessibility of medically assisted treatment for ATS or cocaine users is 
considered to be inadequate and no specific harm reduction interventions targeted at ATS or 
cocaine users exist in Danish prisons.  
NSPs or drug paraphernalia are not available in prisons and measures implemented to prevent 
infectious diseases are inadequate, because the individual prisoner is to actively seek such 
services. Free hepatitis B vaccination programmes are available throughout Denmark, also in the 
penitentiaries. There is no information available whether tuberculosis vaccination programmes are 
offered and accessible for drug users in prisons.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are inadequate. 
Free hepatitis B vaccination is available. No information exists on tuberculosis vaccination 
programmes targeting drug users. 
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Annex A2.4 State of play on harm reduction in Germany 
2.4.1 Summary 
Public health policy. The prevention of drug dependence and the reduction of related risks were 
priority objectives in German Drug Policy before the Council Recommendation was launched. Harm 
reduction is laid down in action plans at federal and Laender level since the nineties.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines and websites. For the reduction of drug-related deaths, the 
dissemination of information materials is the predominant response strategy. Further, communities 
and families of drug users are informed nationwide. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs (including pill-testing) are available in specific geographical areas only. Outreach work as a 
health education approach is a common response strategy to prevent infectious diseases among 
drug users. For the reduction of drug-related deaths, outreach work is the predominant setting for 
the dissemination of information materials. Peers and volunteers are included in outreach work 
practice only in specific geographical regions. Networking and cooperation between outreach work 
agencies also exist in specific geographical regions only. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
detoxification programmes, treatment with buprenorphine, drug free outpatient and inpatient 
treatment and rehabilitation programmes are available nationwide. In specific geographical areas, 
heroin prescription programmes, drug consumption rooms and drop-in centres are available. Opioid 
substitution treatment is a predominant response strategy aiming at the reduction of drug-related 
deaths. Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Methadone detoxification programmes are available nationwide in prison. 
Methadone maintenance treatment, treatment with buprenorphine, needle and syringe exchange, 
screening, prevention, education, and treatment of infectious diseases, counselling and the 
distribution of condoms are available in specific geographical areas only. Drug paraphernalia are 
not available in German prisons, nor is treatment with naltrexone. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, prevention, treatment and vaccination for infectious 
diseases are available nationwide. To prevent infectious diseases among drug users, the 
predominant response strategy is IEC in general. Needle and syringe exchange and drug 
paraphernalia are available nationwide.  
Drug-related deaths. Professionals of emergency departments are trained in specific 
geographical areas only, e.g. to deal with overdoses. The distribution, possession or administration 
of naloxone is regulated. Naloxone on a ‘take home’ basis is only available to some drug users. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in substitution programmes, low threshold programmes and 
treatment facilities. Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. Only few evaluation studies on harm reduction are 
available in Germany. The legal framework how to deal with drug problems is defined by laws and 
guidelines. It is planned that these guidelines will be monitored and evaluated. A computerised 
documentation system is set up by the federal government and the Laender in which prevention 
programmes can be registered. The evaluation of programmes and interventions is a regular 
practice in Germany. In a city like Hamburg, the addiction care system has been evaluated, 
resulting in a number of recommendations for policy development. Germany collaborates with 
many different countries through bilateral programmes. 
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2.4.2 Recommendation 1: Risk reduction and public health policy 
In Germany the governmental body responsible for the implementation of the Council 
Recommendation is the Federal Ministry for Health and Social Security215. This policy exists, but 
was not based upon the Council Recommendation. Prevention of drug dependence and reduction of 
related risks were already priority goals in German Drug policy before the Council Recommendation 
was launched. Since 1990 there have been comprehensive, multidisciplinary action plans on federal 
and Laender level, which have been further developed in the light of new scientific evidence. [RT]  
Harm reduction is part of the ‘Aktionsplan Drogen und Sucht’ of the Federal Government, which 
was adopted in 2003 and covers the period of 2003-2008. [SQ 29]
2.4.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Germany, dissemination of information through various websites216 and through telephone help 
lines are available nationwide. Other ways of providing information and counselling to drug users in 
the framework of risk reduction is available in specific geographical areas217 only (training, 
educational leaflets). [NR 2003/ 2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general is a predominant response strategy, whereas IEC via counselling 
and advice by drugs and health professionals and via peer involvement/ peer approach are 
common response strategies. Safer injecting training is part of general activities in harm reduction 
programmes. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy: materials are predominantly disseminated at low threshold 
agencies, including needle and syringe programmes, and through outreach workers, mass media 
and nightlife or entertainment venues. Common settings are specialised drug treatment services, 
detoxification services and school and educational systems. [SQ 29] 
Risk education/  response trainings as a response to reduce drug-related deaths are uncommon in 
Germany, but risk counselling is a common response strategy. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Communities and families of drug users are informed nationwide. [NR 2004] At a national level 
there is no information available about the involvement of communities and families in the 
prevention and reduction of health risks associated with drug dependence218. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Germany, street-based outreach work and outreach work at dance parties, raves and in clubs 
are available in specific geographical areas only. [NR 2003/ 2004] 
215 Responsible unit: Unit Drugs and Substance Misuse (BMGS).
216 Information on treatment centres, opening hours, location, nature of services. www.dhs.de
217 Available on Laender and regional level.
218 However, a lot of preventive activities take place locally with financial support from the municipalities.
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To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. [SQ 23]. Low threshold agencies, including needle and 
syringe exchange programmes and outreach work are the predominant setting for the 
dissemination of information materials, aimed at the reduction of drug-related deaths. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas only, training for outreach workers, peers and volunteers is 
organised. In specific geographical areas peers and volunteers are included in outreach work 
practice. [NR 2002, NR 2004] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies exist in specific geographical areas 
only219. [NR 2001; NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance programmes, methadone detoxification programmes, treatment with 
buprenorphine, drug-free outpatient and inpatient treatment and rehabilitation220 programmes are 
available nationwide. Substitution treatment is supported by psychosocial care and is sometimes 
obligatory, sometimes upon request by the client (depending on the prescribing institution or 
general practitioner). In specific geographical areas only, heroin prescription programmes, drug 
consumption rooms221and drop-in centres are available. [NR 2003/ 2004] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29] 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide222. [NR 2001/ 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone detoxification223 programmes are available nationwide in German prisons. Methadone 
maintenance treatment, treatment with buprenorphine, needle and syringe exchange 
programmes224 are available in specific geographical areas only; testing/ screening, prevention, 
education, treatment of infectious diseases, counselling and the distribution of condoms, are also 
available, in specific geographical areas only. Drug paraphernalia are not available in German 
prisons, and neither is treatment with naltrexone. [NR 2003/ 2004; NFP 2006] 
219 Nowadays in Germany cooperation is considered part of a professional standard in drug treatment and 
prevention. Institutions working in the field of drug treatment and prevention in a region have regular contacts, 
both through formal cooperation platforms and through workgroups on addiction. 
220 Third phase of official treatment programme; 5,000 places nationwide. 
221 24 in 2003 in urban areas. 
222 Measures include: restricted take home doses, a centralized, nationwide substitution registration, special 
forms for prescription of narcotics.
223 Drug users with long sentences  often get a detox phase, which is not followed by substitution. 
224 Seven pilots, but only one was continued. 
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Prisons are a common implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Measures targeting at the reduction of drug – related deaths are uncommon or non existent in 
German prisons225. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening, education226, prevention, treatment227 and vaccination with regard to infectious 
diseases targeting drug users are available nationwide. [NR 2003/ 2004] 
To prevent infectious diseases among drug users the predominant response strategy is 
information, education, communication (IEC) in general. Other common strategies include IEC via 
peer involvement/ peer approach, safer injection training for drug users, IEC via counselling by 
drugs and health professionals, outreach health education approach, voluntary infectious diseases 
counselling and testing, needle and syringe exchange programmes, hepatitis vaccination 
programmes for drug users, ‘easy access’ programmes for drug users to treatment of infectious 
diseases, e.g. at low threshold agencies. [SQ 23] 
2.10  Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes, vending machines228 and drug paraphernalia are 
nationwide available. In specific geographical areas only, condoms are distributed among drug 
users. [NR 2003/ 2004; NFP 2006] 
Needle and syringe exchange programmes are a common response strategy to prevent infectious 
diseases among drug users in Germany. [SQ 23] Low threshold agencies, including needle and 
syringe exchange programmes, are a predominant setting to provide information materials on the 
reduction of drug-related deaths among drug users. [SQ 29] 
Available types of needle and syringe exchange programmes in Germany are fixed sites, outreach/ 
peer, vending machines, pharmacy-based needle and syringe exchange programmes and prison-
based NSPs. [ST 10]. There are no legal restrictions to the possession of sterile needles in 
Germany and also no prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT]
In specific geographical areas only, professionals of emergency departments are trained. [NR 
2003] Emergency departments are an uncommon setting for dissemination of information 
materials that aim at the reduction of drug-related deaths or for risk education/ response trainings. 
[SQ 29] 
The distribution, possession or administration of naloxone is regulated by laws. Naloxone is only 
available on prescription and administration is limited to physicians. Naloxone on a ‘take home’ 
basis is available to some drug users229. [SQ 29] 
225 Drug users that are released from prison will have the possibility to see a video with information on first aid 
in cases of a drug-related emergency. 
226 There is a need for training and prevention (materials). Safer use and OD training are available only in 
specific areas. 
227 It is advised that injecting drug users are enrolled in substitution treatment before accessing HIV or HCV 
treatment.
228 Around 200 vending machines. 
229 Naloxone is available on a take home basis as part of a project in Berlin for users who have undergone 
training in first aid for drug emergencies during the last 12 months. 
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2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT]
Risk reduction is part of an integrated health strategy for drug users230. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT]
Training is offered nationwide to professionals in substitution programmes231, low threshold 
programmes and treatment facilities. In specific geographical areas training programmes for 
outreach workers are organised. Specific training programmes for prison staff do not exist.  
[NR 2003/ 2004] 
2.4.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
Concerning the implementation of the activities of recommendation 3, not only national, regional 
and local governments are involved, but also the scientific community and NGOs. This 
multidisciplinary and multi sectional approach has always been a very important aspect in German 
drug policy. [RT] 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists and was based upon the Council Recommendation. [RT] 
In Germany only few evaluation studies are available in the field of harm reduction. Where studies 
exist, they often do no meet scientific standards. Bundeslaender, for example Saarland, have 
published reports that critically evaluate 10 years of substitution treatment. [NR 2002] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists and was based upon the Council Recommendation. [RT] 
The legal framework how to deal with drug problems is defined by laws and guidelines. It is 
planned to follow up and analyze the impact of individual guidelines. To this purpose, measures 
and indicators are to be defined for the assessment of results of the Action Plan on Drugs and 
Addiction. [NR 2004] 
As a prompt transfer of knowledge relating to documented and evaluated interventions and 
programmes is the prerequisite for quality-assured planning of measures by different players, all 
institutions active in the field of drug prevention will in future document their measures on a 
regular basis and in a standardised format using the DoSys documentation system developed by 
the Federal Government and the Laender. This data collection will be supported by regional 
systems. [NR 2004]. 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists and was based upon the Council Recommendation. [RT] 
230 National Drug Action Plan (Aktionsplan Drogen und Sucht). 
231 8,000 GPs are qualified to provide substitution drugs, but only 2,300 of them actually do so. 
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Due to the federal structure and the subsidiary principle in the German health system there are no 
unified formal requirements or criteria for quality assurance of measures for demand reduction. 
This despite of efforts in the field of prevention to do so. A variety of approaches, methods and 
instruments are applied in the Laender and by local authority districts. However, there are great 
differences regarding available resources. 
The Federal Centre for Health Education (BZgA) is entrusted with the planning of new measures 
and campaigns and/ or with the evaluation and further development of existing measures and 
campaigns based on actual scientific knowledge. The expected result of this exercise is a renewed 
concept about aims and instruments or measures to reach specific aims.  
At the same time, a series of legal framework conditions with regard to substitution treatment have 
already been changed in order to facilitate access to these services and secure the quality of these 
measures. Together with other drug policy measures these changes are to be evaluated in the 
future with respect to their effectiveness. [NR 2003] 
Furthermore, there are no uniform formal requirements or criteria for quality assurance with regard 
to measures aiming at the reduction of drug demand. Approaches moving in this direction – e.g. 
the development of guidelines and programmes for quality assurance – are solely adopted at a 
technical level by professional and scientific associations as well as by funding bodies. Their 
application, however, is not mandatory.  
At the national level, the Federal Centre for Health Education (BZgA) is responsible for the planning 
and implementation of prevention programmes and the monitoring of preventive activities in 
Germany. [NR 2004] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Germany, among others, the following activities and procedures for evaluation have been 
implemented, which had an impact on national and local drug strategies.  
Within the context of model programmes, new methods of prevention, consultation or treatment as 
well as new forms of organisation (e.g. ‘Case management’) are tested and evaluated on a regular 
basis. Furthermore, experts’ reports have been used to gain an overview about the state of 
research and on current developments in the drug demand reduction field. Different innovative 
projects were monitored and supervised by scientists, who recorded procedures and results and 
who carried out evaluations. One recent example of the latter is the study on drug consumption 
rooms (ZEUS 2002).  [NR 2003] 
At the level of the Laender, many activities take place. A number of these activities are of special 
interest to this report. For example, all Laender have formulated a joint position paper on the 
future focus of outpatient drug and addiction aid systems. The Land of Berlin has reorganized its 
out-patient services and their staff situation, based upon the insights gained through a clients’ 
needs assessment. The Land of Hamburg commissioned an evaluation of the addiction care system 
of the city in order to examine the outcome of its abstinence-based programmes. Receiving an 
overall positive response, the authors made a series of suggestions to further improve cooperation 
and division of work to achieve even better results despite tight budgets. Furthermore, a new 
orientation on a strongly opiate-centred aid system is currently under discussion. [NR 2004] In the 
two last mentioned activities, the objective of the measures is to achieve a better interaction and 
cooperation between aid services regarding licit and illicit substances as well as between drug aid 
and other complementary aid services. [NR 2004] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. [RT] 
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3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists but was not based upon the Council Recommendation. [RT] 
No specific measures exist for the field of harm reduction. However, in the field of prevention, 
projects involving stakeholders exist at – primarily – local level. In 2001/  2002 the Federal Centre 
for Health Education organised a competition called ‘Model Strategies’ of Municipal Drug 
Prevention. This competition was an attempt to draw the attention of the general public to the 
development of drug prevention strategies at local level. There were 220 competition entries from 
193 towns, rural districts and municipalities. The overall picture that was drawn from these entries 
was as follows. Half of all the participating municipalities had established a project group or a 
working group as a tool for regulating municipal cooperation. Forty percent of the municipalities 
that took part in the competition appointed a drug or prevention commissioner to safeguard long-
term drug prevention work. Two-third of the participating municipalities had developed their own, 
written drug prevention concept. Over 76% of these municipalities planned, started or completed 
evaluation activities of preventative interventions, while 20% did not have any plans to do so. [NR 
2002] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] 
In 2003, six Buendeslaender232 participated in the ESPAD survey233. The Federal Ministry of Health 
has financially support the matching of data and the evaluation of the international performance for 
the participating Laender. [NR 2002] 
Germany also participates in the EDDRA234 database, presenting selected examples of good 
practice. A team of prevention experts from the Bundeslaender and the Laender coordinators 
developed - under the supervision of the BZgA - a database in which addiction prevention 
measures are systematically collected and described. [NR 2002] 
On international level, Germany provides development aid with the aim to improve living conditions 
of local inhabitants who are dependent on the cultivation of drugs (cocaine, heroin), such with the 
aim to reduce poverty and offer alternatives. Germany cooperates with countries in the field of 
drugs within the European Union (EU Drug Action Plan, EMCDDA, and Europol) and the United 
Nations (CND, UNODC).  
2.4.5 Information from third data sources 
Issues raised by Fixpunkt/ AkZept 
Information, education and communication (IEC). IEC is inadequate in accessibility and 
coverage, because techniques are not adapted to “hard to reach” users, like hidden users and 
beginners. Drug testing does no longer exist in Germany.  
Outreach work. Outreach work varies greatly in quality and quantity.
(Medically assisted) treatment and specific interventions. In general, medically assisted 
treatment for opiate users is available and accessible in Germany.235 The available heroin 
prescription programmes are considered inadequate in coverage and accessibility. There are no 
ATS or cocaine prescription programmes available. Specific services for cocaine or ATS users are 
inadequate in coverage and accessibility. The coverage and accessibility of drug consumption 
rooms is evaluated as inadequate. Accessibility and effectiveness of consumption rooms is limited, 
232 Bavaria, Berlin, Brandenburg, Hessia, Mecklenburg-West Pomerania and Thuringia. 
233 CAN [2003]. 
234 Exchange on Drug Demand Reduction Action. 
235 Substitution drugs used in medically assisted treatment: methadone, levomethadone, buprenorphine, 
dihydrocodeine and codeine. 
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as regulations deny access to methadone patients236. Coverage and access to low threshold 
agencies can be improved significantly by the elimination of local differences and by providing 
adequate funding for activities. 
Prison interventions. In prison, IEC is hindered through strict control and a lack of free access to 
information. Outreach work in prison also lacks sufficient funding and is not available in all German 
prisons. Availability and accessibility to substitution services vary greatly from Land to Land.237
Specific harm reduction interventions for cocaine/  ATS users are not available in prison. Measures 
implemented to prevent infectious diseases are inadequate because of a lack of awareness and a 
lack of financial resources to change the situation. Hepatitis B vaccination coverage is inadequate. 
NSPs have been discontinued for political reasons rather than lack of effectiveness. At the moment, 
only one NSP in prison remains in the whole of Germany. Drug paraphernalia are not available at 
all. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are inadequate because of a lack 
of awareness in drug services and a lack of financial resources to change the situation. Hepatitis B 
vaccination is available and covered by the general health insurance, but GPs need to be motivated 
to encourage drug users to get vaccinated. Tuberculosis vaccination programmes targeting drug 
users are not available in Germany because of lack of evidence-based research that there is a 
higher prevalence of tuberculosis in the drug-using population. Coverage and accessibility of NSPs 
is considered inadequate. Distribution of drug paraphernalia is inadequate, because of local and 
regional differences.
236 Further information on German consumption rooms can be found in: Zurhold, Heike, Peter Degkwitz, Uwe 
Verthein und Christian Haasen [2003]. Drug consumption rooms in Hamburg, Germany: Evaluation of the 
effects on harm reduction and the reduction of public nuisance. Journal of Drug Issues.
237 Substitution treatment is provided in most German prisons, although access depends to a great extent on 
the state in which the prison is located. While in the northern states substitution treatment is common, it is rare 
to find it provided in the southern states such as Bavaria and Baden-Württemberg. Methadone is the most 
frequently used substitution treatment for detoxification. In: R Simon, E Hoch, R Hüllinghorst, G Nöcker, M 
David-Spickermann [2001]. Report on the Drug Situation in Germany 2001. German Reference Centre for the 
European Monitoring Centre for Drugs and Drug Addiction.
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Annex A2.5 State of play on harm reduction in Estonia 
2.5.1 Summary 
Public health policy. Harm reduction is part of public health policy in Estonia and it was based 
upon the Council Recommendation. Harm reduction is part of the National Strategy on Drug 
Dependence 2004-2012.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
available through telephone help lines and websites. Communities and families of drug users are 
informed and involved in the prevention and reduction of health risks associated with drug 
dependence in specific geographical regions only. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs are available in specific geographical areas only. Outreach work as a health education 
approach is a common response strategy to prevent infectious diseases among drug users. For the 
reduction of drug-related deaths, outreach work is not in use. In specific geographical areas, peers 
and volunteers are included in outreach work practice. Networking and cooperation between 
outreach work agencies exist only at specific geographical regions. 
(Medically assisted) treatment and specific interventions. Methadone detoxification 
programmes are available nationwide. Methadone maintenance treatment, treatment with 
buprenorphine, drug-free outpatient and drug-free inpatient treatment, rehabilitation centres and 
drop-in centres/ shelters are available in specific geographical areas only. Drug consumption rooms 
and heroin prescription programmes do not exist in Estonia. Measures to prevent diversion of 
prescribed drugs are available nationwide. 
Prison interventions. Counselling, testing/ screening, prevention, education and treatment of 
infectious diseases are available nationwide in prison. In specific geographical areas only, 
methadone detoxification programmes, condom distribution and drug paraphernalia are provided. 
There is no needle and syringe exchange. Methadone maintenance therapy is not available. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, prevention, and counselling for infectious diseases are 
available nationwide. In specific geographical areas, treatment and vaccination against hepatitis B 
exist. To prevent infectious diseases among drug users, the predominant response strategies are 
IEC in general, condom distribution and provision and needle and syringe exchange. Needle and 
syringe exchange and the distribution of condoms are available nationwide in Estonia.  
Drug-related deaths. There is no information available whether professionals of emergency 
departments are trained, e.g. to deal with overdoses. Naloxone on a ‘take home’ basis is not 
available. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to prison staff. For professionals in needle and syringe exchange programmes, 
low threshold agencies, outreach work and programmes for substitution treatment, training is 
available in specific geographical areas only. Risk reduction is part of an integrated health strategy 
for drug users. 
Quality, monitoring and evaluation. In 2004, Estonia started to develop a system of health 
education standards and quality assurance management on prevention. The National HIV/ AIDS 
prevention programme, which also focuses on opiate dependent drug use, incorporates 
interventions that are – among others – based upon effectiveness and evidence. Estonia is 
beginning to develop quality criteria and protocols in drug demand reduction. The resources are 
still scarce, though. There is a policy in place that calls for the incorporation of evaluation results in 
drug prevention policymaking, but there are not many evaluated programmes available.  
Estonia has been participating in bilateral and collaborative programmes with a.o. the Global Fund 
(Drug Treatment Guidelines) and the Pompidou Group (staff training).  
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2.5.2 Recommendation 1: Risk reduction and public health policy 
The governmental structure that is responsible for the implementation of the Council 
Recommendation is the Estonian Ministry of Social Affairs238. The prevention and reduction of 
health-related harm associated with drug dependence is a public health objective in Estonia. It was 
based upon the Council Recommendation. The National Strategy on the Prevention of Drug 
Dependence 2004-2012 and a 4-year Action plan was approved by the Estonian Government on 22 
April 2004.  
The National Strategy provides an integrated approach to both drug demand and drug supply 
reduction and includes six fields: prevention, treatment-rehabilitation, harm reduction, supply 
reduction, drugs in prison and monitoring of drug situation and evaluation. The Council 
Recommendation had an important influence on the relevant sections in the Strategy. [RT]
2.5.3 Recommendation 2: Risk Reduction activities and interventions 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists and was based upon the Council Recommendation239. [RT]
In Estonia, the dissemination of information through various websites240 and through telephone 
help lines is available nationwide. Training241 and educational leaflets242 are available in specific 
geographical areas only. [NR 2002-2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general is a predominant response strategy. IEC via counselling and advice 
by drugs and health professionals, and IEC via peer involvement/ peer approach are common 
response strategies. [SQ 23]  
Response strategies aiming at the reduction of drug-related deaths are uncommon in Estonia. 
[SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and was  based upon the Council Recommendation. [RT]
In specific geographical areas only, communities and families of drug users are involved in the 
prevention and reduction of health risks associated with drug dependence243, as well as specific IEC 
for communities and families of drug users. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists and was based upon the Council Recommendation244. [RT] 
In Estonia, street-based outreach work and outreach work at dance parties, raves and in clubs are 
available in specific geographical areas only245. [NR 2003/ 2004] 
238 Public Health Department, Health Policy Unit. 
239 Information on risk reduction and different available services and counselling is provided to drug users and 
their families in low threshold centres and through outreach work. Existing centres are able to serve only a 
limited number of drug users, therefore there is a need to extend such services. 
240 www.lapsemure.ee ; www.narko.ee
241 All needle and syringe exchange programmes are providing training for injecting drug users on HIV/ AIDS 
and other STDs, safer sex and safe injecting. In 2003 new information materials have been provided to 
injecting drug users.  
242 It is a common procedure that all clients in substitution treatment receive information from the centre’s 
medical personnel on overdose prevention.  
243 This depends on the financial resources and priorities of the local governments. 
244 There are special programmes for high risk population groups, but not in sufficient number. 
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To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a predominant implementation setting for infectious diseases prevention 
measures targeting drug users. [SQ 23] 
Outreach work is neither a common response strategy, nor a common implementation setting for 
measures targeting the reduction of drug-related deaths among drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists and was based upon the Council Recommendation. [RT] 
In specific geographical areas only, peers and volunteers are included in outreach work practice, 
and training for peers and volunteers is organised246. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists and was based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies exist in specific geographical areas 
only247. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists and was based upon the Council Recommendation248. [RT] 
Methadone detoxification programmes are available nationwide. Methadone maintenance 
treatment, treatment with buprenorphine, drug-free outpatient and drug-free inpatient treatment, 
rehabilitation centres and drop-in centres/ shelters are available in specific geographical areas 
only249. Substitution treatment is supported by (obligatory) psychosocial care. [NR 2002-2004]   
Aiming at the reduction of drug-related deaths, opioid substitution treatment is an uncommon 
response strategy. [SQ 29] Drug consumption rooms and heroin prescription programmes do not 
exist in Estonia. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, and was based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists and was based upon the Council Recommendation250. [RT] 
245 Almost all syringe exchange points in Estonia use peers to reach difficult to reach risk groups in the 
framework of outreach work. They also provide syringes, needles and/or other injection paraphernalia, 
condoms, leaflets with risk reduction materials in the framework of outreach work.
246 The National Institute for Health Development (NIHD) runs training courses for service providers. Also some 
NGOs and or local communities provide regular trainings to their staff. 
247 Some counties are more active in networking and cooperation. 
248 Different services (substitution treatment, detoxification treatment and long term rehabilitation) are 
available to people with drug addiction. There are not enough treatment and rehabilitation places for drug 
users. 
249 The current scope of treatment and rehabilitation services is far from sufficient despite some efforts made in 
this field in 2004. The shift of the treatment of drug users from psychiatric hospitals, historically known as 
primary treatment providers for problematic drug users, to other types of institutions (i.e day care centres), 
can be considered as a noticeable development in the field of treatment in recent years.
250 It has been considered to continue to provide substitution treatment inside prison to those inmates who 
were enrolled in substitution treatment programmes prior to their imprisonment.  
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Counselling, testing/ screening, prevention, education and treatment of infectious diseases are 
available nationwide in Estonian prisons. In specific geographical areas only, methadone 
detoxification programmes251, condom distribution and drug paraphernalia252 are available. There 
are no needle and syringe exchange programmes in prisons in Estonia and also no methadone 
maintenance programmes are available. [NR 2002/ 2004; NFP 2006] 
Prisons are a predominant implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Measures targeting at the reduction of drug – related deaths
are uncommon in Estonian prisons253. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists and was based upon the Council Recommendation. [RT] 
Nationwide available are testing/ screening, prevention and education with regard to infectious 
diseases as well as (pre- and post testing) counselling. In specific geographical areas only, 
treatment254 and vaccination programmes (against hepatitis B) targeting drug users exist. [NR 
2002-2004; NFP 2006] 
To prevent infectious diseases among drug users the predominant response strategies are IEC 
in general, condom distribution and provision, and needle and syringe exchange programmes. 
Other, common strategies include IEC via counselling and advice by drugs and health 
professionals, IEC via peer involvement/ peer approach, outreach health education approach, 
voluntary counselling and testing. Predominant implementation setting for infectious diseases 
prevention measures targeting drug users are outreach work and high risk group interventions, and 
prisons. Common implementation settings are specialised drug treatment services. [SQ 23]  
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists and was based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes and the distribution of condoms are available 
nationwide; drug paraphernalia are not available in Estonia. [NR 2004; NFP 2006]. Needle and 
syringe exchange programmes are a predominant response strategy to prevent infectious 
diseases among drug users in Estonia. [SQ 23]  
Needle and syringe exchange programmes are neither a strategy nor a setting in Estonia for 
measures targeting the reduction of drug-related deaths among drug users. [SQ 29] 
Estonia counts in total 19 non-pharmacy based needle and syringe programmes255. Needle and 
syringe exchange also takes place  in vans/ buses, and through outreach workers/ peers. [ST 10] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation. [RT]
No further information is available whether emergency services are trained. Estonian ambulances 
routinely carry antagonists256. Naloxone on a ‘take home’ basis is not available in Estonia. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists and was based upon the Council Recommendation. [RT]
Risk reduction is part of an integrated health strategy for drug users. [NR 2002/ 2003] 
251 I.e. a pilot programme for methadone treatment exists in the central hospital of the penitentiary services. 
252 These are only provided through the medical departments of prisons. 
253 In specific geographical areas only, risk education/ response training for inmates is provided. 
254 Anti Retroviral Therapy (ARV) treatment has been funded by the Global Fund Programme since 2003. ARV 
treatment is available in prisons. 
255 Currently there are 21 needle and syringe exchange programmes in Estonia [NFP 2006]. 
256 Flumazenil and naloxone are widely used as an ordinary medication in case of overdose. 
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2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation257. [RT]
Training is offered nationwide to prison staff [NR 2003/ 2004]. Training for professionals in needle 
and syringe exchange programmes, low threshold agencies258, outreach work and substitution 
programmes treatment facilities are available in specific geographical areas only. [NR 2002, NR 
2004] 
2.5.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists and was based upon the Council Recommendation. Estonia has just started to 
develop health education standards and quality assurance management in prevention. Estonia is 
running pilot prevention projects, which are supported by quality management: (Planning 
according to the needs assessment, using processe and outcome evaluation etc.). [RT] 
The National HIV/ AIDS Prevention programme (which includes elements regarding opiate 
dependent drug use) includes principles of effectiveness, responsibility, transparency, research, 
evidence-based and targeted activities, comprehensiveness, administration and respect for human 
rights, co-ordination and partnership. [NR 2004] 
Nevertheless, the majority of projects implemented on the national level have not been evaluated 
according to scientific methods. Ad-hoc evaluation of projects funded by the Alcoholism and Drug 
Abuse Prevention Programme have been carried out over the last years. [NR 2003] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists and was based upon the Council Recommendation. It is not the rule, but Estonia 
has examples of the application of needs assessments in early stages of programmes. Estonia has 
a strategy action plan for the implementation of quality management, which includes needs 
assessment in planning processes. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists and was based upon the Council Recommendation. Estonia is at the beginning of 
developing and implementing evaluation protocols. The future development depends of the overall 
implementation process regarding this issue. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists and was based upon the Council Recommendation. There are some examples of 
the implementation of evaluation criteria, but this area should be much better developed. There is 
general need for training in quality management, but there are not enough trained specialists in 
prevention. [RT]. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation. This area is better developed 
than other areas such as prevention,  because of European technical assistance. [RT] 
257 More training is needed in specialised areas such as quality management (needs assessment, establishment 
of quality criteria, evaluation in general). 
258 The National Institute for Health Development (NIHD) finances and provides trainings for low–threshold 
agencies.
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3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists and was based upon the Council Recommendation. The policy about effective use 
of evaluation results exists, but in terms of quality management Estonia does not have enough 
correctly evaluated programmes. This is mainly due to the lack of resources to conduct evaluations. 
[RT]
In 2001 assessment of the ADAPP (Alcoholism and Drug Abuse Prevention Programme) was 
undertaken. The purpose of the assessment was to improve the quality and efficiency of the 
programme as well as develop the quality criteria of the programme. Within the framework of this 
assessment procedure, five subordinate projects of the ADAPP were assessed. [NR 2002] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists and was based upon the Council Recommendation. [RT]. No examples from 
implementation are available. 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists and was based upon the Council Recommendation. In the past, special training 
programmes existed, but stakeholder involvement and participation (to create advocay) is an area 
in which training is needed most. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] 
A prevalence study on HIV infection (2005) was financed by the Global Fund and carried out in 
cooperation with London Imperial College. [NR 2004]. For the purpose of the development of the 
national drug strategy, also, to ensure its compliance with the European Union Acquis in the drug 
field, the Ministry of Social Affairs of the Republic of Estonia has entered into a project agreement 
with the Ministry of Social Affairs of Schleswig-Holstein, Germany.
Estonian experts drafted “Guidelines for Drug Treatment” within the framework of the Council of 
Europe Pompidou Group Drug Demand Reduction Staff Training Project (DRSTP II). The above-
mentioned guidelines were approved and published by the Estonian Psychiatric Association. [NR 
2002] 
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Annex A2.6 State of play on harm reduction in Greece 
2.6.1 Summary 
Public health policy. Harm reduction is a public health objective in Greece. Measures on harm 
reduction were implemented in Greece before the Council Recommendation was launched.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through websites and telephone help lines. Families of drug users are informed and 
involved in the prevention and reduction of health risks associated with drug dependence in specific 
geographical regions. 
Outreach work. Street-based outreach work is available in specific geographical areas. For the 
reduction of drug-related deaths, outreach work is the predominant setting for the dissemination of 
information materials, as well as for the deliverance of risk education/ response training. Peers and 
volunteers are included in outreach work practice in specific geographical areas. Networking and 
cooperation between outreach work agencies is not an existing policy, although it is practised in 
specific areas. 
(Medically assisted) treatment and specific interventions. In specific geographical areas, 
treatment with buprenorphine and naltrexone-, methadone maintenance and detoxification 
treatment, drug-free outpatient and inpatient treatment, rehabilitation programmes and drop-in 
centres/ shelters are available. Drug consumption rooms and heroin prescription programmes do 
not exist in Greece. Opioid substitution treatment is a common response strategy aiming at the 
reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs are available 
nationwide. 
Prison interventions. Testing, prevention, education and treatment of infectious diseases are 
available nationwide in prisons. Drug paraphernalia are available in specific geographical regions. 
Neither substitution programmes nor condoms are offered in Greek prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Prevention measures on infectious diseases are available nationwide. In specific 
geographical areas, testing/ screening, education, counselling, treatment of HIV, hepatitis C, 
tuberculosis and sexually transmitted diseases and vaccination for hepatitis B and tuberculosis, 
targeting drug users are available. To prevent infectious diseases among drug users, the 
predominant response strategies are IEC via counselling and advice by drugs and health 
professionals, and voluntary infectious diseases counselling and testing. Needle and syringe 
exchange, drug paraphernalia and condoms are available in specific geographical regions.  
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. In specific 
geographical regions, training is offered to professionals working in needle exchange programmes, 
in substitution treatment, in treatment facilities, low threshold programmes and in prison settings.
Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. In Greece, a small number of qualitative and evaluation 
activities in the field of drug demand reduction exist, but there are only few examples from 
practice. Since 2005, the first steps have been taken to incorporate evaluation in interventions. 
Regarding evaluation training programmes, mostly professionals participate in them. Stakeholder 
participation is not common in Greece. 
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2.6.2 Recommendation 1: Risk reduction and public health policy 
The governmental structure that is responsible for the implementation of the Council 
Recommendation is the Greek Ministry of Health and Social Solidarity259. Harm reduction is a public 
policy objective in Greece, but this was not based upon the Council Recommendation. Measures 
and public health objectives regarding the prevention and reduction health-related harm associated 
with drug dependence were implemented in Greece before the Council Recommendation was 
adopted in 2003. [RT] The main objectives are stipulated in the Greek National Action Plan on 
Drugs 2002-2006. [SQ29]  
2.6.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The dissemination of information through many websites and a few telephone help lines is 
nationwide available260. Training and a broad range of educational leaflets is available in specific 
geographical regions. [NR 2001-2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) via counselling and advice by drugs and health professionals is the 
predominant response strategy. Safer injection training is a common response strategy261. [SQ 23; 
NFP 2006] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
and risk counselling are common response strategies; information is disseminated predominantly 
by low threshold agencies, including needle and syringe programmes and outreach workers. 
Specialised drug treatment services are common settings for the dissemination of information 
materials. A common response strategy to reduce drug–related deaths is risk education/ response 
trainings for drug users. These trainings are delivered predominantly at low threshold agencies, 
including needle and syringe programmes and through outreach workers, peers. These trainings 
are common at specialised drug treatment services. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT]
In specific geographical regions, training seminars for (former) drug users and their families are 
organised; all specialised treatment units for adolescent drug users address parents and their 
children equally . The majority of drug-free treatment programmes for adults operate specialised 
family support programmes or provide specialised services for parents of drug users. [NR 2001, NR 
2003; NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
259 International Relations Division. 
260 Furthermore, the major drug treatment agencies in Greece organise mass media campaigns with the aim to 
prevent drug use, to provide information on the drug addiction problem in general as well as on the work of the 
existing drug services. These campaigns include the development and broadcasting of TV and radio spots, the 
production of leaflets, posters and brochures, the organisation of events, etc. They address either the general 
public or special populations and age groups. 
261 Safer injection trainings are provided in those cities where specialised drug treatment centres operate. 
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In Greece, specific geographical areas provide street-based outreach work and trainings for 
outreach workers262. [NR 2004; NFP 2006]  
To prevent infectious diseases among drug users, outreaching health education is a rare 
response strategy. Outreach work and targeted high-risk group interventions are a rare 
implementation setting for infectious diseases prevention measures targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is the predominant setting for the deliverance of risk 
education/ response trainings to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy does not exist263. [RT] 
In specific geographical regions, peers and volunteers are included in outreach work and they are 
offered trainings in outreach work264. Training for outreach work is also available in specific 
geographical areas only. [NFP 2006].  
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy does not exist265. [RT] 
However, in specific geographical regions, outreach work agencies aim –among others- to refer 
users to other health services, encourage and consolidate user contacts with the health system and 
motivate users to join treatment programmes. [NFP 2006]   
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas, treatment with buprenorphine and naltrexone, methadone 
maintenance treatment266, methadone detoxification treatment267, drug-free outpatient and 
inpatient treatment, rehabilitation programmes and drop-in centres/ shelters are provided. 
Substitution treatment is supported by (obligatory) psychosocial care. [NR 2001-2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment (with regard to 
the reduction of heroin/ opiate overdose) is a common response strategy. [SQ 29]  
Drug consumption rooms and heroin prescription programmes do not exist in Greece. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation268. [RT] 
There is a special law stating that psychotropic substances can only be prescribed by specific 
doctors269. [NFP 2006] 
262 A single uniform training scheme at national level has not been implemented so far. Each agency that 
implements outreach interventions provides some type of training for its staff with the aim to enhance the 
services it delivers.
263 Besides health professionals, another group involved in outreached work concerns former drug users who 
have completed treatment. 
264 Training is provided to peers and volunteers, such in context of the training programme that are provided to 
drug services. 
265 However, networking and cooperation has been developed. 
266 Methadone is the most commonly prescribed substance for long-term substitution treatment. 
267 Methadone is the most commonly prescribed substance for detoxification in substitution treatment 
programmes.
268 Measures for preventing diversion of substitution substances have been taken, however access to 
substitution treatment should be improved since not all demand for treatment is currently covered. 
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2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
The implementation of this policy is pending for approval270. [RT] 
Testing, prevention, education and treatment of infectious diseases are available nationwide in 
prisons. Drug paraphernalia are available in prisons in specific geographical regions. Condoms are 
not distributed in Greek prisons.  There are no substitution programmes in Greek prisons271,272.
[NR 2001/ 2004; NFP 2006]  
Prisons are a rare implementation setting for infectious disease prevention measures targeted 
at drug users. [SQ 23]. Aiming at the prevention and reduction of drug – related deaths,
prison pre-release interventions are a common response strategy. Prisons are a rare 
implementation setting for risk education/ response training for drug users. Information materials 
are rarely disseminated in Greek prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation273. [RT] 
Prevention measures of the drug-related infectious diseases have been put in effect nationwide. In 
specific geographical areas274, testing/ screening, education, counselling, treatment of HIV275,
hepatitis C, tuberculosis, sexually transmitted diseases 276 and vaccination programmes for 
hepatitis B and tuberculosis targeting drug users are available. [NR 2003/ 2004] 
Predominant response strategies to prevent infectious diseases among drug users are the 
following: IEC via counselling by drugs and health professionals, and voluntary infectious diseases 
counselling and testing. Common strategies include safer injection training for drug users, condom 
promotion among drug users and hepatitis vaccination programmes for drug users.  
Predominant implementation settings for infectious diseases prevention measures are specialised 
drug treatment services. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes are available in specific geographical regions, as are 
drug paraphernalia and condoms. [NR 2003/ 2004]. Needle and syringe exchange programmes are 
a uncommon response strategy to prevent infectious diseases among drug users. [SQ 23]  
With regard to the reduction of drug-related deaths among drug users, low threshold agencies, 
including needle and syringe exchange programmes, are a predominant setting both for 
dissemination of information materials and for providing risk education/ response training for drug 
users. [SQ 29] 
269 The organisation against drugs (OKANA), which is also the national coordination body on drug affairs, is the 
only agency who is permitted by law to establish and operate substitution treatment programmes. 
270 The Ministerial Decree 149020/1999 already provides for three types of treatment programmes in the 
treatment centre for drug dependent prisoners ((KATK): (1) drug free treatment for  18 years old users; (2) 
drug free treatment for < 18 years old users; and (3) substitution treatment. However, only the first has been 
implemented until now.
271 Nonetheless, the administering of substitution drugs in prison is foreseen for those drug addicts who were 
attending a methadone substitution programme before incarceration. In these cases, the administering of 
methadone can be continued in prison but only for a very short time period, thus aiming at detoxification. 
272 Detoxification is treated with painkillers and tranquilizers. Drug dependent prisoners that require emergency 
treatment are referred to a prison hospital or to public hospitals. 
273 Only for those attending a treatment programme. 
274 Mostly in and around Athens. 
275 HIV cases are to be notified to the Hellenic Centre of Disease Control and Prevention. For every notified case 
HAART is provided free of charge. 
276 OKANA and specialised medical services, for TB and hepatitis.  
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Greece has four non-pharmacy based needle and syringe exchange programmes. Types of needle 
and syringe exchange available in Greece include fixed sites, vans/ buses and outreach/ peers. 
There are no vending machines, pharmacy-based NSPs or prison-based needle and syringe 
exchange programmes. [ST 10] 
There are no specific laws on needle and syringe exchange or on the possession of sterile needles 
in Greece. The police has the right to seize syringes if they are used for injection, but no action is 
taken when syringes are sterile. No prescription is required to obtain or exchange needles and 
syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT]
Emergency departments are rare settings for risk education/ response training that aim at the 
prevention of drug-related death. [SQ 29] 
Ambulances routinely carry antagonists. The distribution or administration of naloxone is regulated 
by laws. Naloxone is not available on a ‘take home’ basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT]
Risk reduction is part of an integrated health strategy for drug users, as it is part of the National 
Drug Strategy. [NFP 2006]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT]
Training for professionals working in needle exchange programmes, in substitution treatment, in 
treatment facilities, in low threshold programmes and in prison settings is available in specific 
geographical regions. [NR 2001/ 2003; NFP 2006] 
2.6.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. Quite recently the 
importance of evaluation has been recognised in Greece and the first steps have been taken in 
order to incorporate evaluation into every application. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
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3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. Particularly the 
professionals working in the field participate in training programmes. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. Participation of 
stakeholders is not conducted as a general rule, though. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] 
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Annex A2.7 State of play on harm reduction in Spain 
2.7.1 Summary 
Public health policy. Harm reduction is a public health objective in Spain and has been for some 
time already. The policy objectives on harm reduction have most recently be reiterated in the 
National Action Plan on Drugs 2005-2008. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through websites, training, educational materials and pill-testing. For the reduction of 
drug-related deaths, the dissemination of information materials and risk education/ response 
training are the predominant response strategies. Communities and families of drug users are 
nationwide informed and involved in the prevention and reduction of health risks associated with 
drug dependence. 
Outreach work. Street- based outreach work and outreach work at dance parties, raves and in 
clubs are nationwide available. Outreach work as a health education approach is a predominant 
response strategy to prevent infectious diseases among drug users. For the reduction of drug-
related deaths, outreach work is the predominant setting for the dissemination of information 
materials, as well as for the deliverance of risk education/ response training. Peers and volunteers 
are included nationwide in outreach work practice. Networking and cooperation between outreach 
work agencies exist in specific geographical regions. 
(Medically assisted) treatment and specific interventions Methadone maintenance and 
detoxification treatment, drug-free outpatient and drug-free inpatient treatment and rehabilitation 
programmes are available nationwide. Treatment with buprenorphine, treatment with naltrexone, 
heroin prescription programmes, drug consumption rooms and drop-in centres/ shelters are 
available in specific geographical areas. Opioid substitution treatment is a predominant response 
strategy aiming at the reduction of drug-related deaths. Measures to prevent diversion of 
prescribed drugs are available nationwide. 
Prison interventions. Methadone maintenance and detoxification programmes, treatment with 
naltrexone, needle and syringe exchange, drug paraphernalia and the distribution of condoms are 
nationwide available in Spanish prisons. Counselling, testing, prevention, education and treatment 
of infectious diseases are also widely available in Spanish prisons, as well as vaccination against 
hepatitis B and tuberculosis. Treatment with buprenorphine and heroin prescription programmes 
are not available. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Treatment of infectious diseases is nationwide available in Spain. To prevent infectious 
diseases among drug users, the predominant response strategies are IEC in general, outreach 
health education approach, needle and syringe exchange, a hepatitis B vaccination programme for 
drug users and easy access’ programmes for drug users to treatment of infectious diseases. Needle 
and syringe exchange and condoms are available nationwide, while the availability of drug 
paraphernalia is restricted to specific geographical areas.  
Drug-related deaths. Professionals of emergency departments are trained in specific 
geographical areas, e.g. to deal with overdoses. The distribution, possession or administration of 
naloxone is regulated. Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to prison staff. Risk reduction is part of an integrated health strategy for drug 
users.
Quality, monitoring and evaluation. In the Spanish National Action Plan on Drugs 2005-2008 
many different actions regarding quality control, monitoring and evaluation have been included. 
The plan calls for a systematic evaluation of all Drug Demand Reduction programmes. 
Furthermore, some of the Autonomous Regions have developed programmes for quality control. 
Evaluation studies that inform policy have been conducted on e.g. heroin prescription. Spain 
collaborates in EU Twinning programmes and is active towards countries in Latin America. 
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2.7.2 Recommendation 1: Risk reduction and public health policy 
The structure responsible for the implementation of the Council Recommendation is the Ministry of 
Health and Consumer Affairs277. [RT] 
This policy exists, but was not based upon the Council Recommendation. Public Health Policy 
objectives on the prevention and reduction of health-related harm associated with drug 
dependence already existed in Spain before the adopted and publication of the Council 
Recommendation. The policy objectives on prevention of health-related harm have been 
reconfirmed in the Spanish Action Plan on Drugs 2005-2008, actions 5-17. Policy objectives on the 
reduction of health-related harm have been reconfirmed in the action 28 of the Spanish Action Plan 
on Drugs. [RT].  
2.7.3 Recommendation 2: Risk reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation278. [RT] 
In Spain, websites279, training and educational materials promoting risk reduction among drug 
users including pill-testing, are nationwide available. Telephone help lines are available in specific 
geographical areas only. [NR 2002-2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general and easy access programmes for drug users to treatment of 
infectious diseases are predominant response strategies. IEC via counselling and advice by drugs 
and health professionals, safer injecting training and IEC via peer involvement/ peer approach280
are common response strategies. [SQ 23; NFP 2006] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
and risk education/ response training are the predominant response strategies and individual risk 
counselling is common. Information materials are predominantly disseminated at specialised drug 
treatment services, low threshold agencies, including needle and syringe exchange programmes, 
and through outreach workers, detoxification services, prisons, and emergency departments/  
hospitals. Risk education/ response training is available in some or few cities and is delivered 
predominantly at specialised drug treatment services, low threshold agencies including needle and 
syringe exchange programmes, through outreach workers/ peers, and emergency departments/  
hospitals and is commonly delivered in prison. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation281. [RT] 
Communities and families of drug users are nationwide involved in the prevention and reduction of 
health risks associated with drug dependence and specific information, education and 
communication is nationwide available to communities and families of drug users282. [NFP 2006] 
277 Government Delegation for the National Plan on Drugs - Deputy Direction of Institutional Relations. 
278 Spanish Action Plan on Drugs 2005-2008; Action 18. 
279 www.energycontrol.com for recreational drug users; www.sindrogas.es; www.osasunekintza.org;
www.pnsd.msc.es.
280 IEC via peer involvement is expanded to many penitentiaries in Spain, such as Ocaña I and Ocaña II in 
Castilla-La Mancha. Autonomous Communities (CCAA) use peer approach as “Snow Ball programme” (peer 
group Programme among drug users of GID –NGO (Madrid). Programme “I decide” CCAA Navarra. 
281 Spanish Action Plan on Drugs 2005-2008; Action 5. 
282 Examples of community and family programmes that work with drug users’ families are: the programme “On 
time” of the Municipal Plan on Drugs of Oviedo; a prevention programme in Basque Country aimed at parents 
with children with risk behaviours including drug use.
164
11350-HRI Rapport binnenwerk.ind164   164 13-03-2007   14:20:05
165
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation283. [RT] 
In Spain, street-based outreach work284 and outreach work at dance parties, raves and in clubs285
are nationwide available. [NR 2002/ 2004] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a predominant response strategy and also a predominant implementation setting. [SQ 
23]
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths, and outreach work is also a predominant setting for the deliverance of 
risk education/ response training, which is delivered in some or few cities. [SQ29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation286. [RT] 
Peers and volunteers are included nationwide in outreach work practice287, and they are also 
trained to do so288. [NR 2002; NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation289. [RT] 
Networking and cooperation between outreach work agencies exist in specific geographical 
areas290. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation291. [RT] 
Methadone292 maintenance and detoxification treatment, drug-free outpatient and drug-free 
inpatient treatment, and rehabilitation programmes are available nationwide. Treatment with 
buprenorphine293, treatment with naltrexone294, heroin prescription programmes295, drug 
consumption rooms296 and drop-in centres/ shelters297 are available in specific geographical areas. 
283 Spanish Action Plan on Drugs 2005-2008; Action 20. 
284 There are 48 mobile units for outreach work. 
285 Various programmes exist, among others ‘Energy Control’, ‘Zona Clave’, ‘Controla club’, etc. 
286 Spanish Action Plan on Drugs 2005-2008; Actions 17 and 44. 
287 In particular young people are involved in peer-to-peer approaches. 
288 There is a course for leisure time monitors and another for volunteers organised by the Drug dependencies 
Direction of Basque Government. NGO “Punto Omega” Association has a training school for volunteers. 
289 Spanish Action Plan on Drugs 2005-2008; Action 20. 
290 Cooperation networks exist, mainly between NGOs. Examples are: UNAD, a network of NGOs involved in 
drug dependencies areas such as outreach work. Association ASECEDI, an association of agencies with day care 
centres. Network ARANA, a network of social agencies for employment. 
291 Spanish Action Plan on Drugs 2005-2008; Actions 22 and 28. 
292 Furthermore, mobile units provide treatment with methadone. Pharmacies are also authorised to dispense 
methadone. 
293 This takes place in two centres in Madrid, covering 36 patients in 2003. 
294 The Extremadura Autonomous Community runs a treatment programme with Naltrexone. A naltrexone 
treatment programme is carried out by the Foundation Marbella Solidaria in the City of Marbella (Málaga). 
295 Two clinical trials are currently running. 
296 DCR’s exist in Madrid, the Basque Country and in Catalonia. 
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Substitution treatment is supported by psychosocial care, upon request by the client. [NR 2003/ 
2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29] 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation298. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide299. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation300. [RT] 
Methadone maintenance and detoxification programmes, treatment with naltrexone301, needle and 
syringe exchange302, drug paraphernalia and the distribution of condoms are nationwide available 
in Spanish prisons. Treatment with buprenorphine and heroin prescription programmes are not 
available in prison. Widely available in prisons are counselling, testing, prevention, education and 
treatment of infectious diseases and vaccination against hepatitis B and tuberculosis. [NR 2002/ 
2004; NFP 2006] 
Prisons are a predominant implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Prison pre-release interventions are the predominant response 
strategy targeting the reduction of drug – related deaths in Spanish prisons. Prisons are a 
predominant setting for the dissemination of information materials aiming at the reduction of drug-
related deaths and a common setting for the deliverance of risk education/ response training. [SQ 
29]
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation303. [RT] 
Treatment of infectious diseases (HIV, hepatitis C, tuberculosis, sexually transmitted diseases) is 
nationwide available in Spain. [NR 2003] 
To prevent infectious diseases among drug users, the predominant response strategies are 
information, education, communication (IEC) in general, outreach health education approach, 
needle and syringe exchange programmes, a hepatitis B vaccination programme for drug users, 
and easy access programmes for drug users to treatment of infectious diseases. Other common 
strategies include IEC via counselling and advice by drugs and health professionals, safer injecting 
training, voluntary counselling and testing, condom promotion among drug users and routine 
screening of high risk groups. Predominant implementation settings for infectious diseases 
prevention measures targeting drug users include specialised drug treatment services, low 
threshold counselling services, outreach work and targeted high risk group interventions and 
prisons. Common implementation settings are primary care/ general practitioners and mass media. 
[SQ 23] 
297 Twenty-seven in 2003. 
298 Spanish Action Plan on Drugs 2005-2008; Action 28. 
299 Measures include a restricted prescription system, in which the adequate dose is prescribed to each patient. 
300 Spanish Action Plan on Drugs 2005-2008; Action 50. Agreement between the Ministry of Health and 
Consumer Affairs and the Ministry of Interior for the treatment of drug abusers in prisons. 
301 Naltrexone treatment is generally provided as an alternative treatment option in all prisons that work under 
the auspices of the Ministry of Interior.
302 In 38 prisons.
303 Spanish Action Plan on Drugs 2005-2008; Action 28. 
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2.10  Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation304. [RT] 
Needle and syringe exchange programmes305 and the distribution of condoms306 are available 
nationwide in Spain. Drug paraphernalia are available in specific geographical areas only. [NR 
2003/ 2004; NFP 2006]  
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Spain. [SQ 23] Low threshold agencies, including needle 
and syringe exchange programmes, are also a predominant setting for the dissemination of 
information materials on the reduction of drug-related deaths among drug users and for risk 
education/ response training. [SQ 29] 
Spain has 297 non-pharmacy based, and 946 pharmacy based needle and syringe exchange 
programmes. Types of needle and syringe exchange that are available in Spain are fixed sites, 
vans/ buses, through outreach/ peers, pharmacy based and prison based needle and syringe 
exchange, but no vending machines. [ST 10]. There are no legal restrictions to the possession of 
sterile needles in Spain, and also no prescription is required to obtain or exchange needles and 
syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation307. [RT] 
In specific geographical areas only, professionals of emergency departments are offered training308.
[NFP 2006]. Emergency departments are a predominant setting for risk education/ response 
training aimed at the reduction of drug-related deaths.  
Spanish ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation309. [RT] 
Risk reduction is part of an integrated health strategy for drug users310. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation311. [RT] 
Training is offered nationwide to prison staff. Training for outreach workers312, professionals in 
needle and syringe exchange313 programmes, low threshold agencies314, substitution treatment315
and treatment facilities316 is available in specific geographical areas only317. [NR 2004; NFP 2006] 
304 Spanish Action Plan on Drugs 2005-2008; Action 28. 
305 Chemists’ offices, 2324 pharmacies and 1224 needle exchange centres. 
306 Distribution takes place through treatment centres for drug users; harm reduction facilities. 
307 Spanish Action Plan on Drugs 2005-2008; Actions 22 and 43. 
308 In Castilla La Mancha trainers of the Health Department provide trainings that focus on priorities derived 
from data on psychoactive drug use in the region. The Health Department of Catalonia provides a training 
titled: “Counselling for emergency services related to young people and drug use”. 
309 Spanish Action Plan on Drugs 2005-2008; Action 22. 
310 National Drugs Strategy 2000-2008: section 4.1.2 describes 7 objectives. 
311 Spanish Action Plan on Drugs 2005-2008. Actions 43 and 44. 
312 In 2003, in Castilla La Mancha 35 courses for outreach workers were organised, including 695 participants. 
Different courses exist for young outreach workers in health education in Asturias (organised by the Health 
department and Youth Council of the Principado de Asturias). 
313 Workshops exist on safer injection and other measures to reduce specific risks associated to drug use (CCAA 
Cataluña). There is a guide for the deployment of needle and syringe exchange programmes, which is published 
by the sub-commission on Prevention of the National Plan on AIDS. Furthermore, there are training courses for 
needle and syringe exchange programmes in pharmacies, which are developed in accordance with the 
cooperation agreement signed between the Pharmacist Association and the Ministry of Health and Consumer 
Affairs.
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2.7.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. It is reflected in the 
Spanish Action Plan on Drugs 2005-2008 (Action 25). 
In Spain, substitution treatment is carried out in the penitentiary settings since 1992, being 
extended to all prisons in 1998. The wide spread of substitution treatment is explained by its high 
efficiency, and especially for its proven effectiveness to prevent HIV infections. [NR 2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. It is reflected in the 
Spanish Action Plan on Drugs 2005-2008 (Action 56), which calls for systematic evaluation of all 
DDR programmes. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 56) calls for systematic evaluation of all DDR programmes. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 56) calls for systematic evaluation of all DDR programmes. [RT] 
In Spain, some Autonomous Communities have started programmes and systems to guarantee 
quality. Those activities cover a wide range of possibilities: Cantabria applies the certification ISO 
9002 to every process and resources in its Autonomous Plan, Andalucia has certified with ISO its 
program management processes, Galicia has started to introduce the model EFQM in its Plan, 
Valencia has developed tools to evaluate the perceived quality, etc. Besides, an important number 
of NGO have included systems of quality management in their programmes and activities.  
[NR 2003] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 45) calls for reinforcement of the National Focal point. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. One example is the 2003 
evaluation report on the Spanish National Strategy on Drugs 2000-2008. [RT] 
314 The association Proyecto Hombre has a training program for professionals in intervention centres. The 
association Caritas has received training for professionals and volunteers of residential centres funded by the 
Government Delegation for the National Plan on Drugs. 
315 Trainings on methadone maintenance programmes in pharmacies are targeted at pharmacists in Catalonia 
and given by trainers of the Health Department. In Castilla La Mancha, similar trainings are provided by the 
Health Department under the title “Pharmacist in view to drug dependencies”. 
316 The Psychologist Association provides a course on prevention and treatment of drug dependencies among 
minors and young people. The NGO Socidrogalcoho runs courses for professionals in treatment. 
317 Several Master Programmes in drug dependencies exist: University of Barcelona (virtual), Psychology Centre 
Alborán, Complutense University of Madrid, University of Valencia, University of Deusto (Bilbao).
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Clinical trials involving the administration of diacetylmorphine (heroin) have recently been 
conducted in Catalonia and Andalusia. In Catalonia, the Regional Department of Health and Social 
Security initiated two clinical tests to evaluate the effectiveness of oral heroin and oral morphine, 
after the Spanish Drug Agency authorized the Department to undertake two surveys on treatment 
with heroin and morphine for patients for whom methadone maintenance programmes had failed. 
The results of these trials have not yet been published. [NR 2004] 
Regarding the National Action Plan on Drugs, a midterm evaluation was conducted in 2003 and a 
final one is foreseen for 2008. [NR 2003] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 57) calls for evaluation of training programmes for professionals 
which is not the development of evaluation training programmes. [RT]
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 41) calls for innovative methods in drug demand reduction. But this is 
not the same as stakeholder participation. [RT]
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. The Spanish Action Plan 
on Drugs 2005-2008 (Action 64) calls for bi- and multilateral cooperation, also with MAGREB 
countries. [RT] 
Spain has participated in several Phare Twinning projects in the field of drugs (e.g. with Lithuania) 
and is also active in cooperation with Latin America. Furthermore, it participated in several 
European cooperation projects funded by DG SANCO. 
169
11350-HRI Rapport binnenwerk.ind169   169 13-03-2007   14:20:08
170170
11350-HRI Rapport binnenwerk.ind170   170 13-03-2007   14:20:08
171
Annex A2.8 State of play on harm reduction in France 
2.8.1 Summary 
Public health policy. Harm reduction has been a public health policy objective in France since 
1993, but it took until 1999 (Three Year Plan on Drugs) until the objective was really made 
operational.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational leaflets. Communities and families 
of drug users are nationwide informed, but their involvement in the prevention and reduction of 
health risks associated with drug dependence is restricted to specific geographical regions. 
Outreach work. Outreach work at dance parties/  raves and in clubs is nationwide available, and 
street-based outreach work is provided in specific geographical areas only. Outreach work as a 
health education approach is a common response strategy to prevent infectious diseases among 
drug users. Peers and volunteers are included in outreach work practice in specific geographical 
regions. Finally, networking and cooperation between outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Treatment with buprenorphine and 
drug-free outpatient treatment are nationwide available. Methadone maintenance and methadone 
detoxification treatment, drug-free inpatient treatment and drop-in centres/ shelters are available 
in specific geographical areas. France does not have drug consumption rooms and has no heroin 
prescription programmes. Opioid substitution treatment is a common response strategy aiming at 
the reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs are 
available nationwide. 
Prison interventions. Condoms and drug paraphernalia are nationwide available in prison. 
Counselling, testing, prevention, education and treatment of infectious diseases, methadone 
maintenance and methadone detoxification treatment and treatment with buprenorphine are 
available in prisons in specific geographical areas. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening for infectious diseases and vaccination programmes for hepatitis B 
and tuberculosis targeting drug users are nationwide available. To prevent infectious diseases 
among drug users the predominant response strategies are IEC in general, IEC via counselling and 
advice by drugs and health professionals, safer injecting training and needle and syringe exchange. 
Needle and syringe exchange and drug paraphernalia are available nationwide, but the distribution 
of condoms is restricted to specific geographical regions.  
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available. 
Training of staff and risk reduction as part of a complementary health strategy. Training 
for professionals working in treatment facilities, in substitution treatment, in low threshold 
programmes and in prison settings is available nationwide. Risk reduction is part of an integrated 
health strategy for drug users. 
Quality, monitoring and evaluation. In France, scientific studies are regularly conducted into 
harm reduction measures, i.e. into low threshold agencies and methadone maintenance treatment. 
In the Three Year Action Plan on Drugs 1999-2001, recommendations were made regarding quality 
assurance in drug demand reductions. The plan also initiated a number of priority programmes 
which involved evaluation and were used to inform policy.  
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2.8.2 Recommendation 1: Risk reduction and public health policy 
In France, drug policy is coordinated by the Interministerial Department for the Fight against Drugs 
and Addiction318, which is based at the Prime-Ministers Office. This department is also responsible 
for the implementation of the Council Recommendation.  
Prevention and reduction of health-related harm associated with drug dependence pre-existed in 
France before the adoption of the Council Recommendation. [RT]. The reduction of health harms 
associated with drug dependence has been part of French drug policy since the Drug Act of 21 
September 1993, but this part of drug demand reduction was ‘boosted’ with the coming into force 
of the Three-Year Plan for the Fight Against Drugs and the Prevention of Dependence 1999-2001
(extended to 2002). This plan placed emphasis on drug demand reduction activities, including 
prevention of drug dependence, early detection of problematic drug use and harm reduction 
(including needle and syringe exchange programmes and re-enforcement of substitution 
treatment). [NR 2002]. 
2.8.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In France, information is disseminated nationwide through telephone help lines319, websites320, and 
a broad range of educational leaflets321,322. Training for drug users323 is available in specific 
geographical regions. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general, IEC via counselling and advice by drugs and health professionals, 
and safer injecting training are the predominant response strategies. A common response strategy 
is IEC via peer involvement/ peer approach. [SQ 23]  
With regard to the reduction of drug-related deaths, individual risk counselling is a common 
strategy. Dissemination of information materials about this topic is rare. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Specific IEC for communities and families of drug users is available nationwide324. In specific 
geographical regions, communities and families of drug users are involved in the prevention and 
reduction of health risks associated with drug dependence325. [NFP 2006] 
318 Mission Interministérielle de Lutte Contre la Drogue et la Toxicomanie (MILDT). 
319 Drogues Alcool Tabac Info Service (DATIS). 
320 www.drogues.gouv.fr; www.toxibase.org; www.asud.org
321 The National Institute for Health Education (INPES) provides educational materials by publishing leaflets and 
internet sites. Numerous local initiatives, promoted by associations and groups with direct field experience, may 
pass the message on. A majority of these local structures benefit from State, public financial support. 
322 New initiatives were made possible in the early months of 2006, with the beginning of the Drug-users 
Shelter, Support, and Risk reduction Centres programme (CAARUD for its French acronym). Following a 
Government decree adopted in December 2005, this national level program aims at standardizing low threshold 
agencies. Financing will be placed under responsibility of the National Social Security. Essentially, this is an 
administrative plan aiming at ensuring the participating NGOs a more stable budget, with more effective and 
faster cash deposit. NGO willing to benefit from the National Social Security funding is allowed to fulfil 
administrative procedures until November 2006.  
323 Provided by the Quinquennial Plan, proposed and lead by the MILDT, the cross-ministerial mission on drugs 
and addictions. In practice, trainings are a local level decision. 
324 The cross-ministerial mission on drugs and addictions (Mission Interministérielle de Lutte contre la Drogue et 
la Toxicomanie, MILDT) produces flyers, advertising. Information is taken over by local structures and 
associations. Special attention is paid to urban and party contexts. 
325 Families of drug users’ advices are sought but there is no official, institutional active participation. Attention 
is paid to prevention, but not to risk reduction. 
172
11350-HRI Rapport binnenwerk.ind172   172 13-03-2007   14:20:09
173
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In France, outreach work at dance parties/ raves and in clubs326 is nationwide available.  Street-
based outreach work and trainings for outreach workers327 are available in specific geographical 
areas. [NR 2004; NFP 2006]  
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a predominant implementation setting for infectious diseases prevention 
measures targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are a rare setting for the dissemination of information materials328, aimed at the reduction of 
drug-related deaths. Outreach work is an uncommon setting for the deliverance of risk education 
/ response training to drug users. [SQ 29; NFP 2006] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In France, peers and volunteers are included in outreach work only in specific geographical regions; 
training for peers and volunteers is not available. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies is nationwide available329. [NR 2004]  
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Treatment with buprenorphine and drug-free outpatient treatment are nationwide available330.
Methadone maintenance and methadone detoxification treatment, drug-free inpatient treatment 
and drop-in centres /  shelters are available in specific geographical areas331. Substitution 
treatment is supported by psychosocial care upon request by the client. [NR 2003,2004; NFP 2006]
326 The French Monitoring Centre on Drugs and Addictions (OFDT) included a specific study upon drug users in 
club scenes (SINTES) since 1999. This general information monitoring system will be replaced by an updated 
system in the coming months. 
327 Beyond standardized trainings, common to outreach workers, there are no specific nationwide on-the-job-
trainings. Initiatives are local.
328 It is difficult to provide information about these specific topics at a national level, due to resistance to 
evaluation programmes. The implementation of CAARUDS should facilitate the gathering and retrieving of 
knowledge, particularly regarding needle and syringe exchange programmes. 
329 French National Association of Drug Addiction Workers (ANIT). 
330 Naltrexone has an official license to be released on the market only in the case of treatment of cancer. 
Naltrexone as substitution treatment is not yet approved of by the Ministry of Public Health. An agreement to 
that purpose is foreseen this year. 
331 Morphine sulphates and codeine derivatives are not officially used as substitution options, due to lack of 
support from the public health and political communities. Therefore these substances do not benefit from a 
strict, legal authorization for being used as substitution. The use of morphine sulphates is rare, sometimes 
distributed unauthorised by physicians and visible in high-urban areas. The use of codeine derivatives is most 
residual. 
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Aiming at the reduction of drug-related deaths, opioid substitution treatment is a common 
response strategy. [SQ 29] France does not have drug consumption rooms and has no heroin 
prescription programmes. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are nationwide available. [NR 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The distribution of condoms and drug paraphernalia332 are nationwide available. Counselling, 
testing, prevention, education and treatment of infectious diseases, methadone maintenance and 
methadone detoxification treatment and treatment with buprenorphine are available in prisons in 
specific geographical areas. [NR 2004; NFP 2006]  
Prisons are an uncommon implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Aiming at the prevention and reduction of drug – related deaths, prison pre-release 
interventions are an uncommon response strategy. Prisons are not in use as a setting for 
disseminating information materials on prevention of acute drug-related deaths and for providing 
risk education/  response training for drug users. [SQ29]. 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening for infectious diseases and vaccination programmes for hepatitis B and 
tuberculosis targeting drug users are nationwide available. [NR 2004]
Predominant response strategies to prevent infectious diseases among drug users333 are: IEC in 
general, IEC via counselling and advice by drugs and health professionals, safer injecting trainings, 
and needle and syringe exchange programmes. Common but not predominant strategies include 
IEC via peer involvement/ peer approach, outreach health education approach, voluntary infectious 
diseases counselling and testing, condom promotion among drug users and hepatitis vaccination 
programmes for drug users. [SQ 23]
Predominant implementation settings for infectious diseases prevention measures targeted at 
drug users are specialised drug treatment services, low threshold counselling services, outreach 
work and targeted high risk group interventions and primary care/  GP’s. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes and additional services such as sterile water, bleach and 
ascorbic acid, are available nationwide. Condoms are distributed among drug users in specific 
geographical regions334. [NR 2004; NFP 2006]  
332 There are no legal obligations to provide drug paraphernalia such as sterile water, bleach, and ascorbic acid. 
Imprisoned drug-users may have access to the mentioned paraphernalia only on personal and voluntary 
requirement. Distribution depends to a strictly personal initiative from the attending physician.
333 The prevention of infectious diseases among DU’s is based on 3 documents: the MILDT 5 year drug plan 
(2004-2007); the National Plan on HIV/ AIDS (2001-2004), which is being evaluated; the national plan on 
hepatitis (2002-2005).
334 Initiatives are mainly local, promoted by associations and groups with direct field experience. A majority of 
these local structures benefit from state financial support.
174
11350-HRI Rapport binnenwerk.ind174   174 13-03-2007   14:20:10
175
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in France. [SQ 23]  
With regard to the reduction of drug-related deaths among drug users, low threshold agencies, 
including needle and syringe exchange programmes, are an uncommon setting both for 
dissemination of information materials and for providing risk education/ response trainings for drug 
users. [SQ 29]
France has 240 non-pharmacy based needle and syringe exchange outlets, 18000 pharmacy based 
needle and syringe exchange outlets, and 250 vending machines Types of needle and syringe 
exchange include fixed/  sites, vans/ buses, outreach/ peers, vending machines and pharmacy-
based. There is no prison-based needle and syringe exchange. [ST10]  
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training programmes for professionals of emergency services are not available. [NFP 2006]. 
Ambulances routinely carry antagonists. The distribution, possession or administration of naloxone 
is regulated by law. Naloxone is not available on a ‘take home’ basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Nationwide, risk reduction is part of an integrated health strategy for drug users335. [NFP 2006]
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training for professionals working in treatment facilities, in substitution treatment, in low threshold 
programmes and in prison settings is available nationwide. In specific geographical regions, 
trainings for professionals working in needle and syringe exchange programmes336 are provided. 
[NR 2004; NFP 2006]  
There is no recognised professional qualification for professionals in the field of prevention and 
reduction of health-related risks associated with drug dependence in France, but this is planned.
[SQ 23] 
2.8.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
The MILDT has drawn up a risk reduction intervention guideline for prevention actions in the part-
scene. Furthermore, several research studies exist in France that are used to further develop and 
select interventions. Examples are:  
During the period 1999-2001, two evaluations directed by the OFDT focused on “low threshold 
centres”. The first concerned an evaluation of the methadone bus in Paris. This evaluation, carried 
335 Risk reduction is provided by the Quinquennial Plan, proposed and lead by the MILDT, the cross-ministerial 
mission on drugs and addictions. Risk reduction is regarded as a “State responsibility”, as stated in the Public 
Health Decree adopted in August 2004. The Decree spotted three axes including topics like health, spread of 
diseases, and social damages. Risk-reduction is part of a larger plan of prevention. A concrete example lies in 
the RMS program (standing for “Réseau Micro-Structures”, or Microstructures network), originally based in 
Alsace: attention and care to any kind of addicted patients is provided by physicians in the presence of social-
workers and psychologists. Recently, the RMS has been extended to Marseille (south) and St Nazaire (south-
west).
336 On-the-job-training is commonly proposed by associations and local-groups to their personnel, once a year. 
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out by the IREP (The Institute for Research on the Epidemiology of Drug Dependency) and 
INSERM, concerned, on the one hand, the facility’s activities and users (effectiveness of the 
implementation) and, on the other, the changes produced (effectiveness of the results) in terms of 
access to the social health network (capture/ referral role), the effects on consumption practices 
and on the health and social rehabilitation of dependent persons. The second study concerned the 
evaluation of a risk reduction and social mediation pilot project in the 18th arrondissement of Paris. 
This evaluation, conducted by ACT Consultants, provided an assessment of the effectiveness of the 
programme in relation to its initial objectives and the extent of the effectiveness of the operation 
with regard to users and residents (interviews and surveys wee conducted). [NR 2003] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist. The culture of evaluation is relatively new to France (and different to a 
culture of ‘control’). [RT]. 
As a result of the evaluation of the three-year Action Plan 1999-2001, recommendations regarding 
quality assurance were made, including:  
x Ensure that there is an on-going system of quality information, based on a restricted 
number of sensitive and up-to-date indicators of resources and achievement of result and, 
to this end, identify such indicators from the definition of the programmes, so as to be able 
to identify any revisions to be made in existing information systems.  
x Procure the necessary resources (personnel and financial) to guarantee the gathering of 
information and its utilisation while avoiding the resort to statistical categories that differ or 
are only loosely connected across the various collecting services. 
x Assure the quality of implementation, making a mid-term assessment of how professionals 
in the field interpret the objectives in their professional practice and of the difficulties they 
encounter [NR 2004].  
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
A working group, bringing together the General Health Department (DGS), the French Health 
Products Safety Agency (AFSSAPS), the MILDT and the OFDT, was set up in 2001 to reassess the 
programmes for the distribution of heroin under medical supervision. In this context, the OFDT has 
entrusted a group of foreign researchers with documentary research on the various clinical trials 
regarding programmes based on heroin prescribed for injection and their effectiveness in the 
prescribing countries (United Kingdom, Switzerland, Germany, Spain, Australia and the United 
States). [NR 2003] 
In the framework of the three-year action plan on drugs of the French government, five priority 
programmes and/ or specific facilities were evaluated. These were a) the departmental prevention 
programmes; b) the inter-ministerial training initiative; c)  the approach to specialised alcohol 
addiction units with a view to general admission; d) the harm reduction and social mediation 
programme in the 18th arrondissement of Paris; and e) the departmental agreements on health 
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and justice objectives. These programme evaluations, which were part of the three-year plan, were 
managed by the OFDT in collaboration with the institutions concerned and were carried out by 
independent teams selected in a call for tenders’ procedure. Their specific results were added to 
the general evaluation report [NR 2003] and resulted in a series of recommendations for policy. 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist . [RT]. The culture of evaluation is relatively new to France (and different 
to a culture of ‘control’). So far there is not a general policy that includes stakeholders at all levels. 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] France has 
participated in a number of SANCO funded projects (e.g. Emtrend project)337
337 The Emerging Trends project focused on the development of an early identification function for the 
assessment of new drug trends, including riskful drug use. 
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Annex A2.9 State of play on harm reduction in Ireland 
2.9.1 Summary 
Public health policy. Harm reduction as a public health objective exists in Ireland, but was not 
based upon the Council Recommendation. Harm reduction is also reflected in the Irish National 
Drug Strategy 2001-2008 and its contents are in coherence with the Council Recommendation.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines and websites. With regard to the reduction of drug-related 
deaths, individual risk counselling is the predominant response strategy. Nationwide, communities 
and drug users are involved in risk reduction.
Outreach work. Street-based outreach work is available in specific geographical areas. Outreach 
work as a health education approach is a common response strategy to prevent infectious diseases 
among drug users. For the reduction of drug-related deaths, outreach work is the predominant 
setting for the deliverance of risk education/ response training and a common setting for the 
dissemination of information materials. Although the policy exists, peers and volunteers are not 
included in outreach work practice. Networking and cooperation between outreach work agencies 
exist in specific geographical regions only. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
methadone detoxification programmes, drug-free outpatient and drug-free inpatient treatment and 
rehabilitation programmes are nationwide available. Drop-in centres/ shelters and treatment with 
buprenorphine and naltrexone are available in specific geographical areas only. Drug consumption 
rooms and heroin prescription programmes do not exist in Ireland. Opioid substitution treatment is 
a common response strategy aiming at the reduction of drug-related deaths. Measures to prevent 
diversion of prescribed drugs are available nationwide. 
Prison interventions. Testing, prevention, education and treatment of infectious diseases are 
available nationwide in prisons. There is a limited counselling service and low access to treatment 
of hepatitis C. In specific geographical areas methadone maintenance treatment and methadone 
detoxification treatment are provided. Treatment with buprenorphine and naltrexone, needle and 
syringe exchange programmes, drug paraphernalia and the distribution of condoms are not 
available in Irish prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). To prevent infectious diseases among drug users, common response strategies include 
IEC in general, IEC via counselling and advice by drugs and health professionals, safer injection 
training, outreach health education approach, voluntary counselling and testing, condom promotion 
among drug users, needle and syringe exchange and hepatitis vaccination programmes. Needle 
and syringe exchange, drug paraphernalia and the distribution of condoms are available in specific 
geographical areas.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g. to 
deal with overdoses. The distribution, possession or administration of naloxone is regulated. 
Naloxone is not available on a ‘take home’ basis.
Training of staff and risk reduction as part of a complementary health strategy. Trainings 
for outreach workers is provided in specific geographical regions. Risk reduction is  part of an 
integrated health strategy for drug users. 
Quality, monitoring and evaluation. In Ireland, a small number of studies regarding the 
effectiveness of harm reduction interventions have been conducted, among others into the use of 
Iofexidine and naloxone, hepatitis B vaccination and into substitution treatment. Needs assessment 
is not common practice in drug demand reduction programmes, but assessment of hepatitis C 
treatment and hepatitis B vaccination coverage have been put in place. Outreach work has been 
evaluated as part of the National Drug Strategy. 
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2.9.2 Recommendation 1: Risk reduction and public health policy 
The implementation of the Council Recommendation in Ireland is a shared responsibility between 
the Ministry of Health and Children Unit for Community Health), the Ministry of Community, Rural 
and Gaeltacht Affairs (Drug Policy Coordination) and the Ministry of Education and Science (Social, 
Personal and Health Education & prevention). [RT] 
Harm reduction is a public health objective in Ireland, but was not based upon the Council 
Recommendation. A comprehensive National Drugs Strategy is in place for the period 2001 - 2008. 
This strategy was developed following widespread consultation. It contains 100 actions under the 
pillars of supply reduction, education and prevention, treatment and rehabilitation, and research. 
The Council Recommendation is very much in line with the Irish policy in relation to preventing and 
reducing health related harm associated with drug dependence. [RT]  
A mid-term review of the National Drugs Strategy was finalised in 2005, resulting in (re-) adjusted 
policy objectives for the period 2005-2008. [SQ29]
2.9.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Ireland, the dissemination of information through various websites and telephone help lines is 
nationwide available. In specific geographical regions, primarily in the Eastern Regional Health 
Authority, training for drug users and a broad range of educational materials are available. [NR 
2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) via counselling and advice by drugs and health professionals, IEC in general 
and safer injection training are common response strategies.338 [SQ 23] 
With regard to the reduction of drug-related deaths, individual risk counselling is the 
predominant response strategy. Risk education/ response training is a common response strategy 
and is delivered predominantly by low threshold agencies, including needle and syringe exchange 
programmes, and through outreach workers and commonly by specialised drug treatment services. 
[SQ29].
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Nationwide, communities and drug users are involved in risk reduction. [NR 2004] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Ireland, street-based outreach work is provided in specific geographical areas. In some rural 
area backpacking needle exchange is available. [NR 2004]. 
To prevent infectious diseases among drug users, outreaching health education is a common 
response strategy. Outreach work and targeted high risk group interventions are a common 
implementation setting for infectious diseases prevention measures targeting drug users. [SQ 23] 
338 In May 2004, senior outreach workers reported two concerns with the current organisation of outreach 
services. They reported that outreach workers need to work from 2 pm to 11 pm in order to suit their clients’ 
lifestyle. Outreach services needed to be reorganised in order to address the growing cocaine use problem 
during weekends. Such re-organisation would make their services more appropriate.  
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Low threshold agencies, including needle and syringe exchange, and outreach work are a common 
setting for the dissemination of information materials, aiming at the reduction of drug-related 
deaths. Outreach work is a predominant setting for the deliverance of risk education/ response 
training to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
However, peers and volunteers are not included in outreach work nor is training for peers and 
volunteers available. Training for outreach workers and training in management for senior outreach 
workers is organised in specific geographical areas. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical regions only (the Eastern Region), senior outreach workers meet on a 
monthly basis. [NFP 2006]  
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT]
Methadone maintenance and methadone detoxification programmes, drug-free outpatient and 
drug-free inpatient treatment and rehabilitation programmes are nationwide available. Substitution 
treatment is supported by psychosocial care upon request by the client. Drop-in centres/ shelters 
and treatment with buprenorphine and naltrexone339 are available in specific geographical areas 
only. [NR 2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment (with regard to 
the reduction of heroin/ opiate overdose) is a common response strategy. [SQ 29] 
Drug consumption rooms and heroin prescription programmes do not exist in Ireland. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are nationwide available. [NR 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing, prevention, education and treatment of infectious diseases are available nationwide in 
prisons. There is a limited counselling service and low access to treatment of hepatitis C. In specific 
geographical areas methadone maintenance treatment340 and methadone detoxification treatment 
are provided. Treatment with buprenorphine and naltrexone, needle and syringe exchange 
programmes341, drug paraphernalia and the distribution of condoms are not available.342 [NR 2003/  
2004; NFP 2006]  
Prisons are a common implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Information materials aiming at the prevention and reduction 
of drug – related deaths are rarely disseminated in Irish prisons, as is the deliverance of risk 
339 Naltrexone is rarely used to facilitate a drug free lifestyle following detoxification. 
340 In five prisons in Dublin. 
341 Needles or syringes distributed inside prisons. 
342 Bleach is not distributed in Ireland as it does not prevent the spread of hepatitis C. 
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education/ response training for drug users. Prison pre-release interventions are also uncommon. 
[SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Common response strategies to prevent infectious diseases among drug users are: IEC in 
general, IEC via counselling and advice by drugs and health professionals, safer injection training, 
outreach health education approach, voluntary counselling and testing, condom promotion among 
drug users, needle and syringe exchange programmes and hepatitis vaccination programmes343. An 
uncommon response strategy is easy access’ programmes to treatment of infectious diseases344.
Predominant implementation settings for infectious diseases prevention measures include 
specialised drug treatment services and primary care/  GP’s. Common implementation settings are 
low threshold counselling services, outreach work and targeted high risk group interventions, and 
prisons. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas, needle and syringe exchange programmes345, distribution of 
condoms and drug paraphernalia such as sterile water and ascorbic acid are available. [NR 2004; 
NFP 2006] 
Needle and syringe exchange programmes are a common response strategy to prevent infectious 
diseases among drug users in Ireland. [SQ 23]. With regard to the reduction of drug-related 
deaths among drug users, low threshold agencies, including needle and syringe exchange 
programmes, are a predominant setting for dissemination of information materials and for 
providing risk education/  response training for drug users. [SQ 29] 
Ireland has twenty non-pharmacy based NSPs, no pharmacy-based NSPs and no vending 
machines. Fixed sites, vans/ buses and outreach/ peer are existing types of needle exchange. 
There are no vending machines, no pharmacy-based and no prison-based NSPs. [ST 10] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training programmes for professionals of emergency services346 are available nationwide. [NR 
2004; NFP 2006] Emergency departments are not in use as a setting for risk education/  response 
training that aim at the reduction of drug-related deaths. [SQ 29] Irish ambulances routinely 
carry antagonists. The distribution or administration347 of naloxone is regulated. Naloxone is not 
available on a ‘take home’ basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
With regard to risk reduction as part of an integrated health strategy for drug users: in theory, the 
implementation of the National drug Strategy is an action in the National Health Strategy. To 
promote appropriate integration, in 2002, the National Advisory Committee on Drugs 
343 Ireland has a national hepatitis B immunization programme since 1999; it has also targeted hepatitis B 
vaccination programmes for drug users, and also programmes in prisons. 
344 In 2003, a protocol has been developed to improve uptake of assessment and access to treatment for 
hepatitis C among injecting drug users.
345 Only Eastern Health Authority.
346 On the management of overdoses. 
347 Since August 2005, Statutory Instrument No 510 of 2005 permits the administration of naloxone by 
advanced paramedics in line with clinical protocol guidelines, and its administration by paramedics and 
emergency medical technicians when prescribed by a medical practitioner.
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commissioned a team at Dublin City University to explore the management of individuals with a 
combination of mental illness and substance misuse in Ireland. [NFP 2006]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training for outreach workers and training in management for senior outreach workers is organised 
in specific geographical areas. [NR 2004] 
2.9.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT]. 
Two small-scale cohort studies published in 2004 and examining the effectiveness of 
methadone maintenance as a therapy were positive with respect to internationally accepted 
indicators. [NR 2004] 
Furthermore, the Working Party at the National Medicines Information Centre at St James’s 
Hospital in Dublin were commissioned by the National Advisory Committee on Drugs to review the 
use of lofexidine and naloxone in the management of opiate dependence.  
The effectiveness of hepatitis B vaccination among injecting drug users may be lower than that 
among the general population because of the generally poorer health status among this group, 
including HIV co-morbidity (Keating and Noble 2003). [NR 2004] 
In the Republic of Ireland, drugs used to detoxify opiate users are methadone, buprenorphine and 
lofexidine. Research indicates that all three drugs are effective in reducing withdrawal symptoms 
and completion rates are satisfactory. [NR 2003]  
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
In 2001 a pilot project was implemented to improve the care of injecting drug users attending 
general practice and at risk of hepatitis C. Prior to implementing the project, the authors did a 
baseline assessment that included hepatitis B vaccine coverage. [NR 2004].  
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
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Policy exists, but was not based upon the Council Recommendation. [RT] 
The Eastern Regional Health Authority (ERHA) commissioned the evaluation of outreach work in 
response to Action 64 of the National Drugs Strategy. One of the recommendations from the 
research report was to develop a monitoring system that includes quantitative and qualitative 
indicators for outreach work. [NR 2004] 
In June 2001, the Minister of State for Local Development with special responsibility for the 
National Drugs Strategy, asked the National Advisory Committee on Drugs (NACD) to undertake a 
review of the use of buprenorphine as an intervention in the treatment of opiate dependence 
syndrome.  As a result, the NACD commissioned a team of experts at the National Medicines 
Information Centre to conduct this review. The review examined the effectiveness of buprenorphine 
as a treatment option, its safety in use, as well as the practical and pharmaco economic 
considerations associated with its use. [NR 2004] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy does not exist. [RT] 
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Annex A2.10 State of play on harm reduction in Italy 
2.10.1 Summary 
Public health policy. 
Harm reduction interventions have existed in Italy for many years, primarily at regional level. Harm 
reduction is a public health objective.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines and websites. For the reduction of drug-related deaths, the 
dissemination of information materials, risk education/ response training for drug users, individual 
risk counselling and prison pre-release interventions are predominant strategies. In specific 
geographical regions, communities and families of drug users are informed and involved in the 
prevention and reduction of health risks associated with drug dependence. 
Outreach work. Street-based outreach work, and outreach work at dance parties/ raves and in 
clubs are available in specific geographical regions only. Outreach work as a health education 
approach is a predominant response strategy to prevent infectious diseases among drug users. For 
the reduction of drug-related deaths, outreach work is the predominant setting for the 
dissemination of information materials, as well as for the deliverance of risk education/ response 
training. Peers and volunteers are included nationwide in outreach work practice. Networking and 
cooperation between outreach work agencies only exist in specific geographical regions and on an 
informal level. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
methadone detoxification treatment, drug-free out-patient and drug-free inpatient treatment and 
rehabilitation programmes are nationwide available. Treatment with buprenorphine and naltrexone, 
and drop-in centres/ shelters are available in specific geographical areas. Italy does not have drug 
consumption rooms and has no heroin prescription programmes. Opioid substitution treatment is a 
predominant response strategy aiming at the reduction of drug-related deaths. Although this policy 
exists, measures to prevent diversion of prescribed drugs are not available. 
Prison interventions. Methadone maintenance, detoxification treatment and treatment with 
buprenorphine are nationwide available in prisons. Also testing, prevention, education, treatment 
and counselling of infectious diseases are provided nationwide. In specific geographical areas, 
naloxone is available on a ‘take home’ basis.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening and vaccination for infectious diseases are nationwide available. To 
prevent infectious diseases among drug users, the predominant response strategies are IEC in 
general, outreach health education approach, voluntary infectious diseases counselling and testing, 
and needle and syringe exchange. Needle and syringe exchange is available nationwide. Drug 
paraphernalia and condoms are available in specific geographical regions.  
Drug-related deaths. The distribution or administration of naloxone is regulated. Naloxone is 
available on a ‘take home’ basis.
Training of staff and risk reduction as part of a complementary health strategy. Training 
for outreach workers is nationwide available. Training for other professionals is not available. Risk 
reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. An evidence-based approach in addiction treatment has 
been adopted in ‘essential standards of care’. Studies are also frequently conducted. In most 
regions a system of quality control has been put in place to assess and monitor the activities in the 
field of drug addiction. 
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2.10.2 Recommendation 1: Risk reduction and public health policy 
The coordination and implementation of drug policy in Italy is a shared responsibility between the 
National government and Regional Authorities. In the field of drug demand reduction, the Ministry 
of Health is responsible for national coordination, monitoring, quality control and finances. Regional 
Administrations have the task to ensure regional health care system legislation and planning, 
services, etc.. Local Health Authorities provide social and health care services, in cooperation with 
NGO’s (incl. out-reach work). As a result, the implementation of respective elements of the Council 
Recommendation is delegated to the subsidiary levels of Italian Public Administration. In Italy, 
prevention and reduction of health-related risks associated to drug dependence was a public health 
objective prior to the adoption of the Council Recommendation. [RT] 
For many years Italy has been pursuing a service-oriented policy for drug-addicts. This policy was 
implemented through a series of legislative and administrative measures in the early '90ies 
(revised and updated in the late '90ies)348. The Italian Government has recently approved a 
National Action Plan, which is being examined by the Regions. The Plan was expected to receive 
final approval through an Agreement in the framework of the Permanent Government-Regions 
Conference. [RT] 
2.10.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. 349 [RT] 
In Italy, information350 is disseminated nationwide through telephone help lines351 and websites. 
Training for drug users352,353, and a broad range of educational leaflets354,355 are available in 
specific geographical regions. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general is the predominant response strategy. Common response 
strategies include IEC via counselling and advice by drugs and health professionals and IEC via 
peer involvement/ peer approach. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information 
materials, risk education/ response training for drug users, individual risk counselling and prison 
pre-release interventions are the predominant response strategies. Predominant settings for the 
dissemination of information materials are specialised drug treatment services, low threshold 
agencies, including needle and syringe exchange programmes and detoxification centres. Common 
settings include mass media/ internet, schools/ educational systems, nightlife or entertainment 
venues. Predominant settings for risk education/  response training are specialised drug treatment 
services, low threshold agencies, including needle and syringe programmes and through outreach 
workers, peers. Nightlife is a common setting for risk education/ response training. [SQ 29] 
348 Legislation of reference: Presidential Decree  n.309 of 9.Oct.1990; Ministerial Decree n.444 of 30 Nov.1990; 
Government-Region Agreement of 21 Jan.1999; Decree of the Council of Ministers of 29 Nov.2001 on the 
Essential Standards of Care (LEA). 
349 Ministerial Decree n. 444 of November 30, 1990 establishing the organisation, functions and staff 
characteristics of Drug Treatment Services. 
350 The materials are distributed through mass media and the internet and through low threshold facilities, in 
specialised agencies, in discotheques, in schools, and - to a lesser - extent in prisons and at rave parties, 
concerts and festivals. [NFP 2006] 
351 DROGATEL, operating since 1993. 
352 Many outreach services use Narcan (Naloxone) for treatment of overdose and inform people how to use it. 
353 Main tools used in educational interventions to protect against the risk of drug-related infectious diseases 
are street units or peer groups operating in at-risk contexts, low threshold facilities and specialised facilities. In 
addition, schools and discotheques represent another intervention context. The main activities include risk-
protection educational efforts, syringe exchange programmes, distribution of informational materials on at-risk 
injection activities and on the risks of contracting drug-related infectious diseases, vaccination programmes 
(hepatitis B), and distribution of condoms. 
354 Many services provide leaflets or cards on how to respond to an overdose. 
355 Information materials (flyers, brochures, multimedia materials) created ad hoc to prevent emergencies and 
deaths from acute intoxication associated with substance use, contain information on: at-risk behaviours, 
mechanisms of overdose, methods to avoid it, medical and legal consequences of intervention and the correct 
use of naloxone.  
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2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation356. [RT] 
In specific geographical regions, families and communities are directly involved in regional and 
local projects to prevent and reduce drug-related health risks357. In some regions, specific IEC for 
communities and families of drug users is available. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy does not exist, since it is not a task for the national government358. [RT] 
In Italy, street-based outreach work and outreach work at dance parties/ raves and in clubs are 
available in specific geographical regions. [NR 2003/ 2004; NFP 2006]  
To prevent infectious diseases among drug users, outreaching health education is a 
predominant response strategy. Outreach work and targeted high-risk group interventions are a 
common implementation setting for infectious diseases prevention measures targeting drug users. 
[SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach workers 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is the predominant setting for the deliverance of risk 
education/ response to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy does not exist, since it is not a task for the national government359. [RT] 
In Italy, peers and volunteers are included in outreach work and training for peers and volunteers 
is nationwide available. [NR 2004] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy does not exist, since it is not a task for the national government360. [RT] 
In specific geographical regions, networking and collaboration between outreach work agencies 
exist, but only on an informal level. [NR 2004]  
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation361. [RT] 
Methadone maintenance and methadone detoxification treatment, drug-free out-patient and drug-
free inpatient treatment and rehabilitation programmes362 are nationwide available. Treatment with 
buprenorphine and naltrexone and drop-in centres/ shelters are available in specific geographical 
356 Presidential Decree n. 309/90, art. 1, comma 12 on the promotion of national awereness campaigns in this 
specific field; art. 106 Creation of info points in schools. 
357 See for instance projects described in the website www.dronet.org.
358 Actions are carried out by the Regions. 
359 Actions are carried out by the Regions. 
360 Actions are carried out by the Regions. 
361 Ministerial  Decree 444 & Government-Regions Agreement on the "Re-organisation of the healthcare system 
in the drug-addiction field" of  January 21, 1999. 
362 Italy does not use the term rehabilitation. Re-integration is usually targeting education, vocational training 
and supported housing. 
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areas. Substitution treatment is supported by psychosocial care and is sometimes obligatory, 
sometimes upon request by the client (depending on the prescribing institution or general 
practitioner). [NR 2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29]  
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation363. [RT] 
However, measures to prevent diversion of substitution substances are not available in Italy364 [NR 
2000/ 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation365. [RT] 
Methadone maintenance treatment, methadone detoxification treatment and treatment with 
buprenorphine are nationwide available in prisons. Also testing, prevention, education, treatment 
and counselling of infectious diseases are provided nationwide. In prisons in specific geographical 
areas, naloxone is available on a ‘take home’ basis [NR 2003/ 2004; NFP 2006]  
Prisons are a predominant implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Aiming at the prevention and reduction of drug – related deaths, prison pre-release 
interventions are a predominant response strategy. Prisons are an uncommon setting for 
disseminating information materials on prevention of acute drug-related deaths and for providing 
risk education/ response training for drug users. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation366. [RT] 
Testing/ screening for infectious diseases is nationwide available367. In specific geographical regions 
education, prevention, counselling and treatment are provided. [NR 2004; NFP 2006]
Predominant response strategies to prevent infectious diseases among drug users are: IEC in 
general, outreach health education approach, voluntary infectious diseases counselling and testing, 
and needle and syringe exchange programmes. Common strategies include IEC via counselling by 
drugs and health professionals, IEC via peer involvement/ peer approach, condom promotion 
among drug users, routine screening of high risk groups, hepatitis vaccination programme for drug 
users, and easy access programmes for drug users to treatment of infectious diseases368. [SQ 23; 
363 The Presidential Decree n. 309/90 establishes very strict rules on the medical prescription of psychotropics, 
and especially of those used in substitution therapy. Law n. 12 of February 8, 2001 : "Rules facilitating the 
medical use of analgesic opioids in pain treatment". 
364 Diversion is a minor problem in Italy. 
365 The legislative decree n. 230/1999 has  transferred to the Regions the responsibility for drug-addicts 
healthcare in custodial settings. 
366 Law no. 135 of 1990 on prevention of HIV infection. Anti-hepatitis B vaccination for new-borns has become 
compulsory in 1991; it is free for all individuals at risk. 
367 The main interventions aimed at the prevention of drug-related infectious diseases consist of outreach to 
make contact with drug users who are not in contact with a treatment service or who are engaged in high risk 
to infection behaviour, efforts to bring drug dependents into treatment and to retain them in treatment and the 
provision of information, sterile equipment and condoms to those who are not yet prepared to enter treatment 
or move away from drug injection. 
368 There are also other specific infectious disease response strategies: (1) a substantial number of public drug-
addiction agencies in Italy have set up forms of assistance for organic pathologies (physical health problems) 
related to the use of illegal psychoactive substances. (2)Facilities of addiction departments frequently make 
agreements with emergency medicine departments in order to diagnose and treat these problems in a fast and 
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NFP 2006] Specialised drug treatment services and prisons are predominant implementation 
settings for infectious diseases, where low threshold counselling, and outreach work targeted at 
high risk group intervention are common settings [SQ 23]. 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy does not exist, since it is not a task for the national government369. [RT] 
Needle and syringe exchange programmes are available nationwide. Drug paraphernalia such as 
sterile water, bleach and ascorbic acid, and the distribution of condoms are available in specific 
geographical regions. [NR 2004]  
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Italy. [SQ 23] With regard to the reduction of drug-
related deaths among drug users, low threshold agencies, including needle and syringe exchange 
programmes, are a predominant setting both for dissemination of information materials and for 
providing risk education/ response training for drug users. [SQ 29]  
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation370. [RT] 
Training programmes for professionals of emergency services are not available. [NR 2003] 
Ambulances routinely carry antagonists. The distribution or administration of naloxone is regulated. 
Naloxone is available on a take home basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation371. [RT] 
No further information is available whether risk reduction is a part of an integrated health strategy 
for drug users, but prevention of social and health consequences is part of such a strategy. [NFP 
2006]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy does not exist, since it is not a task for the national government372. [RT] 
Training for outreach workers is nationwide available. Training for other professionals is not 
available. [NR 2003]. 
2.10.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. A Decree of the Council of 
Ministers of 29 Nov. 2001 reflects on the ‘essential standards of care’. Evidence-based medicine is 
largely used in the Italian healthcare system. Staff is permanently trained according to new 
insights from evidence. [RT] 
appropriate way. (3) Health protective measures for pregnant female dependent drug users is handled 
according to protocols that are well defined in various addiction services. Furthermore, the municipal social 
services organise genuine social and psychological support and assistance with economic problems, as well as 
protection against violence and degradation of these pregnant women. 
369 These actions are carried out by the Regions. 
370 Actions are carried out by the Regions in the whole country. Local actions carried out over the last 5 - 6 
years have reduced mortality caused by overdoses (1016 deaths in 2000 against 441 in 2004). 
371 Government-Regions Agreement of 21 Jan.1999 on the "Re-organisation of the healthcare system for drug-
addicts", point 4. 
372 Government-Regions Agreement of January 21, 1999 on the "Re-organisation of the healthcare system for 
drug-addicts", point 2
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One major research project is the VeDeTTE Study, co-ordinated by the University of Turin and the 
Lazio Region and work on rapidly identifying new drugs or new drug using practices co-ordinated 
by the National Health Institute. Publication of data from both studies is awaited. It is a longitudinal 
research following clients over time and has as its primary objective an evaluation of the 
effectiveness of methadone treatment. [NR 2003]
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, since it is not a task for National government. This is stipulated in the 
Government-Regions Agreement of 21 January 1999. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does exist, since it is not a task for the national government.  Both the Government and 
Regions have funded research on the evaluation of actions undertaken in the field of drug-addiction 
(Government-Regions Agreement of 21 January 1999). [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. Both the Government and 
the Regions have financed experimental projects on the evaluation of the quality of services offered 
to drug-addicts. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. The National Focal Point 
of Reitox network is included in the Monitoring Office of the National Department for Drugs Policy. 
The Government has funded a project for the implementation of EMCDDA standards on data 
collection (“SESIT" project) at a regional level. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
Policy does not exist, since it is not a task for national government. This action is carried out by the 
Regions. [RT] 
To facilitate co-ordination and an integrated approach to primary, secondary and tertiary 
prevention, the Regional Councils in most Regions have adopted formal decisions to provide local 
arrangements for the establishment, organisation and operation of all activities in the dependency 
sector. In many cases this involves a technical or advisory committee to advice on strategy, 
planning and projects and on the evaluation of activities as well as a Department for Dependence 
which provides the operational support for implementing and monitoring the strategy and 
programmes and projects funded through resources available to the Region.  Commonly 
representatives of interested sectors in the public and private social services serve on the advisory 
committee. [NR 2004]  
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, since it is not a task for national government. This action is carried out 
by the Regions. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist. [RT] 
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3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but is not based upon the Council Recommendation. [RT] 
Italy is an important donor to international organisations such as UNODC. Recently, three bilateral 
projects have been undertaken, two in Peru and one in the Maldives and alternative development 
projects have been funded in Columbia, Ecuador and Bolivia. Italy participates in the ESPAD 
project. [NR 2003] 
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Annex A2.11 State of play on harm reduction in Cyprus 
2.11.1 Summary 
Public health policy. Harm reduction is a public health objective in Cyprus, which was reflected in 
the National Action Plan on Drug Demand Reduction.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through a telephone help line. With regard to the prevention of infectious diseases among 
drug users, IEC in general is a predominant response strategy, while IEC via counselling and advice 
by drugs and health professionals, and IEC via peer involvement/  peer approach are common 
response strategies. There is no information whether communities and families of drug users are 
informed or involved in the prevention and reduction of health risks associated with drug 
dependence. 
Outreach work. Street-based outreach work and outreach work at dance parties and in clubs do 
not exist and therefore, outreach work is neither a common response strategy nor a common 
implementation setting for measures to prevent infectious diseases among drug users. Peers and 
volunteers are not included in outreach work practice. Also, networking and cooperation between 
outreach work agencies do not exist. 
(Medically assisted) treatment and specific interventions. In specific geographical areas, 
there are drug-free inpatient and drug-free outpatient treatment facilities, rehabilitation centres, 
and drop-in centres/ shelters (low threshold centres). Substitution treatment, drug consumption 
rooms and heroin prescription programmes do not exist in Cyprus. Measures to prevent diversion 
of prescribed drugs are not available. 
Prison interventions. Counselling with regard to infectious diseases is available nationwide in 
prison. Other prison interventions are either not available or information is lacking. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures targeting infectious diseases do not exist in Cyprus. In specific geographical 
areas, distribution of condoms is available. Needle and syringe exchange programmes do not exist 
in Cyprus. There is no information about the availability of (other) drug paraphernalia.  
Drug-related deaths. Training for professionals of emergency departments is not provided.
Training of staff and risk reduction as part of a complementary health strategy. In specific 
geographical areas, training is provided for prison staff and for professionals working in treatment 
facilities. There is no specific information available whether risk reduction is part of an integrated 
health strategy for drug users, although this policy exists. 
Quality, monitoring and evaluation. In Cyprus, systems for quality control, monitoring and 
evaluation are scarce. Guidelines have been developed for drug treatment centres, though. Policy 
evaluation is a task for the Cyprus anti-drugs council.  
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2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists and was based upon the Council Recommendation. [RT] 
However, networking and cooperation between outreach work agencies do not exist in Cyprus. 
[NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists and was based upon the Council Recommendation377. [RT] 
In specific geographical areas only, there are drug-free inpatient and drug-free outpatient 
treatment facilities378, rehabilitation centres, and drop-in centres/ shelters (low threshold 
centres)379. Substitution treatment is not available in Cyprus. [NR 2004; NFP 2006] 
Drug consumption rooms and heroin prescription programmes do not exist in Cyprus. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy does not exist. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists and was based upon the Council Recommendation380. [RT] 
Counselling with regard to infectious diseases is available nationwide in prison. Other interventions 
are not available in prison or reliable information is lacking. [NR 2004; NFP 2006]  
Prisons are an uncommon implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists and was based upon the Council Recommendation381. [RT] 
Measures targeting drug-related infectious diseases do not exist in Cyprus382. [NR 2004; SQ 23] 
2.10  Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy does not exist383. [RT] 
Nevertheless, in specific geographical areas distribution of condoms is available. Needle and 
syringe exchange programmes do not exist in Cyprus. There is no information about the availability 
of drug paraphernalia. [NR 2004; NFP 2006] 
The possession of sterile needles is an offence in Cyprus, but no prescription is required to obtain 
or exchange needles and syringes. [ELDD] 
377 Substitution treatment is not as yet provided. 
378 Available in 3 centres: Perseas, Prometheas, Toxotis. 
379 An initiative taken by the counselling centre ‘Toxotis” which introduced a day centre “Stochos” with 
counselling and preventing harm reduction activities. 
380 Inadequate services, shortage of staff and resources.
381 Policy partially being enforced. 
382 Drug-related infectious disease programmes are non-existent. 
383 Only with regard to condom distribution. 
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2.11.2 Recommendation 1: Risk reduction and public health policy 
The main structure responsible for the implementation of the Council Recommendation (and 
Cypriote drug policy) is the Cyprus Anti-Drug Council. The prevention and reduction of health-
related harm associated with drug dependence is part of public health policy in Cyprus and was 
based upon the Council Recommendation. [RT].  
In 2005, an Action Plan on Drug Demand Reduction was set in motion, with the aim to implement 
the 2004 National Drug Strategy. The Action Plan calls for further assessment of the benefits and 
need for the implementation of harm reduction programmes in Cyprus (incl. methadone 
substitution, needle and syringe exchange, etc.) [NR 2005].  
2.3.3 Recommendation 2: Risk Reduction services and facilities  
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists and was based upon the Council Recommendation373. [RT] 
A telephone help line promoting risk reduction is nationwide available. In specific geographical 
areas only, information materials are available. Training for drug users and websites promoting risk 
reduction do not exist in Cyprus. [NR 2003/ 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general and voluntary testing and counselling are predominant response 
strategies, whereas IEC via counselling and advice by drugs and health professionals, and IEC via 
peer involvement/ peer approach are common response strategies. Safer injecting training is not 
available in Cyprus. [SQ 23] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and was based upon the Council Recommendation.374 [RT] 
No further information is available. [NR 2004; NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists and was based upon the Council Recommendation375. [RT] 
In Cyprus, street-based outreach work and outreach work at dance parties, raves and in clubs376
do not exist. [NR 2004; NFP 2006] 
Outreach work is neither a common response strategy nor a common implementation setting for 
measures to prevent infectious diseases among drug users. [SQ 23] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists and was based upon the Council Recommendation. [RT] 
Peers and volunteers are not included in outreach work practice and they are also not trained to do 
so. [NFP 2006] 
373 Specific action is carried out in a sporadic and non- structured fashion. 
374 There is lack of expertise and necessary mechanisms.  
375 There is lack of expertise  and infrastructure for data collection. 
376 It was seldom available in 2003 and 2004, but is not available anymore.
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2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation384. [RT] 
However, trainings for professionals of emergency departments are not provided. [NR 2004] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
No further information is available. 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy is not a priority for the national government. [RT]  
In specific geographical areas training is provided for prison staff and for professionals working in 
treatment facilities. Training for other professionals in the field of risk reduction is not available in 
Cyprus. [NR 2004; NFP 2006] 
2.11.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists and was based upon the Council Recommendation. [RT]  
Decision-making processes will be based on scientific evidence, as well as on the demonstrated 
effectiveness of the programmes and actions derived from the experiences of other countries. [NR 
2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists and was based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists and was based upon the Council Recommendation. [RT] However, appropriate 
mechanisms still need to be put in place.  
Evaluation of drug-free treatment at national level is not regularly performed. However, based on 
the Prevention of the Use and Dissemination of Drugs Law 2000, the Anti-Drug Council’s scientific 
committee for tertiary prevention has developed specific guidelines for drug treatment centres to 
ensure minimum quality standards. The guidelines were developed in June 2003 only, thus 
treatment centre evaluations have not yet been made. [NR 2004]  
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA. 
This policy exists and was based upon the Council Recommendation. EDDRA is extensively used 
through the Cypriot national Focal Point. [RT] 
It is the responsibility of the Cypriote Focal Point to ensure quality and compatibility with 
methodological guidelines provided by the European Monitoring Centre for Drugs and Drug 
Addiction. As a result the general population surveys will be made fully compatible with the 
EMCDDA´s guidelines. [NR 2004]  
384 Action is in the process. 
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3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation. [RT]  
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists and was based upon the Council Recommendation. The implementation is in 
process. Evaluation as concerns drug prevention as well as the reduction of health related risks is 
still in the embryonic stage; tools are being sought. [RT]
The main objectives of the Cyprus Anti-Drugs Council are to record, evaluate, approve, coordinate 
and reinforce all programmes, actions and activities against drugs by both governmental services 
and NGO’s. [NR 2004]  
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists and was based upon the Council Recommendation. The National Focal Point is 
responsible for its implementation. [RT]  
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists and was based upon the Council Recommendation. [RT]  
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. Implementation is coordinated 
by the National Focal Point. [RT] 
International cooperation will be promoted in relation to the participation of Cyprus in international 
organizations dealing with the drugs problem as well as on the level of bilateral and multilateral 
relations. [NR 2004] 
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Annex A2.12 State of play on harm reduction in Latvia 
2.12.1 Summary 
Public health policy. Harm reduction is part of public health in Latvia since 2001, when it was 
adopted in the Public Health Strategy.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational leaflets. In specific geographical 
areas, special support groups for families of drug users are available. 
Outreach work. Street-based outreach work is available in specific geographical areas only. 
Outreach work as a health education approach is a common response strategy to prevent infectious 
diseases among drug users. In specific geographical areas, training for peers and volunteers is 
provided. [NFP 2006]. Networking and cooperation between outreach work agencies exist in 
specific geographical areas. 
(Medically assisted) treatment and specific interventions. Drug-free outpatient and drug-
free inpatient treatment and treatment with Naltrexone are available nationwide. Methadone 
maintenance and detoxification programmes, treatment with buprenorphine and rehabilitation 
centres are available in specific geographical areas only. Drug consumption rooms and heroin 
prescription programmes do not exist in Latvia. Opioid substitution treatment is a predominant 
response strategy aiming at the reduction of drug-related deaths. Measures to prevent diversion of 
prescribed drugs are available nationwide. 
Prison interventions. The distribution of condoms is available in prisons in specific geographical 
areas only. Other harm reduction interventions do not exist in Latvian prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Education and treatment of infectious diseases are available nationwide. To prevent 
infectious diseases among drug users, the predominant response strategies are IEC in general and 
needle and syringe exchange. Needle and syringe exchange and the provision of drug 
paraphernalia are limited to specific geographical areas.  
Drug-related deaths. In specific geographical areas, professionals of emergency departments are 
trained, e.g. to deal with overdoses. The distribution, possession or administration of naloxone is 
regulated. Naloxone is available on a ‘take home’ basis. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in substitution programmes. Risk reduction is not part of an 
integrated health strategy for drug users.
Quality, monitoring and evaluation. Latvia does not have many quality assurance or evaluation 
mechanisms in drug demand reduction in general and in harm reduction in particular. Evaluation of 
the National Drug Control and Drug Abuse Prevention Strategy foresees evaluation of drug policy 
as a key activity. 
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2.12.2 Recommendation 1: Risk reduction and public health policy 
The Ministry of Health385 is responsible for the implementation of the Council Recommendation in 
Latvia. Harm reduction is a public health objective in Latvia, but it was not based on the Council 
Recommendation. [RT]  
The main recommendations reflected in the Council Recommendation were already designated in 
the Public Health Strategy 2001 and in the Action Programme of the implementation of Public 
Health Strategy for 2004-2010386. Twelve Ministries and 60 institutions are involved in the 
implementation of the Public Health Strategy. The responsible institution is Ministry of Health. In 
the process of implementation of the Public Health Strategy directives of European Union have 
been taken into account and it is linked on WHO European Region Strategy "Health for All in the 
21st Century”. A Programme on Drug Control and Drug Addiction Restriction 2005-2008 was 
adopted in August 2005. [RT]
2.12.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation387. [RT] 
In Latvia, telephone help lines, websites388 and a broad range of educational leaflets promoting risk 
reduction among drug users are available nationwide. [NR 2003/ 2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication in general (IEC) is a predominant response strategy, whereas IEC via counselling 
and advice by drugs and health professionals, and via peer involvement/ peer approach is a 
common response strategy. Safer injecting training is not provided to drug users. [SQ 23] 
With regard to the reduction of drug-related deaths, individual risk counselling is the common 
response strategy. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation389. [RT] 
In specific geographical areas families of drug users are involved in harm reduction. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but is not based upon the Council Recommendation. [RT] 
In Latvia, street-based outreach work is available in specific geographical areas only. Outreach 
work at dance parties, raves and in clubs is not available.390 [NR 2003; NFP 2006]  
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
385 State Agency for Addiction. 
386 Cabinet Order N150 of 9 March 2004. 
387 Cabinet Order N 733, adopted November 27, 2003 "Program of Restriction of Prevalence of HIV and AIDS 
2003 - 2007". Main objective is to increase the number of new registered cases of HIV, reduce the prevalence 
of HIV in Latvia, and its influence on persons and society in general.   
388 Email service and www.narcomania.lv
389 Programme of Restriction of  Prevalence of  HIV and AIDS for years 2003 - 2007 includes a range of 
obtainable goals where serious attention is paid to drug addiction prevention in different groups and settings. 
390 Riga Addiction Prevention Centre is organizing spot- checks at dance parties and in clubs, in order to find out 
whether the attendance is using drugs. Riga Addiction Prevention Centre staff is specially trained for these spot- 
checks.
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interventions are a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
Outreach work is not in use as a setting or a response strategy aiming at the reduction of drug-
related deaths in Latvia. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas only, training for peers and volunteers is provided. [NFP 2006]. 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy is pending for approval. [RT] 
Currently, networking and cooperation between outreach work agencies exist in specific 
geographical areas only. [NR 2003] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Drug-free outpatient and drug-free inpatient treatment are available nationwide and so is 
treatment with naltrexone391. Methadone maintenance and methadone detoxification 
programmes392, treatment with buprenorphine393 and rehabilitation centres are available in specific 
geographical areas only. Substitution treatment is supported by psychosocial care upon request by 
the client. Drug consumption rooms and heroin prescription programmes do not exist in Latvia [NR 
2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29]. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide 394. [NR 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but implementation is pending for approval. [RT] 
However, the distribution of condoms is available in prisons in specific geographical areas only. 
Other harm reduction interventions do not exist in Latvian prisons. [NR 2003/ 2004; NFP 2006] 
Measures that aim at the prevention of infectious diseases and/ or reduction of drug – 
related deaths do not exist in Latvian prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
391 Treatment with naltrexone is available nationwide. It is a prescription medicament. 
392 Available only at the Narcology Centre in Riga. 
393 Treatment with Subutex ® (buprenorphine) is available only in specific geographical areas under very strict 
regulations. 
394 E.g. registration, urine checks. 
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Vaccination against hepatitis B is provided for all newborn children. [RT] 
Education and treatment of infectious diseases395 are available nationwide [NR 2004, NFP 2006]. 
Testing/ screening and counselling with regard to infectious diseases are available to drug users in 
Latvia in specific geographical areas only396. [NR 2003/ 2004]  
To prevent infectious diseases among drug users the predominant response strategies are 
information, education, communication (IEC) in general, and needle and syringe exchange 
programmes. Other, common strategies include IEC via counselling by drugs and health 
professionals, IEC via peer involvement/ peer approach, outreach health education approach and 
voluntary infectious disease counselling and testing (VCT). Predominant implementation settings 
for infectious diseases prevention measures targeting drug users include specialised drug 
treatment services, and low threshold counselling (non treatment) services. A common 
implementation setting for infectious diseases prevention measures among drug users are outreach 
work and targeted high risk group interventions. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation397. [RT] 
Needle and syringe exchange programmes and the provision of drug paraphernalia are limited to 
specific geographical areas. [NR 2003/ 2004] Needle and syringe exchange programmes are a 
predominant response strategy to prevent infectious diseases among drug users in Latvia. [SQ 
23] Low threshold agencies, including needle and syringe exchange programmes, are a common 
setting to provide information materials on the reduction of drug-related deaths and a 
predominant setting for delivering risk education/  response training. [SQ 29] 
Latvia counts in total 22 non-pharmacy based needle and syringe exchange outlets. Needle and 
syringe exchange takes place through fixed sites, vans/ buses, and through outreach workers/  
peers, but not via pharmacies or vending machines, nor in prisons. [ST 10] 
There are no legal restrictions to the possession of sterile needles in Latvia. Prescription is not 
required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas only, professionals of emergency departments are trained398. [NFP 
2006] Emergency departments are an uncommon setting for dissemination of information 
materials that aim at the reduction of drug-related deaths or for risk education/  response training. 
[SQ 29] 
Latvian ambulances routinely carry antagonists. [SQ29] The distribution, possession or 
administration of naloxone is regulated. Naloxone on a ‘take home’ basis is available399. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy is pending for approval. [RT] 
Risk reduction is not a part of an integrated health strategy for drug users. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
395 Treatment of infectious diseases is available for the general public. There is no special treatment of 
infectious diseases available only for drug users. 
396 Available in ten HIV prevention units. There is a clear need to open counselling/testing sites in the biggest 
towns. 
397 Condoms are distributed and syringes exchanged through needle and syringe exchange outlets. There are 
11 outlets in Latvia at the moment. Their work is supervised by the Ministry of Health but the action is provided 
by staff of the AIDS Prevention Centre. Distribution also takes place on streets. 
398 Highly- skilled professionals working in emergency units are trained for different situations. 
399 Theoretically it is possible if a general practitioner prescribes this substance. 
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This policy is pending for approval. [RT] 
Training is offered nationwide to professionals in substitution programmes. Training for 
professionals in needle and syringe exchange programmes and in low threshold agencies and for 
outreach workers is available in specific geographical areas400. Training programmes for prison staff 
and for professionals in treatment facilities do not exist. [NR 2003; NFP 2006] 
2.12.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy does not exist. There are not enough scientific studies that have data in some specific 
fields. [RT] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist, but is pending for approval. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist, but is pending for approval. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy does not exist, but is pending for approval. Since 1996 The State Addiction Agency is a 
Reitox National Focal Point in Latvia and the collection of information accordingly to EMCDDA 
requirements is included in the State program on Drug Control and Drug Addiction Restriction 
2005-2008 (Strategy and Action Plan on Drugs 2005-2008). [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist. There are evaluation results in some fields. [RT] 
The draft Drug Control and Drug Abuse Prevention Programme foresees the evaluation of drug 
policy as one of the key tasks of the Drug Control and Drug Abuse Prevention Co-ordination 
Commission. According the proposal of the draft Drug Programme the Reitox Latvian Focal point 
should be responsible for preparing tools for policy assessment and evaluation.  
In 2004-2005 Latvia implemented the project ‘Evaluation of Drug Demand and Supply Reduction 
Activities’ within the Transitional Facility programme. The aim of the project was to develop 
evaluation systems for treatment and prevention and supply reduction activities. [NR 2003] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, but is pending for approval.  
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist. [RT] 
400 Provided by staff of the AIDS Prevention Centre.
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3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] Latvia participated in the 
ESPAD Survey 2003. [NR 2004] 
2.12.5 Information from third data sources 
Issues raised by Dia+logs 
Information, education and communication (IEC). IEC is inadequate in coverage and 
accessibility. as the few services providing IEC lack funding.  
Outreach work. Outreach work is efficiently implemented and has adequate coverage and 
accessibility. 
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is inadequate in coverage, but adequate in accessibility. Medically assisted treatment 
for ATS users is inadequate in coverage, but accessibility of the few places where it is implemented 
is considered adequate. There is no information available about medically assisted treatment for 
ATS or cocaine users. Neither ATS nor cocaine prescription programmes are available in Latvia. 
Specific harm reduction interventions for cocaine or ATS users are not available. There are no drug 
consumption rooms in the country and an inadequate coverage and accessibility of needle and 
syringe exchange programmes as not all cities provide the service. Coverage and accessibility of 
drug paraphernalia distribution is adequate.  
Low threshold agencies are inadequate in coverage and accessibility. Existing facilities struggle with 
lack of funding.  
Prison interventions. IEC in prison is adequate in coverage, but difficult to access due to 
attitudinal barriers put on by prison administration. Outreach work does not exist in prison in 
Latvia.  
No medically assisted treatments for ATS users or specific harm reduction interventions for ATS 
and cocaine users are available in prison. No information could be provided on the quantity and 
quality of medically assisted treatment for cocaine users. There are no needle and syringe 
exchange programmes in Latvian prisons and drug paraphernalia are not available either. Measures 
implemented to prevent infectious diseases are inadequate because information is not thorough 
enough. Hepatitis B vaccination programmes targeted at drug users are not available in Latvian 
prisons.  
Measures to involve families and friends of drug users in harm reduction interventions are not 
available in prison.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures to prevent infectious diseases are inadequate in coverage and accessibility. 
Budgets of institutions providing these services are small. Hepatitis B vaccination programmes 
targeting drug users in particular, do not exist. Tuberculosis vaccination programmes for drug 
users are adequate in coverage and accessibility. 
Measures to involve families and friends of drug users in harm reduction interventions are 
inadequate in coverage and accessibility.  
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Annex A2.13 State of play on harm reduction in Lithuania 
2.13.1 Summary 
Public health policy. Harm reduction is part of the Public Health policy in Lithuania and this was 
partly due to the Council Recommendation. Harm reduction was adopted as an aim in the National 
Plan on Drug Control and Prevention 2004-2008.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational materials. For the reduction of 
drug-related deaths, the dissemination of information materials is the predominant response 
strategy. In specific geographical areas communities and families of drug users are informed and 
involved in the prevention and reduction of health risks associated with drug dependence. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and clubs 
is available in specific geographical areas. Outreach work as a health education approach is a 
common response strategy to prevent infectious diseases among drug users. For the reduction of 
drug-related deaths, outreach work is the predominant setting for the dissemination of information 
materials. Peers and volunteers are included in outreach work practice in specific geographical 
areas. Networking and cooperation between outreach work agencies exist in specific geographical 
areas.
(Medically assisted) treatment and specific interventions. In specific geographical areas, 
methadone maintenance, methadone detoxification, treatment with buprenorphine and naltrexone 
are available. Drug-free inpatient and drug-free outpatient treatment facilities, rehabilitation 
centres and drop-in centres/ shelters are also available in specific geographical areas only. Drug 
consumption rooms and heroin prescription programmes do not exist in Lithuania. Opioid 
substitution treatment is a predominant response strategy aiming at the reduction of drug-related 
deaths. Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Harm reduction measures are not available in prison. Only bleach is 
available in specific geographical areas. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). To prevent infectious diseases among drug users, the predominant response strategies 
are IEC via counselling and advice by drugs and health professionals, IEC via peer involvement/  
peer approach, needle and syringe exchange, and routine screening of high risk groups. Needle 
and syringe exchange, drug paraphernalia and the distribution of condoms are available in specific 
geographical areas.  
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training 
for professionals in treatment facilities, needle and syringe exchange programmes and prison staff 
is available nationwide. Integration between health and social care takes place in Lithuania. 
Quality, monitoring and evaluation. 
The assessment of quality, monitoring and evaluation is not common in Latvia. A needle exchange 
programme evaluation has been conducted, but other activities are not reported. 
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2.13.2 Recommendation 1: Risk reduction and public health policy 
The implementation of the Council Recommendation in Lithuania is the responsibility of the Ministry 
of health. Harm reduction is a policy objective in Lithuanian Public Health. Harm reduction policy 
was (partly) based upon the Council Recommendation. [RT] 
The general aims for harm reduction were adopted in the National Plan on Drug Control and 
Prevention 2004-2008, which was adopted in 2004. [SQ29] 
2.12.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists and was based upon the Council Recommendation. [RT] 
In Lithuania, a broad range of educational materials on risk reduction is available nationwide and 
so are telephone help lines401 and websites promoting risk reduction. [NR 2003; NFP 2006]  
Information, education and communication (IEC) via counselling by drugs and health professionals, 
and IEC via peer involvement/ peer approach are predominant response strategies402 to prevent
infectious diseases among drug users, whereas IEC in general is a common response strategy. 
[SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy. Information materials are predominantly disseminated at 
low threshold agencies and needle and syringe exchange programmes and are common in 
specialised drug treatment centres and detoxification services. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and was based upon the Council Recommendation. [RT] 
Communities and families of drug users are involved in harm reduction in specific geographical 
areas only; and in specific geographical areas specific information is also available, as well as 
education and communication for communities and families of drug users. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists and is based upon the Council Recommendation. [RT]
In Lithuania, street-based outreach work and outreach work at dance parties, raves and clubs is 
available, but in specific geographical areas only. [NR 2003/ 2004; NFP 2006] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant settings for the dissemination of information materials, aimed at the 
reduction of drug-related deaths. [SQ 29] 
401 There are national help lines for youth, psychological help etc. Specifically for risk reduction line is HIV/ AIDS 
line, but this line is not targeted specifically at drug users, but at youth, risk groups etc. 
402 Substitution treatment is also a predominant response strategy.
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2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
The implementation of this policy is pending for approval. [RT] 
Currently, in specific geographical areas only, training for peers and volunteers is organised [NFP 
2006]. Peers and volunteers are included in outreach work practice, in specific geographical areas 
only. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
The implementation of this policy is pending for approval. [RT] 
However, networking and cooperation between outreach work agencies already exist in specific 
geographical areas in Lithuania. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT]  
In specific geographical areas only, methadone maintenance, methadone detoxification, treatment 
with buprenorphine and naltrexone403 are available. Substitution treatment is supported by  
psychosocial care, upon request by the client. Drug-free inpatient and drug-free outpatient 
treatment facilities, rehabilitation centres and drop-in centres/ shelters are also available in specific 
geographical areas only. [NR 2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is the 
predominant response strategy in Lithuania. [SQ 29] Drug consumption rooms and heroin 
prescription programmes do not exist in Lithuania. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. [NR 2004; NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
The implementation of this policy is pending for approval. [RT] 
Harm reduction measures are not implemented in Lithuanian prisons. [NR 2003] Prisons are a 
predominant implementation setting for infectious disease prevention measures targeted at 
drug users. Bleach is available in specific geographical areas only. [SQ 23] 
Measures targeting at the reduction of drug – related deaths are uncommon or non existent in 
Lithuanian prisons. [SQ29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists404. [RT] 
403 Both buprenorphine and naltrexone are available; however, the costs are covered by insurance in specific 
geographical areas only. 
404 For injecting drug users, hepatitis B vaccination is not financed by the National budget. The National Budget 
does fund hepatitis B vaccination for all newborns (since 1998) and 12 years’ old children (since 2002). The 
Centres for Addictive Disorders, the Lithuanian AIDS centre and Social workers provide prophylactic measures 
and screening against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases among injection 
drug users. 
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To prevent infectious diseases among drug users the predominant response strategies are IEC 
via counselling and advice by drugs and health professionals, IEC via peer involvement/ peer 
approach, through needle and syringe exchange programmes, and through routine screening of 
high risk groups. Other common strategies include IEC in general, outreach health education 
approach, condom promotion among drug users.  
Predominant implementation settings for infectious diseases prevention measures targeting drug 
users include low threshold agencies, prisons, and mass media. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists405. [RT] 
In specific geographical areas, needle and syringe exchange programmes, drug paraphernalia and 
the distribution of condoms are available. [NR 2003, 2004] 
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Lithuania. [SQ 23] Low threshold agencies, including 
needle and syringe exchange programmes are also a predominant setting for providing information 
materials on the reduction of drug-related deaths among drug users. [SQ 29] 
Lithuania counts in total seven non-pharmacy based needle and syringe exchange programmes, no 
pharmacy-based needle and syringe exchange programmes and no vending machines. Needle and 
syringe exchange takes also place through fixed sites, through vans/ buses, and through outreach 
workers/ peers, but is not available in prisons. [ST 10; NFP 2006] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation406. [RT] 
Emergency departments are a setting which is not used for dissemination of information materials 
that aim at the reduction of drug-related deaths or for risk education/ response trainings. [SQ29]. 
Lithuanian ambulances do not routinely carry antagonists. The distribution, possession or 
administration of naloxone is regulated. Naloxone on a ‘take home’ basis is not available in 
Lithuania. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists and was based upon the Council Recommendation. [RT] 
Integration between health and social care takes place in Lithuania407. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists and was based upon the Council Recommendation408. [RT] 
Training for professionals in treatment facilities, needle and syringe exchange programmes and 
prison staff is available nationwide409. Training for outreach workers exists in specific geographical 
areas. Training programmes for GP's and prescribing physicians in methadone treatment also 
exist410. [NR 2003/ 2004; NFP 2006] 
405 Distribution of condoms was available in Vilnius and Klaipeda in 2004. Needle and syringe exchange 
programmes are implemented in 7 cities: Alytus, Druskininkai, Klaipeda, Mazeikiai, Vilnius, Birzai and Siauliai. 
These programmes are funded from the municipal budget. 
406 In case of an overdose, a drug user can go to the standard emergency services or hospital, or call 
emergency number where he gets appropriate medical support. 
407 E.g., specifications exist to refer patients leaving drug treatment centres to social care institutions and to 
rehabilitation centres.
408 Government institutions support and provide specialized trainings for professionals working in prevention 
and reduction of health-related risks associated with drug dependence field. Academies run special topics on 
drug prevention and early intervention, on health-related risks associated with drug dependence, social work in 
drug field and etc. for public health, psychology, psychiatry and social course students. 
409 In 2006 training programmes for service providers are planned. 
410 According to the executive legal acts, only physicians who took this course are allowed to provide 
substitution treatment with methadone.
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2.13.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy does not exist, but is pending for approval. [RT] 
One example of evaluation of the effectiveness of an intervention is the Blue Bus needle exchange 
project, which is being assessed in monthly reports and by observing changes in the number of 
new contacts, consultations, and distributed syringes and needles, as well as by performing client 
surveys. The data of the programme indicate that the programme corresponds to the needs of this 
marginalised group. [NR 2003] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist, but is pending for approval. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist, but is pending for approval. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist, but is pending for approval. [RT] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, but is pending for approval. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist, but is pending for approval. [RT]. 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy does not exist, but is pending for approval. Information about best practice examples of 
prevention and harm reduction programmes and projects implementation in Lithuania will be 
available in EDDRA Internet database, accessible for everyone. [RT] 
A Phare Twinning project was run in 2002 and 2003 with the theme “Strengthening Illicit Drug 
Demands and Supply Reduction Capabilities” . It had the objective to further align the Lithuanian 
drug supply reduction and drug demand reduction system with the EU Acquis concerning the fight 
against drugs. [NR 2003] 
209
11350-HRI Rapport binnenwerk.ind209   209 13-03-2007   14:20:27
210210
11350-HRI Rapport binnenwerk.ind210   210 13-03-2007   14:20:28
211
Annex A2.14 State of play on harm reduction in Luxembourg 
2.14.1 Summary 
Public health policy. Harm reduction is part of public health policy in Luxembourg for some time 
already, but the Council Recommendation was of instrumental value in that regard.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through a telephone help line. For the reduction of drug-related deaths, the dissemination 
of information materials and individual risk counselling are predominant response strategies. 
Communities and families of drug users are involved in the prevention and reduction of health risks 
associated with drug dependence in two main cities. 
Outreach work. Street-based outreach work is nationwide available. Outreach work as a health 
education approach is a common response strategy to prevent infectious diseases among drug 
users. For the reduction of drug-related deaths, outreach work is the predominant setting for the 
dissemination of information materials, as well as for the deliverance of risk education/  response 
training. Peers and volunteers are included in outreach work practice in Luxembourg City. As only 
one agency in Luxembourg provides outreach work, networking and cooperation between outreach 
work agencies is not an issue. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
methadone detoxification programmes, drug-free out-patient treatment and treatment with 
buprenorphine are nationwide available. Drug-free inpatient treatment, rehabilitation centres and 
drop-in centres/  shelters are available in specific geographical areas. Luxembourg has a drug 
consumption room and a heroin prescription programme is foreseen. Opioid substitution treatment 
is a predominant response strategy aiming at the reduction of drug-related deaths. Measures to 
prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Testing, prevention, education, counselling and treatment of infectious 
diseases are available nationwide in prisons. Methadone maintenance and detoxification treatment, 
treatment with buprenorphine, drug paraphernalia, condoms, syringes and counselling are also 
provided nationwide. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, counselling, and treatment for infectious diseases are 
available nationwide as well as vaccination programmes for hepatitis B and tuberculosis targeting 
drug users. To prevent infectious diseases among drug users, the predominant response strategies 
are IEC in general, IEC via counselling and advice by drugs and health professionals, voluntary 
infectious diseases counselling and testing, condom promotion among drug users, hepatitis 
vaccination programme for drug users, needle and syringe exchange, routine screening of high risk 
groups and easy access’ programmes for drug users to treatment of infectious diseases. Needle 
and syringe exchange and condoms are available nationwide; drug paraphernalia in specific 
geographical regions.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g. to 
deal with overdoses. The distribution or administration of naloxone is regulated. Naloxone is 
nationwide available on a ‘take home’ basis. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in outreach work, in needle exchange programmes, in 
substitution treatment, in treatment facilities, in low threshold programmes and in prison settings.
Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. Regarding scientific information on drug addiction (for 
policymakers), Luxembourg runs a database in which interventions are also registered (RELIS). 
Several studies into needs assessment, effectiveness of interventions and policy evaluations have 
been conducted. Luxembourg is also collaborating actively in bi- and multilateral networks.  
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2.14.2 Recommendation 1: Risk reduction and public health policy 
In Luxembourg, the department that is responsible for the implementation of the Council 
Recommendation is the Ministry of Health411.
A harm reduction policy exists in Luxembourg and was (partly) based upon the Council 
Recommendation. In 1999 the government entrusted the Ministry of Health with the overall 
coordination of drug-related demand reduction actions. The national drug coordinator was 
mandated to elaborate the national strategy and action plan on drugs and drug addiction (2000-
2004) in regard to priorities set by the governmental declaration of 1999 and in close collaboration 
with field actors. To elaborate the successive action plan (2005-2009), national priorities as also 
the European Action Plan on Drugs (2000-2004/ 2005-2008) and the Council Recommendation of 
18th June 2003 were taken into account. The action plan (2005-2009) is based upon two pillars, 
demand and supply reduction as well as upon 4 transversal axes: coordination mechanisms, risk 
reduction, harm and nuisance reduction, research and information and international relations. [RT] 
[SQ29]
2.14.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. 412 [RT] 
In Luxembourg, information is disseminated through a national telephone help line. Educational 
leaflets413 are available in specific geographical regions. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general, and IEC via counselling and advice by drugs and health 
professionals are the predominant response strategies. Safer injection training is a common 
response strategy. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
and individual risk counselling are the predominant response strategies and predominantly done by 
specialised drug treatment services and low threshold agencies, including needle and syringe 
exchange programmes, and commonly in prisons. A common response strategy to reduce drug–
related deaths is risk education/ response training for drug users. This training is delivered 
predominantly at specialised drug treatment services, low threshold agencies, including needle and 
syringe programmes and through outreach workers, peers; the training is commonly delivered in 
prisons. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation414. [RT] 
In specific geographical regions (two main cities), communities and families of drug users are 
involved in the prevention and reduction of health risks associated with drug dependence. [NFP 
2006] 
411 Directorate of Health – Drug Coordination Unit. 
412 Policy was implemented before the adoption of the Council Recommendation. Additional information: since 
the implementation of the first drug action plan (2000-2004), risk reduction constitutes a major governmental 
priority. The new national drug strategy (2005-2009) considers risk reduction, damage and nuisance reduction 
as a specific transversal domain of supply and demand reduction. 
413 Flyers exist on synthetic drugs; documentation kit on overdose prevention. 
414 Universal and community based prevention are main priorities of risk reduction strategy of the Ministry of 
Health since it was entrusted with the overall drug-related demand and risk reduction actions in 1999. 
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2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation415. [RT] 
In Luxembourg, street-based outreach work is nationwide available. Outreach work at dance 
parties and raves is sporadically provided in specific geographical regions. There is no legal 
framework for pill testing to date. [NR 2003/ 2004; NFP 2006] 
To prevent infectious diseases among drug users, outreaching health education is a common 
response strategy. Outreach work and targeted high-risk group interventions are a common 
implementation setting for infectious diseases prevention measures targeting drug users. [SQ 23]  
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is the predominant setting for the deliverance of risk 
education/ response training to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation416. [RT] 
In Luxembourg City, peers and volunteers are included in outreach work. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation417. [RT] 
Networking and cooperation between agencies involved in outreach work does not exist, since only 
one agency provides outreach work given the geographical dimensions of Luxembourg. [NFP 2006]   
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation418. [RT] 
Methadone maintenance and methadone detoxification programmes, drug-free outpatient 
treatment and treatment with buprenorphine are nationwide available419. Substitution treatment is 
supported by psychosocial care and is sometimes obligatory, sometimes upon request by the client 
(depending on the prescribing institution or general practitioner) Drug free inpatient treatment, 
rehabilitation centres and drop-in centres/ shelters are available in specific geographical areas. [NR 
2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment (with regard to 
the reduction of heroin/ opiate overdose) is a predominant response strategy. [SQ 29]  
415 Needs in the domain of outreach work were assessed in 1999 in order to set up the drug action plan (2000-
2004). New low threshold facilities were created and existing ones extended. Contacting a hard to reach 
population of drug users remains a political priority.
416 This policy objective has been implemented in the national policy as a reaction to the increased number of 
overdose deaths registered in 1994. 
417 Cooperation, networking and the creation of working groups are a common culture of agencies involved in 
outreach work since 1999. 
418 The national methadone substitution programme was set up in 1989 jointly by the Ministry of Health and a 
specialised NGO in response to the increasing number of long-term opiate drug addicts. The national drug 
action plan foresees the creation of further treatment and rehabilitation offers. 
419 Morphine in salt form is included in the list of legal substitution substances. Diacetylmorphine is included in 
the national list of legal prescription drugs. It can however only be prescribed in a highly regulated programme 
supervised by the Ministry of Health (by law). 
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Luxembourg has a drug consumption room420 and a heroin prescription programme is foreseen by 
the national drugs action plan.  
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but is not based upon the Council Recommendation421. [RT] 
Measures to prevent diversion of prescribed drugs are nationwide available422. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
The implementation of this policy is pending for approval. [RT] 
However, testing, prevention, education, counselling423 and treatment of infectious diseases are 
available nationwide in prisons. Methadone maintenance treatment, methadone detoxification 
treatment, treatment with buprenorphine424, drug paraphernalia, condoms and counselling are also 
provided nationwide in prisons425. Since the end of 2005, an officially recognised syringes’ 
distribution programme exists nationwide in prisons. [NR 2003/ 2004; NFP 2006]  
Prisons are a predominant implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Aiming at the prevention and reduction of drug – related deaths, prison pre-release 
interventions are a common response strategy. Prisons are a common setting for disseminating 
information materials on prevention of acute drug-related deaths and for providing risk education/  
response training for drug users. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists and was based upon the Council Recommendation426. [RT] 
Nationwide, testing/ screening for infectious diseases, education427, counselling and treatment of 
infectious diseases are available, as well as vaccination programmes for hepatitis B and 
tuberculosis targeting drug users 428.
[NR 2004; NFP 2006]
Predominant response strategies to prevent infectious diseases among drug users are: IEC in 
general, IEC via counselling by drugs and health professionals, voluntary infectious diseases 
counselling and testing, condom promotion among drug users, hepatitis vaccination programme for 
drug users, needle and syringe exchange programmes, routine screening of high risk groups and 
420 The drug consumption room has been integrated in an existing structures which currently provides day and 
night services and the first national drug consumption facility. The new integrated structure is called TOX-IN. 
421 The grand-ducal decree on substitution treatment of January 30, 2002 established the legal framework for 
drug substitution treatment at national level and foresees control measure to reduce diversion of substitution 
substances (e.g. centralised register). 
422 Currently there exists a national mandatory notification system for substitution treatments for prescribing 
authorities. This system will evolve into a national substitution register following the still awaited approval from 
the National Commission on Data Protection. 
423 Specialised NGOs provide counselling in prison on a routine basis. 
424 Buprenorphine is included in the national list of drugs which may be prescribed in the framework of 
substitution treatment. 
425 Information and counselling by specialised interviewers. 
426 Screening of infectious diseases among IDUs is proposed by NGO's and prison centres but is not mandatory. 
Vaccination against hepatitis A and B is free. Prophylactic measures are offered by specialised NGO's at national 
level. The results of the national action-research are due for 2006. 
427 Education is provided by all specialised drug agencies and also in the framework of the above mentioned 
action-research project on HIV and hepatitis among PDUs. 
428 An action-research programme started in 2005 by the National Focal Point providing on-site testing 
(hepatitis a, b, c, HIV) and vaccination (hepatitis a and b) for infectious diseases at all specialised national 
NGOs. 
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easy access’ programmes for drug users to treatment of infectious diseases. Common strategies 
include outreach health education approach and safer injecting training.
Predominant implementation settings for infectious diseases prevention measures are specialised 
drug treatment services, low threshold counselling, and prisons. Outreach work and targeted high 
risk group interventions, primary care/  GP’s and mass media are common settings for this. [SQ 
23]
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation429. [RT] 
Needle and syringe exchange programmes430 and condoms are available nationwide. Drug 
paraphernalia are available in specific geographical regions. [NR 2004] Needle and syringe 
exchange programmes are a predominant response strategy to prevent infectious diseases
among drug users in Luxembourg. [SQ 23]  
With regard to the reduction of drug-related deaths among drug users, low threshold agencies, 
including needle and syringe exchange programmes, are a predominant setting both for 
dissemination of information materials and for providing risk education/  response training for drug 
users. [SQ 29]
Luxembourg has ten non-pharmacy based NSPs and five vending machines. Types of NSPs 
available include fixed sites, prison-based programmes and vending machines. There are no NSPs 
through vans/ buses, and no pharmacy-based431 NSPs. [NSP1-2; NFP 2006] 
The grand-ducal decree of 23 December 2003 regulates the distribution and the exchange of 
syringes432. The police does not confiscate, if syringes do not show traces of illicit substances. No 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation. [RT] 
Training programmes for professionals of emergency services are available nationwide433.
[NFP2006]. Ambulances routinely carry antagonists. The distribution or administration of naloxone 
is regulated. Naloxone is available on a ‘take home’ basis nationwide. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Risk reduction is nationwide part of an integrated health strategy for drug users. [NFP 2006]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but it is not a priority for the national government. [RT] 
Training for professionals working in needle exchange programmes, in substitution treatment, in 
treatment facilities, in low threshold programmes and in prison settings is available nationwide. 
[NR 2002/ 2004; NFP 2006] 
429 Distribution of injecting paraphernalia and condoms are assured by low-treshold services at national level. 
The creation of new treatment offers e.g.consumption rooms, constituting a priority of the drug action plan, will 
help to enlarge the existing risk reduction measures. 
430 Recently, the opening hours of NSP points improved. The TOX-In structure has joined the national NSP in 
2005. 
431 But syringes may be purchases without prescription in all pharmacies. 
432 The decree specifies that the exchange of a sterile syringe to a drug addict can be executed either by a 
pharmacist, a general practitioner of the substitution programme or designated members of specialised drug 
agencies. The decree also includes the legalisation of syringe distribution by means of distribution machines. 
433 But mainly provided by foreign training agencies.
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2.14.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. Since 1994, the 
Luxembourg National Focal Point (NFP) of the EMCDDA has created the Luxembourg Information 
Network on Drugs and drug Addictions (RELIS). RELIS provides scientific data and facilitates 
political decision processes in the framework of drug action plans and strategies. [RT] 
The EMCDDA’s EDDRA database has largely contributed to the promotion of a more scientific 
oriented evaluation approach at the national level. The Ministry of Health has implemented a 
modified version of the EDDRA questionnaire as a standard for funding requests for and evaluation 
of drug-related projects. 
Clear definition of expected outputs, time-limited project funding rather than permanent service 
funding, scientific evaluation of defined objective and project execution frameworks and the 
promotion of continuous training are some of the major elements defining the current approach 
towards a more effective national demand reduction strategy. [NR 2004] 
Regarding research, worth mentioning are the first comprehensive evaluation report on the 
national substitution programme (2003) and the recent study on direct economic expenditures in 
the field of drug policies and interventions (2002). [NR 2003]  
The first scientific evaluation of the methadone programme was conducted in 1995. In 1998, new 
evaluation software was developed in collaboration with the NFP, which, in the medium term, aims 
at the integration of substituted patients' data directly in the RELIS database. In 2000 and 2001 a 
second and third evaluation by an external expert took place on basis of data provided by the 
evaluation software mentioned earlier. [NR 2002] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. The implementation of 
the first Drug Action Plan (2000-2004) required overall analyses of the drug situation at national 
level. The actions retained in the action plans have all been analysed in terms of needs assessment 
and in terms of priorities. [RT]  
An exploratory study on the current situation and needs with regard of prevention in night life 
settings has been included in the Drug Action Plan 2005 – 2009. After  eight months of functioning, 
there have been no major problems in terms of public nuisance. On the contrary, the night shelter 
contributed to reduce rough sleeping in streets, squatting and late night disturbances caused by 
PDUs. The success of the project is believed to be primarily due to the following factors:  
a consensual need analysis involving both service demanders and service providers [NR 2004] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. Since 1998, specialised 
NGO's have to prepare on a yearly basis or on demand activity reports containing evaluation data 
of drug prevention and risk reduction programmes. The Ministry of Health and the NFP promote 
EDDRA among NGO's. RELIS has implemented standardised evaluation data protocols. [RT]. 
Drug treatment agencies have developed proper evaluation strategies mostly in collaboration with 
external evaluators. Recent examples are the evaluation of current offers in the field of socio-
professional integration, which future development has been promoted by the national drugs action 
plan, the implementation of a computer based evaluation procedure by the national substitution 
programme and prevention interventions in schools by CePT. [NR 2004] 
Although the harm reduction interventions adapt to current professional practices by means of 
international exchanges and internal quality control measures, there is an obvious lack of external 
evaluation procedures. [NR 2003]  
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3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. RELIS network aims to 
implement evaluation quality criteria relating to the recommendations of the EMCDDA. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. The NFP elaborated 
standardised data protocols for specialised in-and outpatient treatment centres, low threshold 
agencies, general hospitals, law enforcement agencies and national prisons according to EMCDDA 
recommendations. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. The National Addiction 
Prevention Centre in collaboration with the unit of preventive and social medicine of the Directorate 
assures the development of drug prevention policies. [RT] 
The Drug Action Plan 2000 – 2004 has been submitted to an internal evaluation On basis of those 
evaluation results exercise. The above mentioned new drug strategy and Drug Action Plan is 
currently elaborated  by the national drug coordinators office jointly with concerned ministries and 
field actors. Both the strategy and the action plan cover the period 2005 to 2009.  
Therefore, in accordance with national needs and in accordance with the work plan of the EMCCDA, 
a national study on direct economic costs of drug policies and interventions was performed from 
1999 to 2002 and refers to data from 1999 (Origer 2002 b). (Etude du coût économique direct des 
interventions et de la politique publique en matière de drogues et de toxicomanies).  (http:/ / 
www.relis.lu). One may add that the EDDRA questionnaire is applied as a standard application form 
for drug-related projects’ funding requests addressed to the Ministry of Health.  
Also, the RELIS database on problem drug users provides relevant data for evaluation purposes 
since it includes detailed data on drug consume patterns, socio-economic situation, risk behaviour 
and treatment or law enforcement contacts, etc. In the long run, drug ‘careers’ can be analysed by 
means of the RELIS indexing system, which allows following up treatment demands and law 
enforcement contacts of indexed drug users. These data can be used to assess the impact and the 
performance of specific treatment approaches. A practical example of the application of evaluation 
results is to be seen in the conceptualisation of the National Drug Action Plan 2000-2004, which did 
to a large extent rely on RELIS data and ad hoc evaluation initiatives from field institutions.  
On drug-related infectious diseases: According to EMCDDA’s key indicators and with a view to 
improve quality of national data on infectious diseases, the NFP has set up an action-research plan 
(2002-2004) with the objective to estimate HCV and HIV prevalence in recent drug injectors based 
on medical diagnosis data (blood sample testing) and to implement required health care 
infrastructures. The provisional budget of the project is estimated at 25.000. - EUR. The NFP has 
been granted a full financing of the project by the FLTS. Duration of the project :August 2003 - 
2005. [NR 2004]. 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. The NFP assures 
evaluation training in the framework of EDDRA. [RT] 
Training interventions in drug demand reduction are increasingly developed at national level. The 
CePT publishes an annual training directory including training activities ranging from evaluation 
methodologies to demand reduction action-research strategies targeted at drug prevention and 
public health actors, educators, youth animators and teachers. The ‘Recherche et Innovation 
Pédagogiques et Technologiques (SCRIPT) department is actively involved in the referred training 
activities.’ [NR 2004] 
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3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] 
The Mondorf Group is currently working out a proposal for a interregional training and job 
opportunity network for former or current drug addicts. The project is meant to take advantage of 
socio-economic differences of border regions between Luxembourg, Germany, France and Belgium. 
Furthermore, synergies between the Ministry of Health and the Ministry of Employment have been 
set up in the framework of the EU programme: EQUAL 2000-2006. [NR 2002] 
2.14.5 Information from third data sources
Issues raised by NGO Tox-In 
Information, education and communication (IEC). IEC is adequate in accessibility and 
coverage. It is not known whether drug testing is available and if so, accessible to drug users. 
Outreach work. Outreach work is readily available and adequately accessible. 
(Medically assisted) treatment and specific interventions. In general, medically assisted 
treatment for opiate users and cocaine users is readily available and accessible for drug users in 
Luxembourg. Heroin, ATS or cocaine prescription programmes are not available in Luxembourg. 
There is no information about the existence of specific services provided for cocaine or ATS users. 
The coverage and accessibility of drug consumption rooms is regarded as inadequate as the 
opening hours need to be adapted and more personnel needs to be employed. Accessibility and 
coverage of needle and syringe exchange programmes and the distribution of drug paraphernalia is 
adequate. Coverage and access to low threshold agencies such as drop-ins and shelters can be 
considered adequate.  
Prison interventions. There is no information available whether IEC in prison is available in 
Luxembourg at all. There is a good coverage of outreach work in prisons. There is no information 
about the availability and accessibility to substitution services in prisons. There is no information 
whether specific HR Interventions for cocaine or ATS users is available in prison. Measures 
implemented to prevent infectious diseases are considered inadequate. No information is available 
about needle and syringe exchange programmes and distribution of drug paraphernalia in prison, 
nor about vaccination programmes for hepatitis B and tuberculosis.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are adequate in coverage and 
accessibility. No information is available whether hepatitis B and tuberculosis vaccination is 
available and accessible for drug users. 
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Annex A2.15 State of play on harm reduction in Hungary 
2.15.1 Summary 
Public health policy. Harm reduction has been adopted as key objective in the Hungarian 
National Strategy to Combat the Drug Problem 2000-2009 and is a public health objective. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites, trainings, and educational leaflets. Communities 
and families of drug users are neither informed, nor involved in the prevention and reduction of 
health risks associated with drug dependence. 
Outreach work. Outreach work at dance parties/ raves and in clubs is nationwide available. 
Outreach work as a health education approach is a common response strategy to prevent infectious 
diseases among drug users. For the reduction of drug-related deaths, outreach work is a common 
setting for the deliverance of risk education/ response training. Peers and volunteers are involved 
in outreach work practice in specific geographical regions. Networking and cooperation between 
outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Drug-free outpatient treatment 
and drug-free inpatient treatment are nationwide available. In specific geographical areas 
methadone maintenance and detoxification treatment, naltrexone treatment, rehabilitation 
programmes and drop-in centres/ shelters are available. Drug consumption rooms and heroin 
prescription programmes do not exist. Opioid substitution treatment is not used as a strategy 
aiming at the reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs 
are available in some areas. 
Prison interventions. Treatment of infectious diseases is nationwide available. Testing on 
infectious diseases is available on a voluntary basis. Other interventions are not provided.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing, screening, education, prevention, counselling and treatment for infectious 
diseases are nationwide available. To prevent infectious diseases among drug users, the 
predominant response strategies are IEC in general, IEC via counselling and advice by drugs and 
health professionals, and needle and syringe exchange. Only in specific geographical areas, needle 
and syringe exchange programmes, vending machines, drug paraphernalia and the free of charge 
distribution of condoms are available.  
Drug-related deaths. The distribution or administration of naloxone is regulated. Naloxone is not 
available on a ‘take home’ basis.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals working in prison settings. Although the policy exists, 
integration between health and social care is not promoted as part of risk reduction.
Quality, monitoring and evaluation. Hungary is developing several quality assurance, 
monitoring and evaluation tools in drug demand reduction. An internet database – SZIP – has been 
created with information on programmes and their characteristics, with the aim to improve 
transparency. The Hungarian government allowed for an independent mid-term evaluation to be 
conducted into the implementation of the National Drug Strategy. Hungary has participated in 
several Twinning projects. 
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2.15.2 Recommendation 1: Risk reduction and public health policy 
The governmental structure that is responsible for the implementation of the Council 
Recommendation is the Ministry of Youth, Family, Social Affairs and Equal Opportunities434. The 
prevention and reduction of health-related harm associated with drug dependence has been an 
objective for Hungarian Public Health prior to the adoption of the Council Recommendation and as 
such it was not based on it.  
Harm reduction is one of the key policy areas in the Hungarian National Strategy to Combat the 
Drug Problem 2000-2009, which was adopted in December 2002. [NR 2004] 435
2.15.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Hungary, the dissemination of information through telephone help lines, websites, training436,
and educational leaflets is available nationwide. [NR 2003/ 2004] 
To prevent infectious diseases among drug users, IEC general and IEC via counselling by drugs 
and health professionals are predominant response strategies. Safer injection training for drug 
users is a common response strategy437. [SQ 23; NFP 2006] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
and individual risk counselling are rare response strategies. Counselling on safe injecting 
techniques preventing drug-related deaths is provided by almost half of the organisations. [SQ 29; 
NFP 2006] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation.438 [RT] 
Communities and families of drug users are not at all involved in the prevention and reduction of 
health risks associated with drug dependence, nor is specific information, education and 
communication available for communities and families of drug users. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation.439 [RT] 
In Hungary, outreach work at dance parties / raves and in clubs is nationwide available. Street-
based outreach work is taking place in specific geographical areas. [NR 2003, 2004]  
To prevent infectious diseases among drug users, outreach health education  is a common 
response strategy. Outreach work and targeted high-risk group interventions are a predominant 
implementation setting for infectious diseases prevention measures targeting drug users. There is 
no recognized professional qualification in outreach work and outreach work management. [SQ 23] 
434 Department of Strategic Affairs, Deputy State Secretariat for the Coordination of Drug Affairs. 
435 Ref: Gallà, M.S.J., et. al. [2006]. Report on the Mid-term Evaluation of the Hungarian National Strategy to 
Combat the Drug Problem, Trimbos Institute, The Netherlands.  
436 Education programmes of safe injection through syringe exchange. 
437 Most organisations indicate they offer harm reduction counselling which includes providing information 
related to risks of drug use, their prevention and treatment of overdoses. These activities are very rare in 
prisons, hospitals and emergency rooms. 
438 The Ministry of Youth, Family, Social Affairs and Equal Opportunities supports civil organisations which are 
involved in the above mentioned activities through system of competitions. In 2004 and 2005 the Ministry gave 
extra attention to those civil organisations that focused on the information of parents. 
439 The Ministry of Youth, Family, Social Affairs and Equal Opportunities supports the Safety Club Programme 
and the needle-exchange bus of the Hungarian Baptist Aid.
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Aiming at the reduction of drug-related deaths, outreach work is a common setting for risk 
education/ response training for drug users. Low threshold agencies, including needle and syringe 
exchange, and outreach work are rare and uncommon settings for disseminating information 
materials. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy does not exist, as it is not a task for the national government.440 [RT] 
In specific geographical areas, mobile needle exchange services and street outreach needle 
exchange programmes (including social workers and peer groups) are involved in reaching hidden 
injecting drug user groups. In specific geographical areas, trainings are organised for peers. 
[NR 2003; NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation.441 [RT]  
Networking and cooperation between outreach work agencies exist nationwide. [NR 2004] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation.442 [RT] 
Drug-free outpatient treatment and drug-free inpatient treatment are nationwide available. In 
specific geographical areas methadone maintenance treatment, methadone detoxification 
treatment, naltrexone treatment, rehabilitation programmes and drop-in centres/ shelters are 
available. Substitution treatment is supported by psychosocial care upon request by the client. [NR 
2003/ 2004; NFP 2006] 
Opioid substitution treatment (with regard to the reduction of drug-related deaths) is not in use 
as a response strategy. [SQ 29] Drug consumption rooms and heroin prescription programmes do 
not exist in Hungary. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy does not exist, as it is not a task for the national government.443 [RT] 
In specific geographical areas some measures available to prevent diversion of  prescribed drugs, 
e.g. registration. [NR 2004]  
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation.444 [RT] 
There are no methadone maintenance, methadone detoxification, buprenorphine or naltrexone 
programmes in Hungarian prisons445. Condoms, additional services such as bleach, sterile water 
ascorbic acid and needle and syringe exchange are also not available. Testing on infectious 
440 The Ministry of Youth, Family, Social Affairs and Equal Opportunities draws up recommendations only; the 
elaboration of the professional methodologies is the task of the civil organisations. 
441 The Ministry of Youth, Family, Social Affairs and Equal Opportunities encourages the civil organisations 
involved in outreach work by competitions. The normative assistance system is under development, the 
organisations involved in needle exchange already have the opportunity to get normative assistance. 
442 Substitution treatment is based on the use of methadone. 
443 The Ministry of Youth, Family, Social Affairs and Equal Opportunities supports the methadone-programmes, 
all the other details depend on the contract between the doctor and the patient. 
444 In prisons, programmes that aim to provide maintenance treatment, needle exchange and/or disinfection of 
needles by the use of bleach is under implementation. 
445 Inmates can take part in drug prevention and methadone programmes in Hungarian penitentiary 
institutions. [NFP 2006]. 
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diseases is available on a voluntary basis. Treatment of infectious diseases is nationwide available. 
There are no specific educational activities or training courses for drug users in prison. [NR 2003/ 
2004; NFP 2006]  
Prisons are rarely used as implementation setting for infectious disease prevention measures 
targeted at drug users [SQ 23]. Measures targeting at the reduction of drug – related deaths
(e.g., prison pre-release interventions, dissemination of information materials) are not in use in 
Hungarian prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing, screening, education, prevention, counselling and treatment of HIV, hepatitis C, 
tuberculosis, and sexually transmitted diseases are nationwide available. Since August 29, 2005, 
HIV and hepatitis C, testing of drug users is provided free of charge by the regional laboratories (5) 
of the Public Health Office. For hepatitis B a universal vaccination programme is carried out at the 
of age of fourteen years; for tuberculosis universal vaccination takes place between birth and the 
age of six weeks, but no vaccination programmes targeting drug users exist. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, Hungary has a specific, designed strategy. 
There are also local strategies. Predominant response strategies include information, education, 
communication (IEC) in general and IEC via counselling, advice by drugs and health professionals, 
and needle and syringe exchange programmes. Common response strategies consist of safer 
injection trainings for drug users, outreach health education, voluntary infectious disease 
counselling and testing (VCT). Predominant implementation settings for infectious diseases 
prevention measures targeting drug users include low threshold counselling (non-treatment) 
services, outreach work and targeted high risk group interventions; common settings are 
outpatient and inpatient specialised drug treatment services. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon Council Recommendation.446 [RT] 
In specific geographical areas, needle and syringe exchange programmes, vending machines, drug 
paraphernalia such as disinfecting swabs and sprays, bleach and ascorbic acid, and the free of 
charge distribution of condoms are available. Sterile water, vein generating creams and cookers 
are rarely provided. [NR 2003/ 2004; NFP 2006] To prevent infectious diseases among drug 
users in Hungary, needle and syringe exchange programmes are the predominant response 
strategy. [SQ 23] 
For the reduction of drug-related deaths low threshold services, including  needle and syringe 
exchange programmes, disseminate information and provide risk education/ response trainings, 
though this is rare. [SQ 29]. In Hungary, 12 organisations are involved in needle and syringe 
exchange and together they operate 18 programmes: 7 fixed, 2 mobile, 4 street-outreach, 5 
vending machines. There is no pharmacy-based or prison-based needle exchange in Hungary. [NFP 
2006] 
There are no legal restrictions to the possession of sterile needles in Hungary, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation.447 [RT] 
In Hungary, there are no training programmes for professionals of emergency departments. [NR 
2004; NFP 2006]  
446 For the Hungarian government, harm reduction has a high priority; Hungarian National Strategy to Combat 
the Drug Problem 2000-2009, 2000.  
447 In treatment institutions this recommendation is obligatory. 
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Ambulances routinely carry antagonists. The distribution or administration of naloxone is controlled 
by regulations and administration is limited to physicians. Naloxone is not available on a ‘take 
home’ basis. [SQ 29; NFP 2006] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Nevertheless, in practice integration is not promoted. Harm reduction has not yet become the basic 
framework for interventions and operations. However, outpatient and special primary health-care, 
as well as outreach work, are added to the compulsory tasks of all settlements of a population 
exceeding 30,000 residents and have become state-subsidised in the course of 2005. [NR 2003; 
NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Trainings are offered nationwide to professionals working in prison settings. In specific 
geographical areas, trainings are provided for outreach workers, professionals in low threshold 
agencies and for professionals in treatment facilities, but only on a small scale. Trainings for drug 
service staff (professionals in needle and syringe exchange programmes, and in substitution 
programmes) are usually organised indoors. [NR 2003/ 2004; SQ 23; NFP 2006] 
2.15.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy does not exist, as it is not a task for the national government. [RT] 
The Hungarian National Institute for Drug Prevention has developed a database ‘SZIP’, which has 
the aim to make scientific evidence of effectiveness broadly available. It covers beside prevention 
programmes science-based research on drug issues, the different organisations and institutions 
providing care and their programmes and methods applied. The development of the portal started 
in 2003 and was launched by the end of 2004. [NR 2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, because it is not a task for the national government. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist, because it is not a task for the national government. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist, because it is not a task for the national government. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT]  
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist, as it is not a task for the national government. [RT] 
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The Hungarian National Drug Strategy to Combat Drugs 2000-2009 is based upon scientific 
analysis. Accountability is a key principle in the National Strategy. The National Strategy invariably 
specifies effectiveness indicators to help gauge the extent to which the goals are achieved. This 
makes the implementation process transparent and the outlays accountable. The National Strategy 
is reviewed at predefined intervals. [NR 2002]  
In 2004-2005 a mid-term evaluation was conducted, in which it was concluded that progress had 
been made, but that in the field of harm reduction more efforts had to be made to meet the 
objectives stipulated in the National Strategy. In the evaluation, 17 mid-term objectives from the 
National Drug Strategy had been pre selected, one of them specifically dealing with harm 
reduction448. During the evaluation, over 64 local coordination forums on drug affairs and over 20 
national policymakers were asked for their expert opinion whether this objective was achieved. The 
local representatives indicated it was not achieved (halfway the Strategy), while the national 
policymakers indicated it was partly achieved449.
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, because it is not a task for the national government. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist, because it is not a task for the national government. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The above mentioned mid-term evaluation of the Hungarian National Drug Strategy to Combat the 
Drug Problem was conducted by the Dutch Trimbos Institute in 2004 and 2005 and was funded by 
the MATRA programme of the Netherlands Ministry of Foreign Affairs.  
A second MATRA project has been running in the field of anti-drug policies of Penal Authorities. The 
penal authorities in Hungary realised that prisoners with drug problems need different treatment/ 
care than others and an increase in the number of such prisoners can be anticipated. This is why 
part of the MATRA Project scheduled for the period 2001 to 2004 is titled ‘Management of drug 
problems in penal institutions’. Seventy security guards were trained by the penal authorities in the 
frames of this project. Primary objective of this training was demand-reduction and the 
identification of drug-using prisoners. [NR 2004] 
In 2002 and 2003 a PHARE TWINNING PROJECT was carried out titled “Support for the 
Development and Institutionalisation of the Co-ordination Forums on Drug Affairs (CFDAs) in 
Hungary”. This project was run by the National Institute for Drug Prevention (NDI), the Dutch 
Trimbos Institute and DrugScope (UK). [NR 2003] 
Furthermore, the European Union assisted this by supporting two projects. The PHARE Multi-
country programme EMCDDA-I project, involving 10 countries ran from March 2001 to November 
2002, while the bilateral PHARE COP’2000 programme HU-0006 twinning project ran from 
November 2001 to November 2002. The aim of the former was the direct involvement in the 
activities of the EMCDDA of the Hungarian professionals responsible for data provision, while the 
main goals of the latter was the creation of the national REITOX Focal Point, the new-data-
collection-training of a wide range of professionals in the field, and the introduction of 9 demand-
reduction model projects. [NR 2003]  
448 NDS objective III.3.14: “Programmes for high risk-or special populations need to be set up, e.g. long-term 
care for those struggling with other psychiatric problems (dual diagnosis, co morbidity), medical care for HIV+ 
and AIDS patients, hepatitis carrying drug users, creation and expansion of special programmes for pregnant 
women and drug-dependent infants”.
449 Gallà, M. & F. Trautmann & A. van Gageldonk [2006]. ‘Report of the Mid-term Evaluation of the 
implementation of the Hungarian National Strategy to Combat the Drug Problem', Trimbos Institute, Utrecht. 
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2.15.5 Information from third data sources 
Issues raised by Hungarian Civil Liberties Union 
Information, education and communication (IEC). IEC is inadequate in coverage, as many 
organization providing IEC focus purely on primary prevention rather than on harm reduction. Drug 
testing is not yet available in Hungary, but might be implemented soon.  
Outreach work. Outreach work in Hungary lacks adequate coverage and accessibility. There are 
outreach programmes directly associated with NSPs and a local programme in the area of 
“Dzsumbuj”, an urban living quarter where many IDUs live.  
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is inadequate in coverage and accessibility. Nationwide there are 8 methadone 
treatment sites treating 757 opiate users in 2004, which is an estimated coverage of 6-10%. There 
is no heroin prescription programme in Hungary. Coverage and accessibility of medically assisted 
treatment for ATS or cocaine users is inadequate. Users might be treated with antidepressants. 
ATS or cocaine prescription programmes are not available. Specific harm reduction interventions 
targeted at cocaine and ATS users are inadequate in coverage and accessibility. Those 
interventions that do take place – provision of injecting material for cocaine injectors and harm 
reduction services at dance events – have very low and thus inadequate coverage. There are no 
drug consumption rooms in Hungary. NSPs are implemented by 10 organisations throughout the 
country. In 2004 these NSPs reached 1293 IDUs, which is approximately 10% of all Hungarian 
IDUs. Except for Budapest, no regional agreements have been made with law enforcement 
institutions in order to prevent police from arresting IDUs purely for the possession of unused 
injection materials. Drug paraphernalia are available through the existing needle and syringe 
exchange programmes, but paraphernalia offered are often incomplete to grant true protection. 
Only one of 10 needle and syringe exchange outlets provides an adequate range of injecting 
paraphernalia. Coverage and accessibility for drug paraphernalia is thus inadequate.  
Low threshold agencies are inadequate in coverage and accessibility. In 2003 there were 62 
organizations nationwide to offer low threshold agencies, but many of the institutions incorrectly 
define their activities “low threshold”.    
Prison interventions. There is no information available whether and where IEC in prison is 
performed. Outreach work in prison exists, but does not focus on harm reduction activities.   
Availability and accessibility to substitution treatment is inadequate. In prison opiate users do not 
receive methadone, but get tranquillizers and benzodiazepines such as rivotril. No information is 
available whether medically assisted treatment for ATS and cocaine users is available in prison. 
There are no specific HR interventions for ATS or cocaine users inside Hungarian prisons. NSPs and 
the distribution of drug paraphernalia are not available in prison. Measures implemented to prevent 
infectious diseases are inadequate. Testing is available in prisons, but HIV-positive inmates are 
segregated. Hepatitis B or tuberculosis vaccination programmes targeted at drug users are not 
available in Hungarian prisons. Families and friends are not involved in harm reduction 
interventions. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are inadequate in coverage and 
accessibility. Hepatitis B and tuberculosis vaccination programmes targeting drug users do not 
exist. Measures to involve families and friends of drug users in harm reduction interventions are 
not available in Hungary. 
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Annex A2.16 State of play on harm reduction in Malta 
2.16.1 Summary 
Public health policy. In Malta, harm reduction is a public heath objective, but this was not 
because of the Council Recommendation. Harm reduction programmes exist in Malta for more than 
ten years already. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through educational leaflets. For the reduction of drug-related deaths, risk education/  
response training is the predominant response strategy. Communities and families of drug users 
are involved in the prevention and reduction of health risks associated with drug dependence in 
specific geographical areas. 
Outreach work. Outreach work at dance parties, raves and in clubs is available in specific 
geographical areas only. Peers and volunteers are not included in outreach work practice. 
Networking and cooperation between outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes and methadone detoxification programmes are available nationwide. Further, Malta 
has rehabilitation centres, drug-free outpatient and inpatient centres, and a drop-in centre. 
Buprenorphine is not available and naltrexone is provided in specific geographical areas only. Drug 
consumption rooms and heroin prescription programmes do not exist. Opioid substitution 
treatment is the predominant response strategy aiming at the reduction of drug-related deaths. 
Despite existing policy, measures to prevent diversion of prescribed drugs not available. 
Prison interventions. Methadone maintenance and detoxification programmes, and counselling 
are available in one Maltese prison. Other harm reduction interventions do not exist in Maltese 
prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening and vaccination against hepatitis B and tuberculosis exist 
nationwide. To prevent infectious diseases among drug users, the predominant response strategies 
are IEC, hepatitis B vaccination programmes for drug users, and voluntary counselling and testing. 
Needle and syringe exchange and drug paraphernalia are available in specific geographical areas 
only.  
Drug-related deaths. The distribution, possession or administration of naloxone is not regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training 
for professionals in treatment facilities is available in specific geographical areas only. Risk 
reduction is part of health strategies promoted through the efforts of drug agencies. 
Quality, monitoring and evaluation. Malta does not have an elaborated system of quality 
assurance and monitoring. The human resources in drug treatment services are limited. 
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2.16.2 Recommendation 1: Risk reduction and public health policy 
The main responsible body for the implementation of the Council Recommendation in Malta is the 
Ministry for the Family and Social Solidarity450.
The prevention and reduction of health-related harm associated with drug dependence is part of 
public health policy in Malta, but was not based on the Council Recommendation. It pre-existed the 
Council Recommendation for at least a decade already. The National Drug Agency, SEDQA, run by 
the Government and inauguarated in 1994, is responsible for providing adequate services in 
prevention and treatment. Over the years, prevention in schools, the community, the work place 
and for particular risk groups, has been ongoing. Two NGO's (Caritas and Oasi) also run prevention 
and treatment programmes. [RT]
2.16.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation451. [RT] 
In Malta, a broad range of educational leaflets is available nationwide. In specific geographical 
areas only, telephone help lines and websites452 are available. Training for drug users promoting 
risk reduction is available in Malta at an individual basis for those who attend the Outpatient Unit. 
[NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, free hepatitis B vaccination is available, and 
also needle and syringe exchange programmes and free pre/  post test counselling and testing for 
hepatitis B, C and HIV are available nationwide. [NFP 2006] 
With regard to the reduction of drug-related deaths, risk education/  response training is the 
predominant response strategy. This training is delivered predominantly at specialised drug 
treatment services453. [SQ 29] 
2.2 inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation454. [RT] 
Communities and families of drug users are involved in the prevention and reduction of health risks 
associated with drug dependence in specific geographical areas only; specific information, 
education and communication (IEC) for communities and families of drug users is not available in 
Malta. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation455. [RT] 
In Malta, street-based outreach work is not available, whereas outreach work at dance parties, 
raves and in clubs is available in specific geographical areas only. [NR 2004; NFP 2006] 
450 National Commission on the Abuse of Drugs, Alcohol and Other Dependencies.
451 Government agency Sedqa and the NGO’s Caritas  and Oasi provide information to promote risk reduction. 
452 www.sedqa.org.mt
453 Many consider the centralised detoxification/substitution centre (SMOPU) also to be a ‘low threshold’ agency. 
Many clients have been on substitution treatment for many years and go there every morning for their 
methadone dosage. 
454 Sedqa, Caritas and Oasi provide the necessary information to communities and families. 
455 Outreach work only began in all agencies in 2002. 
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There is no information available about the use of outreach work as a response strategy or 
implementation setting for measures to prevent infectious diseases among drug users, or for 
measures aiming at the reduction of drug-related deaths. [SQ 23/ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation456. [RT] 
However, training for peers and volunteers do not exist in Malta. Peers and volunteers are not 
included in outreach work practice. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation457. [RT] 
Networking and cooperation between outreach work agencies exist nationwide458. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation459. [RT] 
Methadone maintenance programmes and methadone detoxification programmes are available 
nationwide. Further, there are rehabilitation centres, drug-free outpatient and inpatient centres, 
and a drop-in centre. Buprenorphine is not available and naltrexone is provided in specific 
geographical areas only. Substitution treatment is supported by psychosocial care upon request by 
the client. [NR 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is the 
predominant response strategy. [SQ 29] 
Drug consumption rooms and heroin prescription programmes do not exist in Malta. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation460. [RT] 
Nevertheless, measures to prevent diversion of prescribed drugs are not available. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation461. [RT] 
Methadone maintenance and methadone detoxification programmes and counselling are available 
in one Maltese prison. Other harm reduction interventions do not exist in Maltese prisons.  
[NR 2004; NFP 2006] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation462. [RT] 
456 Training undertaken by Sedqa, Caritas and Oas. 
457 Networking between agencies is being provided for by the President’s Forum since 2002. 
458 between all 3 agencies Sedqa, Caritas and Oasi. 
459 Provided for by Sedqa, Caritas, and  Oasi. 
460 Police is deterrent to prevent diversion.
461 In house drug rehabilitation unit in prison as well as the availability of  three programmes for drug users 
outside the confines of prison. 
462 Provided for by the drug agencies Sedqa, Caritas, and Oasi. 
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Testing/ screening and vaccination against hepatitis B/ tuberculosis targeting drug users exist 
nationwide in Malta; prevention and education with regard to infectious diseases is available in 
specific geographical areas only463. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users the predominant response strategies are IEC, 
hepatitis B vaccination programmes for drug users, and voluntary counselling and testing. 
Predominant implementation settings for infectious diseases prevention measures targeting drug 
users include specialised drug treatment services and low threshold counselling services. [NFP 
2006]  
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation464. [RT] 
In specific geographical areas, needle and syringe exchange programmes465 and drug 
paraphernalia are available. Condoms are not distributed among Maltese drug users. [NR 2004] 
Malta has 7 points for the distribution of syringes. [ST 10] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation466. [RT] 
Maltese ambulances routinely carry antagonists [SQ 29]. The distribution, possession or 
administration of naloxone is not regulated. Naloxone on a ‘take home’ basis is not available. [SQ 
29]
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation467. [RT] 
Risk reduction is part of health strategies promoted through the efforts of drug agencies. [NFP
2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation.468 [RT] 
Training for professionals in treatment facilities is available in specific geographical areas only. 
Training programmes for other professionals in harm reduction services do not exist. [NR 2004; 
NFP 2006] 
2.16.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
Policy does not exist, but is pending for approval. [RT] 
Research on the impact, effectiveness and efficiency of prevention activities in Malta has as yet not 
been carried out. Evaluations by the respective agencies in the form of satisfaction questionnaires 
following the completion of a specific programme, are administered and evaluated internally. To 
date, however, Malta does not have a global picture on the overall impact and reach of its 
463 Limited but available to some extent for those clients who are attending treatment at Caritas, Sedqa or Oasi. 
464 Syringe availability provided for by the Department of Health. 
465 There is no needle/syringe exchange but there is syringe distribution reaching national coverage.
466 There is only one single Emergency Department on the island with the required trained staff to deal with 
drug overdoses, run by the Department of Health. 
467 The Foundation for Social Welfare Services provides the infrastructure through which such integration may 
be achieved. 
468 Plans and curricula for drug-related further training of five selected occupational groups have been 
completed. 
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prevention programmes, which would be obtained as a result of independent, co-ordinated and 
continuous monitoring and evaluation of such programmes and their target groups.  
Data on co-morbidity in Malta is still quite fragmented and incomplete. Workers in the field have 
attempted to adapt their existing resources to address the needs of this client group. However, 
further attention is needed in the form of setting up an expert group whereby certain issues such 
as defining the broad clinical definitions of psychiatric co-morbidity, its diagnoses and treatment 
can be discussed. Additionally data sources need to be updated in order to collect more consistent 
and reliable information. This would provide us with a clearer clinical picture, enhance the 
signalling of problems or developments that need to be addressed and allow for a more relevant 
and cost effective implementation of responses.  
Other harm reduction measures that have been implemented by treatment agencies include 
providing information to current clients on the risks involved in sharing needles, the possibilities for 
random testing, pre/ post test counselling and dispersion of public health promotion material. One 
area that warrants further attention is that of looking into the sexual behaviour of injecting drug 
users and promoting safe-sex. 
Information obtained from staff at the various treatment agencies indicates that a large number of 
injecting drug users still engage in unsafe sex, however no documented evidence is as yet 
available. [NR 2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, but is pending for approval. [RT] 
When considering this action, one must take into consideration the limited human resources in 
treatment services, when compared to the number of clients. If a common assessment measure 
were to be used across all types of treatment, one would have to consider the financial and human 
resources that would be needed in order to effectively embark on this action. This would entail 
training existing staff members or employing new staff members who are qualified to administer 
such an assessment. Additionally, treatment centres would have to adapt or extend their current 
services in order to address the needs of this client group appropriately. 
The census scan carried out in October 2001 gave some indications, based on assessments by the 
care workers on the needs and capacity of clients in treatment at that time, to sustain in the 
Maltese society. [NR 2004]. 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist, but is pending for approval. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
Policy does not exist, but is pending for approval. [RT] 
There is currently no monitoring body for quality assurance, however the financing body realises 
the need of introducing such a body due to accountability for funding purposes. The Probation 
Services have a Supervisory Board that reviews the performance of the Probation Officers and 
suggests improvements and monitors the administration of discipline. Agencies do carry out 
internal evaluations and in 2004, the Malta National Focal Point was set up in order to establish a 
common way of collecting, inputting and interpreting data that can be used for monitoring and 
evaluative purposes. [NR 2004]  
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
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3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist, but is pending for approval. [RT] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, but is pending for approval. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist, but is pending for approval. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy does not exist, but is pending for approval. [RT] 
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Annex A2.17 State of play on harm reduction in the Netherlands 
2.17.1 Summary 
Public health policy. Harm reduction has been a public health objective in the Netherlands since 
the 1970’ies as it was one of the cornerstones of public health policy in the field of harm reduction.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and pill-testing. Communities and families of drug 
users are also informed and nationwide involved in the prevention and reduction of health risks 
associated with drug dependence. 
Outreach work. Street-based outreach work is nationwide available. Outreach work as a health 
education approach is a common response strategy to prevent infectious diseases among drug 
users. For the reduction of drug-related deaths, outreach work is the predominant setting for the 
dissemination of information materials, as well as for the deliverance of risk education/ response 
training. Furthermore, peers and volunteers are included nationwide in outreach work practice. 
Finally, networking and cooperation between outreach work agencies also exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes and methadone detoxification programmes are available nationwide. Drug-free 
outpatient and drug-free inpatient treatment are also nationwide available. In specific geographical 
areas only, treatment with buprenorphine and naltrexone is offered, as well as heroin prescription. 
Rehabilitation centres, drug consumption rooms and drop-in centres/ shelters are also restricted to 
specific geographical areas. Opioid substitution treatment is a predominant response strategy 
aiming at the reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs 
are available nationwide. 
Prison interventions. Methadone detoxification programmes are available nationwide in prison. 
Methadone maintenance programmes, and testing/ screening, prevention, education and treatment 
of infectious diseases, as well as counselling are available in specific geographical areas only. 
Treatment with buprenorphine, with naltrexone or needle and syringe exchange programmes are 
not available. The distribution of condoms and drug paraphernalia is available in Dutch prisons in 
specific geographical areas only. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, prevention, counselling, and vaccination for infectious 
diseases targeting drug users are available nationwide. To prevent infectious diseases among drug 
users, the predominant response strategies are IEC in general, IEC via counselling and advice by 
drugs and health professionals, and needle and syringe exchange. Needle and syringe exchange, 
drug paraphernalia and the distribution of condoms are available nationwide in the Netherlands.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g., to 
deal with overdoses. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in outreach work, needle and syringe exchange programmes, 
substitution programmes, low threshold programmes, treatment facilities and prison staff. Risk 
reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. In the Netherlands, many quality assurance systems, 
monitors and evaluation schemes exist. These instruments are part of an integrated approach in 
drug demand reduction. Ample research has been done on interventions such as heroin 
prescription, maintenance treatment, detoxification treatment, drug consumption rooms, etc. Since 
2001, a special research programme ‘Getting Results’ has been run in the Netherlands, which had 
the specific aim to build the evidence base in drug demand reduction. Trainings on quality 
assessment for professionals exist. The Netherlands collaborate in many international projects and 
activities. 
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2.17.2 Recommendation 1: Risk reduction and public health policy 
In the Netherlands, the Ministry of Health, Welfare and Sport is responsible for the implementation 
of the Council Recommendation469. The Netherlands has a long-lasting history regarding harm 
reduction, which pre-exists the Council Recommendation with several decades. [RT]. Drug policy in 
the Netherlands has four major objectives: 1) prevention and treatment; 2) harm reduction; 3) 
maintenance of public order (i.e. reducing public nuisance caused by drug users; 4) supply 
reduction. [NR 2001/ 2002]. [RT]. 
The Netherlands do not have one single National Drug Strategy, but drug policy has been 
formulated in a number of policy documents. One of the most comprehensive documents is titled: 
‘Continuity and Change’470. This document summarised the Netherlands Drug policy as it had been 
developed until 1995 and formulated the objectives for the next decade. It might - in general - be 
regarded as the Dutch Strategy on Drugs. This policy document has seen progress reports in 1996, 
1999 and 2001. Many of the Dutch harm reduction interventions and activities have been 
developed in the seventies and eighties already, often at local level and based upon a pragmatic 
approach. Many of these local activities have seen follow up in other cities and areas of the 
Netherlands and have been adopted in official policy. Not all policy actions have been explicitly 
written down in policy texts, but sometimes adopted in funding guidelines, etc. [RT].
2.17.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation471. [RT] 
In the Netherlands, telephone help lines472, websites and pill-testing473 are available nationwide. 
Training474 and information leaflets are available in specific geographical areas only. [NR 2004; NFP 
2006] 
To prevent infectious diseases among drug users, information, education, communication (IEC) 
in general, and IEC via counselling and advice by drugs and health professionals are predominant 
response strategies, whereas IEC via peer involvement/  peer approach, easy access’ programmes 
for drug users to treatment of infectious diseases and safer injecting training are common 
responses. Safer injecting training is offered in all or most cities475. [SQ 23; NFP 2006] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy: materials are predominantly disseminated at low threshold 
agencies, and needle and syringe exchange programmes, and they are commonly disseminated 
through specialised drug treatment services, mass media/ internet, and at rave events and 
festivals. Common response strategies are risk counselling and   risk education/ response training. 
This training is delivered predominantly at specialised drug treatment services, low threshold 
agencies, through outreach workers and in prisons. Risk education/ response training is delivered 
in all or most cities in the Netherlands. [SQ 29] 
469 Department for Nutrition, Health Protection and Prevention. 
470 Parliament ref. 24 077, nr. 2-3, 1994-1995. 
471 There is a large number of information resources aimed at drug users and dependent drug users in the 
Netherlands, varying from one-on-one counselling to national telephone helplines. Examples are: Drug 
Information and Monitoring System (DIMS), Uitgaan & Drugs, Mainline and Local Service Providers User Groups 
472 The Drugs Info Line (DIL) and some other telephone or internet help lines offer information & counselling 
services. 
473 The Drugs Information and Monitoring System (DIMS) analyses drug samples of consumers delivered at 
drug prevention and treatment services, covering a large part of the country.  
474 E.g. Mainline (see www.mainline.org). However, most training efforts focus on professionals and volunteers 
(e.g. Train the trainer, Trimbos-Institute). 
475 Mainline (a grass root organisation for drug users in Amsterdam) distributes guidelines for safer injecting 
practices to all organisations of addiction care. 
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2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation476. [RT] 
Communities and families of drug users are involved nationwide477 in the prevention and reduction 
of health risks associated with drug dependence, whereas collaboration with professional harm 
reduction agencies is available in specific geographical areas only478. [NR 2003/ 2004] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In the Netherlands, street-based outreach work is nationwide available. Outreach work at dance 
parties, raves and in clubs is available in specific geographical areas only479. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work/ peer approach are also a predominant setting for the 
deliverance of risk education/ response training. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training for peers and volunteers is organised nationwide. Peers and volunteers are included 
nationwide in outreach work practice.  [NR 2004] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies exist nationwide in the 
Netherlands480. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation481. [RT]
476 See above. Local prevention services also run specific information services. Projects exist for children of 
parents with an addiction problem and for parents whose children take drugs. Local Community Initiatives, 
sometimes also in collaboration with User Groups. 
477 The pilot implementation of the American Strengthening Families Project; Karen Kumpfer.  
478 There is an increasing number of mergers between organisations of mental health care and addiction care, 
and in some cases also between different organisations of addiction care during the past five years. An 
important reason for some of these mergers is the growing knowledge from research that addiction is related to 
psychiatric disorders.  
479 E.g. Drugs and Alcohol Info team (activities among tourists along the coast). 
480 The networking and cooperation between outreach work agencies is supported by Trimbos Institute (LSP) 
and Mainline through dissemination of information and by means of training programmes. 
481 Methadone services exist since 1979 [Buster, published dissertation, 2003]. Other substitution treatment 
(on a small scale and/or experimental basis): buprenorphine, naltrexon and heroin prescription. Several drug 
free treatments exist, also in a criminal justice setting. 
235
11350-HRI Rapport binnenwerk.ind235   235 13-03-2007   14:20:41
236
Methadone maintenance482 programmes and methadone detoxification483 programmes are available 
nationwide. Substitution treatment is supported by psychosocial care upon request by the client. 
Drug-free outpatient and drug-free inpatient treatment are also nationwide available. In specific 
geographical areas only, treatment with buprenorphine484, with naltrexone485, as well as heroin 
prescription programmes486 are available. Rehabilitation centres, drug consumption rooms and 
drop-in centres/ shelters are also available in specific geographical areas487. [NR 2003/ 2004] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy in the Netherlands. [SQ 29] 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation488. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation489. [RT] 
Methadone detoxification programmes are available nationwide in Dutch prisons.  Methadone 
maintenance programmes, and testing/ screening, prevention, education and treatment of 
infectious diseases, and counselling are available in specific geographical areas only. Treatment 
with buprenorphine, with naltrexone, and needle and syringe exchange programmes are not 
available in Dutch prisons, and distribution of condoms and drug paraphernalia is available in 
specific geographical areas only. [NR 2002/ 2004; NFP 2006] 
Prisons are an uncommon implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Aimed at the reduction of drug – related deaths, prisons are a 
common setting of the deliverance of risk education/  response training. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, and sexually transmitted diseases, as well as 
screening for all the aforementioned diseases among injection drug users and 
their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation490. [RT] 
Testing/ screening, education, prevention, counselling, and vaccination programmes targeting drug 
users are available nationwide. In specific geographical areas only, treatment of infectious diseases 
is provided. [NR 2003/ 2004] 
To prevent infectious diseases among drug users the predominant response strategies are IEC 
in general. IEC via counselling and advice by drugs and health professionals, and needle and 
syringe exchange programmes are common response strategies. Other common strategies include 
IEC via peer involvement/  peer approach, outreach health education approach, condom promotion 
482 In around 231 facilities for drug treatment (2000). 
483 80-90% of cases result in maintenance treatment. 
484 Buprenorphine for detoxification and maintenance treatment is used by a minority of professionals in 
addiction care. Recently, an import license for higher dose buprenorphine (Subutex®) has been realised and 
registration is underway. 
485 In combination with standardised psychosocial treatment. 
486 Only medical co-prescription. The Government decided in 2005 that places at treatment units for medical 
prescription of heroin for chronic treatment resistant opiate addicts can be extended from 300 to 1000. 
487 E.g. housing units for older addicts. 
488 Substitution substances are mainly distributed through a 'closed' system of medical prescription. In many 
cases substitution drugs are administered in a supervised environment. As a result, illegal distribution of 
personal dosages occurs incidentally. 
489 In recent times, a renewed initiative has been started by the Prison department (Ministry of Justice) to set 
up a national programme on infectious diseases within prisons. Furthermore, methadone distribution and drug 
free treatment exist in prison.
490 A national hepatitis B vaccination campaign for drug users is running for 4 years and has recently been 
expanded to prisons. A study is being conducted on how to guide drug users to hepatitis C screening and 
vaccination. The Ministry of Health is considering to place hepatitis C on national policy agenda. 
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among drug users, routine screening of high risk groups, hepatitis vaccination programmes for 
drug users and easy access programmes for drug users to treatment of infectious diseases. 
Predominant implementation settings for infectious diseases prevention measures targeting drug 
users include specialised drug treatment services and low threshold counselling services. Common 
implementation settings are outreach work and targeted high risk group interventions. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation491. [RT] 
Needle and syringe exchange programmes, drug paraphernalia and the distribution of condoms are 
available nationwide in the Netherlands. [NR 2003, NR 2004; NFP 2006]. Needle and syringe 
exchange programmes are a predominant response strategy to prevent infectious diseases
among drug users in the Netherlands.  [SQ 23] Low threshold agencies, including needle and 
syringe exchange programmes, also are a predominant setting to provide information materials on 
the reduction of drug-related deaths among drug users, and a common setting for deliverance 
of risk education/ response training. [SQ 29] 
The Netherlands counts in total 120 non-pharmacy based needle and syringe programmes and 3 
vending machines. Needle and syringe exchange is not taking place through vans/ buses, and 
through outreach workers/ peers, via pharmacies or in prisons. [ST 10] 
There are no legal restrictions to the possession of sterile needles in the Netherlands, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation492. [RT] 
Professionals of emergency departments493 are trained nationwide. [NR 2004] ‘First aid posts’ are a 
common setting for dissemination of information materials that aim at the reduction of drug-
related deaths or for risk education/  response training. [SQ 29] 
Dutch ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated494. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation495. [RT] 
Risk reduction is part of an integrated health strategy for drug users496. [NR 2003] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
491 More than 100 free of charge needle and syringe exchange locations exist in all regions and big cities in the 
Netherlands. Many pharmacies sell needles to IDUs, although the number seems to be decreasing. Only 15% of 
the Dutch heroin users inject their heroin (85% smokers). Condom distribution is widely available.
492 Emergency services are responsible for first aid in case of overdose. They are trained for this task. Other 
training programmes (for drug professionals) are offered by Trimbos Institute (Uitgaan & Drugs) and Mainline. 
A ‘Red Alert’ system is in place that provides instant alerts to professionals and the public when dangerous 
(acute toxic) drugs are detected on the market. Examples from the past years include: ecstasy pills polluted 
with strychnine or with atropine. 
493 First aid posts. 
494 Naloxone is only administered by, or on behalf of, a medical doctor in case of an emergency. 
495 The integrated care is an official policy objective of the Ministry of Health (Openbare Geestelijke 
Gezondheids Zorg/ OGGZ) and is being implemented by means of covenants between service providers and 
municipalities. 
496 Addiction care activities and general (health) care facilities for housing, finance, general health and day care 
should be better geared to one another. The Netherlands Court of Audit advised to give addiction care a 
coordinating role in this process.
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Training is offered nationwide to outreach workers and professionals in needle and syringe 
exchange programmes, substitution programmes, low threshold programmes, treatment facilities 
and to prison staff. [NR 2003/ 2004] 
2.17.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
The Netherlands have a strong evaluation and monitoring culture as impetus for policy 
development. The Dutch drug policy is focusing strongly at 'what works'. The quality of evaluation 
and monitoring is being improved continuously. At the same time, there is a limited number (and 
funding for) of large scale evaluation studies available (e.g. Randomised Controlled Trials). The 
available treatment options should not be offered in an isolated way and only in a clinical setting, 
but in an integrated and interactive way. This is i.e. reflected in the well formed connection 
between the clinical settings, ambulatory or out patient treatment services and low threshold 
agencies can contribute to get more patients into treatment settings. Another example of the 
integrated approach concerns the chain of early intervention services, in order to tackle the 
problem before it becomes highly problematic, treatment options, rehabilitation and re-socialisation 
contributes to higher change for the patients to regain control of their lives. [RT] 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. A seven-year policy 
programme 'Getting Results' was initiated to push a more evidence-based addiction care 
[Schippers, van Es et al., 2005]. The results are disseminated through a 'knowledge network' that 
includes practically all addiction care and mental health services in the Netherlands. [RT] 
In the Netherlands, ample research is available on a number of harm reduction interventions. In 
2002 the final report on a heroin prescription trial become available. In the study, the effects 
during treatment and after 12 months have been compared. The effects of stopping prescription 
have also been evaluated. A current study aims at determining the additional effects of 
psychosocial treatment. Another (cohort) study evaluates the health and social situation of the 
participants of the experimental study three and six months after the start. The findings of this 
report has led to the decision of the government to extend this type of treatment, (which is a harm 
reduction intervention) from 300 to 1000 users. [NR 2004]  
Over a period a three years the National Coordination Structure on Infectious Diseases (LCI)
published many protocols on infectious diseases, including HIV and hepatitis B and C. The last 
version (3rd edition) is from 2004. 
A recent survey study examined data on syringe exchange in the Netherlands to support activities 
to enhance the quality of this type of harm reduction. The authors also conducted a literature 
review on syringe exchange activities, but could not find any recommendations for quality 
assurance measures. One of their conclusions is that syringe exchange does reduce risk behaviours 
(such as syringe sharing), and is associated with a reduction of HIV infections.  
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, as it is not a task for National government. There is no official guideline 
for inclusion of needs assessment, but several models of best-practice exist that promote such 
(e.g. Preffi, Rapid Assessment and Response). [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist. Several guidelines and protocols for the evaluation of drug prevention 
and risk reduction programmes exist, but are not compulsory. [RT] 
The Amsterdam Institute of Addiction Research (AIAR) is developing criteria and indicators for a 
monitoring system for addiction care services. The target is to improve the effectiveness and 
efficiency of drug prevention and treatment programmes. [NR 2003] 
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Guidelines or protocols to standardise care or prevention activities are not commonly applied and 
existing protocols or monitoring practices are rarely tested and improved. 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist, as it is not a task for national government. These criteria differ between 
several national evaluation guidelines, e.g. PREFFI, OPUS, MEK. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. The Netherlands have 
active involvement in the Reitox Network. The Trimbos Institute was involved in developing the 
drug-related deaths key epidemiological indicator for the EMCDDA. Several (local) monitors and 
data collections exist; the data of many of them are integrated into the National Drug Monitor497
and the EMCDDA annual Reports. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. The National Drug 
Monitoring reports are disseminated among policymakers and the Parliament. Scientific evaluation 
results are often used for policy making. One good example: the heroin prescription experiment. 
[RT]
Two important studies on the effectiveness of addiction care are worth mentioning.  
An evaluation of the care for addicts (of alcohol and opiates) with multiple problems  organized in 
the Netherlands was carried out by the Netherlands Court of Audit. The main conclusion was that 
the activities of the addiction care institutions and general care facilities for housing, finance, 
general health and day care should be better geared to one another. The advice of the Netherlands 
Court of Audit is to give the addiction care a coordinating role in this process. In his reaction to this 
report the Minister of Health announced that he would not develop a separate vision for the 
addiction care, but these problems should be tackled by the future local social support systems.  
The results of a five-year policy programme to improve the quality of addiction care and drug 
prevention (Resultaten Scoren or ‘Getting Results’) were published in 2004.  The evaluation report 
marks the end of the first phase of five years of activities with 50 publications: e.g. literature 
studies, instrument development studies, guidelines and protocols.  
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. The national Focal Point 
cooperates with the National Support Centre for Prevention (LSP) in evaluation training courses. 
[see EDDRA Progress Reports to the EMCDDA]. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist. There is an annual PREFFI (Prevention Effectiveness Instrument) award 
for the best prevention programme. [RT]. 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
497 The Dutch National Drug Monitor (NDM) is among the first of its kind in the EU. It systematically collects and 
presents data and facts on licit and illicit drug use, prevention, treatment, drug-related harms and drug-related 
offences. The NDM annually reports to Parliament, Ministries of Health and Justice and to organisations and 
structures in the drug field. The National Drug Monitor is supervised by an independent scientific council and is 
hosted by the Trimbos Institute, the Netherlands Institute of Mental Health and Addiction. 
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This policy does not exist. However, the Netherlands actively participates in several European 
support and training projects. The Netherlands government is running the MATRA programme, 
which funds both projects in the field of drug demand reduction (incl. harm reduction) and training 
courses for civil servants and experts from applicant (& acceded) countries. [RT] 
An international action plan on cannabis research was launched in 2003. This is a joint effort of 
Belgium, France, Germany, the Netherlands and Switzerland to address the most important 
research questions resulting from an international cannabis conference organised in Brussels in 
2002.
2.17.5 Information from third data sources 
Issues raised by Foundation Mainline 
Information, education, communication (IEC). IEC is inadequate for drug users. Inadequacy 
and lack of accessibility is explained by the lack of suitable techniques used by many professionals 
to transfer knowledge to drug users. Often ineffective strategies and an inadequate tone of voice is 
used to provide IEC. Training and thus funding is necessary to improve efficiency.  
Drug testing is widely available in the Netherlands, but accessibility needs to be improved as it is 
perceived as being high threshold for marginalised users. Most drug testing is aimed at users in the 
party/  rave scene. 
Outreach work. Coverage of outreach work is evaluated as inadequate throughout the country. 
Accessibility is limited because many organisations work with case management, which excludes 
unregistered users.
(Medically assisted) treatment and other interventions. The coverage and the accessibility of 
medically assisted treatment for opiate users is adequate. However, some of the institutions 
providing opiate substitution – mostly methadone – have a maximum dosage-policy that is not 
based on medical criteria.  
For cocaine users, neither medically assisted treatment nor structural harm reduction intervention 
is available. Amphetamine type stimulants or cocaine prescription programmes are not available 
officially, although ATS are prescribed on a small scale to cocaine users. With regards to specific 
harm reduction interventions for cocaine users, coverage in general is inadequate, because NGO 
Mainline is the only organisation implementing harm reduction interventions. There is an adequate 
coverage of needle and syringe exchange programmes and drug paraphernalia throughout the 
country and accessibility so far has been adequate. Accessibility is however declining as opening 
hours are cut down and some of the programmes are only accessible for locally registered users. 
There are sufficient low threshold agencies, drop in centres and shelters throughout the 
Netherlands and accessibility is generally adequate, although there are local differences. Coverage 
of drug consumption rooms is adequate, but accessibility is hindered by rules that most 
consumption rooms can only be accessed by locally registered users. 
Prison interventions. IEC is not available to prisoners. The coverage and the accessibility of 
medically assisted treatment for opiate users is adequate in prisons. No information is available 
about coverage of specific harm reduction intervention for cocaine users in prison. Needle and 
syringe exchange in prison is not allowed. In prison coverage and accessibility of outreach work is 
inadequate as only Mainline is conducting outreach work in a few selected institutions.  
Measures to prevent infectious diseases have an inadequate coverage and accessibility for all users 
in prison. Hepatitis B vaccination programmes especially targeted at drug users are nationwide 
available in prison. In prison hepatitis-vaccination programmes are easily accessible and coverage 
is good. There are no TB-vaccination programmes for drug users in the Netherlands for 
incarcerated drug users. 
Infectious diseases. Measures to prevent infectious diseases have an inadequate coverage and 
accessibility for all users as not enough attention is focused on screening, or the promotion of 
treatment amongst members of the target group. Hepatitis B vaccination programmes especially 
targeted at drug users are nationwide available. Accessibility is however judged inadequate, as not 
enough information is reaching marginalized users to make vaccination programmes effective. 
There are no TB-vaccination programmes specifically targeting drug users in the Netherlands. 
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Annex A2.18 State of play on harm reduction in Austria 
2.18.1 Summary 
Public health policy. Harm reduction is a public health objective in Austria and pre-exists the 
launch of the Council Recommendation. 
Information, education, communication (IEC). Information and counselling to drug users to 
promote harm reduction and to facilitate their access to appropriate services is nationwide provided 
through various websites. Telephone help lines, training, educational leaflets and pill-testing are 
available in specific geographical areas. For the reduction of drug-related deaths, the dissemination 
of information materials is the predominant response strategy. There is no specific IEC available for 
communities and families of drug users. 
Outreach work. Street-based outreach work is nationwide available. Outreach work as a health 
education approach is a common response strategy to prevent infectious diseases among drug 
users. For the reduction of drug-related deaths, outreach work is the predominant setting for the 
dissemination of information materials, as well as for the deliverance of risk education/  response 
training. Peers and volunteers are not included in outreach work practice. Networking and 
cooperation between outreach work agencies exist in specific geographical areas only. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes, methadone detoxification programmes and treatment with buprenorphine and 
naltrexone are available nationwide. Drug-free outpatient and drug-free inpatient treatment are 
available in specific geographical areas only, as well as rehabilitation centres, and drop-in centres/  
shelters. Opioid substitution treatment is a common response strategy aiming at the reduction of 
drug-related deaths. Drug consumption rooms and heroin prescription programmes do not exist in 
Austria. Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Methadone maintenance and methadone detoxification programmes, 
buprenorphine treatment are available nationwide in Austrian prisons. Condoms are also 
distributed nationwide. Testing, prevention, education and treatment of infectious diseases is 
covered by prison staff. Currently, there are no needle and syringe exchange programmes, nor 
drug paraphernalia other than iodine. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). In specific geographical areas only, vaccination against hepatitis B and tuberculosis 
targeting drug users exists. To prevent infectious diseases among drug users, the predominant 
response strategies are IEC via counselling and advice by drugs and health professionals, voluntary 
counselling and testing, condom distribution, and needle and syringe exchange programmes. In 
Austria, needle and syringe exchange, vending machines, drug paraphernalia and the distribution 
of condoms are only available in specific geographical areas.  
Drug-related deaths. In specific geographical areas, professionals of emergency departments are 
trained, e.g., to deal with overdoses. The distribution, possession or administration of naloxone is 
regulated by laws. Naloxone on a ‘take home’ basis is not available. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in substitution programmes. Risk reduction is part of all 
regional drug strategies. 
Quality, monitoring and evaluation. In Austria, evaluation and research play an increasing 
important role. Several pilot projects have been scientifically evaluated. Evaluations of international 
literature have been conducted as well. Quality standards exist for prevention and treatment 
services. Austria participates in many bi- and multilateral projects.  
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2.18.2 Recommendation 1: harm reduction and public health policy 
The Ministry of Health and Women498 is the main responsible department for the implementation of 
the Council Recommendation. In Austria, harm reduction is part of public health policy. Prevention 
plays a central role, which is reflected in a wide range of structural measures. Since the early 90's, 
when Addiction Prevention Units were established, primary prevention was introduced, while 
secondary prevention was expanded. Responses to health correlates and consequences include a 
wide range of interventions.  
Measures relevant for this Council Recommendation focus on the prevention of drug-related 
infectious diseases, thus low threshold assistance aimed at harm reduction prevails. For instance, 
syringe exchange, hepatitis vaccinations and information on safer sex /  safer use are typical 
services performed by low threshold centres and outreach facilities (street work). Treatment of 
health consequences is primarily provided by the general health-care system. In the last few years, 
prevention of overdoses and co morbidity has played increasingly important roles in this context 
(see also the overview of activities in the second recommendation of the Council 
Recommendation). [RT]
2.18.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation499. [RT] 
In Austria, the dissemination of information through various websites is available nationwide. Other 
ways of providing information and counselling to drug users in the framework of harm reduction 
are available in specific geographical areas (telephone help lines, training, educational leaflets and 
pill-testing). [NR 2003/ 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) via counselling and advice by drugs and health professionals is a predominant 
response strategy, whereas IEC in general is a common response strategy. Safer injecting training 
and individual risk counselling with regard to safer injecting are provided in specific geographical 
areas only and are delivered by low threshold agencies, especially outreach work. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy: materials are predominantly disseminated at low threshold 
agencies and through needle and syringe exchange programmes, and they are commonly 
disseminated through detoxification centres, nightlife and entertainment venues, and at raves and 
parties. A common response strategy with regard to the reduction of drug-related deaths among 
drug users is the provision of risk education/  response training. This training is delivered 
predominantly at low threshold agencies and through outreach workers and is common in nightlife 
and at rave events. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence; 
This policy exists, but was not based upon the Council Recommendation500. [RT] 
Communities and families of drug users are not at all involved in the prevention and reduction of 
health risks associated with drug dependence, nor is specific information, education and 
communication available for communities and families of drug users. [NFP 2006] 
498  Department for Public Health.  
499 Measures for the prevention of infectious diseases continue to be a major component of harm reduction. 
Relevant activities in this field include the distribution of information material, syringe exchange and vaccination 
programmes, as well as counselling on safer drug use and safer sex. 
500 Prevention measures are primarily implemented at the local and regional levels and coordinated by the 
Addiction Prevention Units of the individual provinces. Work with parents is given more and more importance.
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2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channel 
This policy exists, but was not based upon the Council Recommendation501. [RT] 
In Austria, street-based outreach work is nationwide available. Outreach work at dance parties, 
raves and in clubs is available in specific geographical areas only502. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work (and targeted high-risk group 
interventions) is a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths, and outreach work is also a predominant setting for the deliverance of 
risk education/  response training, which is delivered in a number of cities. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Peers and volunteers are not included in outreach work practice and they are  not trained to do so. 
[NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation503. [RT] 
Networking and cooperation between outreach work agencies exist in specific geographical areas 
only. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation504. [RT] 
Methadone maintenance programmes, methadone detoxification programmes, and treatment with 
buprenorphine and naltrexone are available nationwide505. Substitution treatment is supported by 
psychosocial care upon request by the client. In specific geographical areas only, there are drug 
free inpatient and drug free outpatient treatment facilities, rehabilitation centres, and drop-in 
centres/ shelters (low threshold centres). [NR 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a common 
response strategy. [SQ 29] 
Drug consumption rooms and heroin prescription programmes do not exist in Austria. 
501 Outreach work continues to be of central importance among harm-reducing measures. Quality assurance 
measures are becoming state of the art also in the field of drug-related demand reduction (projects/activities 
are evaluated, education/ (further) training schemes are organised, quality standards etc.). 
502 ChEckIT! in nightlife and party scene - provides information on-site, by printed material as well as via the 
website, and also runs an on-site pill testing programme www.checkyourdrugs.at. Outreach work/counselling to 
overdose patients is also taking place in specific geographical areas (in Viennese hospitals). 
503 Networking and co-operation between drug-specific services is considered to be a relevant requirement of 
activities in this field.
504 Austria attributes a great importance to a diversification of treatment options. This approach aims at taking 
individual needs into account more strongly. As the general aim is to build a comprehensive care network, most 
centres also provide a variety of preparatory and aftercare measures. 
505 Codidol and slow release morphine are also prescribed nationwide. A review of substitution treatment mainly 
focusing slow release morphine was carried out. Currently a revision of the regulations on substitution 
treatment is discussed that might restrict the prescription of slow release morphine in future. 
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2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation506. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation507. [RT] 
Methadone maintenance and methadone detoxification programmes, buprenorphine treatment and 
codidol and slow-release morphine are available nationwide in Austrian prisons508. Condoms are 
distributed nationwide and testing, prevention, education and treatment of infectious diseases is 
covered by prison staff. 
There are no needle and syringe exchange programmes in prisons in Austria, although a project is 
under preparation. [NR 2004; NFP 2006] Iodine (for the disinfection of wounds) is the only drug 
paraphernalium available in prisons in Austria. [SQ 23] 
Prisons are a common implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Measures targeting at the reduction of drug – related deaths are uncommon or non existent in 
Austrian prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation509. [RT] 
In specific geographical areas vaccination programmes against hepatitis B and tuberculosis 
targeting drug users exists [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users the predominant response strategies are 
information, education, communication (IEC) via counselling and advice by drugs and health 
professionals, voluntary counselling and testing, condom distribution, and needle and syringe 
exchange programmes. Other, common strategies include IEC in general, outreach health 
education approach, hepatitis B vaccination programmes for drug users, and easy access’ 
programmes for drug users to treatment. Predominant implementation settings for infectious 
diseases prevention measures targeting drug users include low threshold counselling services, 
outreach work and high risk group interventions. Common implementation settings are specialised 
drug treatment services and prisons. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation510. [RT] 
In specific geographical areas, needle and syringe exchange programmes, vending machines, drug 
paraphernalia and the distribution of condoms are available. [NR 2004] 
506 Trends towards diversification also show in the field of  medically assisted treatment, where a widening 
range of substances have been prescribed in order to reach different groups of users and to respond to their 
needs. Control measures regarding prescription aim to prevent diversion. 
507 A lot of services aiming to prevent drug-related harm are also available in prison – substitution treatment, 
drug free treatment, safer use and safer sex information and counselling etc. A syringe exchange programme 
has been considered for some time but not implemented so far.
508 There is no information available whether naltrexone is prescribed in prisons. 
509 In several regions and facilities hepatitis B vaccination as well as testing for hepatitis and HIV is available for 
free. Prevention of infectious diseases is a relevant priority in the field of drug specific harm reduction. 
510 Syringe exchange is possible in the majority of the provinces. In some of the provinces the distribution of 
safer use sets is offered, whereas these sets include sterile needles, syringes, swabs (partly condoms) and a 
safer use booklet including addresses of drug help centres.
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Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Austria. [SQ 23] Low threshold agencies, including 
needle and syringe exchange programmes also provide information materials on the reduction of 
drug-related deaths among drug users. [SQ29] 
Austria runs in total 41 programmes for needle and syringe exchange, 12 vending machines and 29 
non-pharmacy based needle and syringe programmes. Needle and syringe exchange takes also 
place through vans/ buses, and through outreach workers, but not through peers, via pharmacies 
or in prisons. [ST 10; NFP 2006] 
There are no legal restrictions to the possession of sterile needles in Austria, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical areas only, professionals of emergency departments are trained [NR 
2004]. Emergency departments are an uncommon setting for dissemination of information 
materials that aim at the reduction of drug-related deaths or for risk education/ response training. 
[SQ 29] 
Austrian ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated by laws. Naloxone is only available on prescription and administration is 
limited to physicians. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation511. [RT] 
Risk reduction is part of all regional drug strategies. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation512. [RT] 
Training is offered nationwide to professionals in substitution programmes. Training for 
professionals in low threshold agencies, outreach work and for prisons staff is available in specific 
geographical areas only. Training programmes for professionals in needle and syringe exchange 
programmes and for professionals in treatment facilities do not exist. [NR 2004; NFP 2006] 
2.18.4 Recommendation 3: Quality assurance, monitoring & evaluation in harm reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. In Austria, evaluation is 
of increasing importance in the field of drug demand reduction. Respective activities also include 
measures aiming at the reduction of drug-related harm (cf. Austrian projects in the EDDRA 
database of the EMCDDA). [RT] 
Generally speaking, evaluation and research have played an increasingly important role. 
Implementation of drug policies is more and more often accompanied and underpinned by studies 
assessing the relevant demand situation (e.g. the Tyrol and Styria), evaluation of pilot projects 
(e.g. Lower Austria, Carinthia and Vienna) as well as scientific studies and analyses (e.g. 
Burgenland, Upper Austria, Vorarlberg and Vienna). [NR 2003] 
In Carinthia a working group has been established to develop guidelines for decisions on 
substitution treatment and drug-free treatment, from which requirements for treatment and care 
structures are derived [NR 2004, pg 26]. Furthermore, in 2004, the Ludwig-Boltzmann Institute for 
511 Promoting an appropriate integration has been continued. The need to coordinate addiction-related care with 
general medical and psychiatric treatment still remains a particular challenge. 
512 Plans and curricula for drug-related further training of five selected occupational groups have been 
completed.
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Addiction Research, commissioned by the Vienna Social Fund, drew up an expert opinion on heroin-
assisted treatment of chronic opiate addicts, in which the results of existing international 
programmes were analysed (Springer 2003a). [NR 2004, p. 31]. Carinthia’s six-month early 
intervention service for young drug using first offenders (‘Way Out’), was extended due to positive 
evaluation results (EDDRA). [NR 2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. There are still few 
programmes and activities where needs assessment is carried out - but the need and usefulness of 
such an approach is increasingly acknowledged. [RT]  
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist. Appropriate resources for implementation were outstanding in the past, 
but are no longer available. [RT]  
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist. Appropriate resources for implementation were outstanding in the past, 
but are no longer available. [RT]  
At the Drug help centres whose names have officially been announced after an examination 
procedure have to meet federal quality standards defined by the Ministry of Health. At the 
provincial level relevant criteria and standards exist for the field of drug counselling and drug 
treatment. [NR 2004, pg 26]. The evaluation of the Needles or Pins reintegration project carried 
out in 2002 (cf. EDDRA) illustrates the success of the measures taken. [NR 2004, p.48]
In the field of prevention a Styrian interdisciplinary decision-making group on addiction prevention 
as a community task has drawn up quality standards for primary and secondary prevention. [NR 
2004, p.18]. The youth department of the competent federal ministry is planning the definition of 
quality criteria for education and support of peer leaders. This is based on the results of an expert 
meeting of young peer leaders in prevention projects. [NR 2003, p.59] 
The quality circle on evaluation coordinated by ÖBIG and including evaluation experts of various 
drug help centres in Vienna drew up the paper Evaluation: Forderungen & Anleitungen (Evaluation: 
demands and instructions; ÖBIG 2002c). [NR 2003, pg 60] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. The further development 
of the national monitoring system in line with the needs and requirements of the EMCDDA has been 
a relevant priority for several years. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist . Appropriate resources for implementation were outstanding in the past, 
but are no longer available. [RT] 
Generally speaking, evaluation and research have played an increasingly important role in Austria. 
Implementation of drug policies is more and more often accompanied and underpinned by studies 
assessing the relevant demand situation (e.g. the Tyrol and Styria), evaluation of pilot projects 
(e.g. Lower Austria, Carinthia and Vienna) as well as scientific studies and analyses (e.g. 
Burgenland, Upper Austria, Vorarlberg and Vienna). In addition Vorarlberg is the first province 
planning an evaluation of the provincial drug strategy. [NR 2003] In addition at both federal and 
provincial levels endeavours are made to intensify drug monitoring, which will improve the data 
situation and thus in future permit a better, and more objective, evaluation of the drug situation.  
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In Upper Austria a second comprehensive demand survey was conducted in the context of a Rapid 
Situation Assessment (RSA). The aim of the RSA was to collect relevant data on addition and drug 
problems as a basis for efficient planning of drug policy interventions. [NR 2003] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. Quality assurance in 
general and evaluation more specifically is included in the plans and curricula for drug specific 
further education (see 2.1 3). Evaluation training was organised the REITOX Focal Point as well as 
by other institutions during the last years. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist. The different stakeholders are not always, but often involved in 
evaluation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
A specific policy does not exist. The exchange of results, skills and experience is taken care of by 
different means: input in the work of the EMCDDA, participation in EU projects and networks etc. 
Moreover, Austria participated in the drug specific PHARE Twinning activities in order to share with 
new Member States and applicants Member States. [RT] 
Together with other organisations in twelve EU member countries, ÖBIG and the Vienna Social 
Projects Association participated in the EU project Living with the Daily Dose. The main objective of 
this project was to describe the situation of HIV-positive drug addicts and the development of 
strategies to improve access to care programmes for this target group (www.oebig.at). The project 
resulted in an extensive publication. [NR 2003] 
Since 2001 the organisation ChEckiT! has taken part in an EU project for evaluating the 
effectiveness of secondary prevention measures and in particular the effects pill-testing 
programmes have on consumption patterns and risk awareness among users of synthetic drugs 
(ecstasy). This project included a comparison of drug screening programmes carried out in Vienna, 
Amsterdam and Hanover, which used different procedures. [NR 2002] 
2.18.5 Additional information 
Issues raised by  NGO Ganslwirt 
Information, education and communication (IEC). IEC is adequate in coverage and 
accessibility. Drug testing (pill-testing) exists, but is inadequate in coverage and accessibility as it 
is organized only occasionally and should be developed into regular intervention.  
Outreach work. Outreach work is adequate in coverage and accessibility.
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is available, but inadequately accessible in Austria due to a lack of services. 
Substitution drugs used are methadone and morphine. Heroin prescription programmes do not 
exist in Austria. No information is available about medically assisted treatment for ATS users and 
treatment for cocaine users is inadequate as no specialized services are offered.  There are no ATS 
or cocaine prescription programmes available. Drug consumption rooms do not exist in Austria. 
NSPs as well as the distribution of drug paraphernalia are adequate in coverage and accessibility 
throughout the country. Low threshold agencies are adequate in coverage, but inadequate in 
accessibility as resources have been cut for facilities for homeless drug users. Specific harm 
reduction interventions targeted at cocaine users are inadequate in coverage and accessibility and 
no information is available if specific harm reduction interventions exists for ATS users.  
Prison interventions. In prison, IEC is inadequate in both coverage and accessibility. Outreach 
work is performed in Austrian penitentiaries and is adequate in coverage and accessibility.  
Availability and accessibility to medically assisted treatment in prison is inadequate, because of a 
lack of staff in prison facilities. Specific HR interventions for cocaine users are inadequate in 
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coverage and accessibility as they are not specifically developed for the target group. For ATS 
users no information is available whether specific HR interventions exist.  
In prison, measures implemented to prevent infectious diseases are inadequate. There is no 
information whether hepatitis B vaccination exists within Austrian penitentiaries. NSPs are not 
implemented in prisons and the coverage and accessibility of drug paraphernalia distribution is 
considered inadequate.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are adequate. Hepatitis B 
vaccination is available and accessible. Tuberculosis vaccination programmes specifically targeting 
drug users do not exist. 
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Annex A2.19 State of play on harm reduction in Poland 
2.19.1 Summary 
Public health policy. Harm reduction is a public health objective in Poland. Harm reduction was 
already adopted in legislation in 1997. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational leaflets. For the reduction of drug-
related deaths, the dissemination of information materials is the predominant response strategy. In 
specific geographical areas, communities are informed and involved in the prevention and 
reduction of health risks associated with drug dependence. Families of drug users are not involved 
in this. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs are nationwide available. Outreach work as a health education approach is a predominant 
response strategy to prevent infectious diseases among drug users. For the reduction of drug-
related deaths, outreach work is a common setting for the deliverance of risk education/  response 
training. Peers and volunteers are included in outreach work practice in specific geographical areas. 
Networking and cooperation between outreach work agencies do not exist. 
(Medically assisted) treatment and specific interventions. Drug-free outpatient treatment, 
drug free inpatient treatment and rehabilitation programmes are available nationwide. Methadone 
maintenance and detoxification programmes and drop-in centres are available in specific 
geographical areas. Treatment with buprenorphine or naltrexone is not provided, nor are drug 
consumption rooms and heroin prescription programmes. Measures to prevent diversion of 
prescribed drugs are available nationwide. 
Prison interventions. Methadone detoxification programmes, distribution of condoms, and 
testing, prevention, education and treatment of infectious diseases are available nationwide in 
Polish prisons. Methadone maintenance programmes are available in specific geographical areas. 
There are neither needle and syringe exchange programmes nor drug paraphernalia available in 
Polish prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening and counselling for infectious diseases are available nationwide. To 
prevent infectious diseases among drug users, the predominant response strategies are IEC in 
general, safer injecting training, outreach health education approach, and needle and syringe 
exchange. Needle and syringe exchange, drug paraphernalia and the distribution of condoms are 
available in specific geographical areas.  
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in substitution programmes. The policy to integrate risk 
reduction into an health strategy for drug users exists, but there is no clear information regarding 
its implementation. 
Quality, monitoring and evaluation. Needs assessment schemes exist in Poland in the format of 
so called Rapid Assessment and Response monitors. Evaluation criteria for harm reduction 
programmes were to be developed by 2004, but have not been established yet.  
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2.19.2 Recommendation 1: Risk reduction and public health policy 
In Poland, the Ministry of Health513 is responsible for the implementation of the Council 
Recommendation.  
Harm reduction is a public health objective in Poland and this policy is in compliance with the 
Council Recommendation, but not the consequence of it. Objectives related to the prevention of 
drug dependence in order to provide for high level of health protection is included in the Act of Law 
of 24 April 1997 on Counteracting Drug Addiction and is further developed in the National 
Programme for Counteracting Drug Addiction for 2002-2005. In addition in the amendment of the 
Act of Law of 24 April 1997 which was adopted in 2001, a legal basis was created for harm 
reduction activities. In general, if this report states that Polish policy and harm reduction activities 
are a consequence of the Council Recommendation, this entails that these measures are in 
compliance with it but not the result of its existence as the measures were implemented before 
2003. [RT] [SQ 29].
2.19.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation514. [RT] 
In Poland, telephone help lines, websites and a broad range of educational leaflets are available 
nationwide. Training515 is available to drug users in specific geographical areas only.  
[NR 2002/2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general, and safer injecting trainings for drug users are predominant 
response strategies. IEC via peer involvement/ peer approach is a common response strategy. 
Safer injecting trainings and individual risk counselling with regard to safer injecting are provided 
in specific geographical areas only516 and this is delivered by low threshold agencies, especially 
outreach work. [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is the predominant response strategy: materials are predominantly disseminated at specialised 
drug treatment services, and low threshold agencies, and they are commonly disseminated through 
detoxification services, prisons, nightlife or entertainment venues rave events. A common response 
strategy is risk education/  response training, which is delivered in some or few cities517. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and was based upon the Council Recommendation518. [RT] 
Families of drug users are not involved in the prevention and reduction of health risks associated 
with drug dependence; communities are involved519 in specific geographical areas. Specific IEC is 
also available for communities of drug users520. [NFP 2006] 
513 National Bureau of Drug prevention. 
514 Information is provided through the media campaign, leaflets, information bulletins or other materials 
published mainly by NBDP but also by National AIDS Center. Counselling to drug users is provided generally by 
the outpatient centres, selected recreational settings and HIV prevention centres. 
515 Also safer injection training, safer use, providing first aid, trainings are available especially targeted at 
people using synthetic drugs. 
516 Street working and syringe / needle exchange is usually connected with the safer injecting training. Training 
is conducted during outreach work and in a drop-in centre. There are also bulletins for active drug users which 
includes permanent column on safer injections. The most common topics are hygiene and syringe / needle 
exchange.  
517 The trainings are available in Warsaw, Krakow, Olsztyn, Pulawy, Lublin, Katowice, Czestochowa, Poznan, 
Szczecin, Wroclaw, Zgorzelec. 
518 Information is provided mainly through national and local information campaigns. 
519 Some communities support harm reduction programmes. 
520 Journal for drug addicts is issued by a NGO in Krakow. The journal is focused on harm reduction messages.
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2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists and was based upon the Council Recommendation521. [RT] 
In Poland, street-based outreach work and outreach work at dance parties, raves and in clubs are 
available nationwide. [NR 2002- 2004] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a predominant response strategy. Outreach work and targeted high-risk group 
interventions are a predominant implementation setting for infectious diseases prevention 
measures targeting drug users. [SQ 23] 
A common response strategy aiming at the reduction of drug-related deaths is risk education/  
response training through outreach workers. Low threshold agencies, including needle and syringe 
exchange programmes, and outreach work are the predominant settings for the deliverance of risk 
education/ response trainings, aimed at the reduction of drug-related deaths. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists and was based upon the Council Recommendation522. [RT] 
In specific geographical areas, peers and volunteers are included in outreach work523 practice and 
they are also trained to do so524. [NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies do not exist525. [NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation526. [RT] 
Drug-free outpatient treatment, drug-free inpatient treatment and rehabilitation programmes are 
available nationwide. Methadone maintenance programmes527, methadone detoxification 
programmes and drop-in centres are available in specific geographical areas only. Treatment with 
buprenorphine or naltrexone is not available. Substitution treatment is supported by (obligatory) 
psychosocial care. [NR 2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is an uncommon 
response strategy. [SQ 29] Drug consumption rooms and heroin prescription programmes do not 
exist in Poland. 
521 Special training for outreach workers are organised by NBDP. Within the National Programme standards and 
methods for this kind of interventions have been elaborating. 
522 In 2004, special training for workers and volunteers working in the dance clubs was organised. Its main 
topics included methods of work, early interventions and first aid. 
523 For example in Warsaw the peer education approach is used. Also the drug user’s network is used for 
implementation of needle and syringes exchange programmes. 
524 National training programmes or training curricula for peers and volunteers involved in outreach work are 
not available. The peers and volunteers are trained within programmes. 
525 Only in an informal way.
526 Availability of substitution treatment is not sufficient. However increase in the access to this kind of 
treatment is one of the main priorities of the national drug policy. Drug-free treatment is considered sufficient. 
527 Ten centres exist throughout the country. 
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2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide528. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists and was based upon the Council Recommendation529. [RT] 
Methadone detoxification programmes, distribution of condoms, and testing, prevention, education 
and treatment of infectious diseases530 are available nationwide in Polish prisons. Methadone 
maintenance programmes are available in prisons in specific geographical areas only531. There are 
neither needle and syringe exchange programmes nor drug paraphernalia available in Polish 
prisons. [NR 2002/ 2004] 
Prisons are a common implementation setting for the dissemination of information materials on the 
prevention of infectious diseases among drug users, and on the reduction of drug-related 
deaths and emergencies. [SQ 23, SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists and was based upon the Council Recommendation532. [RT] 
Testing/ screening and counselling with regard to infectious diseases are available nationwide in 
Poland. In specific geographical areas, education and treatment of infectious diseases are 
available533,534. [NR 2003/ 2004] 
To prevent infectious diseases among drug users the predominant response strategies are IEC 
in general, safer injecting training, outreach health education approach, and needle and syringe 
exchange programmes. Other, common strategies include IEC via peer involvement/  peer 
approach and condom promotion among drug users. Predominant implementation settings for 
infectious diseases prevention measures targeting drug users include low threshold counselling, 
outreach work targeted high risk group interventions. Common implementation settings are 
specialised drug treatment services and prisons. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists and was based upon the Council Recommendation535. [RT] 
In specific geographical areas, needle and syringe exchange programmes,  drug paraphernalia536
and the distribution of condoms are available. [NR 2002/ 2004] 
Needle and syringe exchange programmes are a predominant response strategy to prevent
infectious diseases among drug users in Poland. [SQ 23] Low threshold agencies, including 
needle and syringe exchange programmes, are also a predominant implementation setting to 
provide information materials on the reduction of drug-related deaths among drug users, and 
528 Methadone is under strong control. Methadone is given to patients in liquid condition (syrup) and consumed 
by patients under supervision of staff. 
529 In prisons access to drug-free treatment, and in three custodial institutions substitution treatment is 
available. In general, access to services for drug addicts in prison is still not sufficient. 
530 Vaccinations and blood tests are carried out. 
531 First project in Krakow, 14 participants. 
532 Drug dependent users who wan to test for HIV can do it anonymously and free of charge in special 
counselling points. Screening for mentioned diseases and testing on hepatitis B and C among IDUs is not 
provided.
533 Current drug users are excluded from ARV treatment. 
534 No specific vaccinations for drug users exist. 
535 23 programmes of syringe and needle exchange are conducted in 22 cities in Poland. 
536 Sterile kits. 
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are a common setting for the deliverance of risk education/  response trainings for drug users. [SQ 
29]
Poland has in total 29 non-pharmacy based needle and syringe exchange programmes537. Needle 
and syringe exchange takes place through fixed sites and outreach/ peer but not through vans/ 
buses, vending machines, via pharmacies or in prisons. [ST 10] 
There are no legal restrictions to the possession of sterile needles in Poland, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation538. [RT] 
However, in Poland, trainings for professionals working at emergency units do not exist, and 
emergency departments are not in use as a setting for dissemination of information materials that 
aim at the reduction of drug-related deaths or for risk education/ response trainings. [SQ 29] 
Polish ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated. Naloxone on a ‘take home’ basis is not available539. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
No clear information is available whether an integrated health strategy for drug users exists in 
Poland. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation540. [RT] 
Training for professionals in substitution treatment is available nationwide541. Training is offered in 
specific geographical areas to outreach workers, professionals in low threshold programmes, needle 
and syringe exchange programmes542, treatment facilities and to prison staff 543. [NR 2003/  2004; 
NFP 2006] 
2.19.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
Answers concerning national policy based upon Council Recommendation indicate that national 
solutions or activities are in the line with the decisions of the Recommendation, but were not 
directly based on them (were implemented earlier). [RT]. 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based on the Council Recommendation. Trainings for professionals 
working in the field of prevention aimed at increasing the knowledge about evidence based 
programmes are organized on a regular basis. The NBDP also promote programmes based on 
standards and include evaluation component in their structure. [RT] 
537 In 2003 there were 29 points, in 2002 there were 31. 
538 It is in the standards of trainings for people working in the emergency services.
539 Access to naloxone is limited to medical doctors.  
540 In the special training for people working with drug users, certificated by the Minister of Health, people from 
different sectors are participating (health care, social care).  
541 The training is provided mainly by Institute of Psychiatry and Neurology or/and by other experienced 
substitution treatment facilities. 
542 National training programmes or even training curricula for professional needle and syringe exchange 
programmes are not available. The workers are trained within programmes. 
543 Ad hoc training programmes are organised. They are arranged by the prison administration with 
collaboration of NGOs and other drug professionals.
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Moreover, the National Focal Point conducted and commissioned for implementation and/or 
participation in the following research projects in the framework of harmonising Polish systems of 
data collection with the EU standards  [NR 2004]: 
 Project of “Reporting to treatment due to drug use” 
 ESPAD – questionnaire survey on drug and alcohol use at upper-primary schools (age: 15-16) 
and secondary schools (age: 17-18)  
 EDDRA – programme of recording and evaluation of drug demand reduction activities, pg 10 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists and was based upon the Council Recommendation. Trainings related to the 
proper construction of the prevention programmes and methods of needs assessment such as RAR 
for relevant group of people were organized. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based on the Council Recommendation.  
Selected programmes were evaluated on national level. Within the National Programme for 
Counteracting Drug Addiction trainings in the field of evaluation for different groups were organized 
and currently works on the elaboration of evaluation protocol for risk reduction programmes are 
conducted. [RT] 
In the framework of developing and implementing programmes evaluating treatment, rehabilitation 
and harm reduction services an expert committee was established that made a review of the 
definitions of therapy, conducted research as well as theoretical concept of evaluation process.  
[NR 2004]  
According to the schedule drawn up in the National Programme for Counteracting Drug Addiction it 
was planned to develop methods and indicators for the evaluation of drug use-related harm 
reduction programmes in the years 2003 – 2004.  
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based on the Council Recommendation.  
The evaluation quality criteria are in the process of elaboration. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based on the Council Recommendation.  
EDDRA questionnaires are in the process of implementation on the national level. Cooperation with 
the EMCDDA in the field of prevention and risk reduction programmes is developing. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based on the Council Recommendation.  
Results from the evaluation of selected programmes are used to create conclusions and 
recommendation for prevention and risk reduction programmes conducted on the regional and local 
level. [RT] 
The Central Board of Prison Service in cooperation with the Institute of Psychiatry and Neurology 
and the National Bureau for Drug Prevention conducted two research projects in 2003. The first 
was titled: „Women drug addicts in European prisons”. The aim of the study was the evaluation of 
drug therapy programmes for women implemented in prisons in terms of their effectiveness in 
preventing relapses. The 2003 National Programme for Drug Preventions was based upon the 
conclusions drawn from the above mentioned research projects.  
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In 2003 upon commission of the National Bureau for Drug Prevention a research project called 
“Institutional conditioning of drug prevention”. The project covered organisations operating at 
national level and implementing drug demand reduction programmes. [NR 2004] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based on the Council Recommendation.  
NBDP commissions the evaluation programmes organized for NGO’s workers who created and 
implemented prevention and risk reduction programme on regional and local level. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based on the Council Recommendation.  
NBPD promote the evaluation aspect of prevention and risk reduction programmes among people 
who implement them but also among local and regional authorities in order to underline its 
importance. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based on the Council Recommendation.  
National experts were involved in the cooperation of the EMCDDA with third countries like Turkey 
and some republics of Asia. [RT]. 
Within the scope of international cooperation particularly important is the Bureau’s participation in 
the proceedings of the Pompidou Group by the Council of Europe, the European Monitoring Centre 
for Drugs and Drug Addiction in Lisbon, the United Nations Drug Control Programme and the 
PHARE programme. In 2003 the National Bureau continued performing tasks resulting from the 
programme of Poland’s accession to the European Union. The twinning contract between Poland 
and France was continued. [NR 2003] 
2.19.5 Information from third data sources
Issues raised by NGO Monar 
Information, education and communication (IEC). IEC is inadequate in coverage, but 
adequately accessible. Most IEC is abstinence-oriented. There is little harm reduction information 
and education available for drug users, but there are some exceptions, e.g. a harm reduction 
bulletin. Drug testing is not available in Poland.  
Outreach work. Outreach work is efficiently implemented only in Krakow, Warsaw and Gdansk, 
but lacks national coverage and accessibility. 
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is inadequate in availability and accessibility. Nationwide there are 12 methadone 
programmes. Especially in Warsaw users have to wait for several months to be able to enter the 
programmes544. Generally methadone is the first substitution drug, but buprenorphine (called 
Bunondol) can be purchased. There is no heroin prescription programme in Poland. There is no 
medically assisted treatment for ATS or cocaine users nor prescription programmes for users of 
stimulants. Specific services for cocaine or ATS users are inadequate in coverage and accessibility. 
Officially there are no drug consumption rooms in Poland. Unofficially there is at least one 
consumption room. In Krakow, Warsaw and Gdansk there are some very well operating and low 
threshold NSP, but the majority of Polish cities does not have NSPs. Drug paraphernalia are 
available through the few NSPs, but no paraphernalia are available for non-injectors. 
544 Poland has an integrated model of treatment and care for HIV positive drug users: The AIDS centre of 
Chorzow became one of the first sites in Poland for piloting methadone treatment projects in 1998. The centre 
proposed methadone therapy as part of the AIDS care kit for patients who are IDUs. 
In: CEE-HRN. Scaling Up Provision of Anti-Retrovirals to Drug Users in Central and Eastern Europe and Central 
Asia. www.ceehrn.org/arv4idus; visited June 2006.
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Low threshold agencies are inadequate in coverage, as there are only two drop-in centres in 
Poland. Existing facilities are situated in the big urban centres and are considered adequate in 
accessibility. There are no specific harm reduction interventions for ATS or cocaine users in Poland.   
Prison interventions. IEC in prison is inadequate in coverage as well as in accessibility. Outreach 
work in prison exists in various cities throughout the country, but is underdeveloped.  
Availability of, and accessibility to substitution treatment is inadequate as methadone substitution 
is provided only in three remand prisons (2 in Warsaw, 1 in Krakow) for a small number of 
inmates. Methadone is the only substitution drug provided in prisons. There are no medically 
assisted treatments or specific HR interventions for ATS or cocaine users available in prison. There 
are no NSPs in prisons and drug paraphernalia are also not available. Measures implemented to 
prevent infectious diseases are inadequate because information is not thorough enough. There is 
no information available on hepatitis B or tuberculosis vaccination programmes targeted at drug 
users in Polish prisons.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are inadequate because the 
information is provided only through the few NSPs and condom distribution.  
Hepatitis B and tuberculosis vaccination programmes targeting drug users do not exist, but 
everyone has access to the general hepatitis B and tuberculosis (vaccination) services, which are 
considered inadequate in accessibility for drug users. 
Measures to involve families and friends of drug users in harm reduction interventions are 
underdeveloped and inadequate in coverage and accessibility. 
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Annex A2.20 State of play on harm reduction in Portugal 
2.20.1 Summary 
Public health policy. Harm reduction is a public health objective in Portugal. Harm reduction 
policy exists since 1999. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites, training, and educational leaflets. For the 
reduction of drug-related deaths, risk education/  response training for drug users is the 
predominant response strategy. Communities and families of drug users are involved in the 
prevention and reduction of health risks associated with drug dependence in specific geographical 
areas only. 
Outreach work. Street-based outreach work is nationwide available. Outreach work as a health 
education approach is a predominant response strategy to prevent infectious diseases among drug 
users. For the reduction of drug-related deaths, outreach work is the predominant setting for the 
dissemination of information materials, as well as for the deliverance of risk education/  response 
training. Peers and volunteers are included in outreach work practice in specific geographical areas. 
Networking and cooperation between outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes, drug-free outpatient and inpatient treatment, and rehabilitation centres are available 
nationwide. Methadone detoxification treatment, treatment with buprenorphine and with 
naltrexone, and drop-in centres are available in specific geographical areas. Drug consumption 
rooms and heroin prescription programmes do not (yet) exist in Portugal. Opioid substitution 
treatment is a predominant response strategy aiming at the reduction of drug-related deaths. 
Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Counselling and testing, education, prevention and treatment of infectious 
diseases as well as distribution of condoms and drug paraphernalia are nationwide available in 
Portuguese prisons. In some prisons, methadone maintenance, buprenorphine, and methadone 
detoxification treatment are available. Needle and syringe exchange programmes are not available 
in prisons in Portugal. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/  screening, counselling and vaccination programmes targeting drug users are 
nationwide available. To prevent infectious diseases among drug users, the predominant response 
strategies are IEC in general, IEC via counselling and advice by drugs and health professionals, 
outreach health education approach, condom promotion among drug users, routine screening of 
high risk groups, easy access’ programmes for drug users to treatment of infectious diseases, and 
needle and syringe exchange. Needle and syringe exchange, drug paraphernalia and the 
distribution of condoms are nationwide available.  
Drug-related deaths. The distribution, possession or administration of naloxone is not regulated. 
Naloxone on a ‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in outreach work, substitution programmes, needle and syringe 
exchange programmes, treatment facilities, low threshold programmes and to prison staff. Risk 
reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation Portugal is developing quality assurance and evaluation 
tools. The National Drug Strategy 2000-2004 was evaluated and called for further development of 
harm reduction programmes.  
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2.20.2 Recommendation 1: Risk reduction and public health policy 
In Portugal, the main responsible governmental body responsible for the implementation of the 
Council Recommendation is the Ministry of Health545.
Harm reduction is a public health objective in Portugal, but is not based on the Council 
Recommendation. The policy objectives proposed in the Council Recommendation were already 
established in the Portuguese Strategy on Drugs, adopted in 1999 and also in the National Action 
Plan on Drugs 2000-2004. As a result Council Recommendation did not have any impact on these 
policies. [RT] [SQ29] 
2.20.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but is not based upon the Council Recommendation. [RT]
In Portugal, various telephone help lines546, websites547, training, and a broad range of educational 
leaflets are available nationwide. [NR2003/ 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education, 
communication (IEC) via counselling and advice by drugs and health professionals; and easy 
access’ programmes to treatment of infectious diseases are predominant response strategies, 
whereas safer injecting training, and IEC through peer involvement/  peer approach are a common 
response strategies. [SQ 23] 
With regard to the reduction of drug-related deaths, risk education /  response training for drug 
users is the predominant response strategy; training is predominantly delivered at low threshold 
agencies and through outreach workers and they are commonly disseminated through specialized 
drug treatment services and rave/  festival events. A common response strategy is the 
dissemination of information materials. This information is predominantly disseminated at low 
threshold agencies548 and through outreach workers and is common in specialised drug treatment 
services, detoxification services and rave/  festivals events. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but is not based upon the Council Recommendation. [RT] 
Communities and families of drug users are involved in the prevention and reduction of health risks 
associated with drug dependence in specific geographical areas only. [NR 2003] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but is not based upon the Council Recommendation. [RT] 
In Portugal, street-based outreach work is nationwide available549. Outreach work at dance parties, 
raves and in clubs is available in specific geographical areas only. [NR 2003, NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a predominant response strategy. Outreach work and targeted high-risk group 
interventions are a predominant implementation setting for infectious diseases prevention 
measures targeting drug users. [SQ 23] 
545 Institute of Drugs and Drug Addiction (IDT) – Treatment and Harm Reduction Department. 
546 Linha Vida - SOS Drogas. 
547 www.drogas.pt
548 At national level an institution exists that developed strategies to prevent infectious diseases among IDU 
specifically with regard to HIV. 
549 In 2004, 25 projects were implemented throughout the country.
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Risk education/ response training for drug users through outreach workers is the predominant 
response strategy, and needle and low threshold agencies, including needle and syringe exchange 
programmes, and outreach work are the predominant settings for the dissemination of 
information materials, aimed at the reduction of drug-related deaths. [SQ 29]
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services  
This policy exists, but implementation is pending for approval. [RT] 
Currently, peers and volunteers are trained and included in outreach work practice, in specific 
geographical areas only [NFP2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but implementation is pending for approval. [RT] 
However, networking and cooperation between outreach work agencies exist nationwide550. [NFP 
2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance programmes551, drug-free outpatient, drug-free inpatient treatment, and 
rehabilitation centres are available nationwide. Methadone detoxification treatment, treatment with 
buprenorphine and with naltrexone, and drop-in centres are available in specific geographical 
regions. Substitution treatment is supported by (obligatory) psychosocial care. [NR 2003/ 2004; 
NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29] Drug consumption rooms552 and heroin prescription programmes do not 
exist in Portugal. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide. [NFP 2006] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Distribution of condoms, counselling and testing, education, prevention and treatment of infectious 
diseases and drug paraphernalia are nationwide available in Portuguese prisons. In some prisons, 
methadone maintenance treatment and buprenorphine treatment and methadone detoxification 
treatment are available. Needle and syringe exchange programmes are not available in prisons in 
Portugal. [NR 2003/ 2004; NFP 2006] 
Prisons are a predominant implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Measures targeting at the reduction of drug – related deaths
are uncommon in Portuguese prisons. [SQ 29] 
550 All outreach work agencies have developed protocols and are engaged in cooperation between treatment 
and social services of the region where the intervention was developed. 
551 Also pharmacy-based methadone maintenance treatment. 
552 Though existing legislation allows for the implementation of drug consumption rooms. 
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2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening553, and counselling and vaccination programmes targeting drug users are 
available nationwide. [NR 2003; NFP 2006] 
To prevent infectious diseases among drug users the predominant response strategies are IEC 
in general554 IEC via counselling and advice by drugs and health professionals, outreach health 
education approach, condom promotion among drug users, needle and syringes exchange, routine 
screening of high risk groups, and easy access programmes for drug users to treatment of 
infectious diseases. Other, common strategies include safer injecting training, IEC via peer 
involvement/ peer approach, and hepatitis vaccination programme for drug users. Predominant 
implementation settings for infectious diseases prevention measures targeting drug users include 
specialized drug treatment services, outreach work and targeted high risk group interventions, 
primary care/ GP’s, and prisons. [SQ 23; NFP 2006] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange555, drug paraphernalia and the distribution of condoms are available 
nationwide. [NR 2003/ 2004; NFP 2006]. Needle and syringe exchange programmes and condom 
promotion among drug users are predominant response strategies to prevent infectious 
diseases among drug users in Portugal. [SQ 23]  
Low threshold agencies, including needle and syringe exchange programmes, also are a 
predominant setting to provide information materials on the reduction of drug-related deaths
among drug users. [SQ29]. Portugal counts in 80 non-pharmacy based and 1232 pharmacy-based 
needle and syringe exchange points. Needle and syringe exchange takes place through fixed sites, 
vans/ buses, outreach / peer, pharmacy and non-pharmacy based outlets, but not through vending 
machines or in prisons. [ST 10]. There are no legal restrictions to the possession of sterile needles 
in Portugal, and also no prescription is required to obtain or exchange needles and syringes. 
[ELDD]
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
There are no specific training programmes on drug overdoses available to professionals of 
emergency departments [NFP 2006]. Emergency departments are an uncommon setting for  the 
dissemination of information materials that aim at the reduction of drug-related deaths or for risk 
education/ response training. [SQ 29] 
Portuguese ambulances routinely carry antagonists. [SQ29] The distribution, possession or 
administration of naloxone is not regulated. Naloxone on a ‘take home’ basis is not available.  
[SQ 29; NFP 2006] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but implementation is pending for approval. [RT] 
Risk reduction is part of an integrated health strategy for drug users556. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
553 There is a programme (Klotho) that tracks early the infection of HIV virus among drug users. 
554 Through public treatment network and information leaflets.
555 There is only 1 national needle and syringe exchange programme in Portugal (“Say no to a used syringe”) 
with many outlets/points of distribution. 
556 Responses at this level are integrated with health and social services nation wide. 
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This policy exists, but was not based upon the Council Recommendation. [RT] 
Training is offered nationwide to outreach workers, prison staff, professionals in substitution 
programmes557, needle and syringe exchange programmes558, treatment facilities and low 
threshold programmes559. [NR 2004; NFP 2006] 
2.20.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
Best practice interventions in Portugal are identified and entered into the EMCDDA’s EDDRA 
database on basis of evaluation forms. An evaluation of buprenorphine treatment was organised in 
recent years. [2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
In 2003, the National Commission for the Fight against AIDS started a series of initiatives to 
implement until 2006 with a view to improve the efficiency of this programme, namely to 
elaborate, in cooperation with the IDT, a needs assessment document for professional training to 
outreach workers in order to develop a national training programme for HIV/ AIDS infection 
prevention. Furthermore, needs assessment was carried out at the start of Reintegration 
Programmes, (including reintegration of drug users). [NR 2002]  
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists, but was not based upon the Council Recommendation. The outreach work, such 
as street teams, has evaluation protocols with the IDT. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The National Drug Strategy ‘Horizon 2004’ was evaluated internally and externally, followed up by 
a number of recommendations, among which the following: “To improve the risk reduction and 
harm minimisation systems through further development of the initiatives already in place 
(substitution programmes, syringe exchange, campaigns for the use of condoms, etc.)”. [NR 2004]
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, but is pending for approval.  
557 Buprenorphine. 
558 Specific training for pharmacies concerning needle and syringe exchange. 
559 Training programmes concerning harm reduction policies in the Northern Region of Portugal target to Street 
teams professionals.
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3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. Rezolat Project integrates 
an innovative methodology of evaluation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. The IDT exchange 
programme results, skills and experience with other Member States of the EU, among others 
through EDDRA. [RT] 
Since buprenorphine was first used in Portugal, training and training exchanges have been 
organised with France. Portuguese professionals have participated in trainings in France, Germany, 
Spain, and Scotland. Collaboration, education and information have been shared with the European 
Network T3E and also with the Euro-Methwork, in the development of the European Methadone 
Guidelines. [NR 2004] 
2.20.5 Information from third data sources
Issues raised by NGO Abraço 
Information, Education, Communication (IEC) IEC is inadequate in accessibility. 
Outreach work Outreach work is inadequate in coverage and accessibility. The quality of outreach 
work is not always adequate. 
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users in Portugal is considered inadequate in coverage and accessibility as only about  
13 000 of an estimated 65 000- 100 000 problematic drug users are being treated. Availability of 
treatment access was numerically reduced since 1998 when 35 000-40 000 drug users were in 
treatment. Currently, access is primarily granted to pregnant or HIV-infected drug users. The 
coverage and accessibility of medically assisted treatment to ATS users is inadequate as there are 
no structured programmes and very few specialists can support users in such treatment.  
There are no drug consumption rooms in Portugal. The public debate on the topic shows readiness, 
however, to introduce these services inside and outside prison. Accessibility to needle and syringe 
exchange programmes or drug paraphernalia is poor due to low coverage. Low threshold agencies 
are inadequate in coverage and accessibility, because they offer little places and the quality of 
services is questionable 
Prison interventions In prison, access to substitution treatment is only granted if the detainee 
has received substitution treatment outside prison. Improvements can be expected from the 
anticipated reform of the prison health services in 2006. Medically assisted treatment to ATS users 
in prison is not available. 
Public debate centering around the topic shows readiness, however, to introduce drug consumption 
rooms in prison. There are no NSPs or drug paraphernalia distribution programmes in Portuguese 
prisons. For prisons, outreach work is inadequate in coverage and accessibility. It is difficult to get 
access to prison in order to perform outreach interventions. 
There are no specific harm reduction interventions targeted at cocaine or ATS users in prison  
The distribution of information, education and communication (IEC) is inadequate in prison.
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Annex A2.21 State of play on harm reduction in Slovenia 
2.21.1 Summary 
Public health policy. Harm reduction is a public health objective in Slovenia for some years 
already, and pre-existed the Council Recommendation.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational leaflets. For the reduction of drug-
related deaths, the dissemination of information materials, risk education/  response training for 
drug users, and individual risk counselling are the predominant response strategies. Communities 
and families of drug users are informed and involved in the prevention and reduction of health risks 
associated with drug dependence. 
Outreach work. Outreach work at dance parties/  raves and in clubs is nationwide available. 
Outreach work as a health education approach is a common response strategy to prevent infectious 
diseases among drug users. For the reduction of drug-related deaths, outreach work is the 
predominant setting for the dissemination of information materials. In specific geographical 
regions, peers and volunteers are included in outreach work practice. Networking and cooperation 
between outreach work agencies exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
methadone detoxification programmes, buprenorphine treatment, drug-free in- and outpatient 
treatment and rehabilitation programmes are nationwide available. Treatment with naltrexone and 
drop-in centres/  shelters are available in specific geographical areas. Slovenia does not have drug 
consumption rooms, and has no heroin prescription programmes. Opioid substitution treatment is a 
predominant response strategy aiming at the reduction of drug-related deaths. Measures to 
prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Testing, prevention, education and treatment of infectious diseases are 
available nationwide in prisons. Methadone detoxification treatment, treatment with naltrexone, 
condoms, counselling and prison pre-release interventions are also provided nationwide. 
Methadone detoxification treatment is available in specific geographical regions only. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, prevention, counselling, vaccination programmes 
against tuberculosis targeting drug users, and treatment of infectious diseases are available 
nationwide. To prevent infectious diseases among drug users, common response strategies are IEC 
in general, IEC via counselling and advice by drugs and health professionals, and outreach health 
education, voluntary infectious diseases counselling and testing, condom promotion among drug 
users, needle and syringe exchange, routine screening of high risk groups, a hepatitis vaccination 
programme for drug users, and easy access’ programmes for drug users to treatment of infectious 
diseases. Needle and syringe exchange programmes and condoms are available nationwide. Drug 
paraphernalia are available in specific geographical regions.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g., to 
deal with overdoses. The distribution or administration of naloxone is not regulated. Naloxone on a 
‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals working in outreach work, emergency departments, in 
treatment facilities and in prison settings. Risk reduction is part of an integrated health strategy for 
drug users. 
Quality, monitoring and evaluation. Some programmes for quality assessment and evaluation 
exist in Slovenia. Needle exchange programmes have been evaluated. In the near future, needs 
assessment will become a precondition for funding of interventions. There are formal quality 
assurance guidelines for all governmental programmes.  
263
11350-HRI Rapport binnenwerk.ind263   263 13-03-2007   14:20:57
264
2.21.2 Recommendation 1: Risk reduction and public health policy 
The governmental body that is responsible for the implementation of the Council Recommendation 
in Slovenia is the Ministry of Health560.
Harm reduction is a public health policy objective in Slovenia. The Council Recommendation has 
influenced national policy. The Resolution on the National Programme in the Field of Drugs 
(ReNPPD) was adopted by the National Assembly in February 2004. It is a result of current social 
development and signifies a harmonisation of various sectored approaches in relation to aims, 
priority tasks, sources and costs. The ReNPPD takes into account the international legal framework, 
UN conventions, the provisions of the Council of Europe and European Union and other 
international treaties and recommendations in various professional fields. The Act Prevention of the 
Use of Illicit Drugs and dealing with Consumers of Illicit Drugs sets out the measures for preventing 
the use of illicit drugs and for dealing with consumers of illicit drugs. [RT]
2.21.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but is not based upon the Council Recommendation 561. [RT] 
In Slovenia, information is disseminated nationwide through telephone help lines, various 
websites562 and educational leaflets. In specific geographical regions, training for drug users is 
organised. [NR 2002-2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general, and IEC via counselling and advice by drugs and health 
professionals are the predominant response strategies. Safer injection training is provided in some 
cities. [SQ 23] 
With regard to the reduction of drug-related deaths the dissemination of information materials, 
risk education/ response training563 for drug users, and individual risk counselling are the 
predominant response strategies. Predominant settings for the dissemination of information 
materials are specialised drug treatment services and low threshold agencies, including needle and 
syringe exchange programmes, outreach workers, detoxification services, prisons, and rave events 
and festivals. Common settings include mass media/ internet, doctors’ practices and emergency 
departments. Predominant settings for risk education/ response training for drug users are 
specialised drug treatment services, low threshold agencies, including needle and syringe 
programmes, prisons and rave events. Common settings include outreach workers and nightlife. 
[SQ 29; NFP 2006] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and is based upon the Council Recommendation. [RT] 
Communities and families of drug users are involved in harm reduction; specific information, 
education, communication for these target groups is available. [NR 2004; NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
560 Office for Drugs. 
561 The aim of the Slovenian Drug Action Plan (ReNPPD) is to support the development of programmes that will 
help to stabilise or reduce the numbers infected with AIDS and hepatitis B and C and fatal cases of overdose 
and to ensure more quality programmes for treating drug addiction with the introduction of various approaches 
562 www.drogart.si; www.ivz.si; internet counselling.  
563 Training are available in some or few cities. 
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This policy exists and was based upon the Council Recommendation564. [RT] 
In Slovenia, outreach work at dance parties/ raves and in clubs is nationwide available. Street-
based outreach work is available in specific geographical regions. [NR 2002/ 2004]  
To prevent infectious diseases among drug users, outreaching health education is a common 
response strategy. Outreach work and targeted high-risk group interventions are a common 
implementation setting for infectious diseases prevention measures targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is a common setting for the deliverance of risk education/  
response training to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists and was based upon the Council Recommendation565. [RT] 
In specific geographical regions, peers and volunteers are included in outreach work; training for 
these groups is available also in specific areas. [NR 2002] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists and was based upon the Council Recommendation566. [RT] 
Networking and cooperation between agencies involved in outreach exist nationwide. [NR 2004]   
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists and was based upon the Council Recommendation567. [RT] 
Methadone maintenance and methadone detoxification programmes, drug-free in- and outpatient 
treatment and rehabilitation programmes are nationwide available. Buprenorphine was registered 
in Slovenia in May 2004 and started to be prescribed nationwide in 2005. Treatment with 
naltrexone and drop-in centres/ shelters are available in specific geographical areas. Substitution 
treatment is supported by psychosocial care, upon request by the client. [NR 2003/ 2004; NFP 
2006]  
Aiming at the reduction of drug-related deaths, opioid substitution treatment (with regard to 
the reduction of heroin/ opiate overdose) is a predominant response strategy. [SQ 29]  
Slovenia does not have drug consumption rooms, and has no heroin prescription programmes.  
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists and was based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are nationwide available568. [NFP 2006] 
564 The faculty for Social Work in Ljubljana is permanently involved in development of those organisations that 
provide low threshold services for drug users. The Faculty has established strong and continuing work in the 
field of drug use and harm reduction [NFP 2006].
565 The faculty for Social Work is also regularly involved in the development of new and innovative approaches 
in the field of drugs. Through training and research a lot of contacts and network have been created, including 
co-operation with different state and non-governmental bodies and associations. 
566 The Association of NGO’s in the field of harm reduction was formally established in 2004. 
567 In the Article 8 of The Act Prevention of the Use of Illicit Drugs and dealing with Consumers of Illicit Drugs is 
said Treatment of consumers of illicit drugs shall be carried out in the form of hospital and outpatient clinic 
treatment programmes approved by the Health Council. 
568 The different measures to prevent diversion of prescribed drugs (mostly methadone) are available in CPTDA 
(e.g., availability in specialised centres, solution form, book of narcotics). 
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2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists and was based upon the Council Recommendation569. [RT] 
Testing, prevention, education and treatment of infectious diseases are available nationwide in 
prisons. Methadone detoxification treatment, treatment with naltrexone570, condoms, counselling 
and prison pre-release interventions are also provided nationwide in prisons. Methadone 
detoxification treatment is available in specific geographical regions only. [NR 2002-2004; NFP 
2006]. 
Prisons are a common implementation setting for disseminating information materials to prevent
infectious diseases in drug users. [SQ 23] 
Aiming at the prevention and reduction of drug – related deaths, prison pre-release 
interventions are a common response strategy. Prisons are a predominant setting for providing risk 
education/ response training for drug users. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists and was based upon the Council Recommendation571. [RT] 
Nationwide, testing/ screening for infectious diseases, education, prevention, counselling, 
vaccination programmes against tuberculosis, targeting drug users, and treatment of HIV, hepatitis 
C, tuberculosis and sexually transmitted diseases are available. [NR 2004; NFP 2006]
Common response strategies to prevent infectious diseases among drug users are: IEC in 
general, IEC via counselling by drugs and health professionals, an outreach health education 
approach, voluntary infectious diseases counselling and testing, condom promotion among drug 
users, needle and syringe exchange programmes, routine screening of high risk groups, a hepatitis 
vaccination programme for drug users, and easy access programmes for drug users to treatment of 
infectious diseases.
Predominant implementation settings for infectious diseases prevention measures are specialised 
drug treatment services. Common implementation settings include low threshold counselling 
services, outreach work and targeted high risk group interventions, primary care/ GP’s and prisons.
[SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists and was based upon the Council Recommendation572. [RT] 
Needle and syringe exchange programmes and condoms are available nationwide. Drug 
paraphernalia are available in specific geographical regions. [NR 2004; NFP 2006] Needle and 
syringe exchange programmes are a common response strategy to prevent infectious diseases
among drug users in Slovenia. [SQ 23]  
With regard to the reduction of drug-related deaths among drug users, low threshold agencies, 
including needle and syringe exchange programmes, are a predominant setting both for 
dissemination of information materials and for providing risk education /  response training for drug 
users. [SQ 29] 
569 Regarding the ReNPPD treatment of drug addiction is provided in prisons under the same conditions of 
doctrine as to addicts outside prison. 
570 According to General instructions for treating drug users in prisons adopted in spring 2005, if a patient is 
free of opiates then therapy with naltrexone can be started in prisons or before visits outside prisons or before 
release.
571 Persons in a methadone programme are motivated to be vaccinated against hepatitis B in all centres. During 
the 1999 to 2003 period HIV prevalence consistently remained below 1% among confidentially tested injecting 
drug users demanding treatment in methadone programme. 
572 Programmes intended for harm reduction are programmes covering distribution of intravenous injection 
needles, condoms, advice on reducing the harm caused by the use of illicit drugs, and other programmes 
intended for harm reduction.
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In 2003, Slovenia had 26 needle and syringe exchange programmes. Types of needle and syringe 
exchange available include fixed sites, vans/ buses, outreach/ peer, vending machines, and 
pharmacy-based needle and syringe exchange. Prison-based needle and syringe exchange is not 
available. [ST 10] 
There are no legal restrictions to the possession of sterile needles in Slovenia, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and is based upon the Council Recommendation. [RT] 
Training programmes for professionals of emergency services are available nationwide. [NFP 2006]  
Emergency departments are an uncommon setting for risk education/  response training. [SQ29] 
Ambulances routinely carry antagonists. The distribution or administration of naloxone is not 
regulated. Naloxone is not available on a ’take home’ basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists and was based upon the Council Recommendation573. [RT] 
Nationwide, risk reduction is part of an integrated health strategy for drug users.  
[NR 2002/ 2003]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists and was based upon the Council Recommendation574. [RT] 
Training for professionals working in emergency departments, in treatment facilities and in prison 
settings is available nationwide. Specific geographical regions provide training for outreach 
workers, professionals working in needle exchange programmes, in substitution programmes, and 
in low threshold programmes. [NR 2003/ 2004; NFP 2006] 
There is no recognised professional qualification for professionals in the field of prevention and 
reduction of health-related risks associated with drug dependence in Slovenia, neither is this 
planned. [SQ 23] 
2.21.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists and was based upon the Council Recommendation. [RT]. 
The needle exchange project ‘Stigma’ has been evaluated, but not through a standardised protocol. 
The effectiveness (of the Stigma needle exchange) was evaluated through informal contacts with 
drug users and through statistical data: number of visits/ clients, number of needles issued and 
returned, number of contacts within the counselling programme and outreach work.  
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists and was based upon the Council Recommendation.  
Regarding the ReNPPD in the coming medium term period, all programmes funded from the budget 
must be checked. Similarly in this period, a uniform assessment system must be set up, which 
must start to apply in all phases of planning and implementation of programmes. [RT] 
573 In all programmes of treatment of drug addiction psychotherapeutic and psychosocial treatment must be 
provided together with medical treatment, which is carried out by experts trained in the treatment of drug 
users, and programmes of solving social problems. 
574 In the year 2003/2004 the Faculty of Social Work started with the postgraduate specialist study called drug-
related harm reduction. The programme of study includes the bases of harm reduction, approaches to harm 
reduction and methods of harm reduction, practical work and individual study.
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3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy exists and was based upon the Council Recommendation.  
The aim of the ReNPPD is that the majority of programmes are evaluated by external experts who 
meet conditions for scientific research work. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
Policy exists and was based upon the Council Recommendation.  
In cooperation with various faculties and research institutions and individual researchers, a 
coordination system for preparation and regular implementation of various qualitative and 
quantitative researches must be set up. [RT]. 
There are formal requirements for quality assurance for all governmental and non-governmental 
programmes, especially regarding to staff and responsible persons for implementation of 
programmes. They must have proper professional education, professional state examination and 
additional expert knowledge, especially regarding to competing for state grants. The supervision of 
grant-spending and programme-implementation is assured through partial and final reporting 
questionnaires. There is a number of academic institutions that are involved in the monitoring and 
evaluation of programmes that receive funding. In 2002, quality assurance was introduced as part 
of the selection criteria in Terms of Reference for financial tenders. Quality guidelines were also 
introduced for reports on programme implementation.  
Slovenia has established quite a number of different programmes which include evaluation 
mechanisms. Usually programmes are evaluated internally. The programmes co-financed by the 
government or ministries are also evaluated externally. Expertise in this field was mostly provided 
by professional associations or chambers, while the control of the organisational and administrative 
implementation of programmes was the responsibility of different competent ministries or 
government offices through specialised councils or similar committees. [NR 2002] 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation.  
Inter-sectored working groups for individual indicators, harmonised with EMCDDA, have been 
created in information units, which are the basis for preparing annual national reports for the 
aforementioned European centre. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists and was based upon the Council Recommendation. [RT] 
The New National Drug Strategy envisages regular evaluation of implementing the strategy and 
procedures of implementation, evaluation of achievement of aims regarding to results (through 
indicators) and evaluation of all verified programmes. The Government Office for Drugs took the 
initiative in 2002 for establishing an interministerial group, which should be responsible for 
preparing draft programme of evaluation procedures, especially for evaluating strategic documents 
and legislation. [NR 2003] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists and was based upon the Council Recommendation.  
An expert body is being created for this purpose, which will produce professional standards and 
guidelines. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists and was based upon the Council Recommendation. [RT] 
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3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] 
Slovenia worked together with Spain and Austria in a Phare Twinning project that was aimed at 
supporting drug-demand-reduction programmes and reducing the supply of drugs. Furthermore, 
Slovenia is participating in several international programmes and co-operating with several 
international organisations dealing with drug issues. International co-operation has played an 
important role in facilitating certain activities such as realising harm-reduction approaches. It has 
also provided knowledge and international experience to our experts. Although international co-
operation has clearly influenced drug policy in Slovenia, all the programmes and measurements 
have been adapted to national circumstances. Drugs, organised crime and money laundering are 
considered a serious international problem. [NR 2003] 
2.21.5 Information from third data sources
Issues raised by NGO STIGMA 
Information, education, communication (IEC). IEC is adequate in coverage and accessibility. 
Drug testing for party drugs is available and accessible at one location and considered adequately 
accessible. 
Outreach work. The outreach work network is too small to cover all critical points throughout the 
country, but accessibility is considered adequate.
(Medically assisted) treatment and other interventions. Medically assisted treatment for 
opiate users is adequate for drug users in general. There are 18 methadone maintenance 
treatment centres nationwide, and one detoxification facility.  
Medically assisted treatment specifically developed for ATS users and cocaine users are not 
available in Slovenia. If ATS users seek help in methadone maintenance treatment centres, they 
are referred to a psychiatrist. Detoxification services are also available.  
There are no heroin, ATS or cocaine prescription services in Slovenia. Coverage and accessibility of 
NSP and drug paraphernalia distribution is adequate in Slovenia. Coverage of low threshold 
agencies is inadequate, but accessibility of those available is considered good. There are no drug 
consumption rooms in Slovenia. Harm reduction interventions targeting cocaine and ATS users are 
implemented at dance parties by one NGO. Their accessibility is not adequate, as they are only 
implemented at dance parties. 
Prison interventions. Brochures, internet information, training sessions and help-lines are not 
adequately accessible from within prisons. Medically assisted treatment for opiate users is 
adequate for drug users in prison. Methadone is available and adequately accessible in prisons.575
In prison, detainees have access to medically assisted treatment every week. In prison NSP and 
drug paraphernalia are not available. Outreach work does not take place in all prisons in the 
country. In prisons there are no specific harm reduction interventions for these target groups. In 
some penitentiaries infectious diseases counselling based upon harm reduction is possible, but runs 
short of distributing proactive materials such as clean equipment, which makes services 
inadequate. Hepatitis B vaccination programmes are an integral part of the methadone 
maintenance treatment programme in prison. 
Infectious diseases. Coverage and accessibility to measures preventing infectious diseases is 
adequately available in Slovenia. Hepatitis B vaccination programmes are an integral part of the 
methadone maintenance treatment programme. For those users not in methadone treatment 
accessibility is inadequate. Vaccination for tuberculosis implemented in MMT-programmes was 
discontinued after incidence rate showed no need. There no longer is a vaccination programme for 
tuberculosis in Slovenia. 
575 Also refer to: Sarang, Anya, Raminta Stuikyte and Roman Bykov: “Implementation of harm reduction 
measures in Eastern Europe and Central Asia: Lessons learned,” at: 
http://www.ceehrn.org/index.php?ItemId=939.
269
11350-HRI Rapport binnenwerk.ind269   269 13-03-2007   14:21:00
270270
11350-HRI Rapport binnenwerk.ind270   270 13-03-2007   14:21:00
271
Annex A2.22 State of play on harm reduction in Slovakia 
2.22.1 Summary 
Public health policy. Harm reduction is a public health objective in Slovakia and is partly based 
upon the Council Recommendation. Harm reduction has been adopted in the National Programme 
for the Fight Against Drugs 2004-2008.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through websites and educational leaflets. Communities and families of drug users are 
nationwide informed, and involved in the prevention and reduction of health risks associated with 
drug dependence. 
Outreach work. Street-based outreach work and outreach work at open–air summer festivals and 
similar summer events/ musical parties are available in specific geographical areas. In specific 
geographical areas, peers and volunteers are trained and included in outreach work practice. 
Networking and cooperation between outreach work agencies is not an existing policy. 
(Medically assisted) treatment and specific interventions. Detoxification programmes, drug-
free inpatient and drug-free outpatient treatment, and rehabilitation centres are available 
nationwide. In specific geographical areas, methadone maintenance treatment and treatment with 
buprenorphine are provided. Treatment with naltrexone, drop-in centres, drug consumption rooms 
and heroin prescription programmes are not available in Slovakia. Measures to prevent diversion of 
prescribed drugs are available nationwide. 
Prison interventions. Measures targeting infectious diseases among drug users in prisons are 
available nationwide. There are no substitution treatment, needle and syringe exchange and drug 
paraphernalia available in Slovakian prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, counselling, and treatment of infectious diseases are available 
nationwide in Slovakia. In specific geographical areas, education with regard to infectious diseases 
and hepatitis B vaccination are available. 
To prevent infectious diseases among drug users, common response strategies are IEC via 
counselling and advice by drugs and health professionals, voluntary counselling and testing, needle 
and syringe exchange, routine screening of high risk groups, and hepatitis vaccination programmes 
for drug users. Needle and syringe exchange is available nationwide, while drug paraphernalia and 
condoms are distributed in specific geographical areas.  
Drug-related deaths. Policy exists to ensure that emergency services are trained and equipped to 
deal with overdoses, but information on the implementation of this policy is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in treatment facilities and in harm reduction intervention 
programmes. Risk reduction is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. In Slovakia, policies on quality assurance, monitoring and 
evaluation exist, but concrete activities have not been developed so far.  
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2.22.2 Recommendation 1: Risk reduction and public health policy 
In Slovakia, the Ministry of Health576 is responsible for the implementation of the Council 
Recommendation.  
Harm reduction is a public health objective in Slovakia and is (partly) based on the Council 
Recommendation. [RT] In April 2004, the Slovak Government adopted a National Programme for 
the Fight Against Drugs 2004-2008, adopted in April 2004. One of the key aims in this Programme 
concerns the making available of treatment of dependencies and harm reduction programmes to 
the general public. [NR2004] 
2.22.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists and was based upon the Council Recommendation. [RT] 
In Slovakia, websites577 and a broad range of educational leaflets are available nationwide. In 
specific geographical areas only, telephone help lines578 and training targeted at risk reduction are 
offered. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users, providing information, education and 
communication via counselling and advice by drugs and health professionals is a common response 
strategy. [SQ 23] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists and was based upon the Council Recommendation. [RT] 
Communities and families of drug users are nationwide involved in the prevention and reduction of 
health risks associated with drug dependence579, and also,  specific information, education and 
communication available nationwide for communities and families of drug users580. [NFP 2006] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Slovakia, street-based outreach work is available in specific geographical areas only, and so is 
outreach work at open–air summer festivals and similar summer events/ musical parties. [NR 
2004; NFP 2006] 
Outreach work is not a common strategy or setting to prevent infectious diseases among drug 
users. [SQ 23] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy does not exist, as it is no priority for national government. [RT] 
576 Public health Authority of the Slovak Republic – Section of Health Care; Section of Protection, Promotion and 
Development of Health. 
577 New website www.infodrogy.sk launched in May 2005 is offering 4 on-line counselling services, at least two 
of them can advice in harm-reduction issues. http://www.infodrogy.sk/index.cfm?module=Advisories.
578 Telephone contacts available within the operational time of Citizens Association and Centre for Treatment of 
Drug Dependencies. There is also a helpline of Unicornis, aimed at youth. 
579 46 offices and 14 branches for social prevention exist. 
580 Available via the network of regional/local offices (branches) of CPSCs. Concept of 8 highly specialised 
agencies was developed and three of them were functioning in 2004.
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However, in specific geographical areas, training for peers and volunteers is organised. Peers and 
volunteers are included in outreach work practice, in specific geographical areas. [NR 2004] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy does not exist, as it is no priority for national government. [RT] 
There is no information available about the existence of networking and cooperation between 
outreach work agencies in Slovakia. [NR 2004; NFP 2006] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists and was based upon the Council Recommendation. [RT] 
Detoxification programmes581, are available nationwide. drug-free inpatient and drug-free 
outpatient treatment and rehabilitation centres are also available nationwide [NR 2004]. In specific 
geographical areas, methadone maintenance treatment582 and treatment with buprenorphine583 are 
provided. Treatment with naltrexone and drop-in centres are not available. Substitution treatment 
is supported by psychosocial care upon request by the client. [NR2004]. Drug consumption rooms 
and heroin prescription programmes do not exist in Slovakia. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
No information from policymakers with regard to this policy was available. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide in Slovakia. [NR 2004] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists and was based upon the Council Recommendation. [RT] 
There is no methadone maintenance or methadone detoxification treatment available in Slovakian 
prisons. There are no needle and syringe exchange programmes or drug paraphernalia available in 
prisons. [NR 2004; NFP 2006] Measures targeting infectious diseases among drug users in prisons 
are available nationwide584. [NR 2004; NFP 2006] Information materials with regard to the 
prevention of infectious diseases are not disseminated in Slovakian prisons. [SQ 23] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening, counselling585, treatment586 of infectious diseases are available nationwide in 
Slovakia.  In specific geographical areas, education with regard to infectious diseases and hepatitis 
B. vaccination targeting drug users 587  are available. [NR 2004; NFP 2006] 
To prevent infectious diseases among drug users common response strategies are IEC via 
counselling and advice by drugs and health professionals, voluntary counselling and testing, needle 
and syringe exchange programmes, routine screening of high risk groups and hepatitis vaccination 
581 Methadone, buprenorphine, codeine, ethyl morphine. 
582 1 centre only (Bratislava) - most popular drug is pervetine /amphetamine. 
583 Restricted to a maximum period of 2-3 months.  
584 Voluntary treatment of drug users, drug-free zones, hepatitis C treatment. 
585 As part of outreach work. 
586 Free and available, except for treatment of HCV, where active drug users are excluded. 
587 General vaccination programme incl. TB cover 1991-2003/ up to 98-99% of the population (95% on local 
level in some regions) TB incidence among drug users is not monitored. It is considered to be very low due to 
national programme of immunisation. 
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programmes for drug users. Predominant implementation settings for infectious diseases 
prevention measures targeting drug users are specialised drug services. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists and was based upon the Council Recommendation. [RT] 
Needle and syringe exchange programmes588 are available nationwide. Drug paraphernalia589 and 
condoms are available in specific geographical areas only590.
Needle and syringe exchange programmes are a common response strategy to prevent infectious 
diseases among drug users in Slovakia. [SQ 23] Slovakia has 11 non-pharmacy based needle and 
syringe exchange programmes and no vending machines. Types of needle and syringe exchange 
available in Slovakia are: fixed sites, vans/ buses, and outreach/ peer. No pharmacy based needle 
and syringe exchange, vending machines or prison-based needle and syringe exchange exists in 
Slovakia.  [ST 10] 
There are no legal restrictions to the possession of sterile needles in Slovakia, and also no 
prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists and was based upon the Council Recommendation. [RT] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation591. [RT] 
Risk reduction is part of an integrated health strategy for drug users. [NR 2004] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training is offered nationwide to professionals in treatment facilities and in harm reduction 
intervention programmes592 593. In specific geographical regions, training for outreach workers is 
organised. [NR 2004; NFP 2006] 
2.22.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists and was based upon the Council Recommendation. [RT] 
In the Slovak Republic, the results of international research are being used for the development of 
interventions and policies. For example, WHO reports were and are being used to diagnose the 
'harmful use' of drugs and 'drug dependency', and/or other health disorders related to such 
diagnoses. The system of drug treatment is based on scientifically verified approaches.  
Furthermore, the key background document for the development of drug treatment programmes is 
a research manual published in 1999 by the U.S. National Institute on Drug Abuse, "Principles of 
588 Provided by NGO’s and by specialised centres in Bratislava and Kosice. 
589 Outside big cities pharmacies sell syringes and paraphernalia. 
590 In general the access to needles and syringes and other paraphernalia should be provided by the network of 
public pharmacies. Study outputs showed problem in accessibility. Therefore CTDD – IDD drew up an 
educational leaflet for pharmacists addressing them a message about the need to provide drug users with 
paraphernalia despite their personal attitude to the problem of drug use. 
591 Promoting an appropriate integration has been continued. The need to coordinate addiction-related care with 
general medical and psychiatric treatment still remains a particular challenge. 
592 There is no central system for education of different professionals, but each structure (organisation) provide 
its own internal way of education. 
593 There is a possibility to choose as voluntary subject at the University level (at two Universities in Slovakia) a 
subject “Introduction into harm-reduction issues”.
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Drug Addiction Treatment", which was translated and published in the Slovak language by the 
Institute for Drug Dependencies in 2000. [NR 2004] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy does not exist, but is pending for approval. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist, but is pending for approval. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist, but is pending for approval. [RT]. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists and was based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy does not exist, as it is no priority for National Government. [RT] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, as it is no priority for National Government. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist, as it is no priority for National Government. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists and was based upon the Council Recommendation. [RT] 
The Slovak Republic is involved in co-operation with EU Member States and regional and local 
institutions and forums, such in line with the global, multidisciplinary and integrated EU strategy 
for combating drugs. Furthermore, the Slovak Republic will continue to develop co-operation with 
the Council of Europe’s Pompidou Group in line with the Work Programme for 2004-2006. Slovakia 
will take a more active part in the work of the European Council’s advisory group – the Horizontal 
Working Party on Drugs (HWPD).  
The Slovak Republic will participate in projects and work of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA). Being part of the European Information Network on Drugs 
and Drug Addiction (Reitox), it will co-operate with national monitoring centres for drugs in other 
EU Member States. [NR 2004] 
2.22.5 Information from third data sources
Issues raised by NGO Odysseus Slovakia 
Information, education, communication (IEC). IEC in general is inadequate. A successful 
example of IEC provided is a smaller peer education program provided by an NGO. Drug testing 
does not exist in Slovakia. 
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Outreach work. Outreach work is only conducted in 7 cities throughout the country and is thus 
inadequate in coverage and accessibility for users.  
(Medically assisted) treatment and other interventions. Specific interventions for cocaine 
users are not available. NSPs and distribution of drug paraphernalia show an inadequate coverage 
and accessibility, as they are only installed in 7 cities and strongly differing in quality. In Slovakia, 
no medically assisted treatment for ATS or cocaine users is available and neither are heroin, ATS or 
cocaine prescription programmes. Medically assisted treatment for opiate users is inadequate in 
coverage and accessibility. Only 2 MMT-Programmes exist in Slovakia. Buprenorphine is more 
easily available, but it depends on the treating psychiatrist whether it becomes available for the 
client. For ATS, it is attempted to provide support in some NSP by providing them with the correct 
material and information. The coverage however is inadequate. The coverage of low threshold 
agencies is inadequate, as only one service point for sex workers exists nationwide. No information 
is available whether there are specific HR interventions targeted at cocaine or ATS users, but NSPs 
also reach the big group of pervertin users reacting to their needs by providing adequate injection 
material. Drug consumption rooms do not exist in Slovakia. 
Prison interventions. IEC is not at all available in prison. No information is available if 
vaccination programmes exist in prison. In prison outreach work is not available. There is no 
tuberculosis vaccination program in Slovakia in prison. Needle and syringe exchange and drug 
paraphernalia are not available in prison in Slovakia. In prison there is no medically assisted 
treatment for drug users. 
Infectious diseases. The coverage and accessibility of hepatitis B vaccination programmes 
targeted at drug users is inadequate throughout the country as there is only one centre throughout 
the country providing the vaccination. There is no tuberculosis vaccination programme targeting 
drug users in Slovakia. 
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Annex A2.23 State of play on harm reduction in Finland 
2.23.1 Summary 
Public health policy. Harm reduction is a public health objective in Finland. It pre-exists the 
Council Recommendation. 
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites and educational leaflets. In some areas, drug 
users’ family members are informed. 
Outreach work. Street-based outreach work is available in specific geographical areas. For the 
reduction of drug-related deaths, outreach work is the predominant setting for the dissemination of 
information materials, and a common setting for the deliverance of risk education/  response 
training. Peers and volunteers are included in outreach work practice in specific geographical areas. 
Networking and cooperation between outreach work agencies exist in the capital area only. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
methadone detoxification programmes, treatment with buprenorphine, drug-free outpatient and 
drug-free inpatient treatment and rehabilitation programmes are available nationwide. Drop-in 
centres and naltrexone are available in specific geographical areas only. There is also a medical 
amphetamine treatment trial ongoing. Drug consumption rooms and heroin prescription 
programmes do not exist in Finland. Opioid substitution treatment is a common response strategy 
aiming at the reduction of drug-related deaths. Measures to prevent diversion of prescribed drugs 
are available nationwide. 
Prison interventions. Methadone maintenance treatment, methadone detoxification treatment 
and buprenorphine treatment are available nationwide in Finnish prisons. Testing, prevention, 
education and treatment of infectious diseases, as well as drug paraphernalia and condoms are 
also nationwide available. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Treatment of HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, 
and vaccination programmes for hepatitis B targeting drug users are available nationwide. To 
prevent infectious diseases among drug users, the predominant response strategies are IEC in 
general, IEC via counselling and advice by drugs and health professionals, voluntary infectious 
diseases counselling and testing, condom promotion among drug users, needle and syringe 
exchange, hepatitis vaccination programmes for drug users and easy access’ programmes to 
treatment of infectious diseases. Needle and syringe exchange and drug paraphernalia are 
available nationwide in Finland.  
Drug-related deaths. The distribution or administration of naloxone is regulated. Naloxone on a 
‘take home’ basis is not available.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals working in treatment facilities, needle and syringe exchange 
programmes, in substitution treatment, low threshold programmes, and prison staff. Risk reduction 
is part of an integrated health strategy for drug users. 
Quality, monitoring and evaluation. In Finland, several studies into harm reduction have been 
conducted, including studies on substitution treatment and low threshold agencies. A guidebook on 
quality criteria for health promotion projects was developed in 2002.  
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2.23.2 Recommendation 1: Risk reduction and public health policy 
In Finland, the governmental structure that is responsible for the implementation of the Council 
Recommendation is the Ministry of Social Affairs and Health594.
The prevention and reduction of health-related harm associated with drug dependence is a public 
health objective in Finland, but was not based upon the Council Recommendation as it existed 
already prior to its adoption. [RT] 
These public health objectives are mentioned in the Finnish Drug Policy Action Programme 2004-
2007. Special legislation, decrees and action plans exist that include preventative and harm 
reduction measures595. [NR 2004] 
2.23.3 Recommendation 2: Risk Reduction activities and interventions 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Finland, the dissemination of information through various websites596, telephone help lines and a 
broad range of educational leaflets is nationwide available. [NR 2003] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) via counselling and advice by drugs and health professionals and IEC in 
general are the predominant response strategies.597 Safer injection training is provided in some 
areas.598 [SQ 23] 
With regard to the reduction of drug-related deaths, the dissemination of information materials 
is an uncommon response strategy whereas risk counselling and risk education/ response training 
are common599 and common settings for this training are low threshold agencies, including needle 
and syringe exchange programmes and through outreach workers/ peers and prisons. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Some NGOs provide information, education and communication on drug use targeting especially 
drug users’ family members600[NFP 2006].
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods; outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Finland, specific geographical areas provide street-based outreach work. In the capital area, 
there are some (pilot) outreach projects at dance parties and rave events601. [NR 2003; NFP 2006]  
594 Department for Family and Social Affairs. 
595 E.g. Decree on Substitution and Maintenance Treatment 289/2002. 
596 www.stakes.fi
597 Health counselling and needle exchange for injectors is increasing in primary health care centres. However, 
geographically it is still very limited and very few visitors have used the harm reduction services in primary 
health care centres. Reference: STAKES 
598 Training is provided by needle exchange services in almost all cities >50,000 inhabitants, and some cities 
with less inhabitants 
599 In those cities where the services for substance abusers are available. Also cities that use services from 
outside provide education / training services indirectly for drug abusers, if there is need and demand for it. 
600 Reference: STAKES. 
601 References: STAKES and A-Clinic Foundation.
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To prevent infectious diseases among drug users, outreaching health education is a rare 
response strategy. Outreach work and targeted high-risk group interventions are a rare 
implementation setting for infectious diseases prevention measures targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes, and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is a common setting for the deliverance of risk education 
/ response training to drug users. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical regions, peers and volunteers are included in outreach work and they are 
offered training in outreach work602. [NR 2003] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In specific geographical regions (the capital area), some of the NGOs involved in outreach work 
exchange information and experiences. Furthermore, information is disseminated through a needle 
exchange sentinel site network, e.g. in annual seminars603. [NFP 2006]  
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance604 and methadone detoxification treatment, treatment with 
buprenorphine605, drug-free outpatient and drug-free inpatient treatment and rehabilitation 
programmes606 are nationwide available. Drop-in centres607 and treatment with naltrexone608 are 
available in specific geographical areas only. Substitution treatment is supported by (obligatory) 
psychosocial care. There is also a medical amphetamine treatment trial609 ongoing. [NR 200/ 2004; 
NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment (with regard to 
the reduction of heroin/opiate overdose) is a common response strategy. [SQ 29]. Drug 
consumption rooms and heroin prescription programmes do not exist in Finland. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are nationwide available610. [NR 2004] 
602 As part of the Viitta project and Operation Snowball. 
603 Reference: STAKES. 
604 Waiting lists exist in Helsinki. 
605 Two third of treated patients receive buprenorphine. 
606 E.g., Kankaanpää A-clinic. 
607 There are drop-in centres for people with dependency problems in larger cities, which also drug users can 
use. There are no special drop-in centres for drug users only. Reference: STAKES. 
608 There is no estimate on the extent of naltrexone use in treatment. Reference: STAKES. 
609 "The effect of methylfenidate and placebo on amphetamine use among amphetamine dependent patients: a 
comparative randomized double-blind trial", see http://www.hdl.fi/amfe/index.html). Reference: Helsinki 
Deaconess Institute. 
610 Prescribed drugs have to be taken under supervision of the health care unit and take home doses are 
restricted. 
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2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing, prevention, education and treatment of infectious diseases are available nationwide in 
prisons. Methadone maintenance treatment, methadone detoxification treatment and 
buprenorphine treatment are also available nationwide611. Drug paraphernalia such as sterile 
water, bleach and ascorbic acid, and condoms are nationwide available in prisons612. Treatment 
with naltrexone is not available. [NR 2002/ 2003; NFP 2006]  
Prisons are a common implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23] 
Aiming at the prevention and reduction of drug – related deaths, prison pre-release 
interventions are a common response strategy. Prisons are also a common implementation setting 
for risk education/  response training for drug users. Information materials are rarely disseminated 
in Finnish prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Nationwide, treatment of HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, 
and vaccination programmes for hepatitis B targeting drug users613,614 are available. In specific 
geographical areas615 testing/ screening for HIV, hepatitis tests and education, prevention and 
counselling is offered.  
[NR 2002/ 2004; NFP 2006] 
Predominant response strategies to prevent infectious diseases among drug users are: IEC in 
general, IEC via counselling by drugs and health professionals, voluntary infectious diseases 
counselling and testing, condom promotion among drug users, needle and syringe exchange 
programmes, hepatitis vaccination programmes for drug users and easy access’ programmes for 
drug users to treatment of infectious diseases, e.g. at low threshold agencies. Common strategies 
include safer injection training for drug users and routine screening of high risk groups. 
Predominant implementation settings for infectious diseases prevention measures include 
specialised drug treatment services and low threshold agencies. Common implementation settings 
are primary care/  GP’s and prisons. [SQ 23; NFP 2006] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Needle and syringe exchange616,617 programmes are nationwide available, as are drug 
paraphernalia618. In specific geographical areas619, condoms are distributed. [NR 2002,2004; NFP 
2006]. Needle and syringe exchange programmes are the predominant response strategy to 
prevent infectious diseases among drug users in Finland. [SQ 23]  
611 If treatment started before imprisonment, treatment can continue. 
612 Reference: Ministry of Justice.
613 Finland has a national risk-group (among others drug users) targeted hepatitis B vaccination programme 
since 1998 
614 Hepatitis A vaccination was added to the general vaccination program for injectors and their partners from 
the beginning of the year 2005. 
615 In health counselling centres in 20 municipalities. 
616 Exchange through 21 health counselling centres; selling of syringes and needles through pharmacies. 
617 Since recently, training is provided for primary health care centres to encourage them to start health 
counselling and needle exchange in their own premises. Reference: STAKES. 
618 Sterile water and ascorbic acid are not available for free in needle exchange services, but they can be 
bought in all the pharmacies. Reference: STAKES. 
619 19 municipalities.
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With regard to the reduction of drug-related deaths among drug users, low threshold agencies, 
including needle and syringe exchange programmes, are a predominant setting for dissemination of 
information materials and a common setting for providing risk education/ response training for 
drug users. [SQ 29] 
Finland has 36 non-pharmacy-based needle and syringe exchange programmes. Fixed sites, van/ 
buses and outreach/ peers are available types of needle exchange; vending machines, pharmacy 
based and prison-based needle and syringe exchange programmes. [ST 10; NFP 2006] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training programmes for professionals of emergency departments do not exist. [NR 2002] 
Emergency departments are not in use as a setting for risk education/  response training that aim 
at the reduction of drug-related deaths. [SQ 29] 
Opiate and benzodiazepine antagonists are carried by paramedic units and physician staffed mobile 
intensive care units (MICU) – that is not all ambulances. The distribution or administration of 
naloxone is regulated by laws. Naloxone is not available on a ‘take home’ basis. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Risk reduction is part of an integrated health strategy for drug users, as it is one of the goals of the 
Drug Policy Action Programme 2004-2007. Development of regional mental health and drug and 
alcohol treatment services is supported by government funding for development work within social 
and health care services620. However, there is no special focus on drug-related harm reduction in 
these development projects621. [NR 2004; NFP 2006]  
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training622 for professionals working in needle and syringe exchange programmes, in substitution 
treatment, low threshold programmes, prison staff and training for professionals working in 
treatment facilities is nationwide available. Training for outreach workers is available in specific 
geographical areas only. [NR 2003/ 2004; NFP 2006] 
2.23.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Finland, several studies were conducted in the field of harm reduction, which provided input for 
future interventions. Examples are:  
Currently a study on the effects of long-term use of buprenorphine, methadone and 
benzodiazepines on patients’ cognitive abilities being conducted in Finland. Furthermore, a study 
investigating the effectiveness and costs of buprenorphine treatment provided exclusively in 
outpatient care is being launched. A double-blind study to investigate the possible side effects of 
buprenorphine-naloxone preparation is also being planned. Results are not available so far.  
In Tampère, an assessment has been made on the role in the local service system of the low 
threshold unit (Matala) open around the clock. The primary task of the unit, opened in 2002, was 
620 For a joint project of National Development Project for Social Services, see www.sosiaalihanke.fi; and 
National Programme to Reform Health Care, see www.terveyshanke.fi.
621 Reference: Ministry of Social Affairs and Health. 
622 Drug training is incorporated into the curricula of social welfare and health care education. Further, there is 
an annual nationwide Intoxicant Days-seminar.
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to motivate and refer clients to treatment. In addition, the unit was supposed to develop treatment 
practices for clients who are incapable of quitting drugs, but still need services. The idea was that 
the concentration of drug treatment clients in one place would untangle care chains and reduce 
waiting lists. [NR 2004].
The first Finnish evaluation of medicinal treatment for drug addicts was completed in early 2002. 
The study concerned detoxification by buprenorphine that started in October 1997 by an outpatient 
programme at the Kettutie A-Clinic in Helsinki and by an inpatient programme in Järvenpää 
Addiction Hospital. The results of the follow-up study suggest that as a medicine, buprenorphine is 
an effective tool for involving the patients in treatment. The evaluation concluded that the 
threshold for accessing detoxification by buprenorphine should be lowered and attention should be 
paid to treatment need assessment, i.e. directing the patients to a form of treatment  – be it 
medicinal or non-medicinal – that best suits them. [NR 2003]  
Based upon these evaluations, in Helsinki, a service centre for HIV-positive drug users has been set 
up. The service centre is the only facility in Finland providing methadone maintenance and this 
treatment has proved to be an effective way to avoid risk behaviour and to reduce HIV infections. 
[NR 2003] 
The so-called VP Project, developing welfare for prisoners with substance abuse problems, was 
evaluated in 1999 (Mutalahti 1999). The project showed that good results can be achieved in 
treatment method development, implementation and evaluation, if the existing resources are 
retargeted, if networks are created with substance abuse services outside prison and if this 
responsibility is assumed by the institution as a whole.  
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist.  
Evaluation is conducted on all prevention and risk reduction programmes funded by ministries. 
NGO's programmes are evaluated, when needed. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The general principles of the Drug Policy Action Programme 2004–2007 (2004) are being adhered 
to. One specific objective includes the development of a quality evaluation form which is based on 
the quality framework for substance abuse services is being prepared for use by municipalities.  
[NR 2004] 
The Finnish Centre for Health Promotion has made good progress in systematising and published a 
guidebook on the quality criteria for health promotion projects (Project support – health promotion 
programme work done by NGOs, 2002). The drug and alcohol prevention project database of the 
Finnish Centre for Health Promotion gives a picture of the ongoing and completed projects in the 
field of drug prevention. At the beginning of 2002, external evaluations of the project proposals 
made by two evaluators were included in the register. The external evaluations were made 
according to the criteria in the guidebook and included numerical assessments and graphs made by 
the two evaluators. [NR 2003]
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
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3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
At the beginning of 2002, the Ministry of Social Affairs and Health presented the proposal of an HIV 
expert team for Finland’s national HIV/  AIDS strategy, concluding that health counselling for drug 
users is one of the most important tools for preventing HIV. Health counselling should be made 
available in all major urban areas in three years, and the activities should include needle 
exchanges. Furthermore, various types of health counselling should be developed. The 
effectiveness and implementation of health counselling was to be evaluated nationally by the year 
2004. [NR 2002] 
In Helsinki, the coverage and efficiency of the local substance abuse services and organisations 
were assessed.623 One conclusion was that drug addicts need more low threshold agencies. [NR 
2004] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] 
2.23.5 Information from third data sources
Issues raised by A-Klinikka Foundation 
Information, education, communication (IEC). IEC coverage and accessibility is inadequate in 
general setting as many drug users do not visit the low threshold centres where IEC is provided. In 
prison, there are only two facilities that allow harm reduction based information to be 
distributed.624 Drug testing is not available in Finland. 
Involvement families and friends is inadequate in all intervention measures. 
Outreach work. Coverage and accessibility of outreach work is inadequate as harm reduction 
based outreach work is only conducted in two Finish cities.  
(medically assisted) treatment and other interventions. Medically assisted treatment for 
opiate users is inadequate in coverage and accessibility as most of the programmes are too 
demanding for heavy drug users. No medical assisted treatment for ATS or cocaine users is 
available in Finland, although a study is conducted to check feasibility of treating amphetamine 
users with benzodiazepine. Finland does not have heroin, cocaine or ATS prescription programmes. 
The coverage and accessibility of NSPs and distribution of drug paraphernalia in Finland is 
considered inadequate, as not all Finnish cities have programmes nor is distribution available in 
623 In the Helsinki project, the client feedback data was collected from various types of service units meant for 
different client groups and having different work practices. Data was collected between 1 November 2002 and 
31 December 2002. The respondents included 107 outpatient clients and 177 inpatient clients. In addition, 25 
specialists and co-operation partners of substance abuse services were interviewed in autumn 2002 and spring 
2003. Questions on the treatment system were also answered by 7 outpatient unit directors and a third of 
senior social workers. (Törmä  et al. 2004). 
624 Tammi, Tuukka (2005): Discipline or contain? The struggle over the concept of harm reduction in the 1997 
Drug Policy Committee in Finland. International Journal of Drug Policy, Vol. 16, Issue 6, pp. 384-392 and 
Tammi, Tuukka (2004): Harm reduction school of thought: three fractions. Contemporary Drug Problems Vol. 
31, no 3, pp. 381-399.
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rural areas.625 Drug paraphernalia distribution is not adequate as most of the programmes refrain 
from distributing sterile water or proper filters. Low threshold agencies are not adequate for drug 
users of illicit drugs as most of the facilities target alcoholics as their primary clients. Members of 
these target groups usually do not interact easily. Drug consumption rooms do not exist in Finland.  
There are no specific harm reduction interventions targeted at cocaine users. Some interventions 
that are originally designed for opiate users are also used for ATS users, but results are considered 
inadequate.  
Prison interventions. IEC coverage and accessibility is inadequate in prison setting. In prison, 
there are only two facilities that allow harm reduction based information to be distributed.626 In 
prison coverage and accessibility of hepatitis B vaccination is adequate. In prison outreach work is 
not available. Drug users that are incarcerated are not eligible for methadone/ buprenorphine 
treatment inside of prison if they have not been enrolled in substitution programmes outside. In 
prison NSPs are not available and only disinfection liquids are distributed. There are no specific 
harm reduction interventions targeted at cocaine users in prison. 
Infectious diseases. The coverage of hepatitis B vaccination programmes is considered adequate. 
A problem occurs with the accessibility as there are not enough low threshold agencies frequented 
by drug users that implement the vaccination for the specific target group. Tuberculosis vaccination 
specifically aimed at drug users does not exist in Finland, as this target group shows no higher 
prevalence than other groups. 
625 Table on distribution and number of NSP programmes in Finland in: Tammi, Tuukka (2005): Diffusion of 
public health views on drug policy: The case of needle-exchange in Finland.p. 190 ff, in: Hoikkala, T., 
Hakkarainen, P. & Laine, S. (eds.): Beyond Health Literacy - Youth Cultures, Prevention and Policy. Finnish 
Youth Research Network, publications 52 & Stakes. Helsinki.  
626 Tammi, Tuukka (2005): Discipline or contain? The struggle over the concept of harm reduction in the 1997 
Drug Policy Committee in Finland. International Journal of Drug Policy, Vol. 16, Issue 6, pp. 384-392 and 
Tammi, Tuukka (2004): Harm reduction school of thought: three fractions. Contemporary Drug Problems Vol. 
31, no 3, pp. 381-399. 
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Annex A2.24 State of play on harm reduction in Sweden 
2.24.1 Summary 
Public health policy. Risk reduction is part of Swedish public health policy, but not all harm 
reduction interventions have been implemented so far.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is provided through 
telephone help lines, training and information leaflets in specific geographical areas only. With 
regard to the prevention of infectious diseases among drug users, IEC in general is the 
predominant response strategy. Policy exists to inform communities and families and enable them 
to be involved in the prevention and reduction of health risks associated with drug dependence, but 
there is no information available on the implementation. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs are available in specific geographical areas only. Outreach work as a health education 
approach is a common response strategy to prevent infectious diseases among drug users. Policy 
exists to encourage the inclusion of peers and volunteers in outreach work practice, and to 
promote networking and cooperation between agencies involved in outreach work, but information 
regarding the implementation is not available. 
(Medically assisted) treatment and specific interventions. Methadone maintenance 
programmes, treatment with buprenorphine, drug-free outpatient and drug-free inpatient 
treatment, rehabilitation programmes and drop-in centres/ shelters are available in specific 
geographical areas. Drug consumption rooms and heroin prescription programmes are not available 
in Sweden. Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Testing/ screening, prevention, education and treatment of infectious 
diseases, counselling and the distribution of condoms are available nationwide. Treatment with 
methadone, buprenorphine, needle and syringe exchange programmes and drug paraphernalia are 
not available in Swedish prisons. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/ screening, education, prevention, counselling, treatment and vaccination 
programmes targeting drug users are available nationwide. To prevent infectious diseases among 
drug users, the predominant response strategies are IEC in general and voluntary counselling and 
testing. Needle and syringe exchange programmes and the distribution of condoms are available in 
specific geographical areas only in Sweden.  
Drug-related deaths. The distribution, possession or administration of naloxone is regulated. 
Naloxone on a ‘take home’ basis is not available. 
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to prison staff. Policy exists to promote appropriate integration between health 
and social care for drug users, but there is no information on the implementation. 
Quality, monitoring and evaluation. Sweden is still developing quality protocols in the field of 
harm reduction. Activities implemented through the National Drug Coordinator should be based 
upon evidence and best-practice.  
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2.24.2 Recommendation 1: Risk reduction and public health policy 
The department that is mainly responsible for the implementation of the Council Recommendation 
is the Swedish Ministry of Health and Social Affairs627. [RT] 
The prevention and reduction of health-related harm associated with drug dependence is part of 
Swedish public health policy, but not based on the Council Recommendation. A Swedish action plan 
on drugs was already in force as the negotiations resulting in the recommendation took place. The 
Swedish drugs policy is in line with the Council Recommendation. [RT] 
Some risk reduction interventions were already in place in 1999 (e.g. substitution treatment with 
buprenorphine). [NR 2004]  
2.24.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Sweden, telephone help lines628, training629 and information leaflets are available in specific 
geographical areas. Websites promoting risk reduction among drug users, do not exist in 
Sweden630. [NR 2002/ 2003] 
To prevent infectious diseases among drug users, information, education, communication (IEC) 
in general is a predominant response strategy, whereas IEC via counselling and advice by drugs 
and health professionals and IEC via peer involvement/  peer approach are common responses. 
Safer injecting training is not available in Sweden. [SQ 23] 
With regard to the reduction of drug-related deaths, individual risk counselling is a common 
response strategy. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation. [RT] 
In Sweden, street-based outreach work631 and outreach work at dance parties, raves and in 
clubs632 are available in specific geographical areas only. [NR 2003/ 2004] 
However, to prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
There is no information available with regard to outreach work as a strategy or setting for 
measures that aim at the reduction of drug-related deaths. [SQ 29] 
627 Division for Public Health. 
628 No staffed help lines are available. 
629 Malmo needle exchange programme offers training in overdose prevention. 
630 Various websites are available, but do not focus on risk reduction. 
631 Outreach work in Sweden is nearly extinct. 
632 However, it is unclear whether this is risk reduction-based.
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2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
No further information available. 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
No further information available. 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Methadone maintenance633 programmes, treatment with buprenorphine634, drug-free outpatient 
and drug-free inpatient treatment, rehabilitation programmes and drop-in centres/ shelters635 are 
available in specific geographical areas. Substitution treatment is supported by (obligatory) 
psychosocial care. [NR 2002- 2004] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a response 
strategy not in use in Sweden. [SQ 29] 
Drug consumption rooms and heroin-prescription programmes are not available in Sweden. 
2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide636. [NR 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening, prevention, education and treatment637 of infectious diseases and counselling 
and the distribution of condoms are available nationwide [NR 2002/ 2003]. After recent changes in 
official guidelines, substitution treatment is now available in Swedish prisons [Swedish Ministry of 
Health and Social Affairs, 2006]. Needle and syringe exchange programmes and drug 
paraphernalia are not available in Swedish prisons. [NR 2003] 
Prisons are a common implementation setting for infectious disease prevention measures 
targeted at drug users. [SQ 23]. Measures targeting at the reduction of drug – related deaths
are not available in Swedish prisons. [SQ 29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Testing/ screening, education, prevention, counselling, treatment and vaccination programmes 
targeting drug users are available nationwide. [NR 2002-2004] 
633 Very strict high threshold programme for in total 800 persons. 
634 It is being prescribed since 1999. 
635 Day care units are seldom available. 
636 Urine check.
637 Vaccination for HBV and HIV guidance is available. 
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To prevent infectious diseases among drug users the predominant response strategies are IEC 
in general and voluntary counselling and testing. IEC via counselling and advice by drugs and 
health professionals, IEC via peer involvement/  peer approach, outreach health education 
approach, condom promotion among drug users, and hepatitis vaccination programme for drug 
users are common response strategies. Predominant implementation settings for infectious 
diseases prevention measures targeting drug users include specialised drug treatment services,
and primary care/ GP. Common implementation settings are low threshold counselling, outreach 
work, targeted high risk group interventions and prisons. [SQ 23] 
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation638. [RT] 
Needle and syringe exchange programmes639 and the distribution of condoms are available in 
specific geographical areas only in Sweden. [NR 2003/ 2004] Needle and syringe exchange 
programmes are an uncommon response strategy to prevent infectious diseases among drug 
users in Sweden. [SQ 23]. However, in April 2006 the Swedish Parliament decided on a new law, 
enabling regional health authorities to provide needle exchange facilities, provided that they can 
guarantee a proper level of treatment and detoxification facilities [Swedish Ministry of Health & 
Social Affairs, 2006]. 
Sweden has 2 non-pharmacy based needle and syringe programmes. [ST 10] There are no specific 
laws on the possession or exchange of needles in Sweden, but if used for illicit drugs, it is 
considered a criminal offence640. Needles can only be bought with a valid prescription. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Swedish ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated641. Naloxone on a ‘take home’ basis is not available. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation. [RT] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Training is offered nationwide to prison staff, and in specific geographical areas to professionals 
working in treatment facilities. [NR 2002/ 2003] 
2.24.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy exists, but was not based upon the Council Recommendation. [RT] 
The interventions initiated by the National Drug Coordinator according to the Action plan are 
generally based on evaluated and evidence based methods.   
638 Needle exchange projects are at present being tried out as a experimental activities. These activities take 
place in two Swedish cities. 
639 2 projects exist, in conflict with repressive policy. There are two needle-exchange programmes in the 
southern county of Skåne – Lund since 1986 and Malmö since 1987 – at the clinics for infectious diseases
640 Article 6 of the Narcotic Drugs Punishments Act (1968:64).
641 Only available on prescription or when administrated by medically trained staff in treatment situations. 
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3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation. [RT]. 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist.  
Evaluation protocols have not yet been implemented within all programmes. The reason for this is 
that the Swedish methods in this area are still in progress. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The new Swedish Drug Action Plan has started a mobilization process based on quality assurance 
and certain central agencies are in a process to develop quality assessment instruments. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation. [RT] 
The interventions and efforts initiated by the National Drug Coordinator (NDCo) are in general 
based on the application of evaluated and evidence-based methods. This approach is progressively 
being adopted also in the regular preventive and demand-reduction work in municipalities not yet 
directly involved in the NDCo’s campaign. [NR 2003] 
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy exists, but was not based upon the Council Recommendation. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation. [RT] 
2.23.5 Information from third data sources
Issues raised by Svenska Brukarforeningen 
Information, education and communication (IEC). Neither IEC for drug users nor drug testing  
is available in Sweden.  
Outreach work. Outreach work for drug users is not available.  
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is inadequate in coverage and accessibility. In the few places where it is available, 
resources are scares, which limits accessibility. There is no heroin prescription program in Sweden. 
Neither medically assisted treatment for ATS or cocaine users nor prescription programmes for 
users of stimulants are available. There are no drug consumption rooms in Sweden. The coverage 
289
11350-HRI Rapport binnenwerk.ind289   289 13-03-2007   14:21:11
290
and accessibility of NSPs is inadequate as NSPs are only implemented in two Swedish cities. Drug 
paraphernalia are not available.  
Low threshold agencies such as drop-in centres and shelters for drug users are not available in 
Sweden. There are no specific harm reduction interventions for ATS or cocaine users.   
Prison interventions. Neither IEC nor outreach work exists in Swedish prisons.   
In prison medically assisted treatment for opiate users does not exist. There are no medically 
assisted treatments or specific HR interventions for ATS or cocaine users available in prison. There 
are no NSPs in prisons and drug paraphernalia are not available. Measures implemented to prevent 
infectious diseases do not exist. Hepatitis B or tuberculosis vaccination programmes targeted at 
drug users are not available in Swedish prisons.  
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Measures implemented to prevent infectious diseases are inadequate in coverage and 
accessibility as there are only two NSPs through which these measures are taken.   
Hepatitis B and tuberculosis vaccination programmes targeting drug users do not exist.  
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Annex A2.25 State of play on harm reduction in United Kingdom 
2.25.1 Summary 
Public health policy. Harm reduction is a public health objective in the UK for many years and 
was stipulated in the National Drug Strategy ‘Tackling Drugs for a Better Britain’ in 1998.  
Information, education and communication (IEC). Information and counselling to drug users 
to promote risk reduction and to facilitate their access to appropriate services is nationwide 
provided through telephone help lines, websites, training and educational leaflets. For the reduction 
of drug-related deaths, dissemination of information materials, risk education/  response training 
and individual risk counselling are predominant response strategies. Communities and families of 
drug users are informed and nationwide involved in the prevention and reduction of health risks 
associated with drug dependence. 
Outreach work. Street-based outreach work and outreach work at dance parties, raves and in 
clubs are nationwide available. Outreach work as a health education approach is a common 
response strategy to prevent infectious diseases among drug users. For the reduction of drug-
related deaths, outreach work is the predominant setting for the dissemination of information 
materials, as well as for the deliverance of risk education/  response training. Peers and volunteers 
are included nationwide in outreach work practice. Networking and cooperation between outreach 
work agencies also exist nationwide. 
(Medically assisted) treatment and specific interventions. Methadone maintenance and 
detoxification programmes, and treatment with buprenorphine are available nationwide. Drug-free 
outpatient and drug-free inpatient treatment, rehabilitation centres, and drop-in centres/ shelters 
are also available nationwide. In specific geographical areas, treatments with naltrexone and heroin 
are available. Drug consumption rooms do not exist in the United Kingdom. Opioid substitution 
treatment is a predominant response strategy aiming at the reduction of drug-related deaths. 
Measures to prevent diversion of prescribed drugs are available nationwide. 
Prison interventions. Methadone maintenance and methadone detoxification programmes are 
nationwide available in prison, and so are counselling, testing/  screening, education, prevention 
and treatment of infectious diseases and vaccination of hepatitis B. Treatment with buprenorphine 
and naltrexone, and the distribution of condoms are available in specific geographical areas only. 
Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Testing/  screening, education, prevention, counselling, and treatment for infectious 
diseases, as well as vaccination programmes against HBV targeting drug users, are available 
nationwide. To prevent infectious diseases among drug users, the predominant response strategies 
are IEC in general, IEC via counselling and advice by drugs and health professionals, and needle 
and syringe exchange. Needle and syringe exchange, drug paraphernalia and the distribution of 
condoms are available nationwide.  
Drug-related deaths. Professionals of emergency departments are trained nationwide, e.g., to 
deal with overdoses. The distribution, possession or administration of naloxone is regulated. 
Naloxone is available on a ‘take home’ basis.
Training of staff and risk reduction as part of a complementary health strategy. Training is 
offered nationwide to professionals in needle and syringe exchange programmes, substitution 
programmes, low threshold agencies, prison, treatment facilities. Risk reduction is part of an 
integrated health strategy for drug users.
Quality, monitoring and evaluation. Evaluation is not a formal aspect of UK drug policy, but it is 
encouraged. A National Treatment Agency was set up in 2001, to increase the capacity, quality and 
effectiveness of drug treatment. The Agency has developed key indicators for that purpose. The 
Scottish Executive has set up an evaluation and assessment scheme, which aims to identify and 
disseminate effective practice in relation to drug use.  
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2.25.2 Recommendation 1: Risk reduction and public health policy 
In the UK, the main responsible governmental structure for the implementation of the Council 
Recommendation is the Department of Health642. UK policy on prevention and reduction of health-
related harm predates the Council recommendation. [RT]. Partnership strategies exist for the 
Scottish Executive and the Welsh Assembly Government. [SQ29] 
One key aim of the Drug Strategy of 1998 to enable people with drug problems to overcome them 
and live healthy and crime-free lives (UKADCU (United Kingdom Anti-Drugs Co-ordination Unit, 
1998). Tackling drugs to build a better Britain. The Stationery Office. London. (http:/ / 
www.archive.official-documents.co.uk/ document/ cm39/ 3945/  contents.htm) These aims were 
restated in the 2002 Updated Drug Strategy (Drugs Strategy Directorate (2002). Updated Drug 
Strategy. Home Office. London) http:/ / www.drugs.gov.uk/ ReportsandPublications/ 
NationalStrategy/ 1038840683/ Updated_Drug_Strategy_2002.pdf. With this update there was a 
commitment to increasing access to treatment and of the prevention of health-related harm. [RT]
2.25.3 Recommendation 2: Risk Reduction services and facilities 
2.1 Provide information and counselling to drug users to promote risk reduction and 
to facilitate their access to appropriate services 
This policy exists, but was not based upon the Council Recommendation643. [RT] 
In the United Kingdom, telephone help lines, websites644, training645, and a broad range of 
educational leaflets are available nationwide. [NR 2003, NR 2004] 
To prevent infectious diseases among drug users, providing information, education and 
communication (IEC) in general, and via counselling and advice by drugs and health professionals 
are predominant response strategies. [SQ 23] 
With regard to the reduction of drug-related deaths, dissemination of information materials, 
risk education/ response training and individual risk counselling are predominant response 
strategies. Information materials are predominantly disseminated at specialised drug treatment 
services, low threshold agencies, incl. needle and syringe programmes, outreach workers; 
detoxification services; prison; and emergency departments, and they are commonly disseminated 
through mass media/ internet, schools and education systems, nightlife and entertainment venues, 
and rave events and festivals. Risk education/ response training is offered in most cities, and is 
delivered predominantly at specialised drug treatment services, low threshold agencies, through 
outreach workers, and in prisons, and is common at primary care/ general practitioners, 
emergency departments, nightlife and at rave events. [SQ 29] 
2.2 Inform communities and families and enable them to be involved in the 
prevention and reduction of health risks associated with drug dependence 
This policy exists, but was not based upon the Council Recommendation646. [RT] 
Communities and families of drug users are involved nationwide in the prevention and reduction of 
health risks associated with drug dependence, and also specific information, education and 
communication is available nationwide for communities and families of drug users647 648. [NFP 
2006] 
642 Department of Sexual Health and Substance Misuse. 
643 Policy in the UK predates the Council recommendation with a range of HIV information and counselling 
services since the late 1980s; an action plan to reduce drug-related death in 2001, a hepatitis C strategy in 
2002. A tuberculosis strategy was implemented in 2004, but does not focus on drug users. 
644 E.g. www.knowthescore.info, www.talktofrank.com. 
645 Campaigns for safer sex and safer injecting. 
646 A major part of UK Drug Strategy is to inform communities and familes and for example in 2003 a major 
communication campaign - FRANK  - was launched (see http://www.talktofrank.com). 
647 See footnote 2; Also, families are involved in overdose training to help reduce drug-related death (see 
http://www.nta.nhs.uk/news/040319.htm / National Treatment Agency for Substance Misuse. (2004 
Commissioning services to reduce drug-related deaths Resource pack for commissioners. National Treatment 
Agency for Substance Misuse. London. http://www.nta.nhs.uk/publications/docs/NTACOMMI.pdf
648 In November 2005 the Scottish Executive Board published its strategy for reducing drug-related deaths and 
as in England one recommendation was that:  The Scottish Executive and Alcohol and Drug Action Teams 
(ADATs) should consider methods to raise the level of resuscitation skills among drug users, family members, 
friends, and social networks. It is recommended that the provision of information and training for families and 
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2.3 Include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of 
working standards and methods;  outreach work is defined as a community-
oriented activity undertaken in order to contact individuals or groups from 
particular target populations, who are not effectively contacted or reached by 
existing services or through traditional health education channels 
This policy exists, but was not based upon the Council Recommendation649. [RT] 
In the United Kingdom, street-based outreach work and outreach work at dance parties, raves and 
in clubs are nationwide available. [NR 2003/ 2004] 
To prevent infectious diseases among drug users, outreach work as a health education 
approach is a common response strategy. Outreach work and targeted high-risk group 
interventions are a common implementation setting for infectious diseases prevention measures 
targeting drug users. [SQ 23] 
Low threshold agencies, including needle and syringe exchange programmes and outreach work 
are the predominant setting for the dissemination of information materials, aimed at the reduction
of drug-related deaths. Outreach work is also a predominant setting for the deliverance of risk 
education/ response training, which is delivered in most cities. [SQ 29] 
2.4 Encourage, when appropriate, the involvement of, and promote training for, peers 
and volunteers in outreach work, including measures to reduce drug-related 
deaths, first aid and early involvement of the emergency services 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Peers and volunteers are included nationwide in outreach work practice650.  There is no information 
about the availability of training for peer and volunteers. [NR 2003; NFP 2006] 
2.5 Promote networking and cooperation between agencies involved in outreach 
work, to permit continuity of services and better users' accessibility 
This policy exists, but was not based upon the Council Recommendation. [RT] 
Networking and cooperation between outreach work agencies is nationwide available. [NR 2003] 
2.6 Provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide 
variety of different treatment options should be provided for the drug-abuser 
This policy exists, but was not based upon the Council Recommendation651. [RT] 
Methadone maintenance, methadone detoxification programmes and treatment with buprenorphine 
are available nationwide. Substitution treatment is supported by (obligatory) psychosocial care. 
Drug-free inpatient and outpatient treatment, rehabilitation centres, and drop-in centres/ 
shelters652 are also available nationwide. In specific geographical areas, treatment with 
naltrexone653 and heroin prescription programmes654 are available. Drug consumption rooms do not 
exist in the United Kingdom. [NR 2003/ 2004; NFP 2006] 
Aiming at the reduction of drug-related deaths, opioid substitution treatment is a predominant 
response strategy. [SQ 29] 
friends of drug users and drug users themselves is further developed across Scotland. Scottish Executive 
(2005). Taking Action to Reduce Scotland’s Drug-Related Death: The Scottish Executive Response to the 
Scottish Advisory Committee on Drug Misuse Drug-Related Deaths Working Group, Report and 
Recommendations. Scottish Executive. Edinburgh.
649 In the UK Outreach is a well established means of working to contact 'hard to reach' groups (see DH (2002 
Models of care for substance misuse treatment: promoting quality, efficiency and effectiveness in drug misuse 
treatment services. Department of Health. London).
650 Peer-outreach and needle and syringe exchange is encouraged through user networks.
651 This has been a key aspect of UK policy with respect to treatment (see UKADCU (United Kingdom Anti-Drugs 
Coordination Unit), 1998 and Drug Strategy Directorate 2002). UK treatment options include drug free and a 
range substitution treatments. 
652 There are drop-in centres, often referred to as advice centre or information centres in all areas. 
653 Used after completion of diacetylmorphine treatment. 
654 300-500 people receive heroin in England and Wales. 
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2.7 Establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment 
This policy exists, but was not based upon the Council Recommendation655. [RT] 
Measures to prevent diversion of prescribed drugs are available nationwide656. [NR 2003] 
2.8 Consider making available to drug abusers in prison access to services similar to 
those provided to drug abusers not in prison, in a way that does not compromise 
the continuous and overall efforts of keeping drugs out of prison 
This policy exists, but was not based upon the Council Recommendation657. [RT] 
Methadone maintenance and methadone detoxification programmes are nationwide available in 
prison, and so are counselling, testing/ screening, education, prevention and treatment of 
infectious diseases and vaccination of hepatitis B. Treatment with buprenorphine658 and 
naltrexone659and the distribution of condoms are available in specific geographical areas only. [NR 
2003/ 2004; NFP 2006] 
There are no needle and syringe exchange programmes in prisons in the United Kingdom, and drug 
paraphernalia are also not available. [NR 2004, NFP 2006]. Prisons are a common implementation 
setting for infectious disease prevention measures targeted at drug users. [SQ23] 
Targeting at the reduction of drug – related deaths, prison-pre release interventions are a 
predominant response strategy, and prisons are a predominant setting for disseminating 
information materials and for delivering risk education/  response training. [SQ29] 
2.9 Promote adequate hepatitis B vaccination coverage and prophylactic measures 
against HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as 
well as screening for all the aforementioned diseases among injection drug users 
and their immediate social networks, and take the appropriate medical actions 
This policy exists, but was not based upon the Council Recommendation660. [RT] 
Testing/  screening, education and prevention, counselling and treatment of infectious diseases and 
vaccination programmes against hepatitis B targeting drug users are nationwide available661. [NR 
2003/ 2004] 
To prevent infectious diseases among drug users the predominant response strategies are IEC 
general, IEC via counselling by drugs and health professionals, and needle and syringe exchange 
programmes. Other, common strategies include outreach health education approach, voluntary 
infectious diseases counselling and testing, condom promotion among drug users, and hepatitis 
vaccination programme for drug users. Predominant implementation settings for infectious diseases 
prevention measures targeting drug users include specialised drug treatment services and low 
threshold counselling services. Common implementation settings are outreach work and targeted 
high risk group interventions, primary care/  general practitioners, prison, and mass media. [SQ 
23]
2.10 Provide where appropriate, access to distribution of condoms and injection 
materials, and also to programmes and points for their exchange 
This policy exists, but was not based upon the Council Recommendation662. [RT] 
655 A number of measures are taken to reduce diversion including pharmacy supervised consumption where 
diversion is most likely to occur and restrictions on the prescribing of some drugs. 
656 Supervised consumption, urine testing, daily pick up and instalment prescribing. 
657 Prison authorities have been working towards providing services comparable to those in the wider 
community for a number years; though substitution treatment is only recently being more widely implemented; 
it is expected that all prisons will offer comparable services by 2007/8. 
658 Theoretically prison provide the same treatments as offered to the general population, but buprenorphine is 
not widely available. 
659 Theoretically it is available to all prisoners, in practice not widely available.
660 Prior to the recommendation all drug services, including in prison, have been encouraged to offer 
information, advice, testing and counselling for all diseases except tuberculosis, and hepatitis B vaccination. 
“Stopping Tuberculosis in England”, an action plan was launched in 2004, but does not target drug users. 
661 Specific campaign on HCV available to all injecting drug users, including those in custody. 
662 Syringe exchange and condom distribution has been established since the 1980s, syringe exchange is not 
available in prisons, but condoms can be prescribed. 
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Needle and syringe exchange programmes, drug paraphernalia663 and the distribution of condoms 
are available nationwide. [NR 2003/ 2004]. Needle and syringe exchange programmes are a 
predominant response strategy to prevent infectious diseases among drug users in the United 
Kingdom [SQ 23]. Low threshold agencies, including needle and syringe exchange programmes, 
also are a predominant setting to provide information materials on the reduction of drug-related 
deaths among drug users and for the deliverance of risk education/  response training. [SQ29] 
The United Kingdom has 453 non-pharmacy based and 1607 pharmacy-based needle and syringe 
exchange points. Fixed sites, van/ bus, outreach / peer and pharmacy based outlets are available 
types of needle and syringe exchange in the United Kingdom. [ST 10] 
There are no legal restrictions to the possession of sterile needles in the United Kingdom, and also 
no prescription is required to obtain or exchange needles and syringes. [ELDD] 
2.11 Ensure that emergency services are trained and equipped to deal with overdoses 
This policy exists, but was not based upon the Council Recommendation664. [RT] 
Professionals of emergency departments are trained nationwide23. [NFP 2006] Emergency 
departments are a common setting for dissemination of information materials that aim at the 
reduction of drug-related deaths or for risk education/  response training. [SQ29] 
British ambulances routinely carry antagonists. The distribution, possession or administration of 
naloxone is regulated by regulation. Naloxone on a ‘take home’ basis is available665. [SQ 29] 
2.12 Promote appropriate integration between health, including mental health, and 
social care, and specialised approaches in risk reduction 
This policy exists, but was not based upon the Council Recommendation666. [RT] 
Risk reduction is part of an integrated health strategy for drug users667 668. [NFP 2006] 
2.13 Support training leading to a recognised qualification for professionals 
responsible for the prevention and reduction of health-related risks associated 
with drug dependence 
This policy exists, but was not based upon the Council Recommendation669. [RT] 
Training is offered nationwide to professionals in needle and syringe exchange programmes, 
substitution programmes, low threshold agencies, prison, treatment facilities. [NR 2003, 2004; NFP 
2006] 
2.25.4 Recommendation 3: Quality assurance, monitoring & evaluation in risk reduction 
3.1 Using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention
This policy does not exist.  
Evaluation is not a formal aspect of policy, but is encouraged. A National Collaborating Centre for 
Drugs Prevention was set up in 2004 and may look look at harm reduction projects, evidence 
based practice is the norm and there is a history of local evalaution of drug services. [RT] 
The National Treatment Agency (NTA) was created by the Government on 1 April 2001 with a remit 
to increase the capacity, quality and effectiveness of drug treatment in England. The NTA will 
663 Swabs, utensils for the preparation of a controlled drug, citric acid, sterile water, filters (as of august 2003).
664 Reducing deaths – resource for Accidents and Emergency departments staff was published in 2004 
http://www.nta.nhs.uk/publications/docs/reducing_deaths.pdf.
665 Only in England. This intervention was first piloted in 1999. 
666 This is key aspect of UK Drug Strategy with local Drug Action Teams expected to ensure integration between 
a range of commissioners and providers. 
667 The main target for drugs misuse is to reduce the harms caused by drugs  
668 In England and Wales the Drug Interventions Programme has been developed to integrated services fully for 
those accessed in to services through the criminal justice system, while the focus is on crime and social 
reintegration, health harms are also part of the programme.  See http://www.drugs.gov.uk/drug-interventions-
programme.
669 A range of training programmes have been developed for professionals, including GPs (through the RCGPs), 
prison health care staff and nurses as well as drugs workers.
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promote practice which is evidence-based, appropriately delivered, outcome focused, and 
integrated into a system of co-ordinated drug treatment and care. To equip Drug Action Teams at 
local level (DAT) and service providers to meet this agenda the NTA will: 
o distil and disseminate best practice drawn from research; 
o collaborate with others to initiate research into effectiveness; 
o support the development of quality systems of treatment promoting and building 
o on existing good practice; 
o develop systems of standards and accreditation for services, individuals and 
o programmes of interventions; 
o enhance the competence of managers and staff across the treatment sector; and 
o develop and implement a human resources strategy to attract and retain high 
o quality staff with drug treatment as a career. 
The national drug strategy recognized the need for an increased focus on the provision of effective 
drug treatment services that will work effectively with other health, social care and criminal justice 
service providers in order to provide seamless treatment and care to substance misusers. This has 
resulted in the development of a range of guidance documents on ‘what works’ based on a review 
of research evidence. [NR 2002] 
3.2 Supporting the inclusion of needs assessments at the initial stage of any 
programme
This policy exists, but was not based upon the Council Recommendation.  
Needs assessment is a common aspect of commissioning. [RT] 
3.3 Developing and implementing adequate evaluation protocols for all drug 
prevention and risk reduction programmes 
This policy does not exist.  
Performance monitoring is common, but there are no established evaluation protocols. [RT] 
3.4 Establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
This policy does not exist.  
It is not known whether any organisations involved in evaluation in the UK actively take account of 
evaluation tools developed by EMCDDA  or held by the the EMCDDA Evaluation Instruments Bank. 
[RT]
The NTA has identified four Key Performance Indicators (KPIs) to review the provision of services in 
each DAT area. The purpose of the KPIs is to allow meaningful comparison of services provided to 
local populations. These KPIs will provide information to assess the quality of local service 
provision, and therefore assist DATs and commissioners to make informed commissioning choices 
by enabling meaningful comparison between local service providers and the system of service 
provision in one DAT area with another. 
Through the DAT plans, DATs have to report on organisational arrangements, planning process, 
implementation, performance monitoring and communication with stakeholders. DATs have to 
comply with quality standards across these core activities. [NR 2003]. 
3.5 Organising standardised data-collection and information dissemination according 
to the EMCDDA recommendations through the REITOX national focal points 
This policy exists, but was not based upon the Council Recommendation.  
UK Focal Point, based in the Department of Health, is responsible for working towards standardised 
data collection in the UK. [RT] 
3.6 Making effective use of evaluation results for the refining and development of 
drug prevention policies 
This policy exists, but was not based upon the Council Recommendation.  
The Government commissions a range of research projects and evaluations which are taken 
account of in the development of prevention policy. [RT] 
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The breadth, complexity and intensity of drug policies means that the UK drug strategy is 
'monitored', 'tracked' and 'performance managed' rather than 'evaluated'. There is no formal 
evaluation framework, but there is a very large amount of monitoring work on drug prevalence, 
uptake of treatment and drug supply. This work centres on a framework of drug strategy targets. 
Although England and Wales, Scotland and Northern Ireland have separate sets of drug targets, 
essentially all focus on the same key areas.  
The Scottish Executive’s Effective Interventions Unit (EIU) has a remit to identify and disseminate 
effective practice in relation to tackling drug misuse in Scotland. Evaluation forms a core element in 
achieving this. Activities include: 
x Reviewing, distilling and disseminating evidence from existing evaluation literature, e.g. on 
specific interventions such as training and employment initiatives for drug users; 
x Supporting efforts to improve evaluation practice, e.g. commissioning evaluation 
workshops for every Drug Action Team (DAT) in Scotland; 
x Providing accessible and practical evaluation guides to inform policy makers and 
practitioners working to tackle drug misuse, e.g. EIU series of Evaluation Guides covering 
issues such as definitions, planning and outcomes; 
x Commissioning evaluations of key initiatives or programmes e.g. evaluation of Scottish 
Prison Service Transitional Care Initiative.  
3.7 Setting up evaluation training programmes for different levels and audiences 
This policy does not exist, as it is not a priority for National Government. [RT] 
3.8 Integrating innovative methods that enable all actors and stakeholders to be 
involved in evaluation, in order to increase acceptance of evaluation 
This policy does not exist, as it is not a priority for National Government. [RT] 
3.9 Encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries 
This policy exists, but was not based upon the Council Recommendation.  
UK contributes to the Exchange on Drug Demand Reduction Action (EDDRA). [RT] 
2.25.5 Information from third data sources
Issues raised by United Kingdom Harm Reduction Alliance (UKHRC) 
Information, education and communication (IEC). IEC is adequate in coverage. Drug testing 
is not available in the UK.  
Outreach work. Outreach work is inadequate in coverage. 
(Medically assisted) treatment and specific interventions. Medically assisted treatment for 
opiate users is adequate in coverage, but inadequate in accessibility as waiting lists are long in 
some areas of the country. Substitution drugs used are methadone and buprenorphine. 
The coverage of the heroin prescription program in the UK is inadequate. No information on 
medically assisted treatment for ATS or cocaine users is available. The coverage of ATS 
prescription programmes is inadequate and cocaine prescription programmes are not available. 
Specific harm reduction interventions targeted at cocaine or ATS users exist in counselling and day 
programmes which are generally available. There are no drug consumption rooms in the UK. NSPs 
are adequate in coverage, but there is inadequate access to specialist and pharmacy-based 
services which constitute optimized provision. Drug paraphernalia distribution is inadequate in 
coverage. The same holds true for low threshold agencies that are inadequate in coverage    
Prison interventions. Availability and accessibility to substitution treatment is inadequate.  
There are no needle and syringe exchange programmes in UK prisons and drug paraphernalia are 
not available. Hepatitis B vaccination is available, but inadequate in accessibility as programmes 
are not sufficiently user-friendly. Tuberculosis immunization takes place for all nationals at the age 
15 rather than in prisons.  
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Infectious diseases (HIV, hepatitis B and C, tuberculosis and sexually transmitted 
diseases). Hepatitis B vaccination programmes are offered, but often enough access is not 
sufficiently user-friendly. Tuberculosis vaccination programmes are offered to the whole population 
at age 15 while at school.
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Annex 3 Special Issues 
In this Annex, special attention is paid to 
issues that are often debated in the field of 
harm reduction. These specific themes 
are: drug consumption rooms, heroin 
prescription, pill-testing and harm 
reduction in prisons.  
A3.1 Drug Consumption Rooms 
A3.1.1 Definition 
With the term drug consumption rooms 
(also labelled as ‘supervised injection 
facilities’ or ‘safer injection rooms), 
locations are meant that are legally674
established and organised specifically to 
allow drug users to use their drugs (in 
general by smoking and/ or injecting) in a 
(medically) supervised and safe 
environment. The main objective of 
creating drug consumption rooms is to 
reduce health-related harm associated 
with drug consumption, both for the drug 
user (private harm, e.g. the reduction of 
overdose (death) or infectious diseases) 
and his or her environment (public harm, e.g. prevent scattering of used needles, open drug 
scenes).
In the scientific community there is growing consensus to describe drug consumption rooms as: 
“protected places for the hygienic consumption of pre-obtained drugs in a non-judgemental 
environment and under the supervision of trained staff.” 675
A3.1.2 Background history 
Drug consumption rooms exist for over two decades. Starting in Switzerland, there are now drug 
consumption rooms in six European countries (Germany, Spain, the Netherlands and Luxembourg 
within the European Union, and Switzerland and Norway outside the EU) and in Canada and 
Australia. In Switzerland and especially the Netherlands, strong emphasis was placed on reducing 
public nuisance from the start. In other countries, such as Spain and Canada, private health-
related harm, in particular overdose deaths, have been a driving force behind the setting up of 
drug consumption rooms.676
A3.1.3 Rationale and objectives 
In a recent report on drug consumption rooms677, the EMCDDA describes that the overall rationale 
for drug consumption rooms is to reach and address the problems of specific, high-risk populations 
of drug users, especially injectors and those who consume in public. These groups have important 
health care needs, which are often not met by other services and pose problems for local 
670 Regulated by Law in 2001, not yet implemented. 
671 In Luxembourg, the introduction of heroin prescription is an aim in the National Drugs Action Plan 2005-
2009, but it was decided to wait with introduction until the evaluation of the development and impact of the 
Drug Consumption Room in 2008 (Source: NFP 2006).  
672 In the Netherlands, on-site pill testing facilities do not exist anymore. 
673 In Portugal, pill testing projects in mobile units are currently suspended, pending regulation (Source: IDT, 
Lisbon). 
674 Besides these official facilities, illegal or unofficial drug consumptions rooms exist; e.g. ad hoc locations for 
incidental drug use, but also more structured but not legal places which directly stem from the drug scene.  
675 AkZept [2000] in: Hunt [2006].  
676 Hunt [2006]. 
677 Hedrich [2004].
Type of 
intervention 
Availability in 
EU Member 
States
Availability in 
non-EU Member 
States
Drug 
Consumption 
Rooms  
(Ref.
Recommendation 
6.2.6) 
Germany, the 
Netherlands, 
Spain and 
Luxembourg, 
Portugal670
Switzerland 
Norway
Canada
Australia
Heroin 
prescription  
(Ref.
Recommendation 
6.2.6) 
Germany, Spain, 
the Netherlands 
and United 
Kingdom 
Expected: 
Luxembourg671.
Switzerland 
Canada
Pill testing 
facilities for 
drug users 
(Ref. 
Recommendation 
6.2.1)
Austria, Belgium, 
Czech Republic, 
Spain, the 
Netherlands672,673.
Australia
Table 5.1 – Availability of selected harm reduction 
interventions
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communities that have not been solved through other responses by drug services, social services 
or law enforcement. 
The EMCDDA report also identifies some of the specific objectives of drug consumption rooms, such 
as: to establish contact with difficult to reach populations of drug users; to provide a safe and 
hygienic environment for drug consumption, in particular, injecting drug use; to reduce mortality 
and morbidity associated with drug use as a result of overdose, to prevent transmission of HIV, 
hepatitis, and bacterial infections; to promote access to other social, health and drug treatment 
services; to reduce public drug use and associated nuisance. 
A3.1.4 State of play 
In 1986, the first official drug consumption room was established in Bern, Switzerland. In the early 
nineties, the Netherlands and Germany introduced drug consumption rooms. In 2000, drug 
consumption rooms were opened in Spain. In 2005 Norway and Luxembourg opened their first 
drug consumption room. Outside Europe, legal drug consumption rooms were opened in Sydney, 
Australia in 2001 and in Vancouver, Canada in 2003. It is estimated that currently around 110 drug 
consumption rooms exist worldwide. Roughly 40-45 of them are concentrated in the Netherlands, 
about 25 in Germany and Switzerland. Around 10 drug consumption rooms exist in various 
geographical areas of Spain. Norway, Luxembourg, Australia, and Canada. The number of drug 
consumption rooms tends to increase slightly year by year. 
A3.1.5 Effectiveness of drug consumption rooms 
The results of a long-term study in four German cities show a substantial association between the 
presence of a drug consumption room and a reduction of the number of drug-related deaths. This 
relationship was maintained after corrections for other potential explanatory factors.  
A second study in Vancouver (among far less participants than the German study) suggests that 
drug consumption rooms reduce needle sharing among injecting drug users.  
Thus, drug consumption rooms possibly reduce needle sharing and overdose death among opiate 
users but more studies are needed to draw more firm conclusions. For a more detailed description. 
See Annex 1, paragraph 4.5 
A3.1.6 Discussion 
In discussions about the establishment of drug consumption rooms, a number of assumed 
disadvantages are frequently mentioned. Opponents fear that people other than the intended 
target group might use the service and that new people could be recruited into drug use. 
Furthermore, drug consumption rooms might attract increasing numbers of drug users from other 
neighbourhoods or cities (‘pull effect’)678. However, in the available scientific studies, no such 
negative results of drug consumption rooms were found. 
A3.1.7 Factors to increase effectiveness 
As indicated above, drug consumption rooms may be effective. However, there are important 
differences between existing drug consumption rooms that influence effectiveness. It is important 
to keep the following conditions in mind:  
1. Be aware of the consequences of inclusion and exclusion criteria. The establishment of drug 
consumption rooms is often accompanied by a number of thresholds to limit access to 
specific groups. If limitations are too strict, an unwanted effect may be that high-risk 
groups and individuals may be excluded from these facilities with the result that they may 
continue their risky drug use in public spaces. 
2. House-rules inside the drug consumption room would best aim to encourage users to enter 
(e.g. allow ‘street practices’ such as drug sharing, allow more visits in line with the 
consumption pattern of a user). 
3. Inside drug consumption rooms it is not allowed to buy and sell drugs. The implication may 
be that side-effects occur. For example, drug dealers may hang around in the 
neighbourhood, causing public nuisance for local residents and bad deals for drug users.  
A3.1.8 Recent developments 
In Catalonia, Spain some new concepts have been introduced last year. These include for example 
the re-establishment of a mobile drug consumption room (a bus) with facilities to inject drugs, and 
a treatment centre that includes a drop-in service with 3 injecting places679. In Portugal, the 
678 Hedrich [2004].
679 Source: Xavier Major Roca; Programme on Substance Abuse, Department of Health, Autonomous 
Government of Catalonia, Spain. 
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establishment of drug consumption rooms, inscribed in the national legislation since 2001, has 
been under discussion for some time. Several proposals made in Parliament included their 
establishment in prison settings as well. In that case Portugal would become the first country in the 
world to have a drug consumption room in prison680. In Summer 2006, the Portuguese government 
approved the establishment of supervised drug consumption rooms by 2008681.
A3.2 Heroin prescription 
A3.2.1 Definition 
Heroin prescription means the controlled prescription of pharmaceutical heroin682 to heroin 
dependent drug users. As such, it might also be considered as substitution treatment (it substitutes 
low purity and usually bad quality street heroin with pure factory-made diacetylmorphine). 
A3.2.2 Background history 
In the United Kingdom, licensed physicians have prescribed heroin to opiate dependent users since 
the 1920s.683 In contrast with the rest of the world, physicians in the United Kingdom are allowed 
to prescribe any drug that is expected to benefit their patients. Currently, in the United Kingdom 
46 general practitioners have a license to prescribe diacetylmorphine to their patients. It was only 
in 1994, that prescription of heroin was initiated elsewhere in the Western world. In that year, 
Switzerland started a heroin prescription trial aimed at opiate dependent users. In the years that 
followed, other trials were conducted the Netherlands, Germany, Spain and Canada (Vancouver). 
A3.2.3 Rationale and objectives 
Treatment practice for drug users has learnt that for a specific subpopulation of drug users, regular 
available treatment (e.g. methadone maintenance, detoxification, therapeutic communities, and 
others) is ineffective684. Despite repeated attempts of drug users in this group, treatment does not 
lead to lasting results such as abstinence, reduced drug use and/  or the improvement of their 
personal health situation. The prescription of heroin to this group of drug users is expected to have 
a positive effect on both the personal health of the drug user and his environment.  
The assumption behind heroin prescription is that it has many of positive effects: 
- it may lead to an improvement of the personal health situation of drug users (physical, 
mental and social) 
- more drug users may be persuaded to seek and continue treatment 
- it may help some drug users to reduce or stop their illicit drug use 
- it may reduce the number and severity of criminal offences undertaken by the drug users 
involved in the programme 
- it may lead to benefits for society as a whole, e.g. by a reduction in public nuisance 
(reduction in drug-dealing activities, reduction in drug-related crime, lower health & social 
costs for society). 
In contrast with these assumed benefits to individual and society, opponents of this treatment 
stress possible disadvantages or risks related to the prescription of pharmaceutical heroin to heroin 
dependant drug users. The most persistent is that this prescription will de-motivate heroin users to 
stop their drug use, because the provision of  free and pure heroin will not stimulate the recipient 
to quit the use of this substance. However, once stabilised, part of the participants of heroin 
prescription treatment are likely to start other forms of treatment, including abstinence oriented 
treatment685.
A3.2.4 State of play 
In the European Union, four Member States (Germany, Spain686, the Netherlands687 and the United 
Kingdom688) run heroin prescription programmes. In Belgium and Luxembourg controlled 
680 Sources: Luis Mendão (NGO Abraço, Lisbon) and IDT (Lisbon). 
681 Source: www.todayonline.com/articles/138396print.asp
682 Also known as diacetylmorphine 
683 Jones J. [1995]. 
684 Van den Brink [2003]. 
685 Rehm [2001]; Naaber & Haasen [2006]. 
686 Two trials are running. Source: Spanish National Focal Point [2006]. 
687 This includes only medical co-prescription of heroin alongside methadone. The government decided that 
places at treatment units for medical prescription of heroin to chronic treatment resistant opiate addicts can be 
extended up to 1000 places. 
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prescription of heroin may start in the near future. Elsewhere in Europe, heroin is prescribed to 
opiate dependent drug users in Switzerland only, where it is available in a medical setting 
nationwide. Heroin prescription was also introduced in Vancouver, Canada in February of 2005. 
Despite discussions about this type of treatment, Australia so far has not provided in heroin 
prescription. 
Other countries, such as the Netherlands, Switzerland and Germany have started heroin 
prescription through experimental trials. Both countries have prolonged and extended their heroin 
prescription programmes after finalisation of the trials. In the Netherlands, only medical co-
prescription of heroin (in combination with methadone) exists, and takes place in a clinical setting. 
A3.2.5 Heroin prescription in practice 
Heroin is prescribed in different ways, and under different circumstances. In the UK, a small group 
of drug users can obtain a prescription for heroin from a licensed general practitioner or drug 
dependency clinic doctor specialised in drug dependence. The heroin is dispensed from a 
community or hospital pharmacy for unsupervised injection at home, as part of clinical practice689.
In the Swiss, Dutch and German trials heroin was dispensed and consumption supervised at the 
clinic as part of research studies. In the Netherlands a cabin with negative air pressure was 
provided for those smoking heroin. Patients may receive three dosages a day, seven days a week. 
The daily maximum is 1000mg, the maximum dose per visit 400 mg.  
A3.2.6 Effectiveness of heroin prescription 
Medical heroin (co)prescription for heroin dependent drug users probably improves physical health 
and psychosocial well-being for those who are not responding to maintenance treatment. In 
countries with comprehensive treatment systems (including easily accessible maintenance 
treatment), heroin prescription may be a valuable additive option for these groups. However, 
heroin prescription is generally not considered as a treatment of first choice and there is consensus 
that it should not be implemented instead of, or at the expense of methadone maintenance 
treatment. Six new effect studies on heroin prescription are underway. For more detailed 
information, see annex 1, paragraph 4.2. 
A3.2.7 Conclusions 
The positive results of heroin prescription include a stronger commitment to (this) therapy among 
participants, an improved health status, reductions in drug-related offences and stabilised or 
improved social conditions. 
According to the Dutch study, heroin prescription can be recommended in addition to methadone 
substitution for chronic heroin users who fail in methadone treatment. The German study shows 
positive results among those not reached by conventional treatment and also without the context 
of methadone maintenance. These results support implementation of heroin prescription 
programmes to treat specific subpopulations. However, the trials are conducted in countries with a 
comprehensive treatment system including easily accessible methadone maintenance treatment. 
Here, heroin prescription seems to be a valuable addition to the treatment system. However, 
heroin prescription is not considered as a treatment of first choice and should not be implemented 
instead of, or on the expense of methadone maintenance treatment.  
Further research may explore the generalisibility of the results in heterogeneous social and 
treatment contexts690. It is expected that ongoing studies in Spain and Canada (and in the future 
possibly Belgium, Luxembourg and Australia) will gain additional knowledge and experience on this 
topic. In the framework of these future studies, one issue that certainly requires further discussion 
concerns the question whether it is ethically acceptable to terminate heroin prescription trials for 
those opiate dependent users that are participating in them, especially if the results are positive.  
688 300-500 persons receive heroin in England and Wales. 
689 Hunt [2003]. 
690 Cochrane collaboration [2005]. 
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A3.3 Pill testing 
A3.3.1 Definition 
The term pill-testing in the context of illicit drugs usually refers to the testing of ecstasy pills. There 
are roughly two types of pill testing. On-site pill testing is often done during rave parties or other 
club scenes and involves a physical test and an acid-test. By making use of the physical test (e.g. 
diameter, thickness, colour and logo) and the acid test, the pill is classified and compared to an 
existing list of ecstasy pills. Information is given on-the-spot, accompanied with preventative 
information. In Spring 2006, on-site pill-testing was available in Austria, Belgium, Czech Republic 
and Spain. In the Netherlands a test possibility is available to drug users, which includes laboratory 
analysis. In this test the composition of a pill is tested (e.g. MDMA concentration, other chemicals, 
etc.). Participating drug users receive the test-results.  
A3.3.2 Background 
During the eighties, a new cultural phenomenon emerged: the dance, ‘house’, ‘rave’, or ‘techno’ 
culture. This culture, based on various forms of electronic dance music, quickly gained popularity 
among young people throughout Europe. This new trend was, among other things, accompanied by 
the use of new types of drugs. From its start this rave scene was associated with the use of 
synthetic drugs, especially ecstasy pills. This type of drug use was of a ‘recreational’ character as 
its users seemed to manage to use drugs in a more or less controlled way (only during weekends 
and at parties) as opposed to the traditional opiate dependent drug user.  
As a result of these changes, the use of ecstasy called for a different approach from drug 
prevention workers. Secondary (selected) prevention historically was targeted at opiate drug users. 
With the increasing popularity of ecstasy, new health-risks emerged that required attention. Among 
others, there was a growing concern regarding the content of pills that were sold as ecstasy, but 
that in fact contained a great variety of other substances. Information indicating wide variability in 
pill composition and a number of deaths across Europe. Particularly in Great Britain this led to 
widespread popular media coverage alleging contaminated pills’691.
During the nineties, EU Member States joined forces. In 1997, a Joint Action on new synthetic 
drugs was set up with a view to serve as an early warning system among Member States to detect 
and assess the risk of new synthetic drugs692. In 2005, this Action was replaced by the Council 
Decision on the information, exchange and risk-assessment and control of new psychoactive 
substances693.
In the early nineties, in the Netherlands the Drug Information and Monitoring System (DIMS) was 
established. It aims to serve public health by minimizing the adverse consequences of the use of 
drugs at an individual and societal level. Its foundations lay in information exchange between users 
and monitoring authorities694. In the period 1992-1998, DIMS was engaged in on-site pill testing, 
but when it was prohibited by law to continue this practice, the service shifted to stationary testing 
only695.
In the nineties, other countries such as Germany, Austria and Switzerland introduced pill testing 
schemes as well. These services mainly concerned on-site pill testing (in clubs and raves). In 
addition to formally appointed organisations involved in pill-testing, a large number of small-scale 
services introduced unofficial pill-testing as well, usually as a result of a spontaneous action of 
clubbers and their networks. Pill testing in other EU countries than those mentioned above usually 
concerns laboratory testing of pills that were seized by police and/  or customs.  
A3.3.3 Rationale and objectives 
The overall aim of pill-testing is to warn against harmful and unexpected drugs or 'pollution' of 
known substances with unexpected and possibly dangerous chemicals that currently are on the 
market, e.g. on site or via the Internet (harm reduction). As such it is a good outreach mechanism 
691 Winstock [2001]. 
692 EMCDDA [2001]. 
693 Council Decision 2005/387/JHA. 
694 Winstock [2001]. 
695 Through a countrywide network of local DIMS focal points, (synthetic) drugs are collected from users and 
forwarded to DIMS for (laboratory) analysis. If tests show the presence of harmful chemicals, a ‘red alert’ is 
issued (in consultation with the Ministry of Health) after which all drug prevention services, the media and the 
Early Warning System is informed about the health hazard. In the past, red alerts have been issued for pills 
that were polluted with e.g. atropine and strychnine.  
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to get in touch with potential consumers and those who may engage in risky behaviour. Pill-testing 
furthermore is a one-on-one prevention tool by properly informing potential users about health-
related issues with regard to the use of ecstasy (such as the risk of de-hydration). Finally pill-
testing is also an important tool for monitoring and evaluation purposes; by analysing pills, one 
gains knowledge and insight about which drugs appear on the market but also about changing 
patterns in drug use. 
An important aim of on-site pill-testing practices is to give information about the tested pills, about 
the presence of dangerous and new pills, but also about the dosage of substances in pills (harm 
reduction). The choice whether or not to take a drug is the responsibility of the individual user.  
Thus, an important feature in pill-testing practice is to inform potential users by enabling them to 
make an informed choice, i.e. based on available facts. Compared to on-site testing, stationary 
pill-testing (e.g. in laboratories and only in some countries) is more time consuming and the direct 
harm reduction impact of this service may be more limited. These testing facilities have an 
important function in monitoring. 
Pill-testing projects usually also offer information talks and crisis intervention696 (EMCDDA 2001). 
On-site pill testing is one of the few existing methods to approach drug consumers directly and to 
transmit “safer-use” messages that cover a variety of topics such as acute and short-term hazards 
to health (e.g. dehydration, overdoses), long-term hazards to health and addiction, legal risks and 
safer driving messages (EMCDDA, 2001). Pill-testing brings to the surface severe pollutions, and 
thus it provides important messages to prevention workers, authorities and the public.  
From a monitoring perspective, pill testing data are an important prerequisite to set up and 
improve information and prevention projects and to plan scientific studies on patterns of use and 
related dangers. Results of on-site pill-testing adds insight information about drug markets. It may 
also give qualitative and quantitative data on consumers of illicit substances697.
A3.3.4 Some considerations 
Besides the above-mentioned possible benefits of pill-testing, it should also be borne in mind that 
pill testing remains superficial. An ‘OK’ test result does not mean that it is safe to take the tested 
pill. On site colour (or Marquis) tests do not give a 100% secure result about the content of the 
tablet, and some substances (such as PMA) – if present - are not detected at all. Laboratory testing 
gives more reliable results, but is less attractive to potential consumers because it takes more 
time.
A3.3.5 State of play 
According to the National Focal Points, in spring 2006, six Member States provided drug testing to 
drug users, mainly pill-testing. This service is available in Austria698, Belgium (Walloon Region), the 
Czech Republic, Spain and the Netherlands699. An NGO in Ljubljana also mentions the existence of 
the service in Slovenia700. In a number of countries such as France and Germany, this services has 
been discontinued as a result of changes in law (making the service illegal) or as a consequence of 
the discontinuation of funding of these services.
A3.3.6 Effectiveness of pill-testing 
Sufficient knowledge on the effectiveness of pill testing programmes is still lacking. Some studies 
indicate that pill testing may decrease the use of potentially dangerous drugs. Pill testing 
programmes have several disadvantages. Firstly, pill testing methods are not standardised. 
Secondly, simple tests like colour tests give limited information about the content of synthetic 
drugs. This necessitates full laboratory analysis. Thirdly, pill testing is only one factor influencing 
drug use in recreational settings and probably not the most important one. Pill testing is not 
expected to diminish drug use. On the other hand, pill testing probably does not stimulate non-
users to start with drug use, either. Furthermore, pill testing facilities allow for the monitoring of 
696 E.g. First Aid in case of Drug Accidents: trainings for staff of clubs and pubs.  
697 EMCDDA [2001]. 
698 In Austria, the programme ChEckIT! in nightlife and party scene - provides information on-site, by printed 
material as well as via the website, and also runs an on-site pill testing programme www.checkyourdrugs.at
699 In the Netherlands, the Drug Information and Monitoring System (DIMS; Trimbos Institute) analyses drug 
samples of consumers delivered at drug treatment services. DIMS covers a large part of the country, visit 
www.drugs-test.nl for an overview of cities. 
700 However, it is unclear whether this concerns a test service for drug users or the sale of testing kits.  
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trends in the composition of synthetic drugs. For more detailed information, see Annex 1, 
paragraph 4.3. 
A3.3.7 Recent developments 
In general, the availability of pill-testing services in the European Union changes rapidly and is kept 
low profile, because this service is often considered controversial. Sometimes, changes in 
legislation make pill-testing impossible, which leads to a shift in testing practices. Instead of using 
a Marquis (colour) test, testing practice may move towards thin-layer chromatology (TLC). Finally, 
pill-testing often takes place in a voluntary, unstructured setting, which may cause some 
disruptions in terms of continuity in pill-testing practice. Probably therefore an exact number of 
services is not available. 
A3.4 Harm reduction in prison settings 
A3.4.1 Definition 
The WHO describes harm reduction in prisons as aiming to prevent or reduce negative health 
effects, among others associated with certain types of behaviour (such as injecting drug use and 
unprotected sex). According to the WHO, successful harm reduction is based on a policy, legislation 
and a social environment that minimises the vulnerability of problematic drug use. Such 
approaches recognise that many drug users cannot totally withhold or withdraw from psychoactive 
substances in the short term, even when imprisoned. And these approaches aim to help (potential) 
drug users not only not to start nor to stop drug use, but also to reduce their injection frequency 
and to increase injection safety701.
A3.4.2 Background 
In prisons, drug users are overrepresented as a percentage of the total prison population when 
compared to drug users in society (e.g., in the UK the prevalence of heroin use in a prison 
population has been found to be 40 times higher than would be expected from a random 
population sample)702. With an annual turnover of 50-100 inmates per 100.000 inhabitants in 
European prisons703, prisons are an integral part of society. 
In a large number of EU countries, the prevalence of HIV and viral hepatitis is also higher among 
prisoners than in the general population704. Because drug users employ in risky behaviours (e.g. 
sharing of drug equipment or unprotected sex), prisons also play a key role in the spread of 
infectious diseases. Another specific form of drug-related harm associated with imprisonment is 
mortality from overdose after release from prison. Drug users who start drug consumption again 
after a period of abstinence in prison, have a reduced drug tolerance. Consequently their risk of 
taking an overdose has increased considerably, especially in the first weeks after release705.
The first harm reduction interventions in prison were introduced in the eighties. In Switzerland 
interventions were set up in which information leaflets were provided and condoms distributed 
among prisoners706. Today, these interventions are available in prisons in many countries. Although 
most prisons have a drug-free policy, maintenance treatment in prison is gaining ground (see  
5.3.8). At the same time, needle and syringe exchange in prisons is still highly controversial. 
In the mid-eighties, the so called principle of equivalence has been formulated, which entails “that 
prisoners should have access to the same medical and health care services as outside prison, and 
that the professional standards of care and cure provided outside should be applied also in prison.
Prisoners have the right to receive the highest attainable standard of physical and mental health”
707. The United Nations have adopted a resolution on the basic principles of the treatment of 
prisoners, in which it calls for implementation of the same prevention measures in prison as in 
701 WHO/ Pompidou Group [2005]. 
702 Boys et al. [2002]. 
703 WHO/ Pompidou Group [2005]. p. 6. 
704 WHO/ Pompidou Group [2005]. 
705 Seaman et al. [1998]; Bird and Hutchinson [2003]. 
706 Nelles et al. [1998]. 
707 Stöver, Heino, Laetitia C. Hennebel and Joris Casselman. [2004]. Substitution Treatment in European 
Prisons: A Study of policies and practices of substitution treatment in prisons in 18 European countries. p.23. 
London: Cranstoun Drug Services/ENDHASP.  
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country708. This principle is also reflected in sub-recommendation 2.8 of the Council 
Recommendation. 
A3.4.3 Rationale and objectives 
Harm reduction interventions in prison aim to reduce transmission of, and provide care for, those 
infected with drug-related infectious diseases and aim to reduce overdose deaths. Prevention and 
harm reduction programmes may include: information, education and communication on risk 
reduction with regard to HIV/  AIDS, other infectious blood-borne viruses and sexually transmitted 
diseases; pre-release interventions mainly targeting overdose death; voluntary testing and 
counselling; vaccination programmes for hepatitis B (and sometimes A); distribution of condoms; 
needle and syringe exchange or distribution and provision of drug paraphernalia and treatment 
programmes (either maintenance treatment or rapid detoxification focusing upon drug withdrawal). 
A3.4.4 State of Play 
The availability of harm reduction interventions in prisons differs greatly from outside prisons, 
which is also reflected by this study. However, policies to make harm reduction services available 
to drug users in prison exist, or are pending for approval, in 24 of the Member States. Maintenance  
treatment (methadone, buprenorphine or naltrexone) is provided inside prisons in 17 Member 
States, against 24 Member States that provide maintenance treatment outside prison. 
Detoxification treatment with methadone is offered in 23 countries, but is available inside prisons 
in 19 Member States. Needle and syringe exchange is available in prisons in 3 Member States 
(Spain, Germany and Luxembourg) but available in all but one Member State outside prison. Drug 
paraphernalia, such as bleach or sterile water, are provided in prisons in 11 Member States 
whereas 22 Member States provide this service outside prison walls. Free condoms are distributed 
in penitentiary institutions in 16 Member States, compared to 23 Members States providing 
condoms in the community. Prisons are reported to be a predominant or common implementation 
setting for measures preventing infectious diseases among drug users in 15 Member States, and 
for measures reducing drug-related deaths in 10 Member States. In 19 Member States, trainings 
focusing on harm reduction are offered to prison staff.  
A3.4.5 Effectiveness of harm reduction in prison 
Prison-based maintenance treatment appears to be feasible and if adequate doses are distributed 
during imprisonment, it reduces injecting drug use, needle sharing and transmissions of drug-
related infectious diseases.  
The utility of pre-release counselling may be equal to information, education and communication 
(IEC). It should be part of other interventions, e.g. after care provisions, in order to prevent 
relapse or even overdose death after release from prison.  
Needle (and syringe) exchange programmes in prison are effective in reducing needle sharing, and 
the transmission of infectious diseases.   
HIV testing and counselling may reduce needle sharing and concomitant infections. Both 
experience and scientific evidence show that prison needle exchange programmes have a positive 
effect on safety in prison, both for staff and prisoners.  
There is no evidence of any major, unintended consequences of condom distribution for safety and 
security in prisons. Taking care of sufficient lighting, offering showers and sleeping arrangements 
are important conditions for drug using prisoners. Measures to combat aggressive sexual 
behaviours in prison are even more important. 
Counselling (information, education) should be part of prison-based harm reduction interventions. 
The literature suggests that effectiveness of information and education possibly increases when 
these interventions are part of intervention packages.  
Evidence is currently lacking for the effectiveness of disinfection and decontamination schemes and 
strategies to reduce the occurrence of tattooing practices (as a risk factor for the spread of blood-
borne infections). For more information, see Annex 1, paragraph 5. 
708 UN General Assembly, res. 45/111, annex, 45 U.N. GAOR Supp. (No. 49A) at 200, U.N. Doc. A/45/49 
(1990). WHO [1993]; UNAIDS [1997]. 
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A3.4.6 Conclusions and recommendations 
Despite the principle of equivalence, there is a large discrepancy between harm reduction 
interventions available in the community and in prison. Accumulating evidence on the effectiveness 
of harm reduction measures in prison further advocates a continuation of care during all phases in 
the life of a drug user. Also with regard to public health, prevention of disease transmission should 
have highest priority in order to avoid prisons to become breeding grounds for infectious diseases 
as HIV, hepatitis, tuberculosis and sexually transmitted diseases.  
Since research on the effects of the various harm reduction interventions is limited, it is 
recommended that speculations about possible effects and side effects of these measures in and 
outside prison should be replaced by an evidence-based policy. Pilot studies, such as the 
introduction of drug consumption rooms inside prison walls - is under debate in Portugal - should 
be encouraged. Finally, drug using prisoners should have access to similar harm reduction services 
as outside prison. 
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Annex 4 – List of consulted field organisations in the 
Member States 
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Austria - Ganslwirt 
Ganslwirt is a socio-medical drug service and includes a day care centre, ambulant help (such as 
methadone dispensary) and a crisis night shelter. http:/ / www.vws.or.at/ ganslwirt/ index.html
Belgium - Free Clinic (Flanders) 
Free Clinic in Antwerp runs a socio-medical drop-in centre. The aims of Free Clinic include: 
improvement of the quality of life of drug users, and reducing the harms related to drug use. Free 
Clinic is responsible for a number of harm reduction intervention in Flanders, among which needle 
and syringe exchange, substitution treatment, and outreach work. 
Czech Republic - ANO/  SANANIM 
SANANIM is the largest Czech non-governmental organisation providing prevention, care and 
treatment services in the field of non-alcoholic drug addiction. It was founded in co-operation with 
Youth Centre Klíþov in 1990. Today, after 13 years of existence more than 100 of SANANIM´s 
employees arrange for maintenance and development of eight main projects and some additional 
ones, which all together make a comprehensive system of prevention, care and treatment. All of 
SANANIM´s Prague facilities except for the Outreach programme and Drug information centre have 
the status of health facility. SANANIM is a member of all the important Czech drug associations. 
SANANIM is a member of FESAT, the European Associations of Therapeutic Communities and an 
applicant to SCODA. It has participated in many international projects. 
ANO (www.asociace.org) is the association of Czech harm reduction associations. It is a voluntary, 
independent, and apolitical association that serves as umbrella platform and agency for / of non 
governmental organisations in the field of drug demand reduction.
Germany - Fixpunkt/ AkZept 
AkZept is  the “Verein für akzeptierende Drogenarbeit und humanitäre Drogenpolitik” 
(www.akzept.org). In short it is the national network of harm reduction organisations in Germany. 
It organises – among others - annual conferences.  
Fixpunkt (www.fixpunkt.org) is a Berlin based non-profit harm reduction organisation that aims 
to:
x support drug users to improve the conditions of health and social life, especially those who are 
infected by HIV or Hepatitis; 
x support self-help activities, self-control and survival strategies;  
x harm reduction, prevention of infections which are related to injecting drug users; 
x offer various low threshold employment facilities. 
Denmark – Brugerforeningen (BF) 
BF is an interest organisation for opiate and methadone users. The organisation and activities of BF 
are run by active volunteers, who are methadone users (www.brugerforeningen.dk).
Finland - A-Klinikka Foundation 
A-Clinic Foundation is the leading substance abuse service provider in Finland, with 19 outpatient 
and inpatient service units, and activities in the areas of prevention, training, research and 
information provision. A-Clinic Foundation is a non-profit, non-governmental organisation. The 
Foundation receives funding for the provision of treatment services mainly from municipalities. 
Training, research and information activities are funded through national funding sources, such as 
Finland's Slot Machine Association and the Ministry of Social Affairs and Health. (www.a-klinikka.fi).
Hungary - HCLU (TASZ) 
The Hungarian Civil Liberties Union (HCLU) is a non-profit human rights watchdog NGO established 
in Budapest, Hungary in 1994. HCLU is a law reform and legal defence public interest NGO in 
Hungary, working independently of political parties, the state or any of its institutions. The aim of 
HCLU is to promote the case of fundamental rights and principles laid down by the Constitution of 
the Republic of Hungary and by international conventions. Generally it has the goal of building and 
strengthening the civil society and rule of law in Hungary and the CEE region. Since HCLU is an 
independent non-profit organization the financial resources are largely provided by foundations and 
more and more likely by individuals (www.hclu.org). HCLU is also active in the field of improving 
the legal position and rights of drug users in Hungary. 
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Luxembourg - Tox-in 
Tox-in is a harm reduction based NGO in Luxembourg City, providing low threshold agencies during 
the day (Obrigado) and night shelter (d’ Nuetseil). In July 2005, Tox-In opened the first drug 
consumption room in Luxembourg. 
Latvia - Dia+logs 
DIA+LOGS, a non-governmental and non-profit organisation which was founded in 2002 as a joint 
endeavour between the Latvian NGOs AGIHAS (a self-support group for people living with HIV/  
AIDS) and LCG (a Latvian Contact Group on Urban, Industrial and Rural Mission). The Board of 
DIA+LOGS is comprised of key stakeholders and actors in the HIV/  AIDS field in Latvia. 
The organisation’s primary objective is the development and operation of a low threshold centre for 
people living with HIV/  AIDS and at-risk groups in greater Riga, including injecting drug users. 
Conveying knowledge and experience about HIV and AIDS, providing a social environment, one-to-
one conversations, group sessions for target groups while empowering people living with HIV/  
AIDS and providing advocacy are primary aims. The psychosocial support and prevention 
information are developed with a focus on strong community involvement. 
Netherlands - Mainline 
Mainline is a non-governmental organisation based in Amsterdam , the Netherlands . Embracing a 
Harm Reduction approach, Mainline works to improve the health and quality of life of (injecting) 
drug users. Cooperating with governmental and non-governmental organizations in various regions 
of the world Mainline focuses on prevention of drug-related infectious diseases such as HIV and 
hepatitis B and C as well as care and support for those drug users already infected. Drug 
abstinence is not a prerequisite. Mainline's approach is pragmatic, holistic and non-judgemental 
(www.mainline.org).
Poland - Monar 
Monar is a longstanding harm reduction organisation in Krakow , Poland. Monars services includes 
needle and syringe exchange, outreach work, shelters and a drug user-driven magazine for drug 
users.
Portugal - Abraço 
Abraçao is the leading HIV/  AIDS prevention organisation in Portugal, which also provides a range 
of harm reduction services to drug users. (www.abraco.org.pt).
Sweden - Svenskabrukarforeningen 
The Swedish Users Union (SBF) was founded in October 2002 by patients in substitution treatment. 
In the relatively short period that the Union exists, more than four hundred people have joined in 
and become members. It’s main task is to look after and make visible the needs of the heroin 
dependent drug users (www.svenskabrukarforeningen.com).
Slovenia - Project STIGMA 
Project STIGMA was officially registered in 1992 and offers low threshold programmes for drug 
users in Ljubljana and in Slovenia. HIV/  AIDS prevention measures among injecting drug users are 
part of their services, such as needle and syringe exchange and condom distribution. STIGMA also 
conducts outreach work and other harm reduction interventions. As such, STIGMA is the leading 
harm reduction organisation in Slovenia.  
Slovakia - Odysseus 
Odysseus is a Slovak non-governmental organisation, established in 1997. Its aim is to prevent 
HIV/  AIDS and other blood borne infections and sexually transmitted diseases among drug users 
and sex workers. Odysseus is involved amongst others in outreach work, needle and syringe 
exchange and social assistance to drug users and sex workers. 
United Kingdom - UK Harm Reduction Alliance (UKHRA) 
The United Kingdom Harm Reduction Alliance (UKHRA) is a campaigning coalition of drug users, 
health and social care workers, criminal justice workers and educationalists that aims to put public 
health and human rights at the centre of drug treatment and service provision for drug users. It is 
a campaigning network spread across the UK, as well as promoting harm reduction and evidence 
based drug policy by writing policy proposals and responses to government consultations 
(www.ukhra.org).
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Annex 5 – Council Recommendation (full text) 
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Council Recommendation of 18 June 2003 on the prevention and reduction of health-
related harm associated with drug dependence (2003/ 488/ EC) 
THE COUNCIL OF THE EUROPEAN UNION, 
Having regard to the Treaty establishing the European Community, and in particular the 
second subparagraph of Article 152(4) thereof, 
Having regard to the proposal from the Commission(1), 
Having regard to the opinion of the European Parliament(2), 
Having regard to the opinion of the European Economic and Social Committee(3), 
Having regard to the opinion of the Committee of the Regions(4), 
Whereas:
(1) In accordance with Article 3(1)(p) of the Treaty, Community action is to include a 
contribution towards the attainment of a high level of health protection. The third 
subparagraph of Article 152(1) of the Treaty also makes provision for action in reducing 
drugs-related health damage, including information and prevention. 
(2) The European Council, meeting in Helsinki on 10 and 11 December 1999, endorsed the 
European Union Drugs Strategy 2000 - 2004 that covers all European Union drug-related 
activities and sets main targets. These targets include a substantial reduction over five years 
of the incidence of drug-related health damage (such as HIV, hepatitis B and C and 
tuberculosis) and the number of drug-related deaths. 
(3) The European Council, meeting in Santa Maria da Feira on 19 and 20 June 2000, endorsed 
the European Union Action Plan on Drugs 2000 - 2004 as a crucial instrument for transposing 
the European Union Drugs Strategy 2000 - 2004 into concrete actions which provide an 
effective integrated and multi-disciplinary response to the drug problem. 
(4) The Commission, in its Communication to the European Parliament and the Council on the 
European Union Action Plan to Combat Drugs (2000 - 2004), considered a comprehensive 
approach that should cover all areas of drug abuse prevention, from discouraging the initial 
use to reducing the negative health and social consequences as the best strategy. 
(5) The European Parliament, in its Resolution on the abovementioned Communication 
welcomed the objective of reducing the number of deaths among addicts and called on the 
European Union and its Member States to encourage and develop damage limitation policies, 
without debarring individual Member States from adopting measures and pilot schemes in this 
area.
(6) The programme of Community action on the prevention of drug dependence within the 
framework for action in the field of public health and the programme of Community action on 
the prevention of AIDS and certain other communicable diseases within the framework for 
action in the field of public health have supported projects aimed at preventing and reducing 
the risks associated with drug dependence, in particular by encouraging cooperation between 
the Member States, supporting their action and promoting coordination between their policies 
and programmes. Both programmes have been contributing to improving information, 
education and training aimed at preventing drug dependence and the associated risks, in 
particular, for young people and particularly vulnerable groups. 
(7) The decision of the European Parliament and of the Council adopting a programme of 
action in the field of public health (2003 - 2008) includes the development of strategies and 
measures on drug dependence, as one of the important lifestyle-related health determinants. 
(8) Since, according to research, the morbidity and the mortality associated with drug 
dependence affects a sizeable number of European citizens, the health-related harm 
associated with drug dependence constitutes a major problem for public health. 
(9) In accordance with the principle of subsidiarity, any new measure taken in an area which 
does not fall within the exclusive competence of the Community, such as prevention and 
reduction of risks associated with drug dependence, may be taken up by the Community only 
if, by reason of the scale or effects of the proposed action, the objectives proposed can be 
better achieved by the Community than by Member States. Prevention and reduction of risks 
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associated with drug dependence cannot be confined to a geographical region or Member 
State and action therefore requires coordination at Community level. 
(10) Provisions should be made on reporting at national and Community level to monitor the 
measures taken by the Member States in this area, and the results thereof, and the way these 
Recommendations have been implemented. 
(11) The most important measure to reduce the risk associated with drug abuse is to prevent 
the abuse itself, 
HEREBY RECOMMENDS THAT: 
1. Member States should, in order to provide for a high level of health protection, set as a 
public health objective the prevention of drug dependence and the reduction of related risks, 
and develop and implement comprehensive strategies accordingly. 
2. Member States should, in order to reduce substantially the incidence of drug-related health 
damage (such as HIV, hepatitis B and C and tuberculosis) and the number of drug-related 
deaths, make available, as an integral part of their overall drug prevention and treatment 
policies, a range of different services and facilities, particularly aiming at risk reduction; to this 
end, bearing in mind the general objective, in the first place, to prevent drug abuse, Member 
States should: 
1. provide information and counselling to drug users to promote risk reduction and to 
facilitate their access to appropriate services; 
2. inform communities and families and enable them to be involved in the prevention 
and reduction of health risks associated with drug dependence; 
3. include outreach work methodologies within the national health and social drug 
policies, and support appropriate outreach work training and the development of working 
standards and methods; outreach work is defined as a community-oriented activity 
undertaken in order to contact individuals or groups from particular target populations, 
who are not effectively contacted or reached by existing services or through traditional 
health education channels; 
4. encourage, when appropriate, the involvement of, and promote training for, peers and 
volunteers in outreach work, including measures to reduce drug-related deaths, first aid 
and early involvement of the emergency services; 
5. promote networking and cooperation between agencies involved in outreach work, to 
permit continuity of services and better users' accessibility; 
6. provide, in accordance with the individual needs of the drug abuser, drug-free 
treatment as well as appropriate substitution treatment supported by adequate 
psychosocial care and rehabilitation taking into account the fact that a wide variety of 
different treatment options should be provided for the drug-abuser; 
7. establish measures to prevent diversion of substitution substances while ensuring 
appropriate access to treatment; 
8. consider making available to drug abusers in prison access to services similar to those 
provided to drug abusers not in prison, in a way that does not compromise the 
continuous and overall efforts of keeping drugs out of prison; 
9. promote adequate hepatitis B vaccination coverage and prophylactic measures against 
HIV, hepatitis B and C, tuberculosis and sexually transmitted diseases, as well as 
screening for all the aforementioned diseases among injection drug users and their 
immediate social networks, and take the appropriate medical actions; 
10. provide where appropriate, access to distribution of condoms and injection materials, 
and also to programmes and points for their exchange; 
11. ensure that emergency services are trained and equipped to deal with overdoses; 
12. promote appropriate integration between health, including mental health, and social 
care, and specialised approaches in risk reduction; 
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13. support training leading to a recognised qualification for professionals responsible for 
the prevention and reduction of health-related risks associated with drug dependence. 
3. Member States should consider, in order to develop appropriate evaluation to increase the 
effectiveness and efficiency of drug prevention and the reduction of drug-related health risks: 
1. using scientific evidence of effectiveness as a main basis to select the appropriate 
intervention; 
2. supporting the inclusion of needs assessments at the initial stage of any programme; 
3. developing and implementing adequate evaluation protocols for all drug prevention 
and risk reduction programmes; 
4. establishing and implementing evaluation quality criteria, taking into account the 
Recommendations of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA);
5. organising standardised data-collection and information dissemination according to the 
EMCDDA recommendations through the REITOX national focal points; 
6. making effective use of evaluation results for the refining and development of drug 
prevention policies; 
7. setting up evaluation training programmes for different levels and audiences; 
8. integrating innovative methods that enable all actors and stakeholders to be involved 
in evaluation, in order to increase acceptance of evaluation; 
9. encouraging, in collaboration with the Commission, the exchange of programme 
results, skills and experience within the European Union and with third countries, 
especially the applicant countries. 
4. Member States should report to the Commission on the implementation of this 
Recommendation within two years of its adoption and subsequently on request by the 
Commission with a view to contributing to the follow-up of this recommendation at 
Community level and acting as appropriate in the context of the European Union Action Plan 
on Drugs. 
HEREBY INVITES the Commission to: 
- cooperate with the Pompidou Group of the Council of Europe, the World Health Organisation, 
the United Nations International Drug Control Programme and other relevant international 
organisations active in the field, 
- prepare a report, in accordance with the European Union Action Plan on Drugs and with the 
technical support of the EMCDDA, with a view to the revision and updating of this 
Recommendation, on the basis of the information submitted by the Member States to the 
Commission and the EMCDDA, and the latest scientific data and advice. 
Done at Luxembourg, 18 June 2003. 
For the Council 
The President 
G. Drys 
(1) Proposal of 17 May 2002 (not yet published in the Official Journal). 
(2) Opinion delivered on 13 February 2003 (not yet published in the Official Journal). 
(3) OJ C 61, 13.2.2003, p. 189. 
(4) OJ C 73, 26.3.2003, p. 5. 
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Annex 6 – List of abbreviations 
AIDS   Acquired Immune Deficiency Syndrome 
ARV  Anti Retroviral Therapy
ASI Addiction-Severity Index
ATS  Amphetamine Type Stimulants
CEEHRN  Central and Eastern European Harm Reduction Network 
CND  Commission on Narcotic Drugs 
CR   Council Recommendation  
DCR  Drug Consumption Room 
DIMS  Drug Information and Monitoring System 
DG SANCO  Directorate General Consumer Protection and Health 
DRID  Drug-related Infectious Disease 
DRD  Drug-related Death
EDDRA  Exchange on Drug Demand Reduction Action (EMCDDA)  
ELDD   European Legal Database on Drugs (EMCDDA) 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
ENDIPP European Network on Drugs and Infections Prevention in Prison 
ESPAD  European Survey Project on Alcohol and Drugs 
IDU   Injecting Drug User 
IEC   Information, Education and Communication 
IHRA  International Harm Reduction Association 
HEN   Health Evidence Network 
HIV   Human Immunodeficiency Virus 
LAAM   Levomethadyl Acetate Hydrochloride 
MMT   Methadone Maintenance Treatment 
MS   Member State(s) 
NGO  Non Governmental Organisation 
NIDA  National Institute on Drug Abuse  
NFP   National Focal Point (EMCDDA Reitox Network) 
NR  National Report 
NSP  Needle and syringe exchange programmes 
PR  Permanent Representative
PDU   Problem Drug Use 
RCT  Randomized Controlled Trial 
RT  Reporting tool (European Commission)
SQ   Structured Questionnaire (EMCDDA) 
ST   Standard Table (EMCDDA) 
TB   Tuberculosis 
UNAIDS  Joint United Nations Programme on HIV/ AIDs  
UNODC United Nations Office on Drugs and Crime 
WHO   World Health Organisation 
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Annex 7 – Glossary 
A
Abstinence based therapy 
Abstinence-based therapy aims at a drug-free life. Enrolling in abstinence-based treatment, drug users will 
undergo a phase of detoxification which might be medically supported by the temporary provision of 
substitution drugs (methadone, buprenorphine, benzodiazepines, etc). The detoxification period can however 
also be free of medically assisted treatment and may focus solely on socio-psychological support, enrolment in 
work programmes, individual coaching, or art therapy.  Long time enrolment in counselling services or 
supported housing projects often go alongside with abstinence-based therapy. 
Agonist 
A substance that acts at a neuronal receptor to produce effects similar to those of a reference drug; for 
example, methadone is a morphine-like agonist at the opioid receptors.  
Antagonist 
A substance that counteracts the effects of another agent. Pharmacologically, an antagonist interacts with a 
receptor to inhibit the action of agents (agonists) that produce specific physiological or behavioural effects 
mediated by that receptor. Naloxone (Narcan) is antagonist. 
Antiretroviral therapy (ARV) 
Antiretroviral drugs inhibit the replication of HIV. When antiretroviral drugs are given in combination, HIV 
replication and immune deterioration can be delayed, and survival and quality of life improved. When selecting 
a specific ARV-treatment regimen for individual patients the following factors should be consider: potency, 
frequency of dosage, side effects, maintenance of future treatment options, the anticipated adherence of the 
patient population to a regimen, need for storage, concurrent conditions, the potential for resistant viral strains, 
and cost and access. Additional considerations may include access to only a limited number of ARV drugs, 
limited health service infrastructure, the need to deliver drugs to rural areas, a high incidence of tuberculosis 
and hepatitis B and/ or C, and the presence of varied HIV groups and subtypes.  
B
Bleach 
Disinfectant, used to disinfect syringes when no clean syringes are available. 
Buprenorphine 
Buprenorphine is a mixed opioid agonist/  antagonist which can be used in substitution treatment. It has been 
used extensively in many countries for the short term treatment of moderate to severe pain. The mixed opioid-
action/  blocking-action appears to make buprenorphine safe in overdose. It may also provide an easier 
withdrawal phase, and due to a longer action, may allow for alternate day dosing. Buprenorphine is also 
available under the brand name Subutex ®. See also: Methadone, Maintenance treatment. 
C
Clinical trial 
A clinical trial is a study that is used to test whether one health care intervention is superior to another. Clinical 
trials are often described in terms of testing drugs, but they can be used to investigate many different types of 
health care intervention, including vaccination and health education. Clinical trials are always concerned with 
effectiveness. A characteristic of well-conducted clinical trials is that they identify a set of patients with a 
diagnosed disease, and then randomly allocate them to new or current best treatment. The focus of the study is 
on the outcome of the treatments, seeking the one which is superior. Clinical trials are also concerned with the 
side effect of treatments  
CND
The Commission on Narcotic Drugs (CND) is the central policy-making body within the United Nations system 
dealing with drug-related matters. It analyses the world drug situation and develops proposals to strengthen 
the international drug control system to combat the world drug problem. In 1991, the UN General Assembly 
established the Fund of the United Nations International Drug Control Programme (UNDCP) and expanded the 
mandate of the Commission to enable it to function as the governing body of UNDCP. UNDCP is administered as 
part of the United Nations Office on Drugs and Crime (UNODC). 
Cochrane collaboration 
The Cochrane Collaboration is an international non-profit and independent organisation, dedicated to making 
up-to-date, accurate information about the effects of healthcare readily available worldwide. It produces and 
disseminates systematic reviews of healthcare interventions and promotes the search for evidence in the form 
of clinical trials and other studies of interventions. The Cochrane Collaboration was founded in 1993 and named 
for the British epidemiologist, Archie Cochrane. The major product of the Collaboration is the Cochrane 
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Database of Systematic Reviews which is published quarterly as part of The Cochrane Library. [http:/ / 
www.cochrane.org/ reviews/ clibintro.htm].
Cohort study 
In a cohort study parts of a pre-defined population can be identified who are exposed to factors influencing the 
occurrence of a disease or other outcome. Essential is the measurement of these factors and outcomes for a 
sufficient number of person-years to generate reliable incidence or mortality rates in the populations subsets. 
This generally implies study of a large population and for several years.  
Co morbidity  
See: dual diagnosis
D
DSM-IV
Diagnostic and Statistical Manual of Mental Disorders, IV edition. This manual includes a diagnostic terminology 
of psychiatric and psychoactive substance use disorders classified by the American Psychiatric Association 
(APA).  
Detoxification treatment  
Detoxification treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a 
similar or identical substance to the drug normally used, by gradually cutting the quantity of the drug to zero.  
Drop-in centre 
In drop-in centres, some of the basic needs of people, e.g. drug users are met. A drop-in centre is a low 
threshold service for drug users, usually including needle and syringe exchange, distribution of condoms, free 
(or cheap) meals, laundry and washing, referral to treatment. Drop-in centres are a characteristic feature of the 
low threshold approach. 
Drug consumption room  
There is no universal definition of the term drug consumption room. When the term drug consumption rooms is 
used in this report. reference is made to “protected places for the hygienic consumption of pre-obtained drugs 
in a non-judgemental environment and under the supervision of trained staff.”
Drug dependence 
Drug dependence is often defined as: a maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifested by three (or more) of the following, occurring at any time within a 12-
month period. (1) Tolerance, as defined by either of the following: (a) need for markedly increased amounts of 
the substance to achieve intoxication or desired effect; (b) markedly diminished effect with continued use of the 
same amount of the substance. (2) Withdrawal, as manifested by either of the following: (a) the withdrawal 
characteristic for the substance (refers to Criteria A and B of the criteria sets for withdrawal from the specific 
substances; (b) the same (or closely related) substance is taken to relieve or avoid withdrawal symptoms; (3)
the substance is often taken in larger amounts or over a longer period than was intended; (4) there is a 
persistent desire or unsuccessful effort to cut down or control substance use; (5) a great deal of time is spent 
in activities necessary to obtain the substance (e.g. visiting multiple doctors or driving long distances), use of 
the substance (e.g. chain-smoking), or recovering from its effects; (6) Important social, occupational or 
recreational activities are given up or reduced because of substance use; (7) the substance use is continued 
despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have 
been caused or exacerbated by the substance (e.g. current cocaine use despite recognition of cocaine-induced 
depression, or continued drinking despite recognition that an ulcer was made worse by alcohol consumption) 
(source: DSM IV).
Drug free treatment 
Drug-free treatment involves the application of psychosocial and educational techniques to achieve long-term 
abstinence from drugs. Traditionally, drug-free treatment has been residential and long term, e.g. in 
therapeutic communities. Today, it is often also offered in community-based settings.
Drug paraphernalia  
The term drug paraphernalia refers to equipment used to produce, administer or conceal an illicit drug, e.g. 
bleach, a spoon, ascorbic acid, pipes, etc. 
Drug-related death 
Drug-related death is defined in this report as: deaths caused directly by the consumption of one or more drug 
and generally occurring shortly after the consumption of the substance(s). These deaths are known as 
‘overdoses’, ‘poisonings’ or drug-induced deaths.. 
Drug-related infectious diseases 
The most prevalent types of drug-related infectious diseases are Hepatitis B and C, HIV/  AIDS and 
Tuberculosis.  
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Dual diagnosis 
The term dual diagnosis is a common, broad term that indicates the simultaneous presence of two independent 
medical disorders. Recently, within the fields of mental health, psychiatry, and addiction medicine, the term has 
been popularly used to describe the coexistence of a mental health disorder and alcohol and other drug (AOD) 
problems. The equivalent phrase dual disorders also denotes the coexistence of two independent (but invariably 
interactive) disorders and is used interchangeably here with dual diagnosis. 
The acronym MICA, which represents the phrase mentally ill chemical abusers, is occasionally used to designate 
people who have an AOD disorder and a markedly severe and persistent mental disorder such as schizophrenia 
or bipolar disorder. A preferred definition is mentally ill chemically affected people, since the word affected 
better describes their condition and is not pejorative. Other acronyms are also used: MISA (mentally ill 
substance abusers), CAMI (chemical abuse and mental illness), and SAMI (substance abuse and mental illness). 
Common examples of dual disorders include the combinations of major depression with cocaine addiction, 
alcohol addiction with panic disorder, alcoholism and poly-drug addiction with schizophrenia, and borderline 
personality disorder with episodic poly-drug abuse. Although the focus of this volume is on dual disorders, some 
patients have more than two disorders, such as cocaine addiction, personality disorder, and AIDS. The 
principles that apply to dual disorders generally apply also to multiple disorders. 
See also: Co morbidity
E
Evidence-based medicine 
Evidence-based medicine consists of carefully, explicitly and judiciously using recent scientific evidence for 
medical decision making for individual patients. The practice of evidence-based medicine implies an integration 
of  individual clinical expertise with best evidence available in systematic studies. Preferences and expectations 
of individual patients play a major role in decision making.  
H
Harm Reduction 
There is no universal definition of the term harm reduction. For this report the definition of the International 
Harm Reduction Association (IHRA) is used: “policies and programmes which attempt primarily to reduce the 
adverse health, social and economic consequences of mood altering substances to individual drug users, their 
families and their communities”
Hepatitis B  
Hepatitis B is a virus spread through the blood and bodily fluids of an infected person. Many people do not 
realise they have been infected with the virus, because symptoms may not develop immediately, or at all. The 
hepatitis B virus can then go on to cause a chronic (long-term) illness, which follows the acute infection. This is 
very common if babies or children contract the virus, but can also occur in adults. The virus is present in body 
fluids such as blood, saliva, semen and vaginal fluid. It can be passed from person to person, through 
unprotected sex (without using a condom) and sharing needles to inject drugs. Infected mothers can also 
transmit the virus to their baby during the delivery process (often without the woman being aware that she is 
infected). The incubation period (i.e. the time from coming into contact with the virus to developing the 
infection) is between one and six months. There is a blood test to detect the virus. There is also a vaccine to 
protect you against hepatitis B.  
Hepatitis C  
Hepatitis C is a blood-borne viral infection. Rarely it can also be passed on through other body fluids. Drug 
users sharing needles are particularly at risk. Anyone whose blood has come into contact with the blood of 
someone infected with the hepatitis C virus is also at risk. Approximately 20% of people will fight the infection 
and naturally clear it from their bodies within two to six months . Of the rest some will remain well, and never 
develop liver damage but many will develop mild to moderate liver damage (with or without symptoms). A 
further 20% will progress to cirrhosis of the liver over a period of 20- 30 years. Excessive drinking of alcohol is 
often associated with increased likelihood of progression to severe liver complications. There is no vaccine to 
prevent hepatitis C but treatment can clear the infection in approximately half those infected. 
Heroin prescription 
Heroin prescription means the controlled prescription of pharmaceutical heroin (diacetyl morphine) to heroin 
dependent drug users. In this context it may also be considered as substitution treatment (an alternative to low 
purity ‘street’ heroin with pure factory-made diacetylmorphine). In a number of the countries with heroin 
prescription programmes, heroin is prescribed to heroin dependent drug users, for whom regular therapy with 
methadone or buprenorphine is proven ineffective 
HIV/ AIDS 
AIDS was first recognised as a new condition in 1981. Since then around 40 million people worldwide have been 
infected with HIV, the virus which can lead to AIDS. About a third of them have died. However, developments 
in treatment since the mid-nineties have dramatically improved the life expectancy for those diagnosed with 
HIV. People with HIV may not have any symptoms at all while they are in the latent phase. However, many 
people experience symptoms in the first couple of months after getting infected. These symptoms may include 
high temperature and fever, fatigue, skin rash, muscle pains, headache, nausea, vomiting and diarrhoea. Once 
someone becomes ill with HIV, they are open to many infections. These can include infections of the mouth, 
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such as thrush (oral candidiasis), unusual types of pneumonia, tuberculosis (TB), infections of the brain and 
eyes, unusual skin problems and odd infections of the gastrointestinal tract. Most people with severe HIV 
infection also experience weight loss, enlargement of their lymph glands and persistent diarrhoea.  
Hypotension 
(Extremely) low blood pressure during which there is inadequate blood flow to the heart, brains and other vital 
organs. Hypotension may occur during opioid overdose and can be reversed by the administering of Naloxone. 
I
IDU
Injecting drug user. Injections are usually intravenous, but may also be intramuscular, subcutaneous.  
IEC
Abbreviation of information, education and communication. IEC is usually the first measure in any response 
strategy to prevention or reduce infectious diseases among drug users, or to promote less risky, more healthy 
behaviour and is aimed at raising levels of knowledge, awareness and understanding.  
Inpatient treatment 
Treatment for drug dependence that takes place in a controlled environment such as a hospital or clinic. The 
patient is checked into the hospital and remains there until treatment has ended. 
Interferon mono therapy 
Interferon mono therapy is a treatment option for treating HCV with only alpha-interferon. The treatment with 
alpha-interferon allowed for only limited healing of chronic HCV infections (8-12%) and was replaced by a 
combination therapy with ribavirin and alpha-interferon. Treatment results of healing the liver infection caused 
by HCV rose to 30-40%. Since the year 2000, PEG-interferon was introduced which in combination with 
ribavirin allows for a healing of up to 80% of all patients infected with genotype 2 and 3 of the hepatitis C virus. 
For genotype 1, the combination therapy of PEG-interferon and ribavirin still allows for positive treatment 
results with up to 50% of all patients. 
L
LAAM (Levomethadyl Acetate Hydrochloride) 
LAAM is a long-acting opiate agonist with a similar action to methadone. However, its half life is longer and it 
can be administered once in two days. LAAM has been associated with life-threatening heart arrhythmias and 
therefore it is no longer licensed for treatment in Europe 
Low threshold agencies 
Low threshold agencies are services for drug users which  are easily accessible by clients, and where abstinence 
is not a prerequisite for service provision. Often, such services work with clients on an anonymous basis. They 
are designed to attract future clients by offering, beside drug-related services, other services that respond to 
the immediate needs of clients, such as free or reasonably priced food, clothing or shelter.. Drop in centres, and 
outreach work are main low threshold agencies 
M
Maintenance treatment 
Maintenance treatment is a harm reduction intervention aiming at stabilizing opiate users medically and socially 
allowing for genuine social re-integration. To avoid criminal activity when acquiring the illicit drugs and 
eliminating high risk situation when administrating the drug via injecting, the treatment provides the patient 
with a substitution drug, mostly orally administered methadone or buprenorphine. Often maintenance 
treatment is provided as DOT (Daily Observed Therapy) which allows for thorough monitoring of the effects of 
the provision of substitution drugs in every patient. Furthermore patients are supported by medical and social 
service professionals to guarantee beneficial long-term effects on social re-integration of the individual patient. 
Medically assisted treatment 
Medically assisted treatment (MAT) covers both substitution treatment with agonists (methadone, 
buprenorphine, dihydrocodeine, heroin, slow-release morphine) and other pharmacological treatments (e.g. 
with antagonists such as naltrexone) which is targeted at the drug use itself (not anti-depressives and 
benzodiazepines).
Meta-analysis 
Meta-analysis is the statistical component of a systematic review (see systematic review) in which the 
outcomes of similar studies are statistically drawn together to a mean outcomes for all or for subsets of studies. 
In the international literature, the terms systematic review and meta-analysis often are used interchangeably.
Methadone 
A synthetic opiate drug used in maintenance therapy for those dependent on opioids. It has a long half-life, and 
can be given orally once daily with supervision. Methadone acts as a replacement for opiates in the body and 
thus can lessen withdrawal symptoms and cravings. At higher doses, it can also reduce the euphoric effects of 
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opiates, thereby further protecting opiate users from relapse. Methadone is provided under several brand 
names.
Morphine (slow-release morphine) 
Slow release morphine (SROM) is morphine that is administered orally. It is sometimes used as (agonist) 
substitution for heroin.  
N
Naloxone 
Naloxone is a narcotic antagonist which reverses the respiratory, sedative and hypotension effects of heroin 
overdose. It can be injected intramuscularly, intravenously or subcutaneously. A nasal spray preparation is now 
also available in some countries. It is an opioid receptor blocker that antagonizes the actions of opioid drugs. It 
reverses the features of opiate intoxication and is prescribed for the treatment of overdose with this group of 
drugs. It has a half-life of between 20 and 80 minutes, shorter than the half-life of heroin and much shorter 
than that for methadone, which means the opportunity for it to reduce the effects of opioids is time-limited. 
There is therefore a concern that persons treated with naloxone may again succumb to the respiratory 
depression effects of these other drugs once the effects of naloxone have worn off. Naloxone is also available 
under the brand name Narcan®.  
See also: antagonist, naltrexone.
Naltrexone 
This is a drug that antagonises the effects of opioid drugs. Its effects are similar to those of naloxone, but it is 
more potent and has longer duration of action. It is used in various ways in the treatment of opioid dependence 
and also alcohol dependence. The most widely adopted use is to prescribe at a dose which will block the 
psychoactive effects of all opioid drugs. The idea is that while the drug needs to be taken daily to maintain this 
blockade, it will minimize the chance of impulsive decisions to relapse. Naltrexone has also been used more 
controversially for a treatment known as Rapid Opiod Detoxification in which higher doses are used under a 
general anaesthetic for the purpose of speeding up the withdrawal process. Deaths have been recorded with 
this approach and it has many critics as well as a few proponents. Naltrexone is also available under the brand 
name Nalorex®.  
See also: antagonist, naloxone, drug substitution.
Narcan ® 
Brand name for Naloxone. 
See also: Naloxone
Needle and syringe exchange 
An intervention in which needles, syringes, other injecting equipment (such as alcohol swabs to clean injecting 
sites, and water with which to mix powdered drugs) are provided to IDUs through outreach, drop-in centres, 
clinics or shop fronts, mobile units such as vans and buses and/ or vending machines. Most NSPs include a 
retrieval service for used syringes. 
O
Outpatient treatment 
Treatment (ambulant) of drug dependency that does not include an overnight stay in a clinic. 
Outreach work 
A community based activity with the overall aim of facilitating improvement in health and reduction of drug-
related risk or harm for individuals  and groups not effectively reached by existing services or through 
traditional health education channels. 
P
Paraphernalia 
The term drug paraphernalia refers to equipment used to produce, administer or conceal an illicit drug, e.g. 
bleach, a spoon, ascorbic acid, pipes, etc.
Pill testing 
The term pill-testing in the context of illicit drugs usually refers to the testing of ecstasy pills. On-site pill testing 
is often done during rave parties or other club scenes and involves a physical test and an acid-test. By making 
use of the physical test (e.g. diameter, thickness, colour and logo) and the acid test, the pill is classified and 
compared to an existing list of ecstasy pills. A more thorough test includes a laboratory test, in which the 
substance of a pill is tested (e.g. MDMA concentration, other chemicals, etc.).
Pre-release counselling 
Pre-release counselling is a harm reduction activity offered to inmates who are about to be released from 
prison. Through pre-release counselling inmates are prepared for their return to society outside prison, with the 
aim to support their reintegration in society. Pre-release counselling also provides drug using inmates the 
advice regarding the risks of the possible detrimental effects of drug consumption after release, which may 
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result in drug overdose especially when the inmate has not used drugs or reduced drug use in prison and 
returns to the drug use patterns he had prior to his incarceration.  
Prevalence 
Prevalence is a statistic of primary interest in public health because it identifies the level of burden of disease or 
health-related events on the population and health care system. Prevalence represents new and pre-existing 
cases alive on a certain date, in contrast to incidence which reflects new cases of a condition diagnosed during 
a given period of time. Prevalence is a function of both the incidence of the disease and survival.  
R
Randomised Controlled Trials (RCT) 
Experimental study in which subjects are randomly allocated into groups to receive or not to receive an 
experimental intervention. Randomisation is meant to minimise systematic bias in outcomes. Outcomes are 
assessed and explained by rigorous comparison of groups on rates of disease, death or recovery.
S
Safer injecting training 
A practical training for injecting drug users with the intent to educate drug users in more safe, less risky ways 
of injecting. This training may be given by experienced drug injectors, non-injecting professionals, or a mixture 
of both groups. 
Seroprevalence  
Seroprevalence denotes the condition that antibodies can be detected in a serum sample. The development of 
detectable antibodies in the blood are proof that an infectious agent, such as HIV or HCV, is present. It 
normally takes some time for antibodies to develop after the initial exposure to the agent. This period of time is 
called seroconversion. Following seroconversion, a person tests positive in tests based on the presence of 
antibodies.
Substitution treatment 
Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a 
similar or identical substance to the drug normally used. It is offered in two forms: maintenance — providing 
the user with enough of the substance to reduce risky or harmful behaviour; or detoxification — gradually 
cutting the quantity of the drug to zero. Treatment comes either with or without psycho-social support. 
Systematic review 
Systematic reviews draw together previously performed research (primary studies). A systematic review is a 
literature review of the evidence on a clearly formulated question that uses systematic and explicit means to 
identify, select, and critically appraise relevant primary research. It also  systematically extracts and analyses 
data from the included studies. Statistical methods (meta-analysis) may or may not be used.  
T
Treatment retention 
The degree of treatment completion of participants in a study.  
Tuberculosis  
Tuberculosis (TB) is an infection caused by a germ called the tubercle bacillus or Mycobacterium tuberculosis. 
Until effective anti-tuberculosis drugs were introduced about 50 years ago, TB was one of the main causes of 
death. TB is still a major problem in many countries. It has been on the increase in the developed world in 
recent years, probably because of increased air travel and movement of people from areas where it is common.  
It can affect the lungs (pulmonary TB) or other parts of the body, such as the lymph nodes (tuberculous 
adenitis or scrofula), the skin and the bones. Tubercle bacilli can remain dormant for years before producing 
active disease. In most cases lung infection is well controlled by the immune system, and shows no symptoms. 
Active lung disease occurs if the immune system becomes less effective. 
A person may have had an infection with tuberculosis without being aware. This can be discovered by a 
tuberculin skin test, the Heaf (or Mantoux) test. When positive, it indicates that the person has a degree of 
natural immunity. People who test negative do not have this immunity and are more susceptible to infection by 
TB. Tuberculin-negative people may benefit from BCG (bacille Calmette-Guérin vaccine) inoculation. This uses a 
vaccine made from a modified version of the TB germ. It reduces the risk of developing TB in about 70% of 
those vaccinated for approximately 15 years.  
Twinning 
An agreement between a candidate country and one or more Member State administrations to transfer Acquis-
related skills and knowledge (progress towards adoption of part of the Acquis).  
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VCT
Voluntary Infectious Diseases Testing and Screening. Programmes specifically targeted at at-risk groups to test 
and screen for the presence of drug-related infectious diseases.  
Virus
A virus is a small infectious organism—much smaller than a fungus or bacterium—that must invade a living cell 
to reproduce (replicate).  
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